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ABSTRACT 
 
This thesis combines three research studies with the common interest of identifying novel 
mechanisms underlying human cortical development. This aim is pursued from different 
angles, always basing the investigations on human induced pluripotent stem cell-derived 
2D and 3D in vitro model systems that are partly combined with in vivo studies in the 
developing mouse cortex. Namely, in the pieces of work combined here, we 1) bring to 
light a neurodevelopmental role of a gene already implicated in adult nervous system 
function, 2) discover a novel mechanism that fine-tunes human neurogenesis, and 3) 
identify a novel gene whose mutations lead to a malformation of cortical development. 
The entirety of this work thus adds several aspects to the existing knowledge. 
In the first study, we identified a neurodevelopmental function of a gene mutated in 
patients with the progressive gait disorder hereditary spastic paraplegia (HSP). In this 
group of inherited neurodegenerative diseases, mutations in lipid, mitochondrial, 
cytoskeletal or transport proteins lead to degeneration of primary motor neurons, which, 
due to the length of their axons, are particularly sensitive to disruption of these 
processes. Here, were generated cerebral organoids (COs) derived from HSP patients 
with mutations in SPG11 coding for spatacsin. Previous work had shown impaired 
proliferation of SPG11 patient-derived neural progenitor cells (NPCs). We found a 
proliferation defect also in CO NPCs, leading to a thinner progenitor zone and premature 
neurogenesis due to increased asymmetric progenitor divisions, along with smaller size of 
patient-derived COs. Molecularly, we found a decrease in deactivated GSK3β and 
increase in P-βcatenin at the basis of the observed proliferation/neurogenesis imbalance. 
We thus confirmed the neurodevelopmental role of SPG11 that had previously been 
suggested from 2D human in vitro findings. Both the observed reduction in proliferating 
progenitors and in organoid size were rescued through inhibition of GSK3β, with the Food 
and Drug Administration (FDA) approved compound tideglusib only affecting patient COs. 
These rescue experiments thus stressed the opportunity that COs represent for drug 
testing and translation of findings to precision medicine. 
In the second study, we investigated the role of a novel posttranslational modification 
(PTM) termed AMPylation in neurogenesis. Using a novel probe for the detection of 
AMPylated proteins and a combination of mass spectrometry-based proteomics, 
immunohistochemistry, and acute interference with the expression of the AMPylating 
enzyme, we made several interesting findings: AMPylation takes place on a cell type-
specific set of proteins, is responsive to the predominant environmental condition, and 
both AMPylator and targets localize to cell type-specific intracellular localizations. During 
the process of neuronal differentiation, the set of AMPylated proteins is completely 
remodeled, with a very high number of unique targets in neurons. These include 
metabolic enzymes as in all analyzed cell types and, additionally and specifically, 
cytoskeletal and motor proteins. Cytoskeletal and motor proteins in neural progenitors 
and neurons are known to be differentially modified by several PTMs whose correct 
establishment is highly important during neurodevelopment; AMPylation may thus be an 
additional one. To assess the role of AMPylation in neurodevelopment, we manipulated 
the expression of the AMPylating enzyme FICD in COs. Downregulation kept cells in a 
proliferating progenitor state, whereas overexpression increased neurogenesis. We thus 
suggest AMPylation as a novel PTM fine-tuning neurogenesis. 
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The third study focused on the identification of new mechanisms underlying cortical 
malformations, aiming at a better understanding of how the human brain develops. In 
patients with periventricular heterotopia (PH), a neuronal migration disorder in which a 
subset of neurons fail to migrate to the developing cortical plate and instead form nodules 
of grey matter lining the lateral ventricles as their site of production, biallelic mutations in 
endothelin converting enzyme 2 (ECE2) were identified as candidate causative. 
Combining in vitro and in vivo models, we found a role for ECE2 in neuronal migration 
and cortical development. In the absence of ECE2, several processes of general 
importance to proper neuronal migration were disrupted. Namely, changes in progenitor 
cell polarity and morphology and in apical adherens junctions led to their delamination, 
restricting their use as a scaffold for neuronal migration. This resulted in ectopic neurons 
reminiscent of nodules in PH. Besides a deregulation of cytoskeletal, polarity, and apical 
adhesion proteins, extracellular matrix (ECM) proteins were reduced in absence of ECE2, 
suggesting its role in ECM production and underlining the necessity of ECM components 
for proper neuronal migration during cortical development. Moreover, we detected 
differential phosphorylation of several cytoskeletal, motor and adhesion proteins in the 
absence of ECE2, which is functionally in line with the former findings and suggests an 
additional involvement of ECE2 in the regulation of PTMs. 
Altogether, the studies presented here underline the heterogeneity and complexity of 
pathways and mechanisms that contribute to human cortical development and its 
disorders, converging on the regulation of cytoskeleton and transport within the involved 
cells and of the ECM on their outside. 
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1. INTRODUCTION 
 
The central nervous system was portrayed as an intricate network with a highly complex 
organization already more than 100 years ago by Ramon Y Cajal. The human cerebral 
cortex represents the largest region of the cerebrum – the most highly developed part of 
the human brain. It plays vital roles in processing and integrating information from all 
bodily senses to result in social and motor behaviors, in planning and organization, and in 
determining intelligence and personality (Kandel, 2000). The series of events involved in 
its development are thus highly coordinated and regulated. Their disruption can lead to 
malformations of cortical development (MCDs), affecting the structure and functioning of 
the cerebral cortex, and can cause a wide range of physiological and functional 
consequences. Indeed in humans, MCDs are a recognized cause of developmental 
delay, intellectual disability and epilepsy, and are also associated with dysmorphic 
features (Guerrini and Dobyns, 2014; Jamuar and Walsh, 2015; Romero et al., 2018). 
This introduction shall set the basis for understanding the research results presented and 
discussed in this thesis. To this end, it will commence with an introduction into cortical 
development and evolution with spotlights on mechanisms that are subject to the 
presented investigations, namely cytoskeletal components and their regulation by post-
translational modifications (PTMs). With this background knowledge at hand, additional 
attention will be directed to introducing MCDs with a focus on neuronal migration 
disorders (NMDs) and in vivo and in vitro model systems applied for their investigation. 
Parts of the introduction have been adapted from my recent review (Buchsbaum and 
Cappello, 2019) with permission from Development and were expanded to cover all 
basics of the different presented research studies.  
 
 
1.1. CORTICAL DEVELOPMENT AND EVOLUTION 
The cerebral cortex forms through a series of tightly regulated processes starting with the 
generation of neurons through neurogenesis (Götz and Huttner, 2005; Noctor et al., 
2004; Sun and Hevner, 2014), followed by neuronal migration, neuronal differentiation, 
and their spatial organisation into networks (Kriegstein and Noctor, 2004). Neurogenesis 
and neuronal migration will be shortly introduced here, followed by some regulatory 
mechanisms. 
 
1.1.1. NEUROGENESIS 
Neurogenesis is the process in which neurons are generated from stem and progenitor 
cells. The first structure that forms in early brain development is the neural tube, 
consisting of a single pseudostratified layer of neuroepithelial cells (NECs), which are the 
primary neural stem cells (NSCs) that will give rise to all brain structures in the anterior 
end of the neural tube. The pseudostratified appearance originates from a process called 
interkinetic nuclear migration (IKNM): in synchronization with the cell cycle, nuclei move 
basally (G1 to S-phase) within the cell to acquire most basal positions for their S-phase 
and move back to the apical surface during the G2-phase, to then undergo mitosis at the 
apical surface. This makes room for more cells per area, increasing the density of the 
neuroepithelium (Ohnuma and Harris, 2003). Polarized NECs are connected to both inner 
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(apical = future ventricular) and outer (basal = future pial) surfaces at which they will 
generate the ventricular zone (VZ) and cortical plate (CP) (Stiles and Jernigan, 2010). 
After a phase of symmetric, self-renewing proliferations (around embryonic day 9 (E9) in 
mouse cortical development) enlarging the forebrain progenitor population, NECs acquire 
more fate-restricted identity and convert to apical radial glia cells (aRG; around E11). 
These aRG also undergo IKNM and keep their apico-basal polarity (see 1.1.3.) and 
connections to both ventricular and pial surface. As neural progenitor cells (NPCs), they 
continue to increase the founder stem cell pool in the VZ by symmetric divisions until E13, 
and then switch to more asymmetric divisions to produce neurons directly (direct 
neurogenesis) or via basal intermediate neural progenitors (bIPs; indirect neurogenesis). 
Multipolar bIPs delaminate from the apical and basal surface and form an additional 
neurogenic zone, the subventricular zone (SVZ) (Götz and Huttner, 2005; Lui et al., 2011; 
Taverna et al., 2014).  
Neural progenitors in the VZ and SVZ, located adjacent to the lateral ventricles of the 
mammalian brain, generate excitatory projection neurons and inhibitory interneurons in 
distinct regions (Fig. 1A). In mouse, excitatory neurons are generated from aRG and bIPs 
in the dorsal VZ and SVZ (Fig. 1B). In humans, aRG generate more heterogeneous 
populations of basal proliferative progenitors (BPs): in addition to bIPS, they give rise to a 
second population of RG that lose their apical anchoring. While keeping their basal 
process, these basal radial glia (bRG) move their cell body into the outer SVZ (oSVZ), 
forming an additional germinal zone (Fig. 2). BRG were recently identified as human-
enriched progenitor population that is essential for the expansion of the cerebral cortex 
and the formation of folds, a process called gyrification (Fietz and Huttner, 2010; Hansen 
et al., 2010; Reillo et al., 2011) (see 1.1.5.). 
While excitatory neurons are generated in the dorsal germinal zones, inhibitory 
GABAergic interneurons are specified in the distant medial and caudal ganglionic 
eminences (GEs), which are part of the ventral telencephalon (Anderson et al., 2001) 
(Fig. 1A). Within the mouse GEs, a RG-containing VZ develops, as well as a SVZ that 
contains bIPs and numerous subapical progenitors (SAPs) (Pilz et al., 2013). BIPs and 
SAPs undergo 60-70% of all mitoses found in the GEs, thus expanding the neural 
progenitors and with that the resulting interneuron population prior to its migration. 
Neurogenesis is followed by astrogliogenesis by the same NPCs and towards the end of 
cortical development, the majority of neural progenitors symmetrically divide and give rise 
to two cells that will differentiate, thereby eventually depleting the NPC pool (Caviness 
and Takahashi, 1995). 
 
1.1.2.  NEURONAL MIGRATION 
As postmitotic neurons arise from NSCs and NPCs localized in the dorsal and ventral 
VZs and SVZs, they are required to migrate towards their future location on the outer 
surface of the cortex (Fig. 1A, B). Neuronal migration is thus an essential process for the 
development of the mammalian nervous system (Kriegstein and Noctor, 2004). In 
humans and rodents, a highly coordinated and regulated series of neuronal migration 
events is required to establish the different laminae of the cortex.  
Excitatory neurons of the dorsal cortex have their origin in the dorsal VZ and are thus 
required to migrate in basal direction through different modes of radial migration, which is 
perpendicular to the apical surface (Fig. 1A). At early stages of neurogenesis in mice, 
new-born deep-layer excitatory neurons move basally towards the marginal zone (MZ) by 
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somal translocation. In this RG-independent neuronal migration mode, neurons residing 
in the VZ extend a long radially directed leading process towards the pial surface; the 
leading process is attached to the pial surface and progressively shortens to pull the 
soma up to the developing CP (Nadarajah et al., 2001; Nadarajah et al., 2003). Once the 
cortex becomes thicker, new-born neurons shift to multipolar migration, a slow and 
undirected migration mode which functions through extension and retraction of multiple 
processes, until they reach the intermediate zone (IZ) (Tabata and Nakajima, 2003). In 
the upper SVZ, they undergo a morphological transition from multipolar to bipolar shape 
and get oriented for radial migration. Neurons then begin directed radial migration to the 
CP, using both glia-independent somal translocation and RG-dependent locomotion (Fig. 
1B). Locomoting neurons use RG fibers as a migratory scaffold (Nadarajah et al., 2001; 
Rakic, 1972), attaching to their basal process, and move through the thickness of the 
developing CP. Migration along RG represents the most prominent mode of migration to 
the CP (Rakic, 2009). Bipolar locomoting neurons bear a leading process, preceded by a 
growth cone that explores the microenvironment, and a thin training process, which will 
become their axon (Noctor et al., 2004). In a cyclic, saltatory movement pattern, the 
leading process extends and swells before the nucleus is pulled up into the leading 
neurite and, finally, the trailing process is retracted before a new cycle begins. The 
nuclear movement, called nucleokinesis, is coupled with movement of centrosomes within 
the neurons (Marín, 2013), which position ahead of the nucleus to pull it upward (see also 
1.1.3) (Ayala et al., 2007). 
On their way towards the pia, attracted by Cajal Retzius cells in the MZ, waves of 
locomoting neurons pass earlier-born ones, thus forming the six layers of the cortex in a 
birth-date-dependent and inside-out manner (Sun and Hevner, 2014). During this 
lamination, migrating neurons sense local environmental cues to establish their layer fate 
(Kriegstein and Noctor, 2004), such as the extracellular matrix (ECM; secreted 
macromolecules serving cell-cell communication, cell adhesion, proliferation and 
differentiation (Long and Huttner, 2019)) glycoprotein reelin, produced by Cajal Retzius 
neurons, that is crucial for neuronal correct positioning (D’Arcangelo et al., 1995). 
Beneath the MZ, excitatory neurons switch to RG-independent terminal translocation, 
resembling early somal translocation, to reach their final position within the CP where 
they terminate their migration (Sekine et al., 2011). 
Inhibitory GABAergic interneurons initially migrate tangentially, that means in parallel to 
the ventricular surface, in several streams over long distances from their origin in the 
ventral telencephalon into the cerebral cortex (Fig. 1A). At early and mid-embryonic 
stages, MGE-derived streams of interneurons enter the dorsal CP through the MZ and 
subplate and through the SVZ and lower IZ, respectively. At late embryonic stages, a 
MGE-derived stream enters the dorsal cortex through the MZ, while a LGE-derived one 
crosses through the SVZ (Marín, 2013). In the cerebral cortex, interneurons switch to 
radial migration to disperse and integrate into the various cortical layers (Fig. 1B) 
(Anderson et al., 1997; Peyre et al., 2015; Silbereis et al., 2016; Wonders and Anderson, 
2006). Remarkably, although the distance that they need to overcome is quite different, 
excitatory projection neurons and inhibitory interneurons generated at the same time will 
ultimately reach the same layer in the CP. This was suggested to originate from their 
ability to sense the same layer-fate determining microenvironmental cues (Marín and 
Rubenstein, 2003).  
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An additional route of tangential migration goes from the LGE to the olfactory bulb and 
persists into adulthood in mouse, where it is called rostral migratory stream (Kriegstein 
and Noctor, 2004).  
Ultimately, once neurons have reached their final position within the CP, they differentiate 
and establish dendritic and axonal connections characteristic of mature cortical neurons 
(Ohnuma and Harris, 2003). 
The correct establishment of the cortical layers by neuronal migration is tightly controlled 
by a variety of extracellular and intracellular signals that regulate the actin and 
microtubule cytoskeleton, as well as their dynamics and interplay (Stouffer et al., 2015). 
The following paragraphs are thus dedicated to the cytoskeleton and associated proteins, 
as well as their regulation by posttranslational modifications (PTMs). 
 
 
 
Figure 1: Mammalian cortical development exemplified in the mouse. A, Schematic of a 
coronal section of the early developing anterior telencephalon of the mouse at E14 as example 
mammal, showing neurogenic ventricular zones and routes of neuronal migration. The black 
dotted box is enlarged in panel B. B, Schematic of the cell composition of the developing mouse 
cerebral cortex showing radially migrating excitatory neurons and interneurons that enter the 
cortex tangentially and then switch to radial migration within the dorsal cortex (Abbreviations: Ctx, 
cerebral cortex; CP, cortical plate; GEs, ganglionic eminences; E, embryonic day; IZ, intermediate 
zone; LGE, lateral ganglionic eminence; MGE, medial ganglionic eminence; MZ, marginal zone; 
SP, subplate; Str, Striatum; SVZ, subventricular zone, VZ, ventricular zone). Adapted from 
(Buchsbaum and Cappello, 2019) with permission from Development. 
 
 
  
INTRODUCTION 
5 
 
1.1.3. CYTOSKELETON AND ASSOCIATED PROTEINS IN 
NEURODEVELOPMENT 
We have seen that neurodevelopment requires precise control of behaviors of different 
cell types. Control of adhesion, morphology, proliferation, motility, intracellular transport, 
and many other processes is exerted via pathways ultimately converging on cytoskeletal 
regulation. Here, the neurodevelopmental functions of the RG and neuronal cytoskeletal 
components actin and microtubules (MTs), as well as their associated proteins, shall be 
introduced. Many aspects described here will set the basis for the studies presented in 
Chapter 3 and, especially, in Chapter 4. Some processes of neurogenesis and neuronal 
migration touched upon above will be explained in more detail in the following, but only 
few examples of molecules were chosen for each described function as an extensive 
review would overshoot the mark of this introduction. 
Actin, microtubules, and associated proteins. The actin cytoskeleton is engaged in 
the movement of cellular components such as vesicles and organelles, in cell signaling, 
and in the establishment and maintenance of cell junctions and cell shape. Actin- 
associated proteins regulate the formation of actin filaments (F-actin: filamentous actin) 
from monomeric globular actin (G-actin), such as small GTPases like Rho GTPases (e.g. 
RhoA, Cdc42, and Rac1), which function as master regulators of the cytoskeleton 
(Cappello, 2013; Gonzalez-Billault et al., 2012). They modulate and support the actin 
cytoskeleton in its diverse functions in cell polarity, adhesion, division, and migration (Lian 
and Sheen, 2015). While for example RhoA and Cdc42 are essential for the assembly 
and stability of localized actin cables, F-actin binding and crosslinking filamins are 
responsible for anchoring membrane proteins to the actin cytoskeleton (Gorlin et al., 
1990). The scaffolding protein filamin-1 (FLNA), in turn, has a huge number of known 
interaction partners including cell adhesion proteins (integrins) and cell cycle regulators 
(Lian and Sheen, 2015). Actin fibers additionally serve cargo transport, which is mediated 
by myosins (Semenova et al., 2008).  
The MT cytoskeleton is built by internally polarized tubes assembled from α- and β-
tubulin heterodimers and acts as physical support to shape the different cell types of the 
developing and adult brain. MTs originate from MT organizing centers like the 
centrosome and from there reach into the fine cell structures such as neuronal 
processes. They function not only as structural scaffold, though – they serve as tracks for 
directed transport and as transducers of force generated by MT-based motors, which in 
turn play important roles in diverse processes such as nucleokinesis and protrusion and 
retraction of processes (Sakakibara et al., 2013). Cargo transport along MTs functions 
through ATP-hydrolyzing minus-end directed dynein motors and (mostly) plus-end 
directed kinesins, all of which influence MT dynamics and are pivotal in neuronal 
morphogenesis and migration. Mutations in tubulin genes and such affecting genes 
encoding MT-related proteins lead to a spectrum of brain defects and disorders 
summarized with the term “tubulinopathies” (see also 1.2.2). The stability and dynamics 
of the MT cytoskeleton is regulated by “classical”, e.g. MAP1A, MAP1B, MAP2 and Tau 
(MAPT), and “non-classical” microtubule-associated proteins (MAPs), e.g. Lis1, Dcx, 
Ndel1, dynein complex components, and dynactin (Dehmelt and Halpain, 2004; Moores 
et al., 2004; Morris et al., 1998).  
The coordination between actin and MT cytoskeleton is further regulated by crosslinking 
proteins. Neuron-specific MAPs like MAP1B and MAP2, for instance, can bind both 
microtubules and F-actin (Dehmelt and Halpain, 2004). 
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Role in polarity and adherens junctions. As already mentioned, NECs and derived 
aRG are bipolar cells. Their polarity and morphology is generated by differential 
distribution of cytoskeletal components and of cell fate determining proteins such as 
strictly apically localized Notch (Del Bene et al., 2008). F-actin fibers are selectively 
concentrated at the apical side along the ventricles where, together with adhesion 
molecules, they form a tight but dynamic belt. These apical cell-cell connections, 
consisting of membrane-spanning cadherins (such as N-cadherin), cytosolic catenins 
(e.g. β-catenin and α-E-catenin) and actin microfilaments (Mège et al., 2006), are called 
tight junctions in the case of NECs and – with different molecular constitution – adherens 
junctions (AJ) in aRG. For the function of aRG, AJs and the apico-basal polarity they 
uphold play a crucial role (Florio and Huttner, 2014). This becomes obvious from 
interfering with AJ components, which results in drastic changes in cerebral development 
due to disruption of the RG scaffold integrity (Kadowaki et al., 2007; Schmid et al., 2014; 
Yamamoto et al., 2015) (see 1.2.2). Actin filaments and associated proteins regulate 
these cell-cell adhesions and serve as binding partners for polarity proteins. The following 
examples shall illustrate this. Numb, for instance, interacts with E-cadherin to regulate its 
localization to cell-cell junctions and engages the polarity complex Par3-aPKC-Par6 by 
binding to Par3 (Wang et al., 2009b). Actin associated Rho GTPases are involved in 
remodeling of the actin cytoskeleton (Etienne-Manneville, 2004; Gonzalez-Billault et al., 
2012), together with their effectors, such as non-muscle myosin II, which is indispensable 
both in cell polarity and adhesion (Ma and Adelstein, 2014). Lgl1, an interactor of both 
non-muscle myosin II and Par6 in lateral junctions, is needed for AJ integrity, cell polarity 
and with that also for RG proliferation, morphology, and function as locomotion scaffold 
(Assémat et al., 2008; Zhang et al., 2019). Afadin (encoded by Mllt4) is another AJ-to-
actin scaffolding protein important for the maintenance of AJs, RG apical endfeet and the 
RG scaffold (Yamamoto et al., 2015). The MT cytoskeleton is also associated with apical 
AJ: MT-based transport of (N-)cadherin-containing vesicles by kinesin supplies and 
supports AJs (Mary et al., 2002).  
In addition to cell-cell anchoring and polarity maintenance, AJ proteins can be directly 
involved in signal transduction: AJ-localized β-catenin, which links cadherins to actin 
filaments, is at the same time an essential intracellular component of the Wnt signaling 
cascade in RG that regulates cell fate determination of progenitor self-renewal versus 
neuronal differentiation in the developing forebrain (Hirabayashi et al., 2004). In the study 
presented in Chapter 2, this pathway was identified as misregulated, leading to reduced 
NPC self-renewal. 
Primary cilia. Another structure involved in apico-basal polarity of aRG that shall be 
briefly introduced here are primary cilia. These microtubule-based protrusions are 
maintained apically in aRG, where they can sense signals from the cerebrospinal fluid in 
the ventricles (Johansson et al., 2013). Primary cilia function as key integrators of such 
extracellular ligand-based signals, e.g. the neurodevelopmental sonic hedgehog and Wnt 
pathways. Arl13b, a small GTPase enriched in primary cilia, plays a critical role in the 
establishment of RG polarity (Higginbotham et al., 2013). Through these functions, 
primary cilia are involved in the regulation of neuronal cell fate, migration and 
differentiation (Guemez-Gamboa et al., 2014; Han et al., 2008). In addition to aRG in the 
developing cortex, motile and immotile (primary) cilia are present on cells of nearly every 
major body organ. To this end, disruptions of genes engaged in the cilia structure, their 
anchoring in basal bodies, centrosomes, or involved in their sensing and signaling ability 
lead to disorders affecting diverse organ systems, summarized with the term 
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“ciliopathies”. This emphasizes the importance of the cilium in development and 
homeostasis (Goetz and Anderson, 2010). 
Role in proliferation and cell fate. As indicated earlier, cytoskeletal proteins also 
regulate cell proliferation and cell fate specification (Taverna et al., 2014), e.g. by 
symmetric versus asymmetric inheritance of cell fate determining proteins like Notch. 
Distribution of intracellular signals works via actin polarization and actin-dependent 
trafficking, as well as degradation of cell fate determinants like integrins and cadherins 
(Cappello et al., 2006). For example, conditional deletion of RhoA and Lgl1 causes 
accelerated NPC proliferation and reduced cell-cycle exit (Katayama et al., 2011; Zhang 
et al., 2019) and so does acute downregulation of the cadherins Fat4 and Dchs1 
(Cappello et al., 2013). Conditional deletion of Cdc42 results in increased basal mitoses, 
which induces aRG-to-BP fate change (Cappello et al., 2006).  
MTs function during cell division in the segregation of the chromosomes (Wloga et al., 
2017). MT-based motors additionally participate in the up-and-down movement of the 
nucleus during IKNM of aRG with basally and apically directed movements involving 
kinesins and dyneins, respectively (Taverna and Huttner, 2010).  
While symmetric proliferative division of NSCs and NPCs results in two equal daughter 
cells through symmetric inheritance of polarity factors, asymmetric division gives rise to 
IPs or neurons directly. The first step following asymmetric neural progenitor division is 
the loss of the apical connection, a process called delamination. Delamination was shown 
to involve AJ disassembly and abscission mediated, among others, by acto-myosin 
(Kasioulis et al., 2017). The centrosome translocates and both actin and MT cytoskeletal 
components and their cross-linker drebrin orchestrate delamination through actin fiber 
constriction and MT condensation (Kasioulis et al., 2017). Recently, it was shown that the 
centrosomal protein AKNA is also required during the delamination process of aRG: As 
an organizer of centrosomal microtubule nucleation and growth, high levels of AKNA 
promote the detachment from neighboring cells to trigger their differentiation to SVZ BPs 
and it further regulates the exit from the SVZ (Camargo Ortega et al., 2019). 
Role in neuronal migration. The polarisation and locomotion of new-born neurons 
necessitates a complete remodeling of the cell morphology. For polarization, for instance, 
N-cadherin, reelin, and Rap1 are needed to orient multipolar neurons (Jossin and 
Cooper, 2011), Cdk5 and FlnA are required for neuronal multipolar-to-bipolar transition 
(Nagano et al., 2004), and Cdc42 forms a complex with the polarizing factors Par3 and 
Par6 and recruits these to the leading edge to guide the reorientation of the MTs and 
centrosome (Lian and Sheen, 2015). 
Neuronal migration represents a highly dynamic process involving adhesion, extension, 
protrusion of filopodia and lamellipodia at the leading edge, and formation of a contractile 
structure for retraction of the rear edge. All these processes again require remodeling of 
the cytoskeleton and actin and MTs function in close association (Rottner and Stradal, 
2011). In the tip of growth cones, actin cytoskeletal remodeling results from sensing of 
extracellular signals to determine the direction of migration. Microtubules also extend into 
the periphery, where they interact with Rho GTPases, which then produce changes in 
actin dynamics (Dehmelt and Halpain, 2004). Actin, in turn, mediates the alignment of 
MTs from the growth cone down to the neurite shaft with the help of MAPs that also bind 
actin (Dehmelt and Halpain, 2004; Schaefer et al., 2002). Moreover, MT-based transport 
serves the shuffling of membrane to the leading edge for its extension (Ayala et al., 
2007).  
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For the upward movement of the nucleus, a process called nucleokinesis, MTs and MT-
based motors are highly important. Originating at the centrosome that gets positioned in 
front of the nucleus, MTs extend to and engulf the nucleus in a MT cage by attaching to 
the nuclear envelope, which is facilitated by Ndel1 (Guo et al., 2006), and on the other 
side extend into the leading process (Tsai and Gleeson, 2005; Xie et al., 2003). The 
centrosome moves up into the neurite and, engaging dynein, polarized MTs in the leading 
edge produce a pulling force onto the nucleus (Sakakibara et al., 2013; Tanaka et al., 
2004). The centrosome- and MT-associated proteins Lis1, Ndel1 and dynein promote the 
integrity of MT cytoskeleton during nucleokinesis (Sapir et al., 1997). At the same time, 
below the nucleus, RhoA promotes the retraction of the rear end of the neuron and 
advances the translocation of the nucleus and, via contraction of acto-myosin, generates 
of a pushing force (Ayala et al., 2007; Lian and Sheen, 2015; Schaar and McConnell, 
2005).  
For the formation of short-lived focal adhesion contacts of the neuronal leading edge 
membrane on the RG scaffold membrane (or in translocating neurons for adhesion to 
ECM components), actin and associated components are also needed (Lian and Sheen, 
2015). Local disruption of actin fibers along the leading process therefore disrupts somal 
translocation and neuronal migration (He et al., 2010). In mice lacking Flna, for example, 
migration into the CP is slower and their adhesion to the ECM is impaired (Zhang et al., 
2013). MAPs also act synergistically to support neuronal migration - and in mouse 
deletion mutants, both neuronal migration and neuronal morphology are disrupted 
(Dehmelt and Halpain, 2004). 
Role in intracellular trafficking. Cytoskeleton-based intracellular transport processes 
are required throughout all the described processes of RG polarity and AJs, polarization 
of neurons for locomotion, and RG-guided or -independent neuronal migration 
(Rodriguez-Boulan et al., 2005). Dynamic and directional vesicle trafficking is involved in 
the transmission of extracellular signals into the cytoplasm and nucleus, for degradation 
of cell cycle associated proteins, for exocytosis. And cytoskeleton-associated proteins 
again mediate this trafficking. Rho GTPases, for example, act in endocytosis - the 
internalization of plasma membrane and extracellular molecules (Ridley et al., 2003). 
They bind FlnA and direct various aspects of intracellular actin dynamics, which are 
required for endosomal vesicle transport (Cappello et al., 2006; Katayama et al., 2011). 
Vesicle transport from the Golgi complex to the plasma membrane for exocytosis requires 
filamins, myosins and Cdc42 for myosin-driven movement along actin filament tracks. 
The interplay of FlnA with the guanine exchange factor Big2 orchestrates this process 
(Zhang et al., 2012a). The rate of intracellular trafficking thus influences the turnover of 
proteins and membrane towards the leading edge and with that the migration speed of 
neurons.  
Role of SPG11. The tight regulation of the cytoskeleton and its associated proteins 
becomes especially obvious when they are dysregulated as occurs in 
neurodevelopmental disorders such as NMDs (see Chapter 1.2; Chapter 4) and mental 
disorders or in neurodegenerative diseases. A spectrum disorder classified as 
neurodegenerative is Hereditary Spastic Paraplegia (HSP). HSPs are clinically and 
genetically heterogeneous progressive gait disorders with mutations identified in more 
than 60 genes that have been linked to HSPs with both dominant and recessive 
inheritance modes, and overlapping phenotypes between HSPs and other 
neurodegenerative disorders (Boutry et al., 2019; Elert-Dobkowska et al., 2019). 
Pathophysiological mechanisms include abnormal intracellular transport, changes in 
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endoplasmic reticulum (ER) shape, defects in lipid metabolism, and abnormal lysosome 
physiology, autophagy, myelination, or mitochondrial function. All of these ultimately lead 
to the loss of primary motor neurons and other neurological conditions (Boutry et al., 
2019; Crosby and Proukakis, 2002). Due to the length of their axons, which require 
constant maintenance, corticospinal motor neurons are particularly sensitive to 
disruptions in energy metabolism, cytoskeletal or vesicle trafficking processes. In the 
study presented in Chapter 2, we focused on HSP caused by mutations in Spastic 
Paraplegia Gene 11 (SPG11), coding for spatacsin. Mutations in SPG11 account for 
about 25% of autosomal recessive HSP cases and progressive spastic paraparesis co-
occurs with thin corpus callosum, cortical atrophy and mental retardation, and may also 
cause rare forms of Charcot-Marie-Tooth disease and progressive juvenile-onset 
amyotrophic lateral sclerosis (Faber et al., 2018; Mishra et al., 2016). Even cases of 
association with juvenile-onset parkinsonism were reported (Anheim et al., 2009). The 
affected protein, spatacsin, contains a transmembrane domain and colocalizes with 
synaptic vesicles, MTs and actin in both neuronal axons and dendrites, even in the most 
distal tips of filopodias and membrane protrusions (Pérez-Brangulí et al., 2014). 
Functionally, spatacsin was implicated in anterograde axonal vesicle transport processes 
(towards the plus end of MTs) by influencing kinesin expression and MT turnover (Pérez-
Brangulí et al., 2014). In absence or upon disruption of spatacsin, membranous deposits 
accumulate within axonal processes (Pérez-Brangulí et al., 2014) and the clearance of 
lipids from lysosomes is disturbed (Branchu et al., 2017). In addition to engagement in 
the endolysosomal pathway, a critical role for spatacsin in autophagy was identified 
(Vantaggiato et al., 2019).  
Most research has been conducted on the role of SPG11 in the dying back of axons that 
can start as early as in childhood. In our study, we added findings about the role of 
SPG11 in neurodevelopment, which was suggested from patients’ thin cortical callosum 
and cortical atrophy. Preceding work identified transcriptional dysregulation of genes 
associated with cortical development, including callosal developmental pathways and 
maintenance of neuronal homeostasis, in patient-derived cells, which led to compromised 
NPC proliferation and neurogenesis (Mishra et al., 2016).  
This excursion towards the published study presented in Chapter 2 highlights again the 
role of cytoskeleton-based vesicle trafficking in cortical development and maintenance 
(Pérez-Brangulí et al., 2018). 
Role in terminating migration. Once migrating neurons reach their destined position, 
they are required to stop migration and establish neuronal networks. Examples of 
extracellular stop signals are laminin and reelin: reelin acts through receptor-mediated 
activation of intracellular pathways which ultimately stabilize the actin cytoskeleton 
(Frotscher, 2010) and facilitate the detachment of migrating neurons from the RG scaffold 
(Ayala et al., 2007). The importance of basement membrane components and receptors 
for their sensing becomes apparent in disorders in which neurons fail to stop their 
migration and hence overmigrate (see 1.2.2). 
Regulation of the cytoskeleton. The tight regulation of the cytoskeleton was already 
pointed out in the context of the numerous intracellular actin- and MT-associated 
proteins, examples of which were brought in this section. Extrinsic mechanisms 
influencing the organization and dynamics of actin and MT cytoskeleton are, for example, 
locally secreted ECM components such as reelin and laminin (see above). Laminin and 
its integrin receptors play a role in the formation of the basal membrane and the 
anchorage of RG endfeet (Marín and Rubenstein, 2003). Additionally, long distance 
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guidance molecules such as Netrins, Semaphorins and Slits influence neuronal motility 
by eliciting intracellular responses that ultimately influence the actin and MT cytoskeleton. 
Slit2 and its receptor Robo, for example, guide both tangential and radial migration of 
neurons via modification of an intracellular pathway that converges on actin regulation 
(Ayala et al., 2007). Furthermore, neurotransmitters like GABA and neurotrophins 
represent such extracellular regulators (Behar et al., 2001; Gallo and Letourneau, 2000). 
Intracellularly, especially MTs and associated proteins are heavily regulated by PTMs.  
 
1.1.4. POSTTRANSLATIONAL MODIFICATIONS REGULATE 
CYTOSKELETAL DYNAMICS  
Many different tubulin genes with tissue- and cell state specific expression lead to 
diversity in MTs: There are 7 α- and 8 β-tubulin genes known in mice. Alternatively to 
hollow tube-like MTs, tubulins can build other architectures such as cilium scaffold, basal 
body or centrioles. To acquire different organizations and dynamics, tubulins have to 
differ in their properties extending the gene level (Wloga et al., 2017). In addition to the 
regulation of MT growth, dynamics and stability by MAPs, as was mentioned above (see 
1.1.3), PTMs of tubulins and MAPs further contribute to this heterogeneity, increasing the 
number of “proteoforms” on top of gene expression regulation (Aebersold et al., 2018; 
Song and Brady, 2015). The numerous PTMs can co-occur and a huge effort has been 
invested to understand the “tubulin code” of site-specific MT PTMs in defined intracellular 
locations (Yu et al., 2015). Locally and temporally defined PTMs act as molecular 
landmarks for proteins that can alter their structure and function, thus increasing the 
functional diversity of target proteins. These include reversible and irreversible “simple” 
site-specific PTMs like acetylation and phosphorylation and “complex” branched ones like 
polyglutamylation and ubiquitination (Aebersold et al., 2018). Most tubulin PTMs target 
the most variable C-terminal region which lies on the outer surface of MTs and acts in 
binding MT-interacting proteins. This already indicates a regulation of MT interaction with 
its binding partners by PTMs (Ayala et al., 2007). Molecular motor proteins also serve 
many different functions in cargo transport, regulation of MT dynamics, and as mitotic 
motors. In addition to a plethora of different genes encoding the components of these 
giant molecular complexes, their mechano-chemical behavior is also modified by PTMs 
(Muretta et al., 2018). The same accounts for actin: additionally to above mentioned non-
covalent regulation of the actin cytoskeleton by associated proteins, widely employed 
covalent actin PTMs have been identified that regulate the monomer-polymer equilibrium 
and organization of actin and have been linked to different normal and disease processes 
(Terman and Kashina, 2013). In the following, some cytoskeletal PTMs shall be 
introduced together with examples of their function. 
Tubulin tyrosination and detyrosination. Most α-tubulins contain a terminal tyrosin. It 
is needed to form heterodimers with β-tubulins to be assembled into MTs and tyrosinated 
tubulin (tyr-tub) is thus enriched in newly formed, labile MTs: Highly dynamic MTs in 
growth cones are rich in tyr-tub. For MT stabilization, the terminal tyrosin is then 
reversibly removed to give rise to detyrosinated tubulin (detyr-tub), which is abundant in 
proxismal axon shaft segments and in differentiated neurons that contain stable, long-
lived MTs (Song and Brady, 2015). Functionally, the tyrosination state of MTs influences 
their interaction with motor proteins. Detyrosination of α-tubulin is for example specifically 
required for robust kinesin-2 motility (Sirajuddin et al., 2014).  
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In a next step, the new terminal glutamate can also be irreversibly removed to result in 
Δ2-tubulin (missing the last 2 amino-acids). Δ2-tubulin is enriched in long-lived MTs in 
neurons, centrioles and primary cilia and may represent > 35% of all tubulin in the brain 
(Paturle-Lafanechère et al., 1994). 
Actin, tubulin and motor acetylation. Acetylation of tubulin occurs on the canonical site 
Lys40 in α-tubulin, which localizes to the luminal side of MTs, and is distributed along 
MTs. Like detyr-tub, acetylated tubulin (ac-tub) accumulates in postmitotic cells and is 
associated with long-lived, stable MTs (Song and Brady, 2015). In differentiating neurons, 
both ac-tub and tyr-tub are thus not uniformly distributed: the ratio of ac-tub over tyr-tub is 
highest in the shaft of the future axon, suggesting a role for these PTMs in neuronal 
polarization (Witte and Bradke, 2008). Furthermore, ac-tub is absent from highly dynamic 
MTs in growth cones during development, but is increasingly found in the distal axon and 
presynaptic regions with neuronal maturation (Song and Brady, 2015).  
The binding of kinesin-1 occurs preferentially on detyr- and ac-tub, providing a potential 
basis for spatial targeting of kinesin-1-based cargo transport (Dunn et al., 2008). The MT- 
severing protein katanin preferentially binds to and further severs acetylated MT domains 
(Song and Brady, 2015). Motor proteins can also be acetylated themselves, which may 
fine-tune their motor behavior to fit specific physiological need. For example, acetylation 
of kinesin-5 family member Eg5 in mitosis renders it more resistant to dissociation from 
MTs and increases its motor performance under load, while increasing its propensity to 
stall – properties required for slow spindle pole separation during mitosis (Muretta et al., 
2018). 
Acetylation of actin has been identified at many sites throughout the protein, but only N-
terminal acetylation has so for been functionally implicated: The maturation and 
maintenance of actin’s structural and functional properties may require N-terminal 
acetylation and the role of actin in cell movement and intracellular trafficking was 
suggested to be modulated by acetylation (Terman and Kashina, 2013).  
Tubulin polyglutamylation, polyglycylation and polyamination. C-terminal domains 
of α- and β-tubulins can be modified by additions of one or more glutamate or glycine 
residues to amino acid side chains. While glycylation is restricted to tubulin in primary 
cilia, where it was suggested to play a role in cilia assembly and maintenance, 
polyglutamylation is abundant in neurons in general, where it increases over development 
and is specifically enriched in cilia and centrioles (Okada et al., 2004; Song and Brady, 
2015). Polyglutamylation adds negative charge to the modified tubulin C-terminals and 
differentially alters the binding efficiency of different MAPs, such as Tau, MAP2, MAP1A 
and MAP1B. Their binding depends for example on the length of the polyglutamyl chain 
and thus, polyglutamylation functions in selective MAP recruitment (Bonnet et al., 2001). 
The MT severing protein spastin specifically binds polyglutamylated domains of MTs in 
the absence of tyr-tub (Song and Brady, 2015).  
Synaptic vesicle transport by motor proteins is also regulated by polyglutamylation and 
local changes in this PTM may serve to target selected cargoes (Bonnet et al., 2001; 
Ikegami et al., 2007; Maas et al., 2009). For example, kinesin-1 motility on neuronal β3-
tubulin is increased by polyglutamylation (Sirajuddin et al., 2014).  
Polyamination, in contrast, adds positive charge to MTs and was identified as yet another 
PTM that protects axonal MTs from depolymerization (Song and Brady, 2015).  
Phosphorylation of cytoskeleton(-associated) proteins. Phosphorylation is one of the 
most common PTMs and is more long-lived than other cytoskeletal PTMs (Yu et al., 
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2015). The phosphorylation of tubulins occurs both in soluble and polymerized states and 
has been implicated in polymerization efficacy and in MT interaction with membranes 
(Song and Brady, 2015). Actin phosphorylation can both induce and inhibit its 
polymerization and was linked to F-actin redistribution (Terman and Kashina, 2013).  
Moreover, molecular motors get functionally regulated by phosphorylation: 
phosphorylation of dynein heavy chains influences motor properties, while 
phosphorylation of intermediate chains may modulate dynein interaction with its vesicle 
cargoes (King, 2000) or with Ndel1, with phosphorylation inhibiting Ndel1 interaction and 
contribution to dynein force generation (Gao et al., 2015). Dynein ATPase activity is again 
regulated by phosphorylation, for example by dynactin-dependent phosphorylation of 
dynein light chain (Kumar et al., 2000).  
Especially phosphorylation of MAPs has received substantial attention, though: the 
function of MAPs in stabilization of MTs is dependent on their phosphorylation status. The 
number of identified kinases and their overlapping targets is constantly growing, which 
makes a holistic overview impossible in the context of this thesis. To this end, only a few 
examples of this complex functional fine-tuning shall be brought up here.  
MAP1B, which is highly expressed during neuronal development, associates mostly with 
dynamic MTs such as in distal parts and growth cones of growing axons. This interaction 
is regulated by phosphorylation (Tortosa et al., 2013): Different kinases, such as Cdk5, 
GSK3 and CK2 phosphorylate MAP1B in response to extracellular cues like Netrin. This 
results in an increasing gradient of phosphorylated MAP1B towards the growth cones, 
with phosphorylated MAP1B showing increased interaction with MTs (Ayala et al., 2007; 
Riederer, 2007). The interaction of MAP1B with MT plus-end binding proteins EB1/3 is in 
turn inhibited by MAP1B phosphorylation, which releases EB1/3 to interact with and 
stabilize MTs in growth cones (Tortosa et al., 2013).  
MAP4, which is present in proliferating cells, binds to and stabilizes MTs. This interaction 
again depends on phosphorylation of MAP4: Only phosphorylated MAP4 can support 
increased MT turnover/dynamics at the mitotic stage through its MT polymerization 
function and phosphorylation site mutants show impaired MT binding and altered 
progression into and through cell division (Chang et al., 2001).  
The kinase Cdk5 phosphorylates numerous key cytoskeletal proteins apart from MAP1B, 
for example Tau, Ndel1, DCX, several actin regulatory proteins, other kinases like the 
focal adhesion kinase FAK, and β-catenin. Thereby, Cdk5 regulates many different 
aspects of cellular functions (Ayala et al., 2007). Phosphorylation of DCX by GSK3β or 
Cdk5 decreases its association with MTs (Ayala et al., 2007; Hur and Zhou, 2010). So 
does the phosphorylation of Tau: in the presence of GSK3β, Tau’s MT binding and 
stabilization properties are reduced (Lovestone et al., 1996). 
The cell adhesion protein β-catenin can also be phosphorylated by GSK3β, which triggers 
its proteasome-dependent ubiquitination and degradation. Another component of the β-
catenin destruction complex is Axin, whose intracellular localization is in turn regulated by 
Cdk5-mediated phosphorylation (Ye et al., 2015). Interestingly, the activity of Cdk5 is 
spatially restricted to the radial migration zone, where it phosphorylates also RapGEF2, 
which is essential for the formation of a radially oriented leading process and regulation of 
N-cadherin-mediated adhesion of the migrating neuron to the RG scaffold during 
multipolar-to-bipolar transition (Ye et al., 2014).  
With these examples of protein function regulation by phosphorylation, we are equipped 
with the basic knowledge for the research studies presented in Chapter 2 and Chapter 4, 
in which changes in phosphorylation of different cytoskeleton-associated and signalling 
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proteins were detected and suggested to mechanistically contribute to neurodevelop-
mental disorders. 
Protein ubquitination, sumoylation and neddylation. Ubiquitination (also termed 
ubiquitylation) and the closely related sumoylation and neddylation are complex PTMs 
that have been implicated, among others, in CNS function. Ubiquitin and SUMO are 
evolutionary conserved polypeptides whose polymers can be reversibly conjugated to 
mark target proteins for proteasomal degradation. Addition of monomers, though, may 
affect enzymatic activity, protein interactions and protein transport or localization. 
Sumoylation of tubulins, for example, modifies MT functions such as intracellular 
trafficking (Song and Brady, 2015). Sumoylated actin is retained in the nucleus, while 
mono-ubiquitination of actin increases its stability and regulates its subcellular localization 
(Terman and Kashina, 2013). The ubiquitin ligase parkin binds and ubiquitylates 
(misfolded) tubulin dimers, which leads to increased tubulin degradation and recycling 
(Ren et al., 2003).  
A set of histone PTMs, targeting the N-termini that protrude out of the nucleosomes, has 
been described and functionally categorized in a “histone code” that influences cellular 
outcome (Cobos et al., 2018). Among those, ubiquitination of histone H2A, which is 
involved in regulation of the accessibility of DNA for epigenetic modifications, for DNA 
damage and repair response, has been implicated in brain development. For instance, it 
acts in pluripotency, differentiation and cell lineage commitment (Srivastava et al., 2017).  
Neddylation is abundant in neurons and regulates synaptogenesis during development 
and in mature neurons, where it promotes spine stability. Among the abundant synaptic 
targets of neddylation is the postsynaptic scaffolding protein PSD95 and this PTM is 
required for PSD95-mediated spatial organization of postsynaptic proteins (Vogl et al., 
2015).  
AMPylation – a novel PTM. AMPylation, also termed adenylylation, is the covalent 
addition of adenosine monophosphate (AMP) to hydroxyl side chains of serine, threonine, 
or tyrosine residues by enzymes containing a conserved Fic domain (Engel et al., 2012). 
The AMPylation activity of Fic domain containing proteins is regulated by a conserved 
mechanism of an auto-inhibitory loop that obstructs ATP-binding (Engel et al., 2012). 
Alternative (non-Fic) adenylyltransferases are the bacterial glutamine synthase 
adenylyltransferase and the recently discovered pseudokinase SelO (Kingdon et al., 
1967; Sreelatha et al., 2018).  
AMPylation is more and more recognized as tuner of diverse signaling pathways 
including regulation of bacterial pathogenesis, drug tolerance, cellular trafficking, and 
prokaryotic and eukaryotic stress response (Casey and Orth, 2018). In bacteria, in which 
more than 1000 Fic domain containing proteins were identified, AMPylation serves for 
example bacterial toxicity: secreted Fic proteins AMPylate mammalian host cell Rho 
GTPases RhoA, Rac1, and Cdc42, rendering them inactive, which leads to cytoskeletal 
collapse (Mattoo et al., 2011; Worby et al., 2009). Host cell endocytosis and exocytosis 
was also found to be altered by bacterial AMPylation of Rab1 (Mukherjee et al., 2011). 
For the sole eukaryotic Fic domain-bearing enzyme FICD/HYPE, which is conserved from 
C. elegans to human, only a few protein targets are known so far that function in 
pathways of gene expression, ATP biosynthesis, and maintenance of the cytoskeleton 
(Broncel et al., 2016). FICD was shown to both AMPylate and deAMPylate the ER 
chaperone BiP, thereby altering its ATPase activity and the downstream activation of the 
unfolded protein response (UPR), making AMPylation a key regulator of ER homeostasis 
via UPR (Preissler et al., 2017b; Sanyal et al., 2015). Cellular expression of the 
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transmembrane protein FICD was – in line with its function in regulating UPR – detected 
in the ER. ER localisation was recently confirmed via a novel labeling and cryo electron 
tomography method (Sengupta et al., 2019). In yeast, Ficd was found to inactivate the 
cytosolic heat shock protein Hsp70, suggesting a function for AMPylation in protein 
homeostasis outside the ER (Truttmann et al., 2017). Further studies found that the 
drosophila Fic catalytic domain can be secreted into the lumen of the secretory pathway 
and that Fic localizes to the surface of glia cells (Rahman et al., 2012). 
Recently, α-synuclein, a pre-synaptic protein involved in Parkinson’s disease, was found 
to be AMPylated by FICD and this modification reduced the neurotoxic aggregation of α-
synuclein (Mattoo et al., 2019). Namely, steric hindrance by the covalently bound AMP 
was suggested to interfere both with α-synuclein mediated membrane permeabilization 
and invasion to the ER and with its fibril formation by aggregation. Thus, AMPylation of 
alpha-synuclein is neuroprotective (Mattoo et al., 2019). In C. elegans models of 
neurodegeneration, chaperone AMPylation was shown to modulate aggregation and 
toxicity of neurodegenerative disease associated polypeptides amyloid-β, polyglutamine-
extended polypeptide, and α-synuclein (Truttmann et al., 2018). Another nervous system 
function of AMPylation was identified in drosophila: Flies lacking Fic were blind due to a 
neurotransmission defect, caused by glia-specific defect in histamine recycling (Rahman 
et al., 2012). 
AMPylation has actually been known for half a century, but due to long-lasting lack of 
methods for its in situ monitoring, its profiling has not been a trivial task (Hedberg and 
Itzen, 2015). Only recent findings have started bringing some light into this black box. In 
the study presented in Chapter 3, we developed a probe to monitor AMPylation under 
physiological conditions and with its help identified a huge number of novel AMPylation 
targets in diverse human cell types including NPCs and neurons, characterized the 
intracellular localization of FICD and AMPylated proteins, and by manipulating levels of 
FICD got an insight into the role of this under-studied PTM in neurodevelopment. 
PTMs in neurodevelopmental and neurodegenerative disorders. PTMs vary with 
time, cell type, subcellular compartment and physiological state (Song and Brady, 2015). 
The diverse PTMs and their functions exemplified in this chapter indicate that 
dysregulation of enzymes responsible for these PTMs or mutations of PTM sites in target 
proteins may result in a diversity of nervous system-related disorders. Again, some 
examples of such disorders shall be given here. 
A role for irreversible oxidant-induced PTMs has been found in the etiology of epilepsy: 
The increase in reactive oxygen species levels during epileptogenesis may lead to 
carbonylation of complex I of the mitochondrial electron transport chain, which causes 
disruptive conformational changes of the active site of complex I and impaired 
mitochondrial ATP production (Ryan et al., 2012).  
Aberrant function or regulation of ubiquitylating enzymes has been associated with 
developmental disorders, cancer, and neurodegeneration (Werner et al., 2017). For 
example, disruptions in the H2A ubiquitination axis were identified as cause of 
neurodevelopmental disorders such as autism and microcephaly (Srivastava et al., 2017). 
Histone PTMs may even contribute to sex-specific differences in the brain during 
development and to different susceptibility and outcome of autism spectrum disorder 
(ASD), schizophrenia and major depressive disorder (Singh et al., 2018). 
A link between histone PTMs and neurodegenerative diseases such as ALS, 
frontotemporal dementia and ataxias has also been identified (Cobos et al., 2018). Parkin 
mutations found in patients with Parkinson’s disease or ALS disable parkin’s 
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ubiquitylation and degradation activity. This causes complexes of parkin and misfolded 
tubulin to accumulate in toxic aggregates (Ren et al., 2003).  
 
Altogether, PTMs thus represent an additional level of regulation, fine-tuning protein 
function, interaction and localization – and adding to the complexity of processes involved 
in cortical development. This stresses the need for good model systems and analysis 
methods to uncover their functions. The following paragraph treats evolution-based 
differences in neurodevelopment between mouse and human, which will lead us to the 
necessity of human model systems of neurodevelopment.  
 
1.1.5. EVOLUTION: DIFFERENCES BETWEEN THE MOUSE AND 
HUMAN NEOCORTEX 
The widely used mouse model shows a variety of common features of neurogenesis, like 
the basic steps required for the generation and the migration of excitatory and inhibitory 
neurons described above (see 1.1.1. and 1.1.2). The great macroscopic differences in 
brain morphologies between mouse and primates including humans, though, suggest that 
specific changes occurred during evolution (Betizeau et al., 2013; Borrell and Reillo, 
2012; Lewitus et al., 2014; Lui et al., 2011). Many studies have highlighted fine 
differences distinguishing the process of neurogenesis in mouse and human, and a 
number of primate- and human-specific mechanisms of neocortical development and 
expansion have recently been identified (reviewed in (Florio et al., 2017)). Some of the 
findings that relate to our current understanding of neurogenesis and neuronal migration 
within the cortex shall be summarized here.  
Key aspects in which the mouse and human neocortex development diverge (Fig. 2) 
include differences in progenitor cell numbers, types and expansion capacity, and in the 
composition of the ECM (Pollen et al., 2015). Strikingly, the human cerebral cortex is 
significantly larger than the rodent cortex based on neuronal numbers. Moreover, it is 
highly folded, has greater complexity, and has acquired higher cognitive functions (Lui et 
al., 2011; Rakic, 2009; Sousa et al., 2017). The expansion of cortical progenitor pools 
and increased neuronal production in humans are the main underlying cellular 
mechanisms of the increased neuronal numbers (Borrell and Reillo, 2012). At the onset 
of neurogenesis, the initial pool of stem and progenitor cells per unit of cortical volume is 
larger, and additionally the neurogenic period is prolonged (Charvet et al., 2011; Hansen 
et al., 2010; Noctor et al., 2004).  
Neurogenesis in humans begins with the expansion of the neuroepithelium and aRG, just 
like in mouse. But there are differences both in human aRG morphology and proliferation 
(Kriegstein and Alvarez-Buylla, 2009; Nowakowski et al., 2016), such as more 
regenerative asymmetric cell divisions compared to non-human primates and mice (Fish 
et al., 2008; Lukaszewicz et al., 2005). After the onset of neurogenesis, human aRG 
divide to give rise to an initial population of bRG, which delaminate from the apical 
surface (keeping their basal process and attachment to the pial surface) and migrate 
basally to give rise to the oSVZ (Fig. 2) (Fietz et al., 2010; Reillo et al., 2011; Wang et al., 
2011). Within the oSVZ, bRG then expand massively through several rounds of division 
before terminal differentiation and make the oSVZ the predominant germinal region in the 
human neocortex, thereby increasing neuronal output and cortical folding and complexity 
(Lui et al., 2011; Nonaka-Kinoshita et al., 2013; Stahl et al., 2013). BRG are pivotal in the 
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evolutionary increase in human cortex size and complexity (Fietz et al., 2010; Hansen et 
al., 2010; Lewitus et al., 2013; Lui et al., 2011). Although the focus was set here on the 
evolutionary and developmental differences between mouse and human brain, it remains 
to be clarified that bRG are not a human-specific cell type but are generally found in 
higher number in gyrencephalic than in lissencephalic species, which led to their 
association to the generation of cortical folds (de Juan Romero et al., 2015).  
Migrating new-born excitatory neurons use the basal processes of bRG as additional 
guides for their radial migration. In addition to radial migration, excitatory neurons in the 
human developing cortex disperse tangentially, thereby increasing the surface area of the 
cerebral cortex (Reillo et al., 2011). The basal process of aRG, on the other hand, is later 
lost in human cortical development, resulting in truncated RG bearing only an apical 
process (Nowakowski et al., 2016).  
The germinal zone in the human oSVZ gets further specified as neurogenic niche by 
human-enriched ECM proteins and growth factors that are produced by bRG (Pollen et 
al., 2015) (Fig. 2). The ECM has been implicated both in neocortical expansion and in 
gyrification (Fietz et al., 2012; Florio et al., 2015; Long et al., 2018). As the ECM was 
already touched upon several times throughout this introduction, a few more words shall 
be spent here on its role. It consists of a complex network of proteins surrounding single 
cells within a tissue. ECM components and their receptors have been implicated in many 
aspects of neurodevelopment: proteoglycans, laminins and integrins (laminin receptors) 
constitute the pial basement membrane and influence the structure and basal anchoring 
of aRG and, via signalling pathways, regulate their proliferation. Laminin also promotes 
neuronal differentia-tion and neurite morphology. In neuronal migration, the proteoglycan 
reelin, secreted by Cajal-Retzius cells, and other ECM components play a role: reelin 
promotes the interaction of migrating neurons with the ECM and the RG scaffold and is 
involved both in locomotion and in the switch from locomotion to terminal translation 
(Long and Huttner, 2019). Recently, the ECM components HAPLN1, lumican and 
collagen I were shown to directly and quickly induce folding of the CP in human fetal 
cortical explants via local changes in ECM stiffness (Long et al., 2018). 
A second mechanism regulating gyrification, which is independent of progenitor cell 
expansion, has recently been uncovered (del Toro et al., 2017): Differential expression of 
adhesion molecules such as FLRT1 and FLRT3 between future gyri and sulci leads to 
changes in intercellular adhesion, thereby influencing  the migration of cortical neurons.  
At the basis of the above described cellular-specific differences lie discriminative gene 
expression and regulation. For example, local differences in gene expression in the 
developing neocortex of gyrified species contribute to cortical folding (de Juan Romero et 
al., 2015), as has been shown for adhesion molecules (del Toro et al., 2017) and for 
Trnp1: high levels of Trnp1 in fetal sulci underlie tangential expansion of NSCs, whereas 
in gyri with low Trnp1 expression, radial expansion increases the number of IPs and bRG 
(Stahl et al., 2013). 
Additionally, gene duplications represent a major evolutionary driving force (Dennis and 
Eichler, 2016) and may contribute to species-specific features of neocortical 
development. For example, the human-specific gene ARHGAP11B, a truncated duplicate 
of the ancestral form, promotes the generation of basal progenitors upon forced 
expression in the developing mouse neocortex (Florio et al., 2015). Overexpression of 
TBC1D3, multiple copies of which are present in humans but not mice, promotes BP 
generation via aRG delamination and induces local cortical folding in mice (Ju et al., 
2016). The NOTCH2NL genes, which arose from human-specific gene duplications of 
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NOTCH2, also expand cortical progenitors and increase neuronal output when 
overexpressed in the developing mouse cortex (Fiddes et al., 2018; Suzuki et al., 2018).  
The increase in dendritic spine number and complexity in human neurons is also partly 
caused by a human-specific duplication: The human paralog of SRGAP2, SRGAP2C, 
acts as an inhibitor of its ancestral gene, causing delayed but ultimately increased 
development of dendritic spines (Charrier et al., 2012).  
Altogether, this overview on genetic and cellular heterogeneity between human and 
mouse neurogenesis and neuronal migration shall stress the additional complexity of 
processes governing human cortical development. This increased complexity underlines 
the necessity for tight regulation and control of human embryonic brain development and 
makes humans particularly vulnerable to MCDs and associated psychiatric disorders 
(Bae et al., 2015; Doan et al., 2017). MCDs, with a focus on NMDs, will be introduced in 
the subsequent chapter. 
 
 
Figure 2: Differences between mouse and human dorsal cortical development. Schematics 
illustrating the cell composition and extracellular matrix in the developing mouse (A) and human 
(B) dorsal cortex. A, Cell composition in the developing mouse lissencephalic cerebral cortex with 
aRG giving rise to neurons directly or indirectly through IPs. New-born neurons undergo 
multipolar-to-bipolar transition and locomote or translocate to the CP. B, Cell composition in the 
developing human gyrencephalic cerebral cortex, where the SVZ is subdivided by the IFL into 
iSVZ – corresponding to the mouse SVZ – and oSVZ. As an additional germinal zone, the oSVZ is 
populated by oRG and bIPs that proliferate and generate neurons. Differences in extracellular 
matrix composition between mouse and human are indicated by different shading. Abbreviations: 
aRG, apical radial glia; bIPs, basal intermediate progenitors; bRG, basal radial glia; CP, cortical 
plate; IFL, inner fiber layer; IPs, intermediate progenitors; iSVZ, inner subventricular zone; IZ, 
intermediate zone; MZ, marginal zone; oSVZ, outer subventricular zone; SP, subplate; SVZ, 
subventricular zone, VZ, ventricular zone.  Adapted from (Buchsbaum and Cappello, 2019) with 
permission from Development. 
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1.2. NEURONAL MIGRATION DISORDERS – A HETEROGENEOUS GROUP 
OF CORTICAL MALFORMATIONS 
 
1.2.1. TRADITIONAL CLASSIFICATION OF MCDS AND NMDS 
MCDs that affect the structure and functioning of the cerebral cortex and that are caused 
by deregulation of the molecular and cellular mechanisms of cortical development 
(outlined in 1.1) are a recognized cause of developmental delay, intellectual disability and 
epilepsy, and are also associated with dysmorphic features (Guerrini and Dobyns, 2014; 
Jamuar and Walsh, 2015; Romero et al., 2018). Traditionally, MCDs been classified 
according to the stage or process of cortical development that is affected (see Table 1) 
(Barkovich et al., 2012; Pang et al., 2008). However, the boundaries between the 
differentially classified MCDs are beginning to fade due to recent findings suggesting that 
MCDs are highly heterogeneous on the genetic, cellular and physiological level.  
 
Table 1:  
Traditional classification scheme for malformations of cortical development (MCDs) 
Affected process 
MCDs resulting from 
the disturbance 
Short definition of the MCD 
   
Neural progenitor 
cell proliferation 
and apoptosis 
o Microcephaly 
o Macrocephaly  
o Hemimegalencephaly 
 
o Focal cortical dysplasia 
Abnormally small head and brain 
Abnormally big head and brain 
Overgrowth of (part of) a cerebral 
hemisphere 
Disturbed lamination, dysmorphic neurons 
Neuronal migration 
o Lissencephaly type I 
o Periventricular 
heterotopia (PH) 
 
o Subcortical band 
heterotopia / double 
cortex 
o Cobblestone 
lissencephaly / 
lissencephaly type II 
Absence of normal gyri 
Subset of neurons accumulating at the 
ventricles underneath a normal cortex 
Band of grey matter located between the 
lateral ventricular wall and the cortex 
 
Overmigration of neurons to localize on the    
surface of a brain with reduced gyri 
Neuronal 
organisation 
o Polymicrogyria 
o Schizencephaly 
Increase in (usually small) gyri 
Fluid-filled cleft from ventricle(s) to pia lined 
by heterotopic grey matter 
Adapted from (Buchsbaum and Cappello, 2019) with permission from Development. 
 
 
Although they often overlap with other MCDs, the focus here shall be on NMDs. The 
genetic, cellular and physiological heterogeneity of NMDs shall be discussed and a brief 
summary of the immense existing knowledge shall be given. In the past decades, this 
knowledge has mostly been gained by analyzing mouse models with specific mutations in 
genes that in human lead to NMDs. Additionally, some mouse models have been 
characterized which show features of human NMDs, but with a genetic basis not (yet) 
identified in human patients. Evolutionarily arisen developmental differences between 
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mouse and human (see 1.1.5), though, have led to problems in the recapitulation of 
human diseases in the mouse. To this end, the use of more recently developed human in 
vitro models of cortical development (see 1.4 and 1.5) opens the opportunity to 
understand human-specific neurodevelopmental mechanisms in health and disease.  
A schematic summary of the brain morphological and cellular defects characterizing 
different NMDS is given in Figure 3, illustrating that 1) in lissencephaly type I, disruptions 
in IKNM and both radial and tangential neuronal migration result in a smooth cortex with 
lamination defect; 2) subcortical band heterotopia (SBH) is caused by defects in RG 
morphology and radial neuronal migration, resulting in a second, thin band of ectopic 
neurons in the white matter that runs parallel to the cortex (also called “double cortex”); 3) 
in periventricular heterotopia (PH), due to disturbed RG morphology and radial neuronal 
migration, a subset of neurons remains at the ventricular surface and forms nodules or 
sheets of apical grey matter; 4) in cobblestone lissencephaly/lissencephaly type II, 
defects in the basal lamina lead to overmigration of neurons that build so-called 
“cobblestones” on top of the pial cortical surface (Barkovich et al., 2012).  
 
 
Figure 3: Cellular and morphological defects associated with neuronal migration disorders.  
A, Schematics highlighting the cellular basis of neuronal migration disorders (NMDs) in the 
developing human cortex. RG, cortical layers and radially migrating neuron are depicted. Normal 
cortical anatomy is shown on the left, followed by the cellular defects associated with 1) 
lissencephaly type I, 2) subcortical band heterotopia, 3) periventricular heterotopia, and 4) 
lissencephaly type II. Ectopic neurons are shown in grey and the affected structures or processes 
are indicated. B, Schematic showing the MRI-detectable morphological defects in the adult human 
brain that are caused by the cellular defects of each NMD (A). Ectopically located clusters of 
affected neurons are shown as grey shading. 1) Lissencephaly Type I is characterized by a 
smooth brain surface and a simplified 4-layered cortex (indicated by blue shading). 2) In 
subcortical band heterotopia, the cortex contains an additional band of grey matter underneath the 
white matter. 3) Periventricular heterotopia is characterized by clusters (nodular) or sheets 
(laminar) of neurons accumulating at the ventricles. 4) In lissencephaly Type II, neurons 
overmigrate onto the cortical surface. Schematics are adapted from MRI images, see e.g. 
(Bizzotto and Francis, 2015; Francis et al., 2006; Guerrini and Parrini, 2010). Abbreviations: IKNM 
interkinetic nuclear migration; RG radial glia; RNM radial neuronal migration, TNM, tangential 
neuronal migration. Adapted from (Buchsbaum and Cappello, 2019) with permission from 
Development. 
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1.2.2. GENETIC, CELLULAR & PHYSIOLOGICAL HETEROGENEITY OF NMDS 
As indicated above, recent findings suggest increased complexity in possible causes of 
NMDs, and of MCDs more generally, resulting in a breakdown of traditional boundaries 
between disorders of NSC proliferation, neuronal migration, and cortical organization 
(Guerrini and Dobyns, 2014). In this section, the multiple genetic, molecular, cellular, and 
physiological levels of heterogeneity recently identified in NMDs (see scheme in Fig. 4) 
shall be shortly summarized (Buchsbaum and Cappello, 2019), without touching on 
environmental insults that may additionally predispose to or cause MCDs and, ultimately, 
psychiatric disorders. 
The majority of NMDs are now conceived to have a genetic basis (see Table 2). To this 
end, the focus here will be on genetic causes to date associated with NMDs. 
Genetic variants and mutations that are associated with NMDs often affect genetically 
and functionally interdependent stages of cortical development. Indeed, current evidence 
suggests that distinct clinically defined disorders might be caused by shared risk loci (see 
Table 2, Fig. 3, Fig. 4A) (Sullivan et al., 2012; Zhu et al., 2014), with the resulting 
phenotype influenced by the degree of protein dysfunction or by the levels of remaining 
functional protein. An example of this are tubulinopathies, a wide and overlapping range 
of brain malformations caused by mutation of one of seven genes encoding different 
isotypes of tubulin. Thus, in tubulinopathies, the synthesis and function of microtubule 
and centrosome key components, as well as their interaction with molecular motors and 
other MAPs may be affected. Mutations in TUBA1A, for example, can cause severe 
lissencephaly type I, microgyria, SBH, and abnormal gyrification (Aiken et al., 2017; 
Cushion et al., 2013). Mutations in two genes coding for microtubule-binding proteins, 
namely the dynein regulator PAFAH1B1 (LIS1) and the microtubule stabilizer DCX, can 
cause both lissencephaly type I and SBH, while cases of microcephaly have also been 
reported (Sheen et al., 2006). Further examples of different MCDs caused by disruption 
in the same gene are summarized in Figure 4 as their detailed discussion goes beyond 
the scope of this introduction. 
In the recent years, it has become more and more obvious that the genetics underlying 
NMDs are highly complex and heterogeneous. As a result, genomics approaches, such 
as next generation sequencing (NGS) and whole exome sequencing (WES), are being 
used increasingly to identify the genes that contribute to MCDs. Indeed, the use of NGS 
to investigate families with two or more affected individuals has proven to be 
extraordinarily effective at identifying novel, recessive mutations that contribute to 
neurodevelopmental and other disorders (Karaca et al., 2015; Yu et al., 2013). However, 
this approach is less useful in non-consanguineous families with a single, affected 
patient, which is the case for most patients with NMDs.  
As a result, and since de novo variants are also strongly associated with neurodevelop-
mental conditions, WES combined with in silico prediction has been used to identify and 
prioritize new candidate genes for various neurodevelopmental disorders, including ASD 
(De Rubeis et al., 2014; Iossifov et al., 2012), schizophrenia (Fromer et al., 2014) and 
epileptic encephalopathy (Epi4K Consortium et al., 2013).  
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Table 2: Genes known to cause NMDs in humans upon disruption.
 
     Reprinted from (Buchsbaum and Cappello, 2019) with permission from Development. 
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Several recent studies (Heinzen et al., 2018; O’Neill et al., 2018a; O’Neill et al., 2018b) 
have identified novel candidate genes for PH by focusing on de novo variants and very 
rare inherited risk alleles. The first study (Heinzen et al., 2018) used trio-based WES of 
202 patients with PH and epilepsy to identify a significant enrichment of non-synonymous 
de novo variants in intolerant genes. By combining both de novo and very rare inherited 
variants, they found that loss-of-function MAP1B variants are enriched in patients with 
this disorder, thereby identifying MAP1B as a new locus significantly associated with PH. 
Interestingly, again underlining phenotypic overlap of independently classified MCD, 
patients with MAP1B mutations and PH also had deep perisylvean or insular 
polymicrogyria (Heinzen et al., 2018). The same study also identified de novo variants in 
DCX in patients with PH. In a second trio-based WES study on patients with PH (O’Neill 
et al., 2018a), rare biallelic loss-of-function mutations in the Hippo pathway signaling 
factor MOB2 were identified as candidate disease-causing. In a subfraction of the 
Heinzen et al. cohort, it was additionally demonstrated that a fraction of de novo coding 
variants in patients with PH localize to recently evolved genes associated with bRG 
generation and function, such as a human-specific isoform of PLEKHG6, adding a role of 
bRG to the mechanisms underlying PH etiology (Kyrousi et al., Under Revision; O’Neill et 
al., 2018b) .  
Additional novel, relatively fast and cost-effective approaches to identifying MCD-
associated loci were recently reported (Cellini et al., 2019; Lu et al., 2018). The first 
approach used a forward genetic screen in mice using transposon-mediated somatic 
mutagenesis in the developing mouse cortex to identify 33 candidate genes with potential 
roles in NPC proliferation, neuronal migration or differentiation (Lu et al., 2018). The 
second approach used array-CGH in patients with different MCDs and identified an 
enrichment of copy number variants (CNVs) or other de novo pathogenic chromosomal 
rearrangements in PH, with an overrepresentation of affected genes involved in vesicle-
mediated transport regulation or encoding plasma membrane receptor complexes such 
as ion channels (Cellini et al., 2019). This finding was in line with an implication of the 
previously known PH-genes FLNA, ARFGEF2, and MAP1B in vesicle trafficking (Heinzen 
et al., 2018; Sheen, 2014), and ERMARD coding a putative vesicle associated protein 
(Conti et al., 2013) and added plasma receptor and ion channel complexes as new 
protein classes affected in PH. 
Overall, these findings highlight that multiple genes and types of genetic variants can 
contribute to NMDs, and that the timing, severity and type of genetic factors involved in 
NMDs may influence the type and extent of the resulting malformation.  
The heterogeneous genetic causes of NMDs are mirrored by the heterogeneous cellular 
phenotypes and functional outcomes that characterize these disorders. The genes 
implicated in NMDs encode proteins involved in various progenitor and neuronal 
properties and functions (Table 2). These include the maintenance and regulation of the 
morphology of the RG scaffold, the integrity of the neuroepithelium and the delamination 
of neurons from it, the polarity and motility of neurons, signaling between neurons and the 
RG scaffold, basal membrane integrity, and the signaling that terminates migration in the 
CP (Bizzotto and Francis, 2015) (Fig. 4B). Neuronal migration may be affected by the 
disruption of any of these protein functions – and many implicated proteins function in 
more than one step of neuronal migration and in more than one cell type. The PH-
implicated actin binding protein FLNA (Fox et al., 1998; Lu et al., 2006; Parrini et al., 
2006; Sheen et al., 2004b), for example, is involved in the polarized morphology of aRG, 
as well as in their proliferation (Carabalona et al., 2012), in establishing neuronal polarity, 
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and in neuronal migration itself. FLNA mutations, therefore, can result in an array of 
defects. Similarly, LIS1 has been shown to be essential for both IKNM of aRG and 
neuronal migration (Hippenmeyer et al., 2010; Moon et al., 2014). Thus, the genetic 
heterogeneity that underlies NMDs translates into complexity in terms of the affected 
molecules and processes in neural stem and progenitor cells and neurons (Fig. 4B). 
 
 
Figure 4. Heterogeneity and complexity of neuronal migration disorders at the genetic, 
cellular and clinical levels. A. Scheme depicting NMDs (black) and some overlapping identified 
causative genes (blue). Additional overlap with other differentially classified MCDs, which are not 
currently classified as NMDs (grey), is illustrated. B. Schematic of an aRG cell (white; cellular 
compartments labelled in grey), extending from the apical surface to the basement membrane, 
and a new-born neuron (pink; cellular compartments labelled in pink) using the RG cell as guide 
for its locomotion under healthy conditions. Examples of molecules and processes at the cellular 
level that can be compromised in NMDs in aRG and radially migrating neurons are exemplified to 
picture the complexity of the disorders. C. Common clinical features of patients suffering from 
NMDs. Adapted from (Buchsbaum and Cappello, 2019) with permission from Development. 
 
Finally, the genetic and molecular heterogeneity of NMDs results in highly variable clinical 
features of patients with regard to the absence or presence of seizures, as well as 
intellectual function and congenital neurological deficits (Fig. 4C). PH patient outcome, 
for example, ranges from mild, sometimes subclinical, to very severe (Barkovich and 
Kuzniecky, 2000; Dubeau et al., 1995), and about 40% of NMD patients present with 
various types of epilepsy, while the rest are seizure free. Even PH patients that share 
mutations in the same gene, such as those with familial or sporadic FLNA mutations, 
show phenotypic heterogeneity (Parrini et al., 2006). Furthermore, there is no clear 
relationship between the severity of epilepsy in PH and the extent of neuronal heterotopia 
(Chang et al., 2005), and epileptic activity can originate from a general imbalance of 
excitation versus inhibition, or it can arise locally from heterotopic clusters of neurons that 
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can become intrinsically epileptogenic (Kothare et al., 1998), or from neurons surrounding 
heterotopic nodules. 
Altogether, the heterogeneity of NMDs on genetic, cellular and functional levels (Figure 
4) makes the study of human NMDs highly complex and suggests that NMDs should be 
considered as spectrum disorders. Also, this suggests that appropriate model systems 
are needed for the study of mechanisms contributing to NMDs. In the following, an 
overview of different in vivo and in vitro model systems applied for the investigation of 
cortical development, their advantages and shortcomings in recapitulating human 
features and NMDs shall be given. 
 
 
1.3. ANIMAL MODELS OF CORTICAL DEVELOPMENT: THEIR 
RELEVANCE, ADVANTAGES AND LIMITATIONS 
Ideally, research into cortical development and its disorders would be performed using 
human tissue. However, access to human tissue – in the form of post-mortem and 
pathological specimens – is quite limited, particularly in the case of rare diseases, 
stressing the need for suitable model systems.  
 
1.3.1. MOUSE MODELS OF NMDS 
The principal in vivo model system used for the study of general mechanisms of  
neurodevelopment is the mouse, as extensively reviewed (e.g. (Guerrini and Dobyns, 
2014; Jamuar and Walsh, 2015; Romero et al., 2018)). However, when it comes to NMDs 
and other MCDs, the species differences between mouse and human cortical 
development, outlined in 1.1.5., represent a key challenge. Several mouse models 
recapitulate the morphological phenotypes of MCDs and have thus served as valuable 
tools in the identification of basic disease mechanisms for example of microcephaly, 
lissencephaly type I and neuronal heterotopia (Guerrini and Parrini, 2010; Stouffer et al., 
2015) – even though often, no human patient with mutations in the homologous gene has 
been identified to date. Especially the fact that the mouse cortex is smooth complicates 
the study of lissencephaly type I etiology. For that reason, after two examples of efforts to 
mimic human lissencephaly type I in mouse, the focus here shall be on the other NMDs. 
Insertion of a heterozygous human Lis1 mutation into the mouse caused ectopic 
hippocampal – but not cortical – pyramidal neurons and resulted in increased neuronal 
excitability and seizures (Fleck et al., 2000; Greenwood et al., 2009). Mice carrying 
different human Arx variants showed cortical lamination defects similar to human patients, 
defects in interneurons and spontaneous seizures (Kitamura et al., 2009; Marsh et al., 
2009; Price et al., 2009). 
Conditional knockout (cKO) of genes playing a role in apical AJs, such as Ctnna1 
(Schmid et al., 2014), Mllt4 and Cdh2 (Gil-Sanz et al., 2014), and Rapgef2 and Rapgef6 
(Maeta et al., 2016) in the mouse brain resulted in neuronal migration phenotypes 
reminiscent of SBH and thus revealed the importance of apical adhesion regulation for 
proper neuronal migration. Conditional inactivation of the small GTPase RhoA similarly 
led to SBH: RhoA is involved in the regulation of both actin and microtubule cytoskeleton, 
including focal adhesion formation and microtubule stabilization. The cKO mouse 
revealed the importance of the integrity of both actin and microtubule cytoskeleton in RG 
for their function as scaffold for locomoting neurons (Cappello et al., 2012).  
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Examples of successful models of FLNA-signaling-mediated PH are the cKO of Mekk4 
(Sarkisian et al., 2006) and acute knockdown (KD) of Rcan1 (Li et al., 2015), while PH 
due to vesicle trafficking defect, as is the case in patients with ARFGEF2 mutations, was 
mimicked missense mutations in Napa (αSnap), which is involved in vesicle fusion (Chae 
et al., 2004).  
In the context of cytoskeletal genes, it is important to mention an excellent full KO mouse 
model: KO of the microtubule-associated Eml1 leads to SBH in the mouse, while human 
patients show ribbon-like PH (Bizzotto et al., 2017; Kielar et al., 2014), stressing 
interference  with the cytoskeleton as common mechanism of malpositioned neurons in 
mouse and human. Eml1 functions in microtubule dynamics and its disruptions affect the 
microtubule-based centrosome, primary cilium, and orientation of mitotic spindle and with 
that influence NPC proliferation (Bizzotto et al., 2017).  
Acute KD of the cadherins Fat4 and Dchs1 (Cappello et al., 2013) showed that changes 
in NPC proliferation and neuronal differentiation can result in PH-like accumulation of 
ectopic neurons. In contrast to that, Fat4 KO in mice does not cause cortical heterotopia 
found in patients with FAT4 mutations (Badouel et al., 2015). 
Mouse models of lissencephaly type II (Bizzotto and Francis, 2015) revealed the 
importance of the basement membrane and Cajal-Retzius cells, reelin-producing cells in 
the MZ/layer I, for cortical development and lamination (e.g. (Georges-Labouesse et al., 
1998; Hartmann et al., 1999; Niewmierzycka et al., 2005)). 
We have thus seen that mouse models are highly valuable for the identification of general 
mechanisms and processes underlying NMDs. Though, when manipulating the mouse 
homolog of a gene identified as mutated in patients with NMDs, the expected human 
phenotype is not always produced. In such cases, acute KD in the mouse or rat may lead 
to a better morphological recapitulation of cortical phenotypes, for example of aberrant 
electrophysiology reminiscent of epilepsy by Dcx KD in the rat (but no cortical lamination 
defect in Dcx KO mice) (Nosten-Bertrand et al., 2008; Ramos, 2005) and ectopic neurons 
upon FlnA KD in the rat, highlighting that the underlying genetics are different from 
humans. This indicates that, although highly valuable in modelling basic mechanisms of 
neurogenesis and neuronal migration and differentiation, rodent models remain simplified 
systems lacking human-specific features, including evolutionarily dynamic mechanisms.  
 
1.3.2. NON-RODENT MODELS OF CORTICAL DEVELOPMENT 
The above described challenges of modelling human MCDs in rodents may be partly 
overcome by the use of other in vivo model systems that more closely resemble some 
features of human brain development and morphology, such as the presence of oRG and 
cortical folds. Ferrets and non-human primates are increasingly used to this end (Figure 
5A), aiming at a higher degree of fidelity to which animal models mimic human cortical 
development and MCDs. As in the work related to this thesis these in vivo models were 
not used, this paragraph will be kept rather short.  
The ferret neocortex is folded and contains an oSVZ with abundant bRG (Fietz et al., 
2010). The fact that gyrification is very similar between different animals helped to identify 
discrete domains of differential gene expression between future sulci and gyri (de Juan 
Romero et al., 2015), for example of adhesion molecules (del Toro et al., 2017). With the 
start of gyrification, migrating neurons in the ferret neocortex acquire migration patterns 
that are similar to those in developing primate brains. Namely, they disperse tangentially 
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by using processes of neighboring RG (Gertz and Kriegstein, 2015). Importantly, in utero 
electroporation can be performed in the developing ferret brain, enabling acute 
manipulation of gene expression and making the ferret a powerful model (Kawasaki et al., 
2013; Smith et al., 2018). 
A step further towards the human represent non-human gyrencephalic primates such as 
the macaque, whose brains are very similar to the human cortex in terms of their size, 
neuronal numbers and gyrification. In the developing macaque brain, an inner and outer 
SVZ can be clearly distinguished and the oSVZ contains an abundant population of bRG 
(Dehay et al., 2015; Smart et al., 2002). The diversity of precursor cell types is also much 
higher in primates than in rodent germinal zones, with heterogeneity of bRG evident in 
primates (Betizeau et al., 2013; Dehay and Kennedy, 2007; Dehay et al., 2015; 
Lukaszewicz et al., 2005). Although there are some successful examples of the 
generation of transgenic animals with germ line transmission (e.g. in marmosets (Sasaki 
et al., 2009) and macaques (Liu et al., 2016)), genetic manipulation remains difficult 
compared to mice. Together with their long gestational time and remaining decisive size 
difference in the cortex compared to humans, this stresses the need for more accessible 
human-like model systems. Several human in vitro models have therefore been 
developed to bridge limitations of animal models. As these represented the main model 
systems the studies of this thesis were based on, they will be introduced in detail in the 
following chapter. 
 
 
1.4. IN VITRO MODELS OF CORTICAL DEVELOPMENT  
The in vitro models that will be presented in the following are based on embryonic and, 
mostly, induced pluripotent stem cells (iPSCs) (Evans and Kaufman, 1981; Takahashi 
and Yamanaka, 2006; Thomson et al., 1998). Both 2-dimensional (2D) and 3-dimensional 
(3D) models make use of the ability of PSCs to spontaneously acquire neural identity and 
self-organize and differentiate in vitro (Ying et al., 2003). It has been known for many 
decades that very few external factors are needed for neuroectoderm induction 
(Holtfreter, 1944) and the default fate of NPCs is to give rise to forebrain cells (Levine and 
Brivanlou, 2007). Together with their great accessibility and relatively simple acute and 
permanent (Ran et al., 2013) genetic manipulation, as well as the possibility to transplant 
in vitro generated 2D and 3D systems into animal models, this opens numerous 
opportunities in the exploration of molecular, cellular, and even functional properties of 
human NPCs and neurons (Figure 5B). 
 
1.4.1. 2D IN VITRO MODELS 
In vitro protocols for the 2D generation of neural cells are based on the capacity of 
polarized neuroepithelial cells to self-organize into so-called neural rosettes around a 
pseudo-lumen (Elkabetz et al., 2008): Developing neuroepithelial cells arrange radially 
with neural progenitors in the center that sequentially generate layer-specific neurons in 
the typical temporal order and arrange in inside-out manner as happens in vivo. They 
then mature to build networks of actively firing neurons (Espuny-Camacho et al., 2013; 
Gaspard et al., 2008; Pankratz et al., 2007; Paşca et al., 2011; Shi et al., 2012). Also 
species-specific timing of development and maturation are recapitulated (Suzuki and 
Vanderhaeghen, 2015), rendering 2D in vitro models useful in the study of 
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neurodevelopment and its disorders (Iefremova et al., 2017; Paşca et al., 2014). The 
obvious limitation of 2D systems in the light of neuronal migration is the restricted spatial 
organization – which motivated the development of 3D models. 
 
1.4.2. 3D IN VITRO MODELS OF INCREASING COMPLEXITY 
To generate neural model systems that more closely resemble in vivo tissue, 3D 
suspension cultures have recently been developed. NPCs can self-organize to form 3D 
aggregates – termed spheroids or organoids – that produce various central nervous 
system lineages (Eiraku et al., 2011; Nakano et al., 2012; Reynolds and Weiss, 1992; 
Turner et al., 2016). In this context, “spheroid” generation aims at acquiring a specific 
brain region identity, which is achieved though the addition of morphogens mimicking 
endogenous patterning events. This patterning shall also reduce the variability between 
different organoids of the same and of independent batches (Bagley et al., 2017; 
Bershteyn et al., 2017; Chambers et al., 2009; Eiraku et al., 2008; Kadoshima et al., 
2013; Krefft et al., 2018; Li et al., 2017; Mariani et al., 2012; Qian et al., 2016). Cerebral 
or brain “organoids”, on the other hand, are produced through less directed protocols, 
relying on the intrinsic capacity of cells to differentiate along a lineage and self-organize, 
and may thus contain germinal zones of different regional identities (Lancaster and 
Knoblich, 2014; Lancaster et al., 2013; Lindborg et al., 2016; Renner et al., 2017). As the 
detailed discrimination of existing 3D protocols goes beyond the scope of this introduction 
and has been extensively reviewed (e.g. (Di Lullo and Kriegstein, 2017; Pașca, 2018), 
Table 2 in (Buchsbaum and Cappello, 2019) may serve as a summary of those applied in 
the field of MCD research. Within this work, only an overview shall be given to stress the 
applicability of COs in the presented research studies.  
All approaches exhibit features of 3D organization that are reminiscent of the developing 
cortex and reach higher degree of maturation than 2D cultures. Namely, VZs containing 
aRG are generated that are organized around a ventricle-like lumen. Basally to this 
lumen lie SVZ-and oSVZ-like zones that contain IPs and bRG, a CP-like zone with 
neurons of different layer identities (not clearly separated according to layer identity), and 
a marginal-like zone with Cajal-Retzius neurons. Mostly, 3D models are reminiscent of 
the first trimester of fetal brain development, with reports of spheroids recapitulating mid-
fetal (Paşca et al., 2015) or even postnatal stages with primary-like mature astrocytes 
(Sloan et al., 2017). 
Cerebral organoids (COs) may contain germinal zones with cells of all brain region 
identities, including dorsal and ventral forebrain and forebrain organizing centers, 
midbrain, hindbrain, midbrain-hindbrain boundary, choroid plexus, and photo-responsive 
retinal cells (Lancaster and Knoblich, 2014; Quadrato et al., 2017). Single-cell RNA-
sequencing (scRNA-seq) was used to compare COs to human fetal brain in an unbiased 
way, which demonstrated that cell types are generated via the same transcriptional 
programs and developmental trajectories (Camp et al., 2015; Quadrato et al., 2017). 
Nevertheless, organoids are not without limitations, and they clearly represent a 
simplification of in vivo neural tissue, being relatively immature, small and heterogeneous 
(Camp et al., 2015; Jabaudon and Lancaster, 2018; Pașca, 2018; Quadrato et al., 2017). 
The proportion of astrocytes in COs is lower than in primary tissue and endothelial cells 
are missing, as well as white matter regions and meninges. Due to the absence of 
vascularization, organoid size remains limited. Alternative culturing methods are 
continuously being developed, such as so-called “organoids on a chip” that enable long-
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term in situ live imaging of organoids over weeks (Karzbrun et al., 2018). In addition to 
the use of instructive factors that mimic morphogen gradients, approaches aiming at 
improving CO and spheroid protocols include the addition of microfilaments and 
scaffolding components. This was shown to ameliorate neural induction efficiency, the 
production of regions with dorsal cortical identity, and the generation of a basement 
membrane needed for the establishment of functional radial units (Kadoshima et al., 
2013; Krefft et al., 2018; Lancaster et al., 2017; Zhu et al., 2017). It was recently 
demonstrated that mesoderm-derived progenitors in COs can generate mature microglia 
(Ormel et al., 2018). 
Although showing variability in the efficiency of neural induction and in the generated 
brain regions between organoids of the same batch, as well as between batches (Camp 
et al., 2015; Jabaudon and Lancaster, 2018; Quadrato et al., 2017), a key advantage of 
undirected protocols is the high complexity of the interacting areas - reminiscent of 
different brain regions - that they generate. They thus enable a more comprehensive 
study of brain development and disease, enabling the identification of exact cell types 
affected by (candidate) disease genes. To this end, an undirected protocol was used 
(Lancaster and Knoblich, 2014) in the investigations that are part of this thesis, with 
analysis of a higher number of analyzed germinal zones, isogenic controls, and COs from 
several batches counterbalancing their variability. 
Recently, several groups have fused formerly patterned spheroids of determined regional 
identity to result in “fused-organoids” or “assembloids”: This approach results in increased 
and highly defined complexity. For instance, spheroids of dorsal and ventral telencephalic 
identity have been fused to create mature glutamatergic projection neurons of all layer 
identities, as well as several different GABAergic interneuron types. Interneurons 
subsequently migrated towards a dorsal cortex-like region, integrated into dorsal laminae 
and established electrophysiologically active microcircuits (Bagley et al., 2017; Birey et 
al., 2017; Xiang et al., 2017). In the light of NMDs, these models will be highly valuable 
for future research, e.g. by combining control- and patient-derived spheroids. 
Finally, the presented 2D and 3D in vitro human models can be combined with in vivo 
models again by transplantation, increasing the level of complexity, to study their 
functional characteristics in vivo (Figure 5). 
 
1.4.3. FROM THE DISH BACK TO THE MOUSE: TRANSPLANTATION  
Examples of transplantation of in vitro generated human NPCs and neurons into the 
mouse or rat brain have shown that they migrated into the host tissue, underwent 
morphological and functional maturation at species-specific rate, and functionally 
integrated into neural circuits (Espuny-Camacho et al., 2013; Kriks et al., 2011; 
Reddington et al., 2014; Suzuki and Vanderhaeghen, 2015; Zhu et al., 2016). Disease 
mechanisms may thus be elucidated by studying the development, migration, integration 
and physiological function of neurons in vivo (Espuny-Camacho et al., 2017). This has 
also been demonstrated for iPSC-derived glial progenitors from controls and 
schizophrenia patients, which revealed a role for oligodendrocytes and astrocytes in the 
disease etiology, even changing behavioral outcomes  (Windrem et al., 2017). A method 
for implanting human COs into the adult mouse brain has also been described (Mansour 
et al., 2018): The transplanted organoids integrated into the host brain and became 
vascularized, with grafted neurons establishing functional synaptic connections with host 
neurons and responding to physiological stimuli. 
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Figure 5: In vivo and in vitro model systems of neurodevelopment and its disorders. 
Schematic depicting animal model systems (A) and pluripotent stem cell-based human model 
systems (B) of increasing complexity and similarity to the developing human brain. A, Schematics 
of mouse, ferret and non-human primate brains as in vivo model systems (Axes are indicated for 
orientation). B, Human in vitro 2D models include NPCs and neurons and 3D models include 
rosette-based spheroids, brain region spheroids or whole-brain organoids, and fused-
organoids/assembloids with different brain regions fused together, which are particularly promising 
for the study of both radial and tangential neuronal migration. Pink arrows indicate the possibility to 
transplant in vitro-derived cells/aggregates into the mouse brain, where neurons can integrate, 
mature, become vascularized and generate functional circuits with the host cells, enabling the 
study of physiological functions. Adapted from (Buchsbaum and Cappello, 2019) with permission 
from Development. 
 
Altogether, human-derived in vitro and animal in vivo models may optimally be combined 
to succeed in improved modelling of human cortical development and MCDs. To stress 
the power of 2D and especially 3D human in vitro systems further, successful examples 
shall be introduced in the following. 
 
 
1.5. MODELLING HUMAN-SPECIFIC FEATURES OF 
NEURODEVELOPMENT AND ITS DISORDERS IN VITRO  
2D human model systems have been used to model a diversity of general neural cell 
processes (Flaherty and Brennand, 2017; Wen et al., 2016) and of human neurological 
disorders, such as schizophrenia (Brennand et al., 2011), bipolar disorder (Madison et al., 
2015; Mertens et al., 2015), and Rett syndrome (Marchetto et al., 2010). Also, species-
specific differences between mouse, macaque, chimpanzee, and human have been 
investigated with the help of both 2D and 3D systems (Mora-Bermúdez et al., 2016; Otani 
et al., 2016; Pollen et al., 2019). These studies revealed a species-specific cell-
autonomously regulated neuronal maturation timing, a protracted period of progenitor 
proliferation in primates and especially in human NPCs in parallel to neurogenesis, as 
well as cell cycle differences between the primates, which may contribute to a greater 
neocortical expansion in humans. ScRNA-seq of COs of the analyzed species showed 
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highly preserved cell types, developmental trajectories, and gene co-expression 
relationships between different primates. Genes more highly (co-)expressed in human 
apical progenitors (Mora-Bermúdez et al., 2016) and bRG (Pollen et al., 2019) pointed to 
increased proliferative capacity, supporting evolutionary expansion of the human 
neocortex.  
To elaborate further on evolutionary aspects, effects of genomic variants between 
humans and their hominid ancestors may be elucidated using 3D in vitro models (Cohen, 
2018; Hajdinjak et al., 2018). The regulation of cortical folding have also be addressed 
(Karzbrun et al., 2018; Li et al., 2017).  
Several human neuropsychiatric disorders and MCDs, such microcephaly (Cugola et al., 
2016; Gabriel et al., 2016; Gabriel et al., 2017; Lancaster et al., 2013; Li et al., 2017; 
Ming et al., 2016) have been modelled in 3D human in vitro models. Furthermore, 
cerebral spheroids, organoids and assembloids have been applied by several groups to 
investigate the pathophysiology of ASD (recently reviewed in (Ilieva et al., 2018)), for 
example in patient-derived forebrain spheroids with increased FOXG1 expression 
(Mariani et al., 2015), and in Timothy patient-derived forebrain assembloids (Birey et al., 
2017), which both suggest that neuronal migration and perhaps the (consequent) 
imbalance of excitatory/inhibitory neurons is at the basis of ASD. Importantly, many of 
these studies have provided novel insights into how aberrant neuronal migration can 
contribute to human disease, indicating that human 3D in vitro models may be used to 
model NMDs, thereby circumventing problems of mouse models carrying human disease 
variants to mimic the human neocortical phenotype (see 1.3.1.).  
The following studies successfully modelled aspects of NMDs in COs. 
As the mouse brain cannot serve as a model system for lissencephaly type I due to its 
intrinsic physiological lack of folds, many approaches have focused on modeling 
lissencephaly type I in vitro. Of note, three recent studies, using different, complementary 
3D cell culture technologies, have identified several novel factors that contribute to this 
disease: In the first study (Bershteyn et al., 2017), COs were generated from 
lissencephaly patient-derived iPSCs, with the patient carrying a heterozygous 17p13.3 
deletion which results in Miller-Dieker syndrome (MDS), the most severe form of 
lissencephaly that features epilepsy and intellectual disability. The patient-derived 
organoids recapitulated specific cellular phenotypes previously identified in mouse 
models of this syndrome, e.g. mitotic spindle and neuronal migration defects. However, 
they also revealed additional human-specific features, including severe apoptosis and 
increased horizontal division of aRG, resulting in more neurogenic aRG divisions, 
overproduction of deep-layer neurons, and smaller organoid size. The nuclei of aRG were 
less elongated, consistent with a reduced tension during nucleokinesis, and bRG showed 
a cell-type-specific mitotic defect, causing delayed cell division. In a second study, 
forebrain-specific spheroids were used to elucidate mechanisms contributing to MDS 
(Iefremova et al., 2017). In line with the first study, they identified an increase in 
asymmetric aRG divisions, resulting in reduced NPC expansion and premature 
neurogenesis. In addition, the MT cytoskeleton network of aRG in patient organoids was 
altered and truncated in appearance, with reduced extension towards the basal 
membrane. Altered expression of cell adhesion molecules added to the disruption of 
cortical niche architecture, leading to a non-cell-autonomous disturbance of the N-
cadherin/β-catenin signaling axis. A third study used the “organoids on a chip” approach 
with CRISPR/Cas9-engineered LIS1(+/-) mutant iPSCs (Karzbrun et al., 2018) and found 
that LIS1(+/-) mutant organoids generated fewer convolutions as determined from a 
INTRODUCTION 
31 
 
decreased gyrification index that is consistent with the lissencephaly patient phenotype. 
Using atomic force microscopy, mutant cells were found to be softer and to swell less 
than control S-phase cells, indicating defective IKNM. 
It is of particular interest in this thesis to model PH (Chapter 4), which is only partially 
recapitulated in mouse models with human mutations, in COs. Recently, our group 
published for the first time that COs derived from patients with PH and known causative 
mutations in the cadherin receptor-ligand pair FAT4 and DCHS1 or from isogenic KO 
iPSCs reproduce the NMD (Klaus et al., 2019): COs show neuronal heterotopia, 
disrupted NPC morphology and a defective neuronal migration and navigation system in 
a subset of cells, as well as dysregulated genes involved in axon guidance, neuronal 
migration and patterning in a subpopulation of mutant neurons as identified by scRNA-
seq. This makes sense considering that in patients with PH, only a subset of neurons fails 
to undergo radial migration to the CP and suggests that the described abnormal 
subpopulation may be the neurons that acquire ectopic apical location. Thus, the use of 
COs enabled the identification of human-specific facets of this form of PH (Klaus et al., 
2019).  
Moreover, COs can also be used to identify a cellular role for novel candidate causative 
genes identified in patients with MCDs. In a recent study, COs were used to confirm the 
phenotype seen in a mouse acute KD model of Mob2, biallelic mutations of which were 
associated with PH in a WES study (O’Neill et al., 2018a). As in the KD mouse model, 
defects in primary cilia numbers were observed in COs, stressing the importance of 
proper MOB2 levels for cilia maintenance and neuronal positioning in human neurons. In 
a further study, an enrichment of de novo coding variants associated with bRG was 
identified in patients with PH. One of the variants localized to a human-specific isoform of 
PLEKHG6. Acute manipulations of its expression both in vivo and in vitro revealed its role 
in bRG production and with that a role for bRG in the etiology of PH (O’Neill et al., 
2018b). 
These examples are highly important in the context of the project presented in Chapter 4, 
in which COs were used to model the role of a novel candidate PH gene in 
neurodevelopment and in the etiology of the disorder.  
Taken together, these studies exemplify how COs can serve both to reveal human-
specific roles of known disease-associated genes, adding human-specific aspects to 
knowledge gained in in vivo models, and to decipher new candidate causative genes and 
their human-specific mechanisms of action. A combination of the described novel in vitro 
models with recently advanced methods, such as genome editing (Ben Jehuda et al., 
2018), scRNA-seq (Camp et al., 2015; Klaus et al., 2019; Pollen et al., 2019; Quadrato et 
al., 2017), mass spectrometry (MS)-based proteomics (McClure-Begley et al., 2018), 
single-cell life imaging, and fluorescence-activated cell sorting (FACS) (Klaus et al., 2019) 
enables their unbiased analysis. A complementary approach, combining in vivo and in 
vitro models, will serve to broaden the knowledge of the molecular and cellular 
mechanisms underlying defective neuronal positioning in the human cerebral cortex. 
Specifically, for all the studies presented in this thesis, 2D and 3D in vitro systems were 
applied both for the study of a novel mechanism contributing to neurodevelopment 
(Chapter 3), as well as to decipher neurodevelopmental disease mechanisms (Chapter 2 
and 4), and were partly paralleled by mouse in vivo studies (Chapter 4).  
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1.6. ABOUT THIS THESIS 
This thesis was composed in a cumulative style, embedding three research studies into a 
frame of a common introduction and discussion. 
In the preceding introduction, I aimed at giving a summary of the background knowledge 
required for understanding the research studies presented in Chapters 2-4.  
In the first study (Chapter 2; (Pérez-Brangulí et al., 2018)), we investigated a 
neurodevelopmental role of the HSP gene SPG11. HSP is a progressive juvenile onset 
gait disorder caused by disruption of long corticospinal motorneurons. The role of the 
encoded protein spatacsin in endo- and lysosomal trafficking, together with reduced grey 
matter thickness and corpus callosum agensis in SPG11 patient brains hinted at a 
developmental function of spatacsin. Indeed, a preceding study identified dysregulated 
genes with known neurodevelopmental functions in patient-derived NPCs and suggested 
a mechanism via GSK3β (Mishra et al., 2016). Based on these findings, we generated 
and analyzed neurospheres and cerebral organoids from SPG11 patient and control 
iPSCs. We find an early neurodevelopmental defect upon SPG11 mutations that can be 
rescued by interfering with the altered GSK3β pathway, suggesting a possible 
therapeutical strategy. 
The topic of the second study (Chapter 3; (Kielkowski et al., Under Revision)) is the PTM 
AMPylation. With the help of a novel probe and proteomics, multiple AMPylated proteins 
were identified under physiological conditions in different human cell lines and in 2D and 
3D in vitro models of human neurodevelopment. The sets of AMPylated protein were cell-
type specific and so was the intracellular distribution of both AMPylating enzyme FICD 
and AMPylated protein targets, with enrichment in AMPylated cytoskeletal and motor 
proteins in neurons. Functionally, we found that 1) AMPylation of amino acid residues 
close to the enzymatic active site can inhibit enzymatic function, which may represent a 
general mechanism of action and 2) that manipulation of the levels of the AMPylating 
enzyme FICD in COs leads to a redistribution of AMPylated proteins and a slight but 
significant change in progenitor cell proliferation vs. neuronal differentiation. In the light of 
the multiple regulatory functions that have been described for PTMs targeting cytoskeletal 
and associated proteins in the developing nervous system, we suggest that AMPylation 
may be an additional such mechanism that fine-tunes neurogenesis. 
The third study (Chapter 4; (Buchsbaum et al., Under Revision)) aims at the identification 
and characterization of a novel candidate gene for the NMD PH specifically and, more 
generally, at increasing our knowledge on mechanisms and pathways that are important 
during cortical development and that lead to MCDs upon disruption. The project started 
out as collaboration with Stephen Robertson’s lab in New Zealand, where I learned how 
to analyze WES data from parent-patient trios. One of the genes I found mutated in a 
patient with PH and mega cisterna magna was LGALS3BP, which has been studied by a 
postdoc in our lab in Munich over the last few years (Kyrousi et al.; Under Revision). In 
parallel, Adam O’Neill and the Epi4K study in the recently published work (Heinzen et al., 
2018) identified – for the first time in their cohort of PH patients – two unrelated patients 
with biallelic variants in the same gene: ECE2. Both the fact that two patients were found 
with predicted to be damaging SNVs in the same gene and that most recessive diseases 
are caused by loss-of-function mutations in enzymes (Jimenez-Sanchez et al., 2001) 
drove us to choose ECE2 as a probable candidate for PH. In this study, we combined in 
vivo mouse and in vitro human model systems to study the role of ECE2 in 
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neurodevelopment. Indeed, we found that ECE2 plays a role in neuronal migration and 
positioning, being involved in apico-basal polarity and cytoskeletal integrity, as well as in 
the production and secretion of ECM factors and in the regulation of protein 
phosphorylation. 
In the discussion, I start by debating the three presented studies separately, followed by 
setting all findings into a common context. 
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2. HUMAN SPG11 CEREBRAL ORGANOIDS REVEAL 
CORTICAL NEUROGENESIS IMPAIRMENT 
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Abstract 
Spastic paraplegia gene 11(SPG11)-linked hereditary spastic paraplegia is a complex monogenic neurodegenerative 
disease that in addition to spastic paraplegia is characterized by childhood onset cognitive impairment, thin corpus 
callosum and enlarged ventricles. We have previously shown impaired proliferation of SPG11 neural progenitor cells 
(NPCs). For the delineation of potential defect in SPG11 brain development we employ 2D culture systems and 3D 
human brain organoids derived from SPG11 patients’ iPSC and controls. We reveal that an increased rate of asymmetric 
divisions of NPCs leads to proliferation defect, causing premature neurogenesis. Correspondingly, SPG11 organoids 
appeared smaller than controls and had larger ventricles as well as thinner germinal wall. Premature neurogenesis and 
organoid size were rescued by GSK3 inhibitors including the Food and Drug Administration-approved tideglusib. These 
findings shed light on the neurodevelopmental mechanisms underlying disease pathology. 
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Introduction 
Mutations in ALS5/SPG11/KIAA1840-encoding SPATACSIN 
cause a spectrum of neurodevelopmental and neurodegenerative 
diseases including the most frequent form of autosomal recessive 
hereditary spastic paraplegia (HSP) (36), termed spastic 
paraplegia gene 11 (SPG11), young onset amyotrophic lateral 
sclerosis (ALS5) (28) and Charcot–Marie–Tooth disease (CMT1a) 
(26). Spatacsinopathies converge a clinical spectrum ranging 
from cognitive impairment and thin corpus callosum (TCC) to 
spastic paraplegia and peripheral motorneuropathy. This 
multisystemic involvement points towards distinct temporal and 
spatial, yet incompletely understood functions of SPATACSIN. 
The prominent nervous system involvement in SPG11-linked HSP 
is connected to SPATACSIN’s active temporal and spatial 
expression throughout the nervous system. The 
neurodegenerative phenotype was linked to autophagy: together 
with another HSP-related protein (ZFYVE26), the SPG11 protein 
SPATACSIN is instrumental for the reformation of lysosomes 
from autophagolysosomes, i.e. a recycling pathway that 
generates new lysosomes (7,39). 
Among others, SPG11-HSP belongs to a subset of complex 
forms of HSPs characterized by TCC and is often associated with 
cognitive impairment (15), indicative of a neurodevelopmental 
defect. In conjunction, a majority of SPG11 patients show mild to 
severe enlargement of the lateral ventricles and of the cerebral 
sulci, in addition to a TCC and diffuse white matter hyperintensity 
(31). 
The functional role of SPG11 in neurodevelopmental alterations 
remains largely unexplored. Induced pluripotent stem cell (iPSC)-
derived neuronal models have been decisive for characterizing 
the cellular phenotypes of neurodevelopmental deficits in autism, 
Rett syndrome and Williams syndrome (6,22,23). We have 
previously described a proliferation deficit in neural progenitor 
cells (NPCs) derived from SPG11 patients’ iPSC (25). More 
recently, 3D iPSC-derived organoid systems opened the 
opportunity to model brain diseases in a system with remarkable 
similarities to human organogenesis (18,24,34). 
Here, we took advantage of the cerebral organoid system and of 
live-cell imaging to recapitulate the temporal and spatial pattern of 
NPC division and differentiation in SPG11HSP patients. Using 2D 
and 3D culture conditions, namely differentiating NPCs, 
neurospheres and cerebral organoids, we identified an increased 
asymmetric division in SPG11-NPCs at the germinal zone of 
cortical ventricles at the expense of symmetric division. This 
impairment in self-renewal contributes to the premature 
generation of cortical neuroblasts and neurons and is dependent 
on GSK3 signalling. Inhibition of GSK3 activity using the Food 
and Drug Administration (FDA)approved compound tideglusib is 
sufficient to rescue premature neurogenesis and more importantly 
increases organoid size in SPG11. Our data provide insights into 
how SPG11 alters neurodevelopment and further links this 
disease to the group of neurodevelopmental disorders. Moreover, 
we provide a proof of concept that 3D brain organoids are 
valuable tools for precision medicine. 
Results 
SPG11 patients and controls included in the study 
The SPG11-HSP patients reported in this study are characterized 
by an early onset of cognitive impairment in the first and second 
decade (15). In total, we derived iPSC from three patients (two 
lines each), referred to as SPG11-1, SPG11-2 and SPG11-3. 
SPG11-1 and SPG11-2 are sisters with compound heterozygous 
mutations c.3036C>A/ p.Tyr1012X in exon 16 and c.5798 delC/ 
p.Ala1933ValfsX18 in exon 30. SPG11-3 has compound 
heterozygous mutations at c.267G>A/ p.Trp89X in exon 2 and at 
1457-2A>G in intron 6 (splice site mutation corresponding to the 
previously reported mutation c.1757-2A>G) (15). The detailed 
clinical, genetic and imaging characteristics of the patients were 
previously published (15).The controls are two age-matched 
healthy Caucasian individuals with no history of movement 
disorder or neurologic disease. 
SPG11-NPCs display an altered self-renewal pattern in 
cerebral organoids 
To experimentally mimic the temporal and spatial division of 
neural cells in SPG11 patients and controls, we generated and 
analyzed cerebral organoids derived from iPSC. The size of 
organoids derived from SPG11-iPSC (SPG11 organoids) was 
significantly smaller compared to controls during early 
development of the organoids (6 days) and was not compensated 
over time (6 weeks, Fig. 1A and B). Organoids developed a 
structural organization into germinal zones and cortical regions 
(Fig. 1C; Supplementary Material, Fig. S1A). Germinal zones of 
SPG11 organoids cultured for both 6 and 9 weeks contained 
significantly less proliferating phospho-histone H3 positive (PH3+) 
cells when compared to controls (Fig. 1D, E and G). The 
thickness of the progenitor zone was significantly reduced in 
SPG11 organoids after 9 weeks, but not at 6 weeks (Fig. 1F and 
H), indicating that fewer dividing cells impact the thickness of the 
germinal wall already at 6 weeks (young organoid stage). In 
addition, the lumen of the ventricles appeared larger in SPG11 
organoids compared to controls (Fig. 1D). It is important to note 
that cell death levels did not differ between controls and SPG11 
organoids (Supplementary Material, Fig. S5), possibly due to a 
constant rate of ongoing cell death occurring in cerebral 
organoids model  (21). 
While vertically dividing NPCs in the apical ventricular zone result 
in two daughter cells (symmetric division), horizontal (asymmetric) 
divisions give rise to one stem cell and one neuroblast (13,27). 
Spindle orientations were evaluated by analyzing division angles 
of nuclear mitotic apparatus-positive cells in the progenitor zone 
of organoids. We found a significantly increased amount of 
horizontally dividing cells at the expense of vertically dividing cells 
in SPG11 organoids, indicating a shift towards asymmetric 
division in SPG11 (Fig. 1I and J). We also noticed structural 
changes in the ventricular zone; while the apico-basal polarity 
was correctly established as shown by ß-catenin (ßCat) staining 
next to the ventricle-like lumen, the progenitor zone and the 
cortical plate were less clearly separated as visible by more 
neuroblasts within the progenitor zone in SPG11 organoids (Fig. 
1D; Supplementary Material, Fig. S1B and C). 
Longer cell cycle duration in SPG11-NPCs 
To explore the duration and the frequency of cell division, we 
carried out single-cell tracking time-lapse microscopy in 
SPG11and control-NPCs (Supplementary Material, Fig. S1D). 
SPG11NPCs underwent lesser divisions than controls after 6 
days in culture (Supplementary Material, Fig. S1E). To follow the 
fate of individual cells and their progeny, single-cell tracking of 
GFP-labeled NPCs was performed acquiring phase contrast 
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Figure 1. Altered size and self-renewal pattern in SPG11 organoids. (A) Representative bright field images of 6-day-old cerebral organoids generated from SPG11- and 
control-iPSCs. (B) Significant decrease in total organoid size in SPG11 at 6 weeks (****P< 0.0001; n≥ 9 organoids per group). (C) Control cerebral organoids with apical 
progenitor zones (Sox2+, green) and basal neurons (Map2+, red). (D) Cerebral organoids from control- and SPG11-iPSCs, cultured for 9 weeks. PH3 (green): 
proliferating cells, nestin (red): NPCs, DCX (grey): neuroblasts. Apical surface indicated by dotted lines. Quantification of (E–H) PH3+-cells in the progenitor zone per 
100 μm apical surface length, progenitor zone thickness (μm) of 6-week-old (E, F) and 9-week-old (F, H) organoids, respectively (*P< 0.05, **P< 0.01, ***P< 0.001, 
****P< 0.0001; n≥ 5 organoids per group). (I) Orientation of NuMA+ cells (green): horizontal and vertical divisions (micrographs exemplify angle of division). Nuclei 
labeled with DAPI (red). (J) Percentage of NuMA+ cells undergoing horizontal and vertical division at the ventricle wall of 6-week-old organoids (****P< 0.0001; n≥ 200 
cells per group). Controls were grouped in (B), E–J). All data: mean ± SD. Scale bars: 200 μm in (A), (C), (D). 5 μm in (I). 
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Figure 2. SPG11-NPCs undergo premature neurogenesis. (A) NPC spheres from controls and SPG11 patients; NPCs (green) and neuroblasts (red) were labeled with 
antiSox2 and anti-DCX, respectively. (B, C) Quantification of migrating DCX+- and Sox2+-cells in relation to the area of the assessed spheres (dotted lines: borders of 
the analyzed area; **** P< 0.0001 for all comparisons of control versus SPG11-1, SPG11-2, and SPG11-3; n≥ 24 spheres per group). (D) Neuronal differentiation of 
NPCs, labeled for the neuronal marker ßIIITubulin (ßIIITub; green), the astrocyte marker GFAP (red), and DAPI (blue). (E–G) The numbers of ßIIITub+-cells are 
significantly decreased in SPG11 patients’ lines at 2,4 and 8 weeks of differentiation when compared to control (*P< 0.05,**P< 0.001,****P< 0.0001; n≥ 10 per group).(H) 
Neuronal differentiation of NPCs, labeled for ßIIITub (green) and the cell death dye IT-DEAD (magenta), DAPI (blue). Arrows indicate dead neurons. (I–K) Significantly 
increased numbers of dead cells in SPG11 cortical cultures at 2 (I), 4 (J) and 8 (K) weeks in culture (****P< 0.0001 for all comparisons of control versus SPG11-1, 
SPG11-2, and SPG11-3; n≥ 26 per group). All data: mean ± SD. Scale bars: 200 μm [overview (A)] and 50 μm [magnification (A), (D) and (H)]. 
and fluorescent images every 8 and 160 min, respectively. The 
temporal analysis showed significantly reduced division rounds 
per clone in SPG11-NPCs (Supplementary Material, Fig. S1F and 
G) and delineated that SPG11-NPCs need more time to complete 
a full cell cycle (Supplementary Material, Fig. S1H). 
 
Premature neurogenesis in SPG11-NPCs 
To evaluate changes in migration and neuronal differentiation in 
NPCs, we analyzed neural stem cell (Sox2/Nestin) and 
neuroblast markers (DCX) in NPCs growing in spherical 
structures under mitogenic culture conditions as neurospheres 
(3). When 
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quantifying cells migrating out from the sphere borders 48 h after 
plating, significantly more DCX+-cells were present in the SPG11 
groups, indicating an increased number of migrating neuroblasts 
(Fig. 2A and B). As expected, the number of Sox2-positive NPCs 
was significantly reduced in SPG11, while no GFAP-positive cells 
were present (Fig. 2A and C; Supplementary Material, Fig. S2A). 
This indicates an increase of migrating neuroblasts at the 
expense of NPCs, which is in line with the shift in division towards 
an asymmetric pattern in organoids. 
To test if premature neurogenesis, associated with the 
dysfunction of SPG11, implies a decrease in the total number of 
neurons, we induced neuronal differentiation in SPG11-NPCs. 
Compared to controls, SPG11-NPCs differentiated for 2, 4 and 8 
weeks showed a severe reduction of neurons (Fig. 2D–G) and 
significantly increased rates of cell death (Fig. 2H–K). The 
number of GFAP-positive astrocytes was unchanged in weeks 2 
and 4. There was a significant increase in GFAP-positive 
astrocytes at week 8 (Supplementary Material, Fig. S2B). 
Partners for the modulation of neurogenesis in 
spatacsinopathies 
SiRNA-mediated knockdown of SPG11 was performed to model 
SPATACSIN loss of function in HEK cells (Fig. 3A). P-ßCat levels 
were significantly increased upon SPG11-siRNA transfection 
when compared to control luciferase-siRNA transfection (Fig. 3B 
and C). βGSK3 activity is regulated by phosphorylation at specific 
sites and phosphorylation of serine-9 (PS9-βGSK3) results in 
inactivation (16). In SPG11-silenced cells, despite a trend, the 
inactivated form of βGSK3 (PS9-βGSK3) was unaltered (Fig. 3D). 
Since this result might have been influenced by the cell type (HEK 
cells) used for the analysis and to proceed towards the crucial 
step of translating these findings into precision medicine, 
knowledge about the biochemical changes in complex neural 
models is essential. We thus analyzed components of the 
GSK3/βCat pathway in SPG11 organoids. Dysregulation of 
βGSK3 was also observed in SPG11 organoids, i.e. P-ßCat 
levels were increased and PS9-βGSK3 levels were significantly 
decreased (Fig. 3E–G). 
Phosphorylated cAMP response element-binding protein 
(pCREB) is a key factor in the regulation of neurogenesis (12) 
and previous studies described a direct interaction between 
pCREB and three amino acids in βGSK3 (17). We therefore 
investigated, if activated CREB (Supplementary Material, Fig. 
S3A and B) is altered in SPG11-NPCs. We found a significant 
increase in SPG11-NPCs, indicative of increased transcription of 
neurogenic genes (20). These findings imply that premature 
activation of neurogenesis in SPG11 was driven by a concomitant 
repression of proliferative pathways of the Wnt/ßCat system. 
Modulation of the GSK3/β-catenin pathway rescues 
SPG11 phenotypes 
In a first step, we investigated how the premature neurogenesis 
phenotype in SPG11 can be rescued. We first tested in SPG11- 
and 
Figure 3. GSK3 overactivation in SPG11. (A–E) HEK cells transfected with control siRNA (siLuc) and siRNA against spatacsin (siSPG11). β-Actin served as loading 
control. (A) Demonstration of spatacsin knockdown in HEK cells upon siSPG11 transfection, but not siLuc transfection. (B) Western blots of hyperphosphorylated βCat 
(P-βCat), total βCat, inactivated (PS9-βGSK3) and total βGSK3. (C) Quantification of P-βCat. Data were related to total βCat (***P< 0.001; n= 3). (D) Quantification of 
PS9-βGSK3, related to total βGSK3 (no significant change; n= 3). (E) Western blots of protein preparations of untreated control- and SPG11-organoids, blotted for the 
same proteins as in (B). (F) Quantification of P-βCat in control- and SPG11-organoids. Data were related to total βCat (**P< 0.01; n= 3). (G) PS9-βGSK3 in control- and 
SPG11-organoids. Data were related to total βGSK3 (**P< 0.01; n= 3). All data: mean ± SD. 
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control-NPCs whether overexpression of SPATACSIN was able 
to rescue premature neurogenesis. Overexpression of 
SPATACSIN reduced the number of DCX+-cells in SPG11-NPCs 
under proliferating conditions (Supplementary Material, Fig. S3C–
E), indicating that restoration of SPATACSIN levels can revert the 
phenotype. To further examine proliferation of SPG11 
neuroblasts, we labeled NPCs with EdU 1 h before harvesting 
(paradigm: Supplementary Material, Fig. S4B). We then counted 
EdU/KI67/ DCX-positive cells within the total population of 
KI67/DCX double positive cells. While the percentage of total Ki-
67/DCX double positive cells was decreased in SPG11 neurons, 
there was no significant difference in the EdU-positive 
subpopulation of the proliferating neuroblasts (EdU/Ki-67/DCX-
positive cells; Fig. 4A and B). 
We next asked whether the observed phenotype can be rescued 
by manipulation of the βGSK3 pathway. For this aim 
 
 
Figure 4. Rescue of premature neurogenesis in SPG11-NPCs. (A) Images of untreated (left) and tide-treated (right) control- and SPG11-NPCs. The cells were stained 
for EdU (orange), Ki-67 (green) and DCX (purple). Proliferating cells are indicated with arrows. (B) Quantification of the percentage of Ki-67-positive cells out of DCX-
positive cells, with representation of the subpopulation of EdU/Ki-67/DCX-positive cells within the proliferative population of neuroblasts (DCX+). (C) Images of SPG11-
NPCs, untreated (NT) or treated with tideglusib (Tide) and stained for DCX (red). (D) Quantification of the percentage of neuroblasts (DCX+) in relation to the total 
number of cells. Three control NPC lines (grouped) and SPG11-NPC lines (SPG11-1 and SPG11-2, SPG11-3, respectively) were analyzed (n≥ 20 per condition). (E) 
Non-treated (NT) and CHIR-treated neurospheres generated from SPG11-NPCs, labeled with DCX (red) and Sox2 (green). (F) Quantification of DCX+-cells in NT or 
CHIR-treated spheres per mm2 (n≥ 20 per condition). ∗P< 0.05; ∗∗P< 0.01; ∗∗∗P< 0.001; ∗∗∗∗P< 0.0001. Data in (D), (F): mean ± SD; data in (B): mean ± SEM. Scale 
bars: 50 µm. 
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we employed compounds that specifically inhibit βGSK3, an FDA-
approved tideglusib and CHIR. We found that tideglusib was able 
to increase the number of proliferating neuroblasts in SPG11. 
(Fig. 4A and B). Interestingly, tideglusib or CHIR treatment 
reduced the premature generation of neuroblasts in SPG11-NPCs 
(Fig. 4C and D) and in neurosphere model, respectively (Fig. 4E 
and F; paradigms Supplementary Material, Fig. S4). 
In summary, in addition to the rescue of SPATACSIN loss of 
function by overexpression, also pharmacological inhibition of 
ßGSK3 decreased neuroblast numbers and thus attenuated 
premature neurogenesis in SPG11-NPCs. 
When treating organoids with CHIR or tideglusib (paradigm 
Supplementary Material, Fig.S4D), SPG11 organoids significantly 
increased in size compared to untreated controls (Fig. 5A–D). We 
conclude that decreased organoid size in SPG11 is partially 
rescued by ßGSK3 inhibition. CHIR had effects on both control 
and SPG11-organoid sizes. Interestingly, tideglusib specifically 
increased the size of SPG11 organoids, but did not influence 
organoid size of controls. Moreover, the significantly lower 
amount of Ki-67+/Sox2+ cells at the apical surface of SPG11 
organoids compared to controls was rescued by tideglusib 
treatment (Fig. 5E and F). This indicates that tideglusib might be 
a potent compound for SPG11 in 3D structures. 
 
Figure 5. Rescue of SPG11 phenotypes in organoids. (A) Bright field images of control- and SPG11-organoids, NT or treated with CHIR or Tide, at 4, 6 and 9 days in 
culture. (B–D) Quantification of organoid size at day 4, 6 and 9 for the respective groups. (E) Organoids (40d) stained for Ki-67 (red) and Sox2 (white). (F) Quantification 
of 40d organoid proliferation (treated according to the paradigm in Supplementary Material, Fig. S4D; ∗P< 0.05, ∗∗P< 0.01 ∗∗∗P< 0.001, ∗∗∗∗P< 0.0001; (A–C): n≥ 9 
organoids per condition; E-F: n≥ 3). All data: mean ± SD. Scale bars: 200 μm in (A); 20 μm in (E). 
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Discussion 
We employed iPSC-derived multidimensional neuronal cultures of 
SPG11 patients to demonstrate that disruption of SPATACSIN 
leads to impaired self-renewal of cortical NPCs, resulting in 
premature neurogenesis due to an increase in asymmetric versus 
symmetric division and consequently a progressively reduced 
survival of neurons. The addition of an FDA-approved βGSK3 
modulator (tideglusib) increased organoid size in SPG11. 
Although animal models have provided insights into SPG11, 
specifically early onset pathologies are inconsistent; a previously 
published SPG11-null mouse, generated by inserting a gene-trap 
cassette in the first exon of the SPG11 gene,exclusively showed 
late-onset motor impairments, together with a massive loss of 
neurons in the cortex and cerebellum of old mice (39). In contrast, 
the disruption of SPG11 by introduction of a stop codon in exon 
32, mimicking the most frequent mutation observed in SPG11 
patients, resulted in early cognitive deficits, together with 
abnormal callosal projections and neuronal death in the cortex of 
mutant mice (2). This considerable variability reflects the need for 
alternative strategies to decipher the function of spatacsin in 
human models. 
The invention of generating iPSCs opened the unique possibility 
of modeling disease phenotypes in a human cellular system (38). 
IPSC-derived 3D neuronal models, so-called cerebral organoids, 
mimic fetal development and hold great promise of providing the 
spatial and temporal solution for elucidating disease mechanisms 
(5,18). Our findings parallel cellular neurodevelopmental 
phenotypes recently described in human cerebral organoids of 
severe lissencephalies such as the Miller–Dieker syndrome (1) or 
other microcephalies (18). Changes at the NPC stage may 
represent the cellular phenotype of cortical atrophy observed in 
SPG11 patients. Traditionally considered as a neurodegenerative 
disease with juvenile onset, cortical MRIs of SPG11 patients 
evidenced early reductions of grey matter volumes (37). These 
imaging studies were complemented by the post-mortem finding 
of severe neuronal loss in the frontal cortex of SPG11 patients 
(10). Specifically, TCC and childhood onset atrophy of the cortex, 
combined with early onset cognitive impairment might be 
characteristic of early childhood onset in SPG11 patients. Our 
finding that dysfunction of SPG11 interferes with the development 
of iPSC-derived brain organoids is in line with early cortical 
atrophy diagnosed in the patients included in this study (15). Our 
data thus support the hypothesis of an additional 
neurodevelopmental phenotype in SPG11-HSP. 
Our results in SPG11 iPSC-derived neural models suggest a 
reduced rate of symmetric division of NPCs, a higher proportion 
of proliferative neuroblasts and defects in the germinal zone of 
organoids, which ultimately result in premature neurogenesis (Fig. 
5G). More specifically, we observe defects at two distinct stages. 
First of all, SPG11-NPCs present with longer cell cycle, which is 
complemented by increased asymmetric division rate, resulting in 
increased number of neuroblasts, or premature neurogenesis. For 
instance, rodent models revealed interplay between the duration 
of the cell cycle and the initiation and the total period of 
neurogenesis (4). A prolonged duration of mitosis was previously 
connected to premature neuronal differentiation of radial glia cells 
and an increase in apoptotic cells in a murine model of mago 
homolog, exon junction complex core component Magoh (33). 
Likewise, in humans, disease-causing mutations have helped to 
identify molecular mechanisms of cell cycle and neurogenesis 
regulation. For example, the protocadherin 19 gene, mutated in 
intellectual disability, modulates neurogenesis via excessively 
prolonged mitosis of progenitors (9). Second, at neuroblast stage, 
there are less proliferating cells, possibly due to premature 
differentiation. Overall, the combination of these defects 
culminated in defective SPG11 neurons (Supplementary Material, 
Fig. S6). 
SPATACSIN was previously linked to a significant decrease of 
axon-related genes and neurite complexity (32). Activated GSK3 
is implicated in neurogenesis, promoting the degradation of ßCat 
and the activation of an array of transcription factors like CREB, 
but also in glutamate-induced neuronal death (8). Therefore, our 
results point out that the dysfunction of SPATACSIN impairs the 
delicate balance of the GSK3 signaling system. The activation of 
GSK3, in turn, significantly contributes to changes in NPC 
proliferation, neurogenesis and neuronal maturation (11). Our 
previous observations in SPG11-NPCs indicated impaired ßCat 
signaling in SPG11-NPC that could be rescued by administration 
of specific βGSK3 inhibitors (25). We took advantage of this 
knowledge in order to assess whether the same observations are 
present also in the neurosphere and cerebral organoids models. 
Along this line, two different GSK3 inhibitors (CHIR and 
tideglusib) reversed neurodevelopmental defects in SPG11 
cortical cultures, and organoids. Tideglusib, an FDA-approved 
drug, improved cognitive function in mild Alzheimer’s Disease 
(19) and is currently in phase II clinical studies for adolescents 
with autism spectrum disorder and myotonic dystrophy 
(clinicaltrials.gov). Tideglusib therefore appeals as a promising 
compound based on its specificity in blocking ßGSK3, which is 
the isoform distinctively implicated in proliferation/neurogenesis 
tasks, and thereby rescuing SPG11 neurodevelopmental 
phenotypes. Furthermore, since the blockade of GSK3 also 
activates lysosomal/autophagy pathways (30), tideglusib might 
also attenuate aberrant accumulation of membranous bodies 
associated with dysfunction of SPG11 (35). 
Our previous study indicated the beneficial effect of βGSK3 
inhibition on NPCs. Here, for the first time we link 
SPG11/SPATACSIN in their roles for the Wnt/ßCat pathway in a 
3D brain organoid system. By confirming the potency of tideglusib 
in a complex, human brain organoid system we emphasize the 
clinical relevance of the compound. 
In addition, our findings are the first report to decipher impaired 
cortical neurogenesis in SPG11-HSP. We provide a rigorous 
spatial and temporal analysis of the related pathology in 2D and 
3D systems. Alterations of the natural ratio of cell divisions and 
proliferation rate are tightly linked to the observed morphological 
changes of brain organoids. These observations are crucial for 
the understanding of disease etiology and contribute a novel 
aspect for clinical intervention. 
Experimental procedures 
SPG11 patients and controls 
Three patients (UKERi6O6-R1, UKERi4AA-R1 and UKERiK22-
R1, described as SPG11-1, SPG11-2 and SPG11-3) and two 
controls (UKERi1JF-R1 and UKERi1E4-R1) were included. 
Patients were described in detail previously (15). The underlying 
Institutional Review Board approval (Nr. 4120: Generierung von 
humanen neuronalen Modellen bei neurodegenerativen 
Erkrankungen) and informed consent were obtained at the 
movement disorder clinic at the Department of Molecular 
Neurology, Universitätsklinikum Erlangen (Erlangen, Germany). 
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IPSC-derived neuronal model 
IPSCs were reprogrammed from fibroblasts using Yamanaka’s 
retroviral transduction (two iPSC lines per individual). The lines 
were maintained and controlled for pluripotency as previously 
described (14).From every individual, two independent NPC lines 
and respective neurons were generated using an embryoid body 
(EB)/rosette protocol (14) and further differentiated into neurons. 
Multidimensional cultures 
Cerebral organoids were generated from iPSC as previously 
described (18). For control lines, EBs were generated from 9000 
cells each. For patient lines, EBs were generated from 9000 and 
18 000 cells with no visible difference in size or development. 
Two control- and two SPG11-iPSC lines (SPG11-1 and SPG112) 
were analyzed. Controls were grouped. Cerebral organoids were 
cultured for 40 to 61 days (6 and 9 weeks) at 37
◦
C under 5% CO2 
and atmospheric oxygen. For the rescue experiment, control- and 
SPG11 organoids were treated with 1 μM of the GSK3 blockers 
CHIR99021 and tideglusib and kept in culture for 40 to 60 days (6 
and 9 weeks). Compounds were replaced every 2–3 days 
(Supplementary Material, Fig. S4D). 
For the neurosphere assay (3), NPCs were kept in suspension in 
96 well ultra-low attachment plates (Corning, Amsterdam, the 
Netherlands) for 72 h at a density of 5 × 10
4 
cells/cm
2 
under 
proliferative conditions. For the analysis of NPC migration, 
neurospheres grew attached to polyornithine/laminin (Invitrogen, 
Carlsbad, California, United States) coated coverslips for 48 h 
(Fig. 2A). Spheres generated from six SPG11-NPC lines (SPG11-
1, SPG11-2 and SPG11-3) were compared to controls. 
Time-lapse video microscopy 
Control- and SPG11-NPCs were infected with a pEF1-GFP 
lentivirus. Time-lapse assays were performed for 6 days under 
mitogenic conditions. Time-lapses and single-cell tracking (29) of 
SPG11- and control-NPCs were performed with a cell observer 
(Zeiss Jena, Germany) at 37
◦
C and 5% CO2. Phase contrast and 
fluorescent images were acquired every 8 and 160 min 
respectively using a 20× phase contrast microscopy objective 
(Zeiss), an AxioCam HRm camera and Zeiss AxioVision 4.7 
software (Zeiss). Time-lapses were assembled using ImageJ 
whereas single-cell tracking was carried out using a self-written 
computer program (TTT). Per every assessed NPC line, at 
least40– 50 videos were analyzed and 50 single cells tracked. 
Time-lapse analyses were evaluated from two control- and three 
SPG11NPC lines (SPG11-1, SPG11-2 and SPG11-3). Control 
NPC lines were grouped. 
Statistical analysis 
Immunofluorescence analyses, neurite measurement, protein 
expression and phosphorylation were statistically analyzed using 
Prism (GraphPad, San Diego, California, United States). Unless 
indicated otherwise, all data are shown as mean ± SD. Statistical 
analysis was carried out employing the Student’s t test for 
unpaired variables (two-tailed) and one-way analysis of variance 
followed by Bonferroni multiple comparison tests when three or 
more groups were compared. P-values < 0.05 were considered 
significant. 
Detailed information on the transfection of human cells and 
details for immunofluorescence, protein sample preparation and 
western blot assays are listed in the supplemental methods. 
Supplementary Material 
Supplementary Material is available at HMG online. 
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Supplemental figures: 
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Fig. S1. Altered ventricle structure and cell cycle dynamics in SPG11 organoids. 
Related to Fig. 1. (A) Staining for Ctip2 (red) indicating cortical differentiation in control 
organoids, separated from the basal localization of PAX6-positive cells (green) close to 
the lumina. (B, C) β-catenin staining (red) shows that apico-basal polarity is correctly 
established but the apical border of the proliferative zone (arrowheads) is less clearly 
defined in 9 weeks old SPG11 organoids (C) compared to controls (B) Scale bars=100 
μm. (D-H) 6-day time lapse analysis of control- and SPG11-NPCs expressing GFP. (D) 
Visual representation of single cells of control and SPG11 cortical NPCs (arrows) over 
time. Scale bar=10 μm. (E) Total numbers of cell cycles per assessed time-lapse. (F) 
Scheme of division round quantification of single NPCs. (G) Number of division rounds of 
single clones. (H) Length of each cell cycle in single clones. All data are presented as 
mean ± SD. Two-way ANOVA and Bonferroni’s adjustment for multiple comparisons were 
performed; ****P <0.0001 for comparison of Controls vs. SPG11-1, SPG11-2, and 
SPG11-3, respectively (n≥200 cells per condition). 
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Fig. S2. Astrocytes in SPG11 and control neurospheres and NPCs. Related to Fig. 2. 
(A) Absence of GFAP labeled astrocytes in neurospheres generated from controls and 
SPG11 patients (SPG11). Neurospheres were labelled with the neural stem cell marker 
Sox2 (green), the astrocyte marker GFAP (red) and the neuronal marker βIIITubulin 
(βIIITub, grey). Scale bars=200 μm. (B) Neuronal cultures of SPG11 and controls 
differentiated for 2, 4, and 8 weeks. The % of GFAP within the culture is not significantly 
different at 2 and 4 weeks, but there is a significant increase in the portion of GFAP 
positive cells at 8 weeks in the SPG11 group ****P<0.0001. Data: mean  SD.  
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Fig. S3. Spatacsin mediated impairments in SPG11-NPCs. (A) Western Blot of the 
nuclear (nuc) fraction of NPCs for phosphorylated CREB (P-CREB) and total CREB. (B) 
Quantification of the ratio of P-CREB over CREB (related to Fig.3; ***P<0.001; n=3; 
means  SD). (C, D) DCX+-cells (red) in SPG11-NPCs transfected with GFP or GFP-
spatacsin (SPAT). (D) Quantification of DCX+-cells (ratio of DCX+/ DAPI+, **n=4 
transfections, each with 10 images). (E) Quantification of DCX/ DAPI double positive cells 
over all (DAPI+) cells (n=4 transfections, each with 10 images). Scale bars=200 μm. 
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Fig. S4. Paradigms of rescue strategies of premature neurogenesis in SPG11. (A) 
NPC-derived NPCs. (B) Paradigm for Tide treatment and addition of EdU (Fig 4E, F). (C) 
Neurospheres were treated with CHIR for 48h. (D) For organoid treatment, compounds 
were added to culture medium at 1 μM concentration from plating of cells during the 
formation of embryoid bodies until fixation; medium including compounds was changed 
every 2-3 days (every 2 days after plating and every 3 days from embedding in Matrigel).  
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Fig. S5. Cell death in SPG11 and control organoids. Co-staining for cleaved caspase-
3 (cCASP3; red) and Sox2 (green) positive cells within the apical surface of ventricular 
zones. Scale bar=20 µM. Quantification of the cCasp3+/Sox2+ in 3 ventricular structures 
of organoids (n=3 per condition) reveals no significance difference between controls and 
SPG11 patients. Additionally, Tide treatment has no significant effect on cell death. All 
data are presented as mean ± SD. One-way ANOVA and Bonferroni’s adjustment for 
multiple comparisons were performed.  
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Fig. S6. Schematic representation of premature neurogenesis observed in SPG11. 
Compared to controls, SPG11 iPSCs derived NPCs have longer cell cycle, reduced 
proliferation and increased level of asymmetric divisions, leading to increased number of 
neuroblasts that exhibit proliferation defects. Overall, the impairments lead to premature 
neurons.   
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Supplemental Table 1 
Antibody Host Exp. 
used 
Concen- 
tration 
Company 
anti-ßCatenin (clone H-102) rabbit polyclonal IB/IF 1:500 Santa Cruz 
anti-NuMA rabbit polyclonal IF 1:500 Abcam 
anti-GSK3 (clone 4G-1E) mouse monoclonal IB 1:500 Millipore 
anti-ßActin (1:1000) mouse monoclonal IB 1:2000 Sigma-Aldrich 
anti-H2A (Histone 2A, clone JBW301) mouse monoclonal IB 1:1000 Millipore 
anti-HA (Hemagglutinin tag,  
clone HA.C5) 
mouse monoclonal IB/IF 1:1000 Abcam 
anti-GFP  rabbit polyclonal IB/ IF 1:1000 ThermoFisher 
anti-ßIIITubulin (TUBB3) rabbit monoclonal IF 1:1000 BioLegend 
anti-ßIIITubulin (TUBB3) mouse monoclonal IF 1:1000 BioLegend 
anti-Glial fibrillary acidic protein rabbit monoclonal IF 1:1000 Millipore 
anti-Nestin (clone 10C2) mouse monoclonal IF 1:1000 Millipore 
anti-Sox2 (clone D6D9) rabbit monoclonal IF 1:400 Cell Signaling 
 anti-DCX (clone C-18) goat polyclonal IF 1:200 Santa Cruz 
anti-Sox2 (clone Y-17) goat polyclonal IF/IHC 1:200 Santa Cruz 
anti-Ctip2 (clone 25B6) rat monoclonal IF 1:500 Abcam 
anti-β-catenin (clone14) 
mouse IgG1 
monoclonal 
IHC  1:500 
BD 
Biosciences 
anti-doublecortin  guinea pig polyclonal IHC  1:2000 Millipore 
anti-Nestin (clone 10C2) 
mouse IgG1 
monoclonal 
IHC  1:200 Millipore 
anti-phospho-Histone H3 (Ser10) rabbit polyclonal IHC  1:500 Millipore 
anti-cleaved caspase 3 Rabbit polyclonal  IHC 1:300 Cell Signaling 
anti-Ki67 Mouse monoclonal   IF/IHC 1:300 
BD 
Biosciences 
Table S1. Antibodies used in this study. Related to Methods. Legend: Immunoblotting 
(IB), Immunofluorescence (IF), Immunohistochemistry of organoids (IHC). 
 
Supplemental experimental procedures 
Transfection of human cell lines  
Human embryonic kidney 293 (HEK) cells were cultured according to manufacturer’s 
instructions and transfected with the respective constructs using polyethylenimine (PEI) 
as previously described (Perez-Branguli et al., 2014). Control and SPG11 NPCs were 
transfected with plasmids expressing GFP or GFP-spatacsin (SPAT) by employing 
Lipofectamin-LTX (Invitrogen) according to manufacturer’s instructions. 0.5 µg of DNA 
per transfection was used. 
 
Immunofluorescence (IF) 
HEK cells, NPCs, neurospheres, and forebrain cultures were fixed in 4 % 
paraformaldehyde (PFA) for 10-30 min at room temperature (RT). After several rinses 
with phosphate buffered saline (PBS), cultures were pre-incubated for 60 min at RT in 
immunofluorescence buffer [IFB: PBS supplemented with 0.1 % Triton X-100 (PBST) and 
3-5 % normal donkey serum] for 60 min at RT, followed by overnight (ON) incubation at 
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4 °C with primary antibodies diluted in IFB. EdU detection procedure was conducted 
according to the user manual (BCK-EdU555; baseclick, GmbH).   
Organoids were fixed in 4 % PFA on a shaker for 4h at 4 °C and then cryoprotected in 
PBS supplemented with 30 % sucrose at 4 °C ON. Organoids were embedded in 
CryostorTM CS 10 Cryopreservation Medium (Sigma-Aldrich) and cut at 16 µm thickness. 
For IF, primary antibodies were diluted in blocking solution (BS: PBS supplemented with 
10 % normal goat serum and 0.5 % Triton® X-100) at 4 °C ON. For cleaved-caspase 3 
(cCasp3) an additional step of permeabilization within acetic acid and ethanol solution 
(1:2 ratio) was added prior to blocking.  
All rinses were performed using PBST. Incubation with respective fluorescent secondary 
antibodies diluted in PBS was performed for 60 min at RT. Dead cells were detected by 
incubating unfixed iPSC-derived forebrain cultures with 100 nM IT-DEAD for 30 min at 
37 °C. After several washes with PBS, samples were mounted for further microscopic 
analysis. All IFs were visualized using a Zeiss inverted fluorescent Apotome.2, a confocal 
LSM-780 microscope (Carl Zeiss) or a confocal TCS-SP8 microscope (Leica).  
 
Protein sample preparation 
For the protein analysis, NPC lines were harvested and washed twice in cold PBS buffer, 
gently resuspended in cold hypotonic buffer (20 mM Tris pH 7.4, 10 mM NaCl, 3 mM 
MgCl2 supplemented with protease and phosphatase inhibitors) and incubated on ice for 
15 min. After adding 10 % NP40, homogenates were centrifuged for 15 min at 3000 rpm 
at 4ºC to separate supernatant 1 (S1; cytosolic fraction) from pellet 1 (P1; nuclear pellet). 
P1s were resuspended in cold homogenization buffer (HB: 100 mM Tris pH 7.4, 1 mM 
EDTA, 100 mM NaCl, 1 % Triton X-100, supplemented with protease and phosphatase 
inhibitors) and incubated on ice for 30 min, and afterwards centrifuged at 14000 rpm for 
30 min at 4ºC. Supernatants (S2; nuclear fraction) were collected.  
Transfected HEK cells were resuspended in HB, incubated on ice for 30 min and 
centrifuged at 14000 rpm for 30 min at 4ºC. Resulting supernatants (total protein extract) 
were harvested. 
 
Immunoblotting (IB) 
20 µg to 50 µg of total protein were separated by SDS-PAGE and blotted onto 
nitrocellulose (NC) or PVDF membranes. Primary antibodies were incubated ON at 4ºC in 
Tris buffered saline and 0.1 % Tween-20 (TBSTB) supplemented with 3 % bovine serum 
albumin (BSA). After several washes with TBST, blots were incubated with secondary 
antibodies conjugated to horseradish peroxidase (HRP) and developed by chemical 
luminescence. 
 
Measurements and analysis 
To analyze migration in neurospheres, numbers of migrating cells (cells located in the 
"migrating area” outside of dotted lines in Fig. 2A) were normalized by the area of seeded 
neurospheres (core of the spheres outlined in Fig. 2A). Migration was studied in 
untreated neurospheres and in neurospheres chronically treated with 3µM CHIR99021. 
Migration rates were analyzed using ImageJ (http://imagej.nih.gov/ij/). 20 to 50 spheres 
 
59 
 
per experimental condition and NPC line were analyzed. Likewise, the number of neurons 
and dead cells in forebrain 2D cultures derived from iPSC of SPG11 patients and controls 
were analyzed as previously described (Perez-Branguli et al., 2014). 
Organoid area and organoid progenitor zone thickness were measured using ImageJ. At 
least 3 organoids per experimental condition were assessed. To analyze the number of 
dividing cells in the progenitor zone of organoids, the number of PH3+ and Ki-
67+/Sox2+cells was normalized to the length of the apical surface of ventricle-like 
structures (shown per 100 µm). Multiple ventricles per organoid were analyzed.  
Angle of division of dividing cells labeled with anti-NuMa at the germinal wall of ventricles 
of organoids was analyzed using the tools “angle measurement” and “area measurement” 
included in AxioVision (Zeiss). Cells with a division angle between 0-45 degrees were 
classified as cells dividing asymmetrically (horizontal; Fig 1J), while cells with division 
angles between 45-90 degrees were considered as cells dividing symmetrically (vertical; 
Fig 1J). 10 to 20 cells per image, and at least 20 randomly taken images per 
experimental condition were analyzed.  
For the investigation of β GSK3 signaling pathway in SPG11-NPCs, we compared protein 
extracts from untreated NPCs and NPCs treated with 3µM CHIR99021 for 4 hours at 
37 °C. Protein expression and phosphorylation were evaluated by dividing the signal 
intensity of each protein of interest by the signal intensity of housekeeping markers and 
pan-proteins respectively. At least 3 independent experiments were analyzed. Protein 
evaluation was carried out using ImageJ. 
 
Immunohistochemistry and pharmacological compounds 
Nuclei were counterstained with DAPI (1:5,000). CHIR99021 was obtained from R&D 
Technologies, Tideglusib from Selleck-Chem, (Houston, TX) and auto-fluorescent reagent 
IT-DEAD from Invitrogen. pGFP-Spatacsin and siRNAs sequences to knock down SPG11 
(Sigma-Aldrich) have been described previously (Perez-Branguli et al., 2014; Murmu et 
al., 2011). 
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FICD activity and AMPylation remodelling modulate human 
neurogenesis. 
Pavel Kielkowski1+, Isabel Y. Buchsbaum2,3+, Volker C. Kirsch1, Nina C. Bach1, Micha 
Drukker4, Silvia Cappello2,3*, Stephan A. Sieber1* 
 
Posttranslational modification (PTM) of proteins represents an important cellular 
mechanism for controlling diverse functions such as signalling, localisation or 
protein-protein interactions1. AMPylation (also termed adenylylation) has 
recently been discovered as a prevalent PTM for regulating protein activity2. In 
human cells AMPylation has been exclusively studied with the FICD protein3-5. 
Here we investigate the role of AMPylation in human neurogenesis by 
introducing a cell-permeable propargyl adenosine pronucleotide probe to 
infiltrate cellular AMPylation pathways and report distinct modifications in intact 
cancer cell lines, human-derived stem cells, neural progenitor cells (NPCs), 
neurons and cerebral organoids (COs) via LC-MS/MS as well as imaging 
methods. A total of 162 AMP modified proteins were identified. FICD-dependent 
AMPylation remodelling accelerates differentiation of neural progenitor cells into 
mature neurons in COs, demonstrating a so far unknown trigger of human 
neurogenesis. 
 
Introduction of protein PTMs is a tightly controlled and almost ubiquitous 
process that often modulates critical protein function. PTMs such as tyrosination, 
acetylation and neddylation are known to play a crucial role in the development of the 
nervous system and in particular of neurons by broadening the diversity of the tubulin 
and microtubule proteoforms6, 7. 
AMPylation was first discovered in Escherichia coli as regulator of glutamine 
synthetase activity8. Later, it was found that bacterial effectors from Vibrio 
parahaemolyticus and Histophilus somni AMPylate Rho guanosine triphosphatases 
(GTPases) in human host cells9,10. These bacterial effectors contain highly conserved 
Fic (filamentation induced by cAMP) domains, which catalyse the transfer of AMP onto 
a serine, threonine or tyrosine residue of a substrate protein (Fig. 1a). Approximately 
3,000 members of this family are known to contain the conserved 
HXFX(D/E)GNGRXXR sequence motif throughout all domains of life11. Despite their 
abundance in bacteria, only one human protein AMPylator containing the signature Fic 
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domain termed FICD (also known as Huntingtin yeast partner E, HYPE) has been 
discovered11. Structural and biochemical studies with FICD have revealed that its 
activity is tightly regulated and controlled by an autoinhibitory loop. Mutation of E234 to 
glycine overrides autoinhibition and results in a constitutively activated enzyme11; the 
mutant form H363 to alanine is catalytically inactive3. One known substrate of FICD is 
HSPA5, which is a chaperone located in the endoplasmic reticulum (ER) and master 
regulator of the unfolded protein response (UPR)3-5. Recent data show that FICD 
regulates the ATPase activity of HSPA5 and its interactions with unfolded proteins but 
the exact function is not yet clear12. However, it was found that the HSPA5 AMPylation 
associates with changes in neuronal fitness in drosophila13-16. 
Just recently, the highly conserved pseudokinase selenoprotein-O (SelO) was 
found to possess AMP transferase activity in eukaryotic cells17. Pseudokinases account 
for about 10% of the human kinome but lack the characteristic active site residues and 
hence their function is largely unknown. However, their putative AMPylation activity is 
pointing to a possibly larger number of AMPylated proteins in human cells. 
Lately, N6-propargyl adenosine-5‘-O-triphosphate (N6pATP)-derived probes 
have been applied to profile substrates of AMPylation in cell lysate18-20. Nevertheless, 
the most pressing, unaddressed challenge in discovering the function of AMPylation is 
the global analysis of AMPylated substrates under physiological conditions inside living 
cells. Particularly, ATP-derived probes suffer from restricted uptake of the charged 
nucleotides as well as competition with high endogenous ATP levels. Thus, new 
concepts are urgently needed to unravel the function of AMPylation in eukaryotic cells. 
Here we present a chemical-proteomic approach for identification of protein AMPylation 
in living cells using a pronucleotide probe and uncover FICD-dependent AMPylation 
remodelling responsible for acceleration of neuronal differentiation in cerebral 
organoids (COs). 
 
Results 
6-Propargyl adenosine pronucleotide reports on protein AMPylation. To approach 
the challenge of identifying AMPylated proteins in situ, we selected a phosphoramidate 
pronucleotide strategy (Fig. 1a, b)21. This delivery method not only enhances the 
probes’ cell membrane permeability but also bypasses the first phosphorylation of the 
nucleoside analogue by kinases. Based on these considerations, we designed and 
synthesized a N6-propargyl adenosine phosphoramidate pronucleotide (pro-N6pA, Fig. 
S1). We initiated our investigations with metabolomics experiments to determine pro-
N6pA in situ metabolic activation to the corresponding N6pATP. A maximum 
concentration is reached 8 hours after pro-N6pA addition and it is maintained for at 
least 24 hours (Fig. S2). For the subsequent analysis of AMPylated proteins we treated 
living (intact) HeLa cells with pro-N6pA (100 µM in DMSO) or dimethylsulfoxide 
(DMSO). Subsequent click-chemistry to a rhodamine-biotin-azide tag, enrichment on 
avidin beads and SDS-PAGE analysis via in-gel fluorescence detection revealed 
several distinct protein bands in the soluble fraction (Fig. 1c). Next, we performed 
quantitative proteome profiling in HeLa cells22. Enriched proteins were trypsin digested 
and resulting peptides were either isotopically marked by dimethyl labelling (DiMe) prior 
to LC-MS/MS measurement or analysed directly using label-free quantification (LFQ) 
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(Fig. 1d)23,24. Comparing pro-N6pA labelling (Fig. 1e) with parent N6-propargyl 
adenosine (N6pA, Fig. 1f, Fig. S3) yielded a larger number of significantly enriched 
proteins with the pronucleotide. Using pro-N6pA, a diverse group of 19 proteins were 
identified in HeLa cells, including the known FICD substrate HSPA5 (Fig. 1e, Table 
S1). Immunoprecipitation of the two selected proteins PFKP and PPME1 from the 
probe treated HeLa cells followed by click reaction with rhodamine-azide tag confirmed 
incorporation of the probe into these proteins (Fig. S3). 
Although the N6-propargyl ATP analogue could, in principle, serve as precursor 
for ADP-ribosylation25, our controls indicate that ADP-ribosylation is not a major route. 
ADP-ribosylation is usually induced by stress conditions e.g. by addition of hydrogen 
peroxide to the cells’ media26. First, HeLa cells were pre-treated with poly(ADP-
ribose)polymerases (PARP) inhibitors 4-aminobenzamide (4-ABA) or olaparib (Ola) 
prior to pro-N6pA labelling. For both PARP inhibitors no influence on labelling intensity 
was observed based on in-gel fluorescence analysis (Fig. S3). In addition, MS-based 
chemical-proteomic experiments with Ola and pro-N6pA treated cells confirmed no 
changes in AMPylation (Fig. 1g and Table S2). Second, only two of our identified 
AMPylated proteins in HeLa cells (HIST1H2AH, RPS10) matched known ADP-
ribosylated proteins (Fig. S3)27. Known ADP-ribosylated proteins were excluded as 
potential hits in the following experiments (Table S3). 
 
 
Figure 1 | Pronucleotide probe reveals AMPylation of diverse proteins in HeLa cells. a, 
AMPylation on Ser, Thr or Tyr. b, Scheme of the pronucleotide probe pro-N6pA and parent 
adenosine derivative (N6pA) and its in situ activation. c, SDS-PAGE with in-gel fluorescence 
scanning showing in situ HeLa cell labelling by pro-N6pA compared to control (DMSO). d, 
Schematic representation of the chemical-proteomic approach used for in situ identification of 
AMPylated proteins. e, Volcano plot of fold-enrichment in HeLa cells by pro-N6pA labelling 
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compared to DMSO versus significance upon two-sample t-test (FDR 0.05, s0 0.3; n = 12). f, 
Box plot representing comparison of labelling efficiency of pronucleotide pro-N6pA (light grey, n 
= 12) and parent nucleoside N6pA (black, n = 11); Squares represent the mean of the distances 
to zero for enriched proteins, lines represent the median of the distances to zero and whiskers 
stand for min and max values. Statistical significance was calculated with two-tailed Student’s t-
test; ***𝑃 < 0.001. g, Volcano plot of fold-enrichment by pro-N6pA labelling compared to probe 
and Ola treated HeLa cells versus significance upon two-sample t-test (FDR 0.05, s0 0.3; n = 
8). Green circles represent proteins identified as AMPylated in HeLa cells. 
 
AMPylation of cathepsin B inhibits its peptidase activity in vitro. In order to 
validate our approach in more detail we have employed an azide-TEV-cleavable-biotin 
linker during the pull-down procedure to identify the corresponding AMPylation sites of 
modification via MS/MS (Fig. 2a, b)28. We were able to directly analyse AMPylated 
peptides on three different cysteine cathepsin proteases CTSB (S104 and S107), 
CTSC (S254) and CTSL (S137) (Fig. S4 and S5). All of the AMPylation sites were 
located on serine residues within the conserved sequence surrounding the catalytically 
active cysteine (Fig. 2c), suggesting that the bulky AMP modification might obstruct the 
binding of the peptide substrates and thus inhibit protease activity29. To determine 
whether FICD is the AMPylator of these cathepsins, we used an in vitro peptidase 
activity assay and found that cathepsin B is indeed inhibited upon FICD (wild-type (wt) 
or E234A mutant) treatment and did not observe any inhibition without the addition of 
ATP (Fig. 2d, Fig. S4). The direct measurement of AMPylation sites in CTSB 
(S104,107) in vitro was restricted by preparation of the recombinant double mutant 
CTSB which did not fold into the active protein, likely due to the mutation of the crucial 
amino acid residues within the conserved active site. Moreover, the TEV-linker based 
enrichment of modified peptides was performed with other cell types used in this study 
and three additional sites on MYH9, RAI14 and AASS (on Thr, Ser and Tyr residues 
respectively) were detected (Table S4). Of note, the MS-based identification of 
AMPylated sites in living cells is limited by the endogenous degree of modification. We 
thus assume that site identifications of proteins with lower AMP abundance are 
challenged by the detection limit. Here, previous trials in cell lysates using an active 
recombinant FICD E234G mutant yielded a complementary set of proteins likely due to 
an increased degree of modification (Fig. S6 and Table S5)20. 
Chemical-proteomics profiling shows cell type dependent AMPylation pattern 
and in part independency of FICD. We performed proteome profiling in three different 
cancer cell lines, HeLa, A549 and SH-SY5Y, which revealed a total of 58 significantly 
enriched proteins, of which 38 were contributed solely from the latter neuroblastoma 
cells (Fig. 3a, Fig. S7). Overall, AMPylated proteins identified here are involved in 
diverse metabolic pathways including a widely conserved key regulator of glycolysis 
ATP-dependent 6-phosphofructokinase (PFKP)30, proteolysis (CTSA, CTSB)31, 
regulation of PTMs (PPME1)32 and UPR (HSPA5 and SQSTM1)33. Intriguingly, only 
PFKP was found to be AMPylated in all three cell lines, which otherwise exhibited 
unique AMPylation patterns. 
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Figure 2 | CTSB peptidase activity is inhibited by FICD catalysed AMPylation. a, Identified 
AMPylation sites on serine residues (red) of cathepsins B, C and L using pro-N6pA in HeLa 
cells. b, Exemplary MS/MS spectrum (MaxQuant) for the CTSB AMPylation site identification on 
S107 (see Fig. S4 and S5). c, Amino acid motif surrounding the active site cysteine of cysteine 
cathepsins. d, In vitro peptidase assay of CTSB activity after incubation with wt FICD or E234A 
mutant and with or without ATP for 6 h. Normalized to CTSB activity without FICD protein. Lines 
represent the mean and whiskers stand for 25
th
 and 75
th
 percentile. Two-tailed Student’s t-test; 
**𝑃 < 0.01, ****𝑃 < 0.0001. 
 
 To directly dissect the descent of AMPylated proteins from FICD we compared 
the AMPylation levels of proteins in probe treated HeLa cells comprising FICD 
knockdown, wt FICD overexpression (OX) and activated FICD E234G OX (Fig. 3b, Fig. 
S8 and Table S6). Interestingly, HSPA5 is a clear FICD-dependent responder where 
AMPylation is significantly upregulated in FICD E234G OX and downregulated in wt 
FICD OX, which is also known to perform de-AMPylation5. Remarkably, while all 
previous studies have been carried out in vitro18-20, we here independently confirm this 
data by the first in situ experiments. A direct in situ interaction is further corroborated by 
MS-based pulldown experiments of wt FICD and FICD E234G in the presence of a 
chemical crosslinker which revealed HSPA5 together with other sets of proteins as 
interacting partners, while proteins like SQSTM1, PFKP and PPME1 were not enriched 
and thus considered as not interacting with FICD (Fig. 3c)34. Of note, FICD E234G 
revealed a more pronounced interaction with HSPA5, confirming our OX studies (Fig. 
S9 and Table S7). GO term analysis of the overlapping interacting partners indicated a 
link to basal metabolism (Fig. 3d). With HSPA5 as a validated candidate we moved on 
and analysed other AMPylated proteins. The set of hits including PPME1, PFKP and 
SQSTM1 exhibited no significant changes in AMPylation levels upon FICD KD and OX, 
suggesting an FICD-independent mode of AMPylation (Fig. 3b) for which the origin of 
the AMP transfer could not be fully deduced. Given the recent discovery of an 
additional AMPylating enzyme also in eukaryotic cells it is likely that the other proteins 
detected here descent form a yet undiscovered AMPylator(s)17. 
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 Next, proteome profiling under endoplasmic reticulum (ER) stress conditions 
was performed to determine whether modifications are altered as previously reported 
for thapsigargin (Tg)-treated cells5. Only a slight increase in AMPylated HSPA5 was 
observed in HeLa and A549 cells. Normalization of the AMPylation upon Tg-treatment 
to the increased levels of the HSPA5 expression in HeLa shows overall decrease of the 
AMPylation on HSPA55. Despite the moderate impact of ER stress on AMPylation in 
these cells, we found 145 dysregulated proteins in SH-SY5Y neuroblastoma cells (Fig. 
S7). The high amount of AMPylated proteins in SH-SY5Y under baseline and ER 
stress conditions indicates that AMPylation may have a specific role in the nervous 
system. 
 
 
Figure 3 | AMPylation in cancer cell lines, FICD-dependent AMPylation and FICD-
interacting proteins. a, Heatmap representation of enriched proteins identified in cancer cell 
lines. Colour represents distance to zero of enriched proteins from respective volcano plot (FDR 
0.05, s0 0.3; n = 8 or 9). b, Changes in AMPylation on selected proteins (those identified in 
HeLa cells from Fig. 1e) upon FICD overexpression (OX) or siRNA-mediated knock-down in 
(KD) HeLa cells. Statistical significance was tested using two-tailed Student’s t-test; *𝑃 < 0.05 
**𝑃 < 0.01, ***𝑃 < 0.001. c, Volcano plot representing FICD interacting proteins identified in the 
pull-down experiment of his tag labelled FICD and DSSO cross-linking reagent (FDR 0.01; s0 
1.5; n = 3). Green circles represent proteins identified as AMPylated in HeLa cells. Red circles 
represent hits overlapping with parallel experiment with FICD E234G mutant. Orange circles are 
hits enriched only with wt FICD. d, Panther Pathways enriched from FICD-interacting proteins, 
cut-off FDR 0.05. 
 
Chemical-proteomics profiling reveals remodelling of AMPylation during 
neuronal differentiation. The large number of hits in neuroblastoma cells (Fig. 3a) 
indicates a specific importance of AMPylation in neural cells. To study AMPylation in a 
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model system of developing neurons, neural progenitor cells (NPCs) and neurons were 
generated from human induced pluripotent stem cells (iPSCs, Fig. S10)35. 
Successively, iPSCs, NPCs and neurons were each treated with pro-N6pA and the 
enriched proteins were analysed via LFQ LC-MS/MS (Fig. 4a, Fig. S11 and S12 and 
Table S1 and S9). While PFKP was AMPylated in both the proliferating cell lines and 
neurons, the proteins CTSB, PSAT1 and PPME1 were only AMPylated in proliferating 
cells. Importantly, neurons exhibited the largest number of significantly and 
differentially AMPylated proteins (55 total), including transport proteins (KIF21A, 
KIF5C, MYH3, MYH7, MYH8) and cytoskeletal proteins (TUBB, TUBB2B, TUBB3B, 
TUBB4B, MAP2) (Fig. 4a). This is of particular interest as the cytoskeletal remodelling, 
which is required for neuronal polarisation, migration, and proper axon guidance, is a 
highly dynamic processes precisely regulated by several PTMs on tubulin and 
microtubules - and AMPylation may indeed be an additional one (Fig. S13)6,7,36,37. 
AMPylation remodelling could be involved in the process of cell type specification and 
differentiation from iPSCs through NPCs to neurons, with cellular proteins undergoing 
substantial de- and re-AMPylation following an hourglass-like model (Fig. 4b, Fig. 
S11)2,3,20. Further, parallel chemical-proteomics studies of AMPylation under ER stress 
induced by Tg in iPSCs, NPCs and neurons showed distinct responses ranging from a 
strong change of AMPylation on several proteins in iPSCs over mild alterations in 
NPCs to an obvious upregulation on two proteins (HSPA5 and SQSTM1) in neurons 
(Fig. S11). 
 To specify if the observed AMPylation in neurons is common for differentiated 
postmitotic cells we performed chemical profiling in fibroblasts (Fig. 4c, Fig. S14). 
Analysis of the enriched proteins revealed similarities with tested cancer cells and 
proliferating cell types. Most significantly enriched proteins included HSPA5, CTSB, 
PFKP and PPME1, all common to the proliferating cells. This highlights a distinct 
AMPylation remodelling in neurons. 
GO term analysis of AMPylated proteins found in all screened cell types using 
the Panther Pathway tool displayed enrichment of basal metabolism such as TCA cycle 
and glycolysis as well as neuronal specific pathways including cytoskeletal regulation 
by Rho-GTPase and FGF signalling. Interestingly, pathways marking neuro-
degenerative diseases, e.g. Alzheimer, the disease-amyloid secretase pathway and 
Huntingtin disease were identified as well (Fig. 4d). 
FICD and AMPylated proteins have different cellular localisations. The chemical-
proteomic results were corroborated by fluorescence imaging of probe-treated HeLa, 
iPSCs, NPCs and neurons (Fig. 5, Fig. S15 and Table S8). In order to rule out signals 
derived from N6-propargyladenosine nucleotide incorporation into RNAs (e.g. in polyA 
tails of mRNA)38, we performed a control experiment in which the RNA of the fixed cells 
was digested with different concentrations of RNase prior to click-chemistry and as 
positive control of the RNase digest 5-ethynyl uridine (5-EU) stained RNAs were 
degraded in parallel to pro-N6pA labelling. Indeed, we observed only a slight decrease 
in overall cell staining by pro-N6pA rather than disappearance of the bright AMPylation 
spots, while we observed a strong decrease in 5-EU labelling (Fig. S16). 
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Figure 4 | AMPylation remodelling is specific for the development of the neuronal cells. a, 
Heatmap representation of enriched proteins identified in different cell types and COs. Color 
represents distance to zero of enriched proteins from respective volcano plot (FDR 0.05, s0 0.3; 
n = 8 or 9). b, The hourglass model of AMPylation remodelling hypothesises a complete de- and 
re-AMPylation in the process of neuronal differentiation: from a high number 
of AMPylated proteins in proliferative iPSCs, most of which are involved in metabolic processes 
and possess catalytic activity, differentiating cells pass through a state of very 
sparse AMPylation as NPCs, with final neuronal differentiation resulting in neuronal identity with 
a high number of newly and uniquely AMPylated proteins which are enriched in metabolic 
functions on the one hand and in cytoskeletal and molecular motor functions on the other hand. 
c, Volcano plot of fold-enrichment by pro-N6pA labelling compared to DMSO versus 
significance upon two-sample t-test (FDR 0.05, s0 0.3; n = 9) in fibroblasts. Red circles 
represent proteins identified AMPylated in proliferating cell types while blue circles stand for 
overlap with hits in neurons. d, Panther Pathways enriched within the identified AMPylated 
proteins in all tested cell types, cut-off FDR 0.05. 
 
Given that the cellular localisation of FICD and AMPylated proteins might play 
an important functional role, we combined click chemistry with rhodamine-azide for 
intracellular probe visualisation with immunohistochemistry (IHC) for FICD and various 
cellular markers: PDI for rough endoplasmic reticulum, GM130 for Golgi complex, 
TUBB3 for total neuronal microtubule cytoskeleton, MAP2 for neuronal dendrites, 
phospho-TAU for neuronal axons, and DAPI to visualize nuclei (Fig. 5, Fig. S15). 
Staining performed in HeLa cells revealed that AMPylated proteins are enriched in the 
nucleus, additional small spots were found in the cytoplasm partially overlapping with 
the ER. As expected, FICD is localized in the ER but also present in the cytoplasm and 
nucleus (Fig. 5a). On the contrary, in NPCs AMPylation strictly localized next to the 
rough ER and in the nucleus, while FICD is ubiquitously distributed (Fig. 5b, c). In 
neurons, AMPylation was observed in nucleus and to a lesser extent in neurites, 
including MAP2+ dendrites and phospho-TAU+ axons (Fig. 5d-g). Here, FICD is 
localized in the nucleus, cytoplasm as well as ER (Fig. 5d). Finally, fibroblasts showed 
another specific localisation pattern with AMPylation accumulated around the nucleus 
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and its’ complete absence inside, while FICD is homogenously spread across the cells 
(Fig. S15). Differences in localisation of FICD and AMPylated proteins support the 
presence of additional AMP transferases with complementary cellular distribution.  
Decrease of FICD levels in in vitro neural model systems reveals a role of FICD-
dependent AMPylation remodelling in neuronal differentiation. To understand if 
FICD-mediated AMPylation plays a role in neuronal differentiation, we utilized both 
NPC-to-neuron differentiation and the recently developed 3-dimensional human 
cerebral organoids (COs)39,40. COs contain areas which closely resemble the structure 
and organisation of the germinal zones of developing human neocortex (Fig. S17)41. 
Treatment of COs with pro-N6pA and subsequent analysis via LFQ LC-MS/MS 
confirmed the AMPylation of PFKP, found in all cell types, and CTSB, another 
prevalent target in other studied cell lines (Fig. 4a and Fig. S5 and S12). Analysis of the 
significantly enriched proteins using a STRING database revealed that several proteins 
are located in extracellular space (Fig. S13). Interestingly, visualization of the pro-
N6pA probe-treated COs via click-chemistry with rhodamine-azide revealed strongest 
fluorescence in the neuronal layer (Fig. 5i, j and Fig. S15), which is in line with the 
highest number of AMPylated proteins identified in neurons (Fig. 4a). 
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Figure 5 | Characterization of intracellular FICD and probe localisation in HeLa (a), NPCs 
(b, c), neurons (d-g) and cerebral organoids (h-j). Click chemistry of pro-N6pA with 
rhodamine-azide and immunohistochemical stainings. a, HeLa cells contain big nuclear (DAPI – 
blue) clusters of AMPylated proteins (pro-N6pA, red) and additional, small cytoplasmic spots of 
probe localisation. FICD colocalises with rough ER (PDI – white) and is present both in nucleus 
and cytoplasm. FICD rarely colocalises with probe-containing proteins. b, In NPCs, probe-
containing AMPylated proteins (pro-N6pA, red) localize mostly to ER and only rarely with Golgi 
(GM130, green) with additional small nuclear and cytoplasmic clusters. c, FICD localizes to the 
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ER, nucleus, and the cytoplasm including short processes of NPCs. d, In differentiated neurons, 
clusters of AMPylated proteins localise to nucleus and processes (white arrows), both inside 
and outside rough ER, partly overlapping with FICD. FICD also localises to nucleus and cytosol 
including neuronal processes and only partly to ER. e, Pro-N6pA partly colocalises with the 
TUBB3+ neuronal cytoskeleton (green, white arrows), with TUBB3 being identified as 
AMPylation target in neurons. f, AMPylated proteins can be found both in neuronal dendrites 
(MAP2+, green, white arrows indicating colocalisation; also identified as neuronal AMPylation 
target) and g, in axons (phosphoTAU+, green, white arrows for colocalisation). h, In cerebral 
organoids, FICD (green) is enriched in the DCX+ neuronal layer (white), which is in line with 
qPCR data from 2D in vitro generated NPCs and neurons (Fig. S18). i, j, AMPylated proteins 
are enriched right below and within the neuronal layer (TUBB3+ and MAP2+, green) and 
include TUBB3 (g, white arrows indicating colocalisation) and MAP2 (h, white arrows indicating 
colocalisation). See also Fig. S15. 
 
To examine the function of AMPylation in neurogenesis and neuronal 
differentiation in more detail, we first characterized the expression of FICD in NPCs, 
neurons, neuroblastoma cells and COs and found a clear enrichment of FICD in the 
neurites of neurons, SH-SY5Y and in the neuronal layer of COs compared to the 
progenitor zone (Fig. 5d, h; Fig. S15). Results of imaging were paralleled by qPCR 
studies demonstrating higher baseline expression levels of FICD in neurons compared 
to iPSCs and NPCs (Fig. S18). We knocked down FICD levels (Fig. S19) in NPCs 
differentiating to neurons (Fig. 6a, b) and found a significant increase in transfected 
cells that remain in cell cycle (KI67+) (Fig. 6a). This result suggested a potential role of 
FICD-mediated AMPylation in neurogenesis. We then performed down- or upregulation 
of FICD expression in ventricle-like germinal zones of 50 days old COs by 
electroporation, as this model system better resembles the 3-dimensional organization 
of the developing brain. Only apical radial glia cells (aRGs), which are bipolar neural 
stem cells that will subsequently give rise to intermediate progenitors and neurons 
directly, are capable of taking up the vectors via their apical process to the ventricle-like 
lumen (Fig. 6c). To asses if FICD-mediated AMPylation has a function in neurogenesis 
during development, COs were analysed 7 (Fig. 6 and 7, Fig. S20) and 14 days post-
electroporation (dpe) (Fig. S21). Cortical-like germinal zones were defined by 
immunohistochemical (IHC) analysis using PAX6 as a marker for dorsal aRGs (Fig. 6d, 
Fig. 7b) with mitotic cells labelled for PH3 (Fig. 6e, Fig. S20). The position and number 
of neurons was analysed by IHC using two different markers for mature neurons: 
MAP2, a microtubule-associated protein which is enriched in neuronal dendrites (Fig. 
7c, Fig. S20) and the nuclear marker NEUN (Fig. 6g, Fig. 7d). Most of miRNA-
transfected (GFP+) cells (FICD KD) were positive for PAX6 (Fig. 6d) 7 dpe. The 
proportion of mitotic PH3+GFP+ cells was significantly increased (Fig. 6e, f) at the 
expense of neurons, as shown by the significantly reduced number of NEUN+GFP+ 
cells (Fig. 6g, h). 
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Figure 6 | AMPylation remodelling in differentiating neurons and cerebral organoids by 
downregulation of FICD levels keeps cells in a cycling state. a, FICD knockdown (KD) in 
neural progenitors (NPCs) differentiating to neurons inhibits cells from cell cycle exit. NPCs 
were transfected with miRNAs targeting FICD (Fig. S19) and cultured under differentiating 
conditions for 7 days. IHC stainings for the proliferation marker KI67+ and the early neuronal 
marker doublecortin (DCX) showed that FICD KD leads to a significant increase in KI67+ 
compared to control, while the amount of generated neurons tends to be decreased (analysis of 
3 coverslips/condition with at least 20 transfected cells each; two-tailed Student’s t-test: KI67+: 
*P<0.05 ; DCX+: P = 0.068). b, Example image of transfected and IHC stained culture with 
transfected cells (GFP+) in green, proliferating cells (KI67+) in red and differentiating neurons 
(DCX+) in white. c, Scheme showing the electroporation of DNA into ventricle-like structures of 
cerebral organoids (COs) and the organisation of different cell types within the germinal zone. 
DNA (constructs are listed; supplemented with fast green for visualisation) is injected into the 
lumen and taken up by aRG via their apical processes. The transfected construct can be found 
in IPs and neurons upon differentiation of transfected aRG (green, 7 days post electroporation 
(dpe)) (VZ = ventricular zone, SVZ = subventricular zone, IZ = intermediate zone, CP = cortical 
plate; aRG = apical radial glia, bRG = basal radial glia, IP = intermediate progenitor). d, Upon 
acute miRNA-mediated KD of FICD in ventricles of COs (50d+7), most GFP+ cells (green) have 
aRG identity (PAX6+, white). e, f, FICD KD leads to an increased number of cycling progenitors 
(e, IHC staining for PH3+ cells in M-Phase. GFP+ PH3+ cells marked by yellow arrowheads; f, 
Quantification of GFP+ PH3+ progenitor cells 7 dpe). g, h, aRG transfected with FICD-targeting 
miRNAs differentiate less to neurons (g, IHC staining for neuronal nuclei marker NEUN, red; 
GFP-positive neurons shown by white arrowheads; h, Quantification of GFP+ neurons 7 dpe 
shows significant decrease upon FICD knockdown). d, e, g, 50+7d old organoids; 
electroporated cells and their progeny shown in green; Scalebar = 50 µm, dotted line = apical 
surface. f, h, 1n = 1 electroporated germinal zone; box plot: mean (red line), median (black line), 
box represents 25th and 75th percentiles, whiskers extend to 10th and 90th percentiles, all 
outliers are shown; Significance was tested using Kruskal-Wallis One-way ANOVA on Ranks 
and Dunn’s Pairwise Multiple Comparison (*** 𝑃 < 0.001 ). See also Fig. S19 for miRNA 
validation, Fig. S17 for characterisation of COs, and Fig. S20 for analysis of MAP+ neuronal 
processes upon FICD KD in COs.  
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Forced expression of FICD wt and E234G in vitro leads to an increased neuronal 
differentiation. Conversely, when electroporating vectors carrying wt FICD, activated 
FICD E234G mutant or catalytically inactive FICD H363A mutant into ventricles of 50 
days old COs, those transfected with FICD wt or E234G showed an increase and 
redistribution in fluorescent signal upon pro-N6pA treatment indicating a remodelling of 
AMPylation upon FICD overexpression (Fig. 7a), while there were no changes in 
distribution or intensity of the signal upon OX of FICD H363A used as a control (Fig. 
S20). Despite the lack of obvious changes in differentiation with the FICD H363A 
control we cannot exclude other cellular processes to be affected by this methodology. 
Similar increase in fluorescent signal was observed in pro-N6pA treated SH-SY5Y 
cells upon transfection with wt FICD and FICD E234G mutant (Fig. S22). The opposite 
was the case upon FICD KD in CO ventricles (Fig. S20). Upon FICD wt or E234G OX 
in COs, progenitor zones had regions sparse in PAX6+ cells (Fig. 7b). At the same 
time, MAP2+ neurites increasingly invaded these progenitor zones 7 dpe (Fig. 7c, blue 
arrowheads; S20) and 14 dpe (Fig. S21), which was not the case upon control or FICD 
H363A electroporation (Fig. 7c), nor upon FICD KD (Fig. S20). Interestingly, both the 
E234G mutant and wt FICD-transfected aRGs gave rise to a significantly higher 
number of neurons compared to H363A inactive mutant or control already at 7 dpe 
(Fig. 7e, f), which was consistent also at 14 dpe (Fig. S21).  
Thus, FICD may regulate the transition from neural progenitors to neurons. The 
direct comparison to catalytically inactive FICD H363A, showing no difference to 
control condition, demonstrates the importance of FICD catalytic activity in proper 
progenitor cell cycle exit and neuronal differentiation. These results suggest that 
remodelling of AMPylation may play a role in neuronal differentiation during human 
brain development. However, it remains to be investigated whether the specific 
AMPylation/de-AMPylation activity on HSPA5 and subsequent changes in the UPR are 
responsible for modulation of the neuronal differentiation, which would be supported by 
the known connection between UPR and brain development.42 Alternatively, the 
synergistic action of AMPylation on cytoskeletal protein targets and associated 
changes in cellular polarization as described for MAP6 palmitoylation could be 
responsible for these effects.43 
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Figure 7 | AMPylation remodelling in cerebral organoids by FICD overexpression 
increases neuronal differentiation. FICD wt, E234G and H363A were overexpressed in 50d 
old cerebral organoids (COs, see Fig. 6c for electroporation scheme) and sections were 
analysed 7 days later by immunohistochemistry (IHC). a, Acute overexpression (OX) of FICD wt 
and E234G (green) in ventricles of COs (50+7d) leads to remodelling of AMPylation, visualised 
by the redistribution of fluorescence labelling using pro-N6pA (red). b, Germinal zones rich in 
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cells overexpressing FICD wt or E234G (green) show patchy “holes” lacking PAX6+ dorsal 
NPCs (grey) in their ventricular zone (VZ) (indicated by grey circle). c, Upon FICD wt and 
E234G OX, MAP2+ neuronal processes (red) increasingly extend into the VZ (blue 
arrowheads), which does not occur upon control and FICD H363A OX. d, e, RGs 
overexpressing FICD wt or E234G show increased differentiation to neurons compared to 
control. (d, IHC staining for nuclei of differentiated neurons (NEUN, red; GFP+ neurons shown 
by white arrowheads, GFP+ neuron in the progenitor zone by blue arrowhead. e, Quantification 
of GFP+ neurons shows significant increase upon FICD wt or E234G OX). f, OX of the 
catalytically inactive FICD H363A does not lead to an increase in GFP+ neurons. a, b, c, d, 
50+7d old organoids; electroporated cells and their progeny shown in green; Scalebar = 50 µm, 
dotted line = apical surface. e, f, 1n=1 electroporated germinal zone; box plot: mean (red line), 
median (black line), box represents 25th and 75th percentiles, whiskers extend to 10th and 90th 
percentiles, all outliers are shown; significance was tested using Kruskal-Wallis One-way 
ANOVA on Ranks and Dunn’s Pairwise Multiple Comparison (**𝑃 < 0.01 ; ***𝑃 < 0.001). 
See also Fig. S20 for analysis of PH3+ progenitors upon FICD wt/E234G/H363A OX in COs 
and for scoring of MAP2+ progenitor cells intruding the VZ upon FICD KD or FICD 
wt/E234G/H363A OX in COs. 
 
Discussion 
Our pro-N6pA phosphoramidate probe design facilitated in situ identification of 
162 potentially AMPylated proteins in different cell types and uncovered FICD as a 
modulator of neuronal differentiation. We successfully identified FICD dependent 
AMPylation as exemplified on HSPA5 and FICD independent AMPylation as shown for 
other proteins like PFKP, PPME and SQSTM1. FICD is the only known human 
AMPylator and all previous studies utilize this enzyme for deciphering substrates in 
vitro. Our in situ approach is global and does not only depend on FICD. Thus FICD-
independent AMPylation supports the existence of additional AMP transferases such 
as an emerging group of pseudokinases which were identified as AMPylators in 
eukaryotic cells17. Moreover, our in situ profiling allowed to screen AMPylation 
remodelling during neuronal development from iPSCs in 2D and 3D in vitro 
approaches, connecting biological implications of FICD dependent AMPylation/de-
AMPylation with human brain development: Acute KD of FICD in differentiating 
neurons (2D) and cerebral organoids (3D) kept cells in a cycling state, while OX of the 
only known human AMPylating enzyme was shown to drive the differentiation of NPCs 
to neurons in cerebral organoids. The subtle but always significant dysregulation of 
neurogenesis resulting from FICD OX and KD may be caused by impaired AMPylation 
remodelling, influencing catalytic activity of metabolic enzymes or stability of 
cytoskeletal proteins. The remarkable number of AMPylated targets identified 
altogether in NPCs, neurons and COs indicates a synergistic influence in fine-tuning 
neurogenesis, but it is not trivial to pinpoint the function of each target protein 
individually, leaving the precise molecular mechanism unresolved. Furthermore, 
alternation of the neuronal differentiation process might be influenced as well through 
the AMPylation of HSPA5 and successive changes in UPR.16 
Our study highlights both the promises and challenges of using chemical-
proteomics for identification of protein PTMs. Although we have successfully identified 
a large group of AMPylated proteins in various cell types and elucidated its functional 
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implications, the method itself yielded rather low rate of identified sites needed for 
biochemical testing of the AMPylation function in vitro. Although we were able to 
identify seven sites and show that this PTM can inhibit target protein activity, as 
exemplified by CTSB, the abundance of AMPylation likely limits in situ detection. 
Future studies will thus focus on methods to quantify AMPylation levels and fine-tune 
enrichment and MS-based detection procedures. Interestingly, taking together both 
approaches of chemical-proteomics and fluorescence imaging utilizing the pro-N6pA 
probe suggests a cell type-specific AMPylation pattern. This is a combination of the 
particular AMPylated proteins and their intracellular localisation in a certain cell type. 
For example, postmitotic fibroblasts exhibit highly enriched proteins shared with the 
proliferating cell lines, but their subcellular localisation is very distinct from the 
localisation in the cycling cells. Aside the dependence of AMPylation on the cell type, 
we have shown with the example of thapsigargin-induced ER stress that the prevalent 
environmental condition can affect AMPylation.  
With these features, we believe our method will lead to discovery of new 
functions for protein AMPylation beyond neuronal development e.g. in stem cell 
differentiation, unfolded protein response or regulation of complex network of cysteine 
cathepsins. 
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METHODS 
Synthesis. The nucleoside (N6-propargyl adenosine, N6pA) and the rhodamine-biotin-
azide tags were synthesized as described previously44,45. Synthesis of the 
phosphoramidate probe pro-N6pA is described in the Supplementary Information 
following a methodology described previously46. Chemical identity and samples purity 
were established using NMR, HRMS and HPLC analysis. 
 
Cell lines. Human epitheloid cervix carcinoma cells (HeLa, CCL-2) and human lung 
carcinoma cells (A549) were cultivated in high glucose Dulbeccos´s Modified Eagle´s 
Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and 2 mM l-
glutamine. Cells were grown under a humidified atmosphere at 37 °C and 5% CO2. 
Cells were seeded into 6 cm diameter dishes and grown to 80-90% confluency. Human 
neuroblastoma cells SH-SY5Y (CRL-226) were cultivated in DMEM/F12 1:1 media 
supplemented with 10% (v/v) FBS. 
 
Chemical-proteomics. Cells were treated with the probes at 80-90% confluency (n 
represents number of cell culture dishes). Culture medium was removed and the cells 
or COs were labelled in fresh media containing 100µM N6pA or 100µM pro-N6pA 
(both stocks 100mM in DMSO) for 16 h at 37 °C in cells incubator. Subsequent cell 
lysis, click chemistry, avidin beads enrichment and MS sample preparation were 
performed as described previously22-24,47. A total amount of 500 µg (HeLa, A549, SH-
SY5Y or COs) or 250 µg (iPSCs, NPCs, neurons) of proteins in lysate was used for 
each MS sample preparation. For details see Supplementary Information.  
 
Site identifications. Site identification experiments were performed in HeLa and SH-
SY5Y cells and COs. Cells or COs were cultivated and treated with pro-N6pA. After 
the cells lysis and protein concentration measurement, 3.6 and 16 mg of HeLa or 6 mg 
of SH-SY5Y or 8 mg of CO protein lysates were used for further MS sample 
preparations. The protocol used for enrichment and digest with TEV-cleavable linker 
was adapted from ref. 28. For details see Supplementary Information. 
 
Mass Spectrometry. Nanoflow LC-MS/MS analysis was performed with an UltiMate 
3,000 Nano HPLC system coupled to an Orbitrap Fusion or Q Exactive Plus (Thermo 
Fisher Scientific). Fragments were generated using higher-energy collisional 
dissociation (HCD) and detected in the ion trap at a rapid scan rate. Raw files were 
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analysed using MaxQuant software with the Andromeda search engine. Searches were 
performed against the Uniprot database for Homo sapiens (taxon identifier: 9606, 7th 
July 2015, including isoforms). At least two unique peptides were required for protein 
identification. False discovery rate determination was carried out using a decoy 
database and thresholds were set to 1 % FDR both at peptide-spectrum match and at 
protein levels. For AMPylation site identification spectra were searched for AMP 
conjugated with TEV tag (+694.2700) and only one unique or razor peptide was 
required. For details of MS measurement and data analysis see Supplementary 
Information and Tables S1, S4 and S9. 
In vitro CTSB activity assay. Cathepsin B (CTSB, 0.4 g/L, R&D Systems) was 
diluted in activation buffer (25 mM MES, 5 mM DTT, pH 5.0) to 10 g/mL and 
incubated at 25 °C for 25 min. The activated CTSB was further diluted to 2 g/mL in 
AMPylation buffer (20 mM Hepes, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, 0.1 mg/mL 
BSA, pH 7.5) and supplemented with 100M ATP, 2.8 M wt FICD or FICD E234G 
mutant (gift from A. Itzen, TUM) or ddH2O and incubated at 25 °C for 0 – 6 h. 
Subsequently, 3 L of the mixture was used in 57 L assay buffer (25 mM MES, 10 M 
Z-Arg-Arg-7-amido-4-methylcoumarin hydrochloride (Sigma), pH 5.0) in 96-well plate 
and the fluorescent intensity was read by TECAN 200M Pro after 20 min using 380 nm 
and 460 nm as excitation and emission wavelengths. 
 
iPSC culture. Induced pluripotent stem cells reprogrammed from fibroblasts (for 
reprogramming see Supplementary Information) were cultured at 37 °C, 5 % CO2 and 
ambient oxygen level on Geltrex coated plates (Thermo Fisher Scientific) in mTeSR1 
medium (StemCell Technologies) with daily medium change. For passaging, iPSC 
colonies were washed with PBS and incubated with StemPro Accutase Cell 
Dissociation Reagent (A1110501, Life Technologies) diluted 1:4 in PBS for 3 minutes. 
Pieces of colonies were washed off with DMEM/F12, collected by 5 min centrifugation 
at 300 x g and resuspended in mTeSR1 supplemented with 10 µM Rock inhibitor Y-
27632(2HCl) (72304, StemCell Technologies) for the first day. 
 
Generation of neural progenitor cells (NPCs) and neurons from iPSCs. Neural 
progenitors were generated as described previously35 with the following modifications. 
Embryoid bodies (EBs) were generated from feeder-free iPSCs by incubating colonies 
with Collagenase Type IV (7909, StemCell Technologies) for 10 min, followed by 
washing with DMEM/F12, manual disruption and scraping with a cell lifter (3008, 
Corning Life Sciences). Resulting pieces of colonies were plated in suspension in 
Neural Induction Medium (NIM) consisting of DMEM/F12+Hepes (31330095, Life 
Technologies) with 1x N2 and B27 supplements (without vitamin A, Thermo Fisher) 
with medium change every other day. Resulting NPCs were passaged using Accutase 
(StemCell Technologies) and split at a maximum ratio of 1:4. NPCs were only used for 
up to seven passages. For differentiation to neurons, single NPCs were plated at a 
density of 104 cells/cm2 on Polyornithine/Laminin plates and cultured in NPM for 1 more 
day to reach about 30% cell density. Afterwards, medium was changed to Neuronal 
Differentiation Medium NDM (NIM containing 20 ng/mL BDNF (248-BD, R&D Systems) 
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and 20 ng/mL GDNF (212-GD, R&D Systems)) and cells were differentiated for 40 
days with medium change every 5 days. 
 
Cerebral organoids. Cerebral organoids were generated starting from 9,000 single 
iPS cells/well as previously described40. Organoids were cultured in 10 cm dishes on 
an orbital shaker at 37 °C, 5% CO2 and ambient oxygen level with medium changes 
twice a week. Organoids were electroporated at 50 days after plating (see 
Electroporation of cerebral organoids) and analysed 7 and 14 dpe. For 
immunostaining, 16 µm sections of organoids were prepared using a cryotome. For 
analysis 7 dpe, 24-34 different ventricles in 7-12 organoids from 2 independent batches 
were analysed per construct. For 14 days, 4 organoids per construct with altogether 
13-21 electroporated ventricles per construct were analysed. 
 
Generation and validation of microRNAs targeting FICD: MicroRNAs (miRNAs) 
targeting FICD were generated using the BLOCK-iT system from Invitrogen (Thermo 
Fisher, Waltham, MA, USA). MiRNA sequences were determined using Invitrogens 
RNAi design tool 
https://rnaidesigner.thermofisher.com/rnaiexpress/setOption.do?designOption=mirnapi
d=1961720787891316464, accessed on December 6th, 2017, with the NCBI 
Reference Sequence NM_007076.2 as seed sequence. Three miRNA sequences were 
chosen and ordered as oligonucleotides from Sigma. FICD miRNA oligonucleotides 
were annealed and ligated into a GFP-containing entry vector pENTR-GW/EmGFP-
miR using T4 DNA Ligase (Thermo Fisher, Waltham, MA, USA). Subsequently, the 
miRNA sequences were cloned into the pCAG-GS destination vector using the 
Gateway system (Thermo Fisher). The resulting miRNA expression plasmids were 
sequenced, the knockdown efficiency was validated in Hela cells via qPCR and 
Westernblot and the most efficient construct was used for NPC transfection and for 
electroporation of COs (Fig. S19, Fig. 6). 
 
 
Transfection of differentiating NPCs. For transfection of differentiating NPCs, 104 
cells/cm2 were plated on Polyornithine/Laminin-coated coverslips in 24-well plates. 
After one day in NPM (see Generation of neural progenitor cells (NPCs) and neurons 
from iPSCs), medium was changed to growth-factor free NIM (see Generation of neural 
progenitor cells (NPCs) and neurons from iPSCs.) to generate differentiating 
conditions. 4 days after plating, NPCs were transfected with 500 ng DNA/well following 
Lipofectamine® 3000 protocol (Thermofisher) and continuously cultured in NIM with 
medium change every other day. Cells were fixed 7 days post transfection with 4 % 
PFA for 20min at RT and processed by immunohistochemistry. 
 
Electroporation of cerebral organoids. For electroporation (see scheme in Fig. 6c), 
cerebral organoids were kept in NDM+A without antibiotics. The organoids were placed 
in an electroporation chamber (Harvard Apparatus) and pCMV-SPORT6 plasmid with 
FICD wt, FICD E234G (gift from A. Itzen, TUM), or FICD H363A plus pCAG-IRES-GFP 
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(FICD to GFP ratio 2:1), GFP only as overexpression control, miRNA against FICD (or 
scrambled miRNA negative control) in pCAG-GS at a concentration of 1 µg/µl, 
supplemented with fast green for visualization, was injected into ventricle-like cavities 
at several positions per organoid. Electroporation was performed with an ECM830 
electroporation device (Harvard Apparatus) by subjecting the organoids to a 1 second 
interval with 5 pulses of 50 ms duration at 80mV. 
 
Immunohistochemistry: Frozen organoid sections were thawn to rt for 20 min and 
then rehydrated in PBS for 5 min. For nuclear antigens, an antigen retrieval step 
(HIER) was performed in which the sections were boiled in 0.01M citric buffer pH 6 for 
1 min at 720 Watt and an additional 10 min at 120 W. Slides were then left to cool 
down for 20 min. Half of the citric buffer was replaced by H2O, slides were incubated for 
another 10 min and then washed in PBS. Subsequently, a postfixation step of 10 min 
was carried out with 4 % PFA in PBS. Then, the sections were permeabilized using 0.1 
% Triton X100 in PBS for 5 min. After permeabilization, sections were blocked at rt for 
at least 1 h with 10 % Normal Goat Serum in 0.1 % Tween in PBS. The primary 
antibody (Table S11 in Supplementary information) in blocking solution was then 
incubated overnight at 4 °C. Following several washes with 0.1 % Tween in PBS, 
sections were incubated with 1:1,000 dilutions of Alexa Fluor-conjugated secondary 
antibodies (Life Technologies) in blocking solution for at least 1h at rt, using 0.1 µg/ml 
4,6-diamidino-2-phenylindole (DAPI, Sigma Aldrich) to counterstain nuclei. Finally, 
sections were washed again several times with 0.1 % Tween in PBS and mounted with 
Aqua Polymount (18606, Polysciences). Sections were visualized using a Leica SP8 
confocal laser scanning microscope. Cells were cultured on round coverslips (13 mm 
diameter, VWR) in 24 well plates, washed with PBS and fixed with 4 % PFA in PBS for 
15 min at rt. HIER, permeabilization, blocking and staining were carried out as 
described for the organoid sections.  
 
Cell quantifications. For quantification of GFP+ mitotic cells or neurons upon NPC 
transfection or in electroporated CO ventricles, all GFP+PH3+ , GFP+KI67+, GFP+DCX+,  
and GFP+NEUN+ cells were counted using the cell counter plugin in Fiji48. Double 
positive cells were normalized to the total number of GFP+ cells. 
 
Statistics. Statistical analysis of the MaxQuant result table proteinGroups.txt (Table 
S2) was done with Perseus 1.5.1.6. Putative contaminants and reverse hits were 
removed. Dimethyl-labelling ratios or normalized LFQ intensities were log2-
transformed, hits with less than 3 valid values in each group were removed and -
log10(p-values) were obtained by a two-sided one sample Student’s t-test over 
replicates with the initial significance level of p = 0.05 adjustment by the multiple testing 
correction method of Benjamini and Hochberg (FDR = 0.05), the -log10 of p-values were 
plotted against the log2 of geometric mean of ratios “heavy”/”light” (H/L) for dimethyl 
labelling or by volcano plot function for LFQ. Distance from zero was calculated from 
significance and fold enrichments from respective volcano plot as 
𝑑 = √((𝑓𝑜𝑙𝑑 𝑒𝑛𝑟𝑖𝑐ℎ𝑚𝑒𝑛𝑡)2 + (𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑐𝑒)2). Venn diagrams were generated with a 
drawing tool at http://bioinfogp.cnb.csic.es/tools/venny/ using gene names as a key. All 
graphs were processed in Microsoft Excel or OriginPro 2017. Statistics for qPCR data 
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and quantifications of immunohistochemical stainings in cells and COs was performed 
in SigmaPlot (Version 13.0; Systat Software, San Jose, CA) using Kruskal-Wallis 
ANOVA on Ranks with Dunn’s Pairwise Multiple Comparison. For NPC transfection, 3 
coverslips with at least 20 transfected cells each were analysed. For COs, 2-4 batches 
of organoids were analysed for each construct (Data shown with n = total number of 
electroporated ventricles analysed per construct). 
 
Data availability. The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD012118 reviewer account detail, username: reviewer94371@ebi.ac.uk 
password: 2i1CmP0u. 
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(A) Supplementary Figures 
 
 
Figure S1 | Synthesis and cytotoxicity of pro-N6pA. a, Synthetic approach to 
pronucleotide probe. b, Cytotoxicity MTT assay of pro-N6pA probe. Dots represent the 
means of four replicates with standard deviation. 
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Figure S2 | In situ metabolic activation of the pro-N6pA probe to N6pATP. HeLa 
cells were treated with 100 µM pro-N6pA for indicated period of time. Horizontal 
represent the mean of the duplicates. 
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Figure S3  Validation of phosphoramidate pronucleotide probe pro-N6pA as 
probe for cellular AMPylation. a, Direct comparison of the pro-N6pA labelling in HeLa 
cells with immunostaining of the western blot using anti-AMPylated tyrosine antibody. 
b, Volcano plot visualization of fold-enrichment using pro-N6pA or parent nucleoside 
(N6pA) compared to DMSO (control) versus significance upon performing a two-
sample t-test (FDR 0.05, s0 0.3; n = 12 (pro-N6pA) or 11 (N6pA)). Pro-N6pA or N6pA 
treatment with 100 M probe, 16 h incubation. c, Volcano plot visualising the pro-N6pA 
identified targets using LFQ method in HeLa cells. d, Fluorescence SDS-PAGE 
showing immunoprecipitated PFKP and PPME1 from pro-N6pA treated HeLa cells. 
Immunoprecipitated proteins were labelled via click-chemistry with rhodamine-azide. e, 
Venn plot representing overlap of known ADP-ribosylated proteins and hits identified by 
pro-N6pA probe in HeLa cells. f, Inhibition of poly(ADP-ribose) polymerases by pre-
treatment of the HeLa cells with 20 mM 4-aminobenzamide (4-ABA) for 2 h before 
addition of pro-N6pA. g, Inhibition of poly(ADP-ribose) polymerases by pre-treatment of 
the HeLa cells with 10 µM Olaparib (Ola) for 2 h before addition of pro-N6pA. 
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Figure S4  AMPylation site identification on cathepsins in HeLa cells and 
inhibition of CTSB activity upon AMPylation by FICD. a, Scheme of site 
identification using the TEV-cleavable-linker. b, MS/MS spectra (MaxQuant) for the 
CTSB, CTSC and CTSL AMPylation site identification. CTSC AMPylation site was 
identified by two MS/MS scans with PEP scores 0.0224 and 0.0168. Additional sites on 
cathepsins were identified in SH-SY5Y cells and COs (Table S4). c, MS/MS spectra 
(MaxQuant) for the CTSS and CTSV identified in COs. d, In vitro CTSB peptidase 
activity upon incubation with wt FICD or E234A mutant at 25 °C for 0 – 6 h with or 
without ATP (0.1 mM). Boxes represent 25-75 percentile, whiskers stand for min and 
max values, square is mean value and line is median. 
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Figure S5 | AMPylation sites identified in SH-SY5Y cells and cerebral organoids. 
a, MS/MS spectra (MaxQuant) for the CTSB, CTSL AMPylation sites from SH-SY5Y 
cells. b, Cathepsins CTSV, CTSS AMPylation sites identified in cerebral organoids. c, 
Cathepsins CTSB, CTSC AMPylation sites identified in cerebral organoids (Table S4). 
 
 
 
 
Figure S6 | Comparison of proteins identified in previous studies16 and our 
study. 
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Figure S7  AMPylation is dependent on cell type and changes upon ER stress 
induction. a, b, Pro-N6pA 100 M probe, 16 h incubation. Complete list of the proteins 
identified by chemical-proteomic experiments is in Table S1 and S9. a, Volcano plot 
visualizations of fold-enrichment using pro-N6pA compared to DMSO versus 
significance upon performing a two-sample t-test (FDR 0.05, s0 0.3; n = 8) from in situ 
labelling of A549 and SH-SY5Y cells. The MS intensities were quantified in A549 via 
DiMe, in SH-SY5Y via LFQ. b, Volcano plot visualizations of fold-enrichment using pro-
N6pA upon Tg treatment (1 µg/mL, 24 h) compared to pro-N6pA treated cells versus 
significance upon performing a two-sample t-test (FDR 0.05, s0 0.3; n = 8 or 7 (HeLa + 
Tg)) from in situ labelling of HeLa, A549 and SH-SY5Y cells. The MS intensities were 
quantified in HeLa + Tg via DiMe, in A549 and SH-SY5Y via LFQ. c, Immunoblot of 
endogenous HSPA5 levels in HeLa cells without or with Tg treatment (1 µg/mL, 24 h). 
d, Graph representation of fold change in AMPylation and HSPA5 expression levels 
after Tg treatment based on normalized MS intensities (MaxQuant) and immunoblot 
analysis, respectively. e, f, Venn diagrams show minor overlap of known ADP-
ribosylated proteins with identified AMPylated proteins in different cell lines with or 
without induction of ER stress by Tg. 
 
 
Figure S8 | Volcano plots of FICD overexpression and knockdown in HeLa cells. 
a, Volcano plot of fold-enrichment by pro-N6pA in HeLa transfected with FICD or 
siRNA compared to pro-N6pA treated cells versus significance upon performing a two-
sample t-test (FDR 0.05, s0 0.3; n = 8). Green dots represent proteins identified as 
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AMPylated in HeLa cells. Red dots represent proteins which overlap for the presented 
three volcano plots. Orange dots represent other significantly enriched proteins see 
Table S6. b, Overexpression of FICD E234G in HeLa cells. In-gel analysis of the 
labelling with pro-N6pA probe. 
 
 
Figure S9 | Pull-down of FICD interacting proteins using DSSO crosslinker. a, 
Structure of the DSSO crosslinker. b, Workflow of identification of the FICD interacting 
proteins using the DSSO crosslinker. c, Volcano plot representing FICD E234G 
enriched proteins from HeLa cells. Green dots represent the proteins found AMPylated 
in HeLa cells (FDR 0.01; s0 1.5; n = 3). Red dots represent proteins which were 
significantly enriched in the parallel experiment with the wt FICD. Orange dots 
represent proteins significantly enriched only in this experiment see Table S7. 
 
 
 
Figure S10  NPCs and neuron preparation. Timeline for generation of Neural 
progenitor cells (NPCs) and neurons (according to ref. 31) and their treatment with pro-
N6pA (neural rosettes: yellow arrows; hIPSCs = human induced pluripotent stem cells; 
EBs = embryoid bodies; PO/L = poly-ornithine-laminin coated plates; NIM = neural 
induction medium; NPM = neural progenitor medium).  
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Figure S11 | Neurons show specific AMPylation of cytoskeletal and motor 
proteins. a, Volcano plot visualizations of fold-enrichment using pro-N6pA with or 
without Tg treatment (1 µg/mL, 24 h) compared to DMSO or pro-N6pA treated cells 
versus significance upon performing a two-sample t-test (FDR 0.05, s0 0.3; n = 9) from 
in vitro labelling of iPSCs, NPCs, neurons and COs.  
 
 
 
Figure S12 | Heat map summarising the data from all tested cell lines. a, Heatmap 
representation of enriched proteins identified in different cell types and COs; Colour 
represents the proteins’ distance from zero of enriched proteins from respective 
volcano plot (FDR 0.05, s0 0.3; n = 7 – 9). Table S1, S9. 
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Figure S13 | Network and GO Term Analysis of AMPylated Proteins. Network 
analysis of AMPylated (and not ADP-ribosylated) hits in cancer lines (a), iPSCs (b), 
NPCs (c), neurons (d), and COs (e) with examples of enriched GO Terms highlighted 
in different colours and stars marking recurrent hits (PFKP underlined as only hit found 
in all analysed cell types; green stars for hits in NPCs already present 
in iPSCs). Network Analysis was performed in STRING.db. See also Table S10. 
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Figure S14 | Fibroblasts chemical proteomics. Volcano plot of fold-enrichment in 
fibroblasts by pro-N6pA labelling compared to DMSO or pro-N6pA + Tg versus 
significance upon two-sample t-test (FDR 0.05; s0 0.3; n = 9). 
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Figure S15 | Characterization of intracellular FICD and probe localisation in HeLa, 
fibroblasts, iPSCs, NPCs, neuroblastoma, neurons and cerebral 
organoids.  a, AMPylated proteins (red) localise to the nucleus and rough ER (PDI, 
white) in HeLa, but not to cis-Golgi (GM130, green). b, In fibroblasts, FICD (green) is 
localised in the nucleus and cytoplasm, including processes. AMPylated proteins 
(red; b, c) accumulate in the perinuclear area, including ER (PDI, white, white 
arrows). c, with additional probe localisation to the processes, while the nucleus is free 
of probe signal. d, In iPSCs, AMPylated proteins form nuclear clusters similar to those 
in HeLa. e, Probe localises to NESTIN+ (green) processes (white arrowheads) in 
NPCs. f, FICD (green) is both in the nucleus and in processes of NPCs, partly 
colocalising with rough ER (PDI, red). g, IHC of FICD in SH-SY5Y neuroblastoma cells 
overlaid with DAPI, DCX and MAP2 markers reveals FICD localisation in cytoplasm 
and neurites (white arrowheads). h, Probe rarely localises to Golgi (GM130, green) in 
neurons (yellow arrowheads). i, Additional example showing the localisation of 
AMPylated proteins in MAP2+ (green) neuronal processes (white arrowheads). j-l, In 
cerebral organoids, AMPylated proteins accumulate basally, below and within the 
neuronal layer (MAP2+, green, j), with some degree of colocalisation with Golgi 
(GM130, green; k) and more with ER (PDI, white; l). 
 
 
 
Figure S16  pro-N6pA is specifically incorporated into proteins. RNAse treatment 
of cells cultured with pro-N6pA or 5-EU demonstrates that pro-N6pA is only to a small 
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extent incorporated into RNAs. a, HeLa cells were grown on coverslips in 24-well 
plates and incubated with 100 µM pro-N6pA for 16 h before PFA-fixation. Prior to 
addition of rhodamine-azide by click reaction, they were treated with different amounts 
of RNAse If (5U or 100U of RNAse per one well). The dotty pattern of localisation of the 
probe seems to be specific to the proteins it was incorporated in (Scalebar = 100 µm). 
b, 5-EU signal strongly vanishes with RNAse If treatment, whereas pro-N6pA staining 
does not. 
 
 
 
Figure S17  Cerebral organoids preparation and characterization. a, Timeline for 
generation of cerebral organoids and their treatment with pro-N6pA (according to ref. 
35), early neuroectoderm: grey arrows; expanded neuroepithelium: orange arrows; 
(EBs: embryoid bodies; hESC: low bFGF human embryonic stem cell medium; NIM: 
neural induction medium; Y: Rock inhibitor Y-27632; bFGF: basis fibroblast growth 
factor FGF-2; NDM: neural differentiation medium; +/- A: B27 supplement with or 
without vitamin A).  b, Generation of cerebral organoids containing germinal zones 
comprised of different cell types that arise during dorsal cortical development. The 
progenitor zone, consisting of proliferative (e.g. PH3+ for M-phase) PAX6+ radial glia is 
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apically delineated by ARL13B+ primary cilia of radial glia, pointing into the ventricle-
like lumen, and by apical junctions containing F-ACTIN and CTNNB1. Radial glia give 
rise to neuroblasts (DCX+) that migrate basally, where they differentiate fully to become 
NEUN+ neurons. The neocortical layers form in an inside-out manner with TBR1+ and 
CTIP2+ deep-layer projection neurons being generated first (Immunostainings of 
cerebral organoids cultured for 55-60 days, apical surface indicated by dotted line, 
Scalebar = 100 µm). 
 
 
 
Figure S18  Neurons exhibit higher expression levels of FICD. qPCR based 
analysis of FICD expression in different cell types confirms highest level in neurons. 
Error bars represent standard deviation.  
 
 
 
 
 
Figure S19 | Validation of miRNAs targeting FICD. miRNAs were generated 
following the BLOCK-iT™ Pol II miR RNAi Expression Vector Kits protocol by 
Invitrogen. Validation in HeLa via qPCR (a) and Westernblot (b, c) showed a 
knockdown efficiency to 50% of the control expression level both for RNA and protein 
(a: *P=0.029). 
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Figure S20 | pro-N6pA signal and MAP2+ processes in COs upon FICD KD, rating 
of MAP2 intrusion, and mitotic cells upon FICD OX. a, Click chemistry (red) in 
electroporated COs shows no difference in probe distribution in the case of catalytically 
inactive FICD H363A, but a decrease in signal upon FICD KD (transfected cells shown 
in green). b, IHC shows that MAP2+ neuronal processes (red) do not intrude the 
progenitor zone in COs upon FICD KD. c, d, e, Rating of intrusion of MAP2+ neuronal 
processes into the progenitor zone of COs electroporated with constructs for FICD KD 
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(c), FICD wt or E234G OX (d) or FICD H363A (e) shows increase upon FICD wt and 
E234G OX, but no change for KD and inactive FICD H363A. (Looking at IHC staining 
for MAP2, each ventricle was rated concerning the amount of neuronal processes 
inside the progenitor zone as 0 = none, 1 = few, 2 = many.) f, Example images of IHC 
for PH3+ mitotic cells (magenta) upon FICD wt/E234G/H363A OX in COs. g, h, 
Quantification of PH3+ electroporated (GFP+) cells in germinal zones of COs 
eletroporated with FICD wt or E234G (g) or H363A (h) shows significant decrease 
when wt or activated FICD is overexpressed, but no change for H363A.  
Electroporated organoids were analysed at 50d+7. a, b, f, electroporated cells and 
their progeny are shown in green; Scalebar = 50 µm; dotted line = apical surface. c, d, 
e, g, h, 1n = 1 electroporated germinal zone; box plot: mean (red line), median (black 
line), box represents 25th and 75th percentiles, whiskers extend to 10th and 90th 
percentiles, all outliers are shown; significance was tested using Kruskal-Wallis One-
way ANOVA on Ranks and Dunn’s Pairwise Multiple Comparison (∗P<0.05; ∗∗P<0.01 ; 
∗∗∗P<0.001).  
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Figure S21  Overexpression of FICD in radial glia accelerates neurogenesis. a, 
Scheme showing electroporated cells in CO germinal zone at day 0 and day 14: Over 
14 days culture after electroporation, transfected (green) radial glia cells give rise to 
more differentiated cell types (green IPs, immature migrating neurons and 
differentiated neurons on day 14).  b, Quantification of GFP+ neurons 14 dpe shows 
natural increase in GFP+ neurons over time (higher percentage than 7 dpe) and a 
significant increase in neuronal differentiation upon overexpression of FICD wt or 
E234G compared to control. c, Immunohistochemical (IHC) staining for electroporated 
cells (green) and neuronal dendrites (MAP2, red) shows neuronal processes in the 
progenitor zone. d, Immunostaining of electroporated cells (GFP, green) and nuclei of 
differentiated neurons (NEUN, red). a, e, f, Scalebar = 50 µm, dotted line = apical 
surface; b, d, Box plots: mean (red line), median (black line); box represents 25th and 
75th percentiles, whiskers extend to 10th and 90th percentiles, all outliers are shown; 
significance was tested using Kruskal-Wallis One-way ANOVA on Ranks and Dunn’s 
Pairwise Multiple Comparison (∗ P < 0.05;  ∗∗ P < 0.01 ;  ***𝑃 < 0.001).  
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Figure S22 | pro-N6pA signal upon FICD overexpression in SH-SY5Y cells. 
Transfection of SH-SY5Y cells with overexpression construct vs. GFP (3 µg DNA per 1 
Mio. cells), plating on 3 separate coverslips per condition. Pro-N6pA treatment for the 
last 16 h of culture. Fixation 48h post-transfection, followed by click-chemistry and 
nuclear counterstaining with DAPI. AMPylation signal was measured using Fiji, 
selecting transfected GFP+ cells and normalising to their area. Mean (red line), median 
(black line), box represents 25th and 75th percentiles, whiskers extend to 10th and 90th 
percentiles, all outliers are shown. One-tailed Student’s t-test. ***𝑃 < 0.001. 
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Cytotoxicity. Cytotoxicity of pro-N6pA and N6pA was measured by MTT assay. The 
IC50 of pro-N6pA is 300 µM and IC50 of N6pA is above 1 mM. pro-N6pA low cytotoxicity 
makes it suitable for the use in high concentrations for cell treatment (Fig. S1). 
 
Immunoprecipitation of PFKP and PPME1. In order to further corroborate the 
efficiency of incorporation of pro-N6pA probe as a protein PTM, the PFKP and PPME1 
proteins identified in HeLa cells were immunoprecipitated from pro-N6pA treated HeLa 
cell lysates and after the click-chemistry with rhodamine-azide and SDS-PAGE, in-gel 
fluorescence was scanned showing strong labelling at 85 kDa (PFKP) and 42 kDa 
(PPME1) while no signal was observed in control sample (without antibody) (Fig. S3). 
 
Cell type dependent changes in AMPylation during endoplasmic reticulum 
stress. Proteome profiling under endoplasmic reticulum (ER) stress was performed to 
determine whether modifications are altered as a result of HSPA5 upregulation, as 
previously reported for thapsigargin (Tg)-treated HEK293T cells3. Surprisingly, only a 
slight increase in AMPylated HSPA5 was observed in HeLa and A549 cells. Despite 
the moderate impact of ER stress on AMPylation in these cells, we found 145 
dysregulated proteins in SH-SY5Y (Fig. S7 and S12). This further corroborated the role 
of AMPylation in neuronal-like cells. Further, Tg induced ER stress in iPSCs, NPCs and 
neurons results in very distinguished changes in AMPylation (Fig. S11), with strong 
response in iPSCs and only two proteins were influenced in neurons. 
 
Site identifications on cathepsins in SH-SY5Y cells and cerebral organoids. In 
addition to the AMPylated serines identified on cathepsins in HeLa cells (Fig. 2 and Fig. 
S4) we confirmed the AMPylation on CTSB (S104 and S107) and CTSL (S137) also in 
SH-SY5Y cells (Fig. S5) and found two new sites on CTSV (S137) and CTSS (S135) in 
COs, the CTSB (S107) and CTSC (S254) AMPylation sites were confirmed (Fig. S5). 
See Table S4 for complete characterization. We used similarly to previous site 
identifications approach employing the TEV-cleavable linker (Fig. S4). 
 
HSPA5 is AMPylated on T518 in U2OS cells. In addition to the identified AMPylation 
sites on cathepsins using biotin-TEV-cleavable linker we have searched by MaxQuant 
MS spectra measured in ref. 42. These were acquired to identify the protein ADP-
ribosylation sites in bone osteosarcoma epithelial cells (U2OS) on Orbitrap Fusion 
using a combination of higher-energy collision-induced dissociation (HCD) and electron 
transfer dissociation (ETD) acquisition. The ETD ion source was triggered by adenine 
diagnostic peak (136.062 Da). Since both ADP-ribosylated and AMPylated peptides 
contain the adenine base this setup inherently leads to the raw MS spectres which 
include also an intact AMPylated peptides. The MaxQuant search for AMPylated 
peptides (+329.052 Da) revealed HSPA5 AMPylation on T518. This corroborates the 
findings by Preissler et al. (ref. 4 and 5). 
 
ADP-ribosylation exclusion. MS raw files obtained from site identification 
experiments using the TEV-cleavable linker were searched for potential ADP-
ribosylation (+906.2786) on the amino acids EDSTR. However, none of the identified 
ADP-ribosylation sites was included as a hit in the chemical-proteomic pull-down 
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experiments. A reference list of ADP-ribosylated proteins was adopted from ref. 23 and 
can be found in Table S3. To exclude experimentally incorporation of the pro-N6pA 
probe into ADP-ribosylation we have pre-treated HeLa cells with poly(ADP-
ribose)polymerases (PARP) inhibitors 4-aminobenzamide (4-ABA) or olaparib (Ola) 
before the pro-N6pA labelling, similarly reported in ref. 10. For both PARP inhibitors we 
have not observed any influence on labelling intensity or change in labelling pattern 
thus concluding that majority of the labelling yield from the AMPylation (Fig. S3). 
 
Protein interaction and GO term analysis. In order to understand if AMPylation plays 
a role in the regulation of specific biological processes or pathways, network and GO 
term analysis was performed using STRING.db43. Resulting networks for AMPylation 
targets identified in cancer cell lines and iPSCs have significantly more interactions 
than expected (cancer cell lines: PPI enrichment p-value P = 0.00028; iPSCs P = 
1.7∙ 10−5 and are significantly enriched for proteins with metabolic function (Table S1). 
In NPCs, there is only an enrichment for a single KEGG pathway (“biosynthesis of 
amino acids”) and the number of targets is very low. Their differentiation to neurons 
results in a state with a high number of AMPylated proteins again, which are different 
from those in pluripotent stem cells and NPCs and build a strongly interacting network 
(PPI enrichment p-value P = 0.000124). This network is, in addition to a new set of 
proteins involved in metabolic processes, significantly enriched for proteins with 
cytoskeletal and motor function (Table S10). Interestingly, these proteins are known to 
be important for neuronal development and function and have been shown to be 
modified by multiple other PTMs. Looking at AMPylated targets in iPSCs, NPCs and 
neurons, it becomes clear that during neuronal differentiation, cellular proteins undergo 
a process of complete remodelling of AMPylation that resembles an hourglass (Fig. 4b 
and Fig. S13): of many targets in iPSCS hardly any are left in NPCs and differentiation 
to mature neurons goes along with AMPylation of a big and unique group of new target 
proteins. As expected, additional targets were found in the more heterogeneous and 
complex COs. Thus, AMPylation of proteins known to play a role in neuronal 
development and function could represent one additional level of fine tuning and 
regulating cortical development. 
 
Overexpression of wt FICD and E234G mutant in SH-SY5Y cells. In order to 
quantify AMPylation upon different levels of FICD, wt FICD and E234G mutant were 
overexpressed in SH-SY5Y neuroblastoma cells. We observed a significant increase of 
AMPylation in SH-SY5Y cells upon transfection with wt FICD and FICD E234G mutant 
proteins (Fig. S22).  
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(B) Structures and synthesis 
 
General methods. Reagents and solvents were purchased from commercial suppliers 
(Sigma-Aldrich Co. LLC, Thermo Fisher Scientific Inc., Merck KGaA, TCI Europe 
GmbH, Fluorochem Ltd. and Alfa Aesar GmbH) and used without further purification. 
HPLC-grade solvents or anhydrous solvents (max. 0.01 % water content, stored over 
molecular sieve under an argon atmosphere, Sigma-Aldrich Co. LLC) were used for all 
reactions. All experiments were monitored by analytical thin layer chromatography 
(TLC). TLC was performed on pre-coated silica gel plates (60 F-254, 0.25 mm, Merck 
KGaA) with detection by UV (λ = 254 and/or 366 nm) and/or by colouration using a 
potassium permanganate (KMnO4) stain and subsequent heat treatment. Flash 
chromatography was performed on silica gel 60 (0.035 – 0.070 mm, mesh 60 Å, Merck 
KGaA) with the indicated eluent. 1H, proton-decoupled 13C and proton-decoupled 31P 
NMR spectra were recorded on a Bruker Avance III HD 300 (300 MHz), a Bruker 
Avance I 360 (360 MHz) or a Bruker Avance III HD (500 MHz) at 298 K. Chemical 
shifts are reported in delta (δ) units in parts per million (ppm) relative to distinguished 
solvent signals. The following abbreviations are used for the assignment of the signals: 
s – singlet, d – doublet, t – triplet, q – quartet, m – multiplet. Coupling constants J are 
given in Hertz [Hz]. HR-MS spectra were recorded in the ESI mode on a Thermo 
Scientific LTQ-FT Ultra (FT-ICR-MS) coupled with an UltiMate 3000 HPLC system 
(Thermo Fisher Scientific Inc.). 
 
4-(Prop-2-yn-1-ylamino)-7-(2’,3’-O-Isopropylidene-β-D-ribofuranosyl)-1H-purine. 
After suspending N6-propargyl-adenosine (106 mg, 0.506 mmol) in acetone (13.0 mL), 
2,2-dimethoxypropane (0.620 mL, 5.06 mmol) was added. Then p-toluenesulfonic acid 
monohydrate (1.61 g, 8.47 mmol) was added and the mixture was stirred for two hours 
at room temperature. The reaction was stopped with aqueous NaHCO3 (24 mL), 
extracted with EtOAc (3×30 mL) and the combined organic phases were dried over 
Na2SO4 and filtered. The solvents were removed under reduced pressure and the 
residue was purified by column chromatography on silica gel (2% → 5% MeOH in 
DCM) to give the product as a pale yellow solid (149 mg, 85 %). Spectral analysis was 
in good accordance with the literature44. 
 
Phenyl(benzyloxy-l-alaninyl)phosphorochloridate45. Anhydrous triethylamine (264 
µL, 1.896 mmol) was added dropwise to a stirred solution of the phenyl 
dichlorophosphate (142 µL, 0.948 mmol) and the l-alanine benzyl ester p-
toluenesulfonate salt (333 mg, 0.948 mmol) in anhydrous DCM (4 mL) at -78 °C. 
Following the addition, the reaction mixture was stirred at room temperature for 1 h. 
After   this   period   the   solvent   was   removed under reduced pressure and the 
residue triturated with anhydrous THF. The precipitate was filtered and the solution was 
concentrated to give a colourless oil. The crude product was used for the next step. 
 
4-(Prop-2-yn-1-ylamino)-7-(2’,3’-O-isopropylidene-β-D-ribofuranosyl)-1H-purine 5’-
O-[phenyl(benzyloxy-L-alaninyl)]phosphate. Protected N6-propargyl-adenosine (89 
mg, 0.26 mmol) was dissolved in THF (3 ml). Solution of tBuMgCl in THF (1M, 0.52 ml, 
0.52 mmol) was added drop-wise and the reaction mixture was stirred for 15 minutes. 
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Then solution of a phenyl(benzyloxy-L-alaninyl)phosphorochloridate (228 mg, 0.64 
mmol) in THF (3 ml) was added and the reaction mixture was stirred overnight at room 
temperature. Reaction was quenched by saturated NH4Cl solution (1 ml) and mixture 
was extracted with EtOAc and water. Organic layer was dried over Na2SO4, filtered and 
evaporated under reduced pressure. Crude product was purified using column 
chromatography on silica gel (10% HEX in EtOAc) protected phosphoramidate (100 
mg, 63 %) was obtained as colourless oil (mixture of diastereoisomers ∼1:1). 1H NMR 
(300 MHz, CDCl3) δ 8.43 (s, 1H), 8.41 (s, 1H), 7.94 (s, 1H), 7.91 (s, 1H), 7.37 – 6.97 
(m, 20H), 6.38 (bs, 2H), 6.09 (d, J = 5.3 Hz, 1H), 6.08 (d, J = 5.3 Hz, 1H), 5.37 (dd, J = 
6.3, 2.3 Hz, 1H), 5.16 – 4.99 (m, 4H), 4.92 (dd, J = 6.3, 2.6 Hz, 1H), 4.53 – 4.38 (m, 
6H), 4.37 – 4.19 (m, 4H), 4.09 – 3.91 (m, 4H), 2.35 – 2.17 (m, 2H), 1.62 – 1.57 (m, 6H), 
1.41 – 1.16 (m, 12H). 13C NMR (75 MHz, CDCl3) δ 153.21, 139.71, 139.45, 129.74, 
128.74, 128.58, 128.31, 128.25, 125.09, 125.03, 120.27, 120.21, 120.15, 120.08, 
114.50, 91.62, 91.15, 85.70, 85.60, 84.37, 84.30, 81.57, 81.41, 80.15, 77.58, 77.36, 
77.16, 76.74, 71.71, 71.65, 67.32, 66.48, 66.41, 50.51, 50.33, 27.26, 27.17, 25.47, 
25.30, 21.08, 20.90. 31P NMR (121 MHz, CDCl3) δ 2.56, 2.45. MS (ESI+): m/z (%): 
663.18 (100). [M + H]+. HRMS (ESI+): m/z [M + H]+ calculated for C32H36N6O8P
+: 
663.23323; found 663.23219. 
 
4-(Prop-2-yn-1-ylamino)-7-(β-D-ribofuranosyl)-1H-purine 5’-O-[phenyl(benzyloxy-
L-alaninyl)]phosphate. Protected phosphoramidate (100 mg, 0.15 mmol) was 
dissolved in 90% aqueous TFA (2 ml) and stirred for 2 h at room temperature. Then the 
solvent was repeatedly co-evaporated with methanol under reduced pressure. Product 
was purified using column chromatography on silica gel (10% MeOH in DCM). Several 
co-evaporations with chloroform gave phosphoramidate PRO-N6PA (61 mg, 65 %) as 
a white solid (mixture of diastereoisomers ∼1:1). 1H NMR (500 MHz, MeOD) δ 8.26 (s, 
2H), 8.20 (s, 1H), 8.17 (s, 1H), 7.32 – 7.20 (m, 14H), 7.19 – 7.10 (m, 6H), 6.00 (m, 2H), 
5.11 – 4.99 (m, 4H), 4.63 – 4.57 (m, 2H), 4.40 – 4.31 (m, 8H), 4.31 – 4.23 (m, 2H), 4.22 
– 4.18 (m, 2H), 2.58 (t, J = 2.5 Hz, 2H), 1.33 – 1.19 (m, 6H). 13C NMR (126 MHz, 
MeOD) δ 173.42, 173.39, 173.22, 173.18, 152.47, 152.43, 150.66, 150.61, 139.46, 
139.41, 135.82, 135.74, 129.35, 128.14, 127.87, 127.84, 124.78, 120.03, 119.99, 
119.93, 119.63, 88.52, 82.95, 82.91, 82.88, 82.84, 79.75, 73.96, 70.86, 70.14, 70.02, 
66.53, 66.51, 66.12, 66.08, 65.69, 65.65, 50.26, 50.14, 19.01, 18.96, 18.85, 18.79. 31P 
NMR (121 MHz, MeOD) δ 3.89, 3.64. MS (ESI+): m/z (%): 623.25 (100) [M + H]+. 
HRMS (ESI+): m/z [M + H]+ calculated for C29H32N6O8P
+: 623.20193; found 623.20224. 
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(C) Biological methods 
 
Metabolomics samples preparation. Samples were prepared according to protocol 
from Matano et al. with minor changes46. Cells were seeded in 60 mm cell culture 
dishes (approx. 800,000 cells/dish) till 90% confluency. Media was removed, cells 
washed with 3 mL PBS and incubated with 8 mL media, supplemented with pro-N6pA 
in DMSO (100 µM final conc.) or DMSO respectively. After the particular incubation 
times, cells were washed twice with 2 mL warm PBS and twice with 2 mL water (LC-
MS grade, Fisher Chemical). Subsequently 4 mL of cold quenching solution 
(ACN:MeOH:H2O 2:2:1 incl. 0.5M FA, -20°C) was added, cells detached by scraping 
and transferred to falcons. Washing and quenching of cells was completed in 1-2 min. 
Cell lysis was carried out by sonication (30s, Sonorex RK 100, Badelin) while cooling 
followed by incubation on ice (15 min) prior to snap-freezing in liquid nitrogen. Samples 
were freeze-dried until complete dryness and stored at -80°C until day of 
measurement. For MS-analysis dried samples were dissolved in 20 µL water (LC-MS 
grade, Fisher Chemical), centrifuged (21000 x g, 10 min, 4°C) and transferred into LC-
MS vials. A pooled sample was prepared from all samples for column equilibration  
 
Metabolomics sample measurement and evaluation. Metabolic profiling and MS/MS 
analysis was carried out on an Ultimate 3000 RSLC system (Thermo Scientific) 
coupled to an LTQ Orbitrap XL mass spectrometer (Thermo Scientific). 
Chromatographic separation was performed using a SeQuant® ZIC®-pHILIC (250 x 
2.1 mm, 5 µm, 100 Å) (Merck Millipore) at 40 °C. Gradient elution was carried out with 
5 mM NH4OAc (LC-MS grade, Fisher Chemical) in 100% H2O (LC-MS grade, Fisher 
Chemical) (A) and 5 mM NH4OAc in 95% ACN (LC-MS grade, Fisher Chemical) (B). 
After 5 min pre-equilibration with 98% B, samples were eluted with a linear gradient 
from 98% to 53% B over 20 min at a flow rate of 250 µl/min followed by a 9 min 
washing step with 5% B and re-equilibration with 98% B for 4 min. Mass spectrometric 
measurements were accomplished in HESI- mode (H-ESI-II probe, Thermo Scientific) 
with following source parameters: capillary voltage 4.5 kV, tube lens  -110 V, vaporizer 
temperature 80 °C, sheath gas 30 l/h, aux gas 10 l/h, capillary voltage -60 V and 
capillary temperature 275 °C. Parent ions of interest (N6pATP m/z = 544.00) was 
isolated (Isolation width 0.5 m/z) at 60,000 resolution in the orbitrap in profile mode and 
subjected to collision-induced dissociation (normalized collision energy 45 V) in the 
SRM mode and most intense daughter ion (N6pATP m/z = 446.03) isolated (SIM width 
5 m/z) at a resolution of 7,500 in the orbitrap and used for quantification. Retention 
time, exact mass and MS/MS spectra of quantified compound were matched to an 
authentic synthetic standard. Prior to measurement, 15 pooled quality control (QC) 
samples were injected to equilibrate the column. In order to take into account metabolic 
degradation over time, the sample order was randomized. Data were processed with 
Xcalibur 2.2 SP1.48 Quan Browser (Thermo Scientific) using the Genesis algorithm for 
peak detection and manual integration mode. Peak detection was carried out with the 
following track peak parameters: Genesis Peak Detection: Highest Peak, Minimum 
peak height (S/N) = 3.0. Intensities of the corresponding daughter ion was extracted 
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and plotted for each time point. (Experiments were carried out in two biological 
replicates). 
 
Cytotoxicity assay. Human epitheloid cervix carcinoma cells (HeLa) cultivated in high 
glucose Dulbeccos´s Modified Eagle´s Medium supplemented with 10% (v/v) fetal 
bovine serum and 2 mM L-glutamine were seeded at a density of 5,000 cells per well 
(100 μL of a solution of 50,000 cells/mL) in a transparent, flat-bottom 96-well plate. 
Cells were grown over night in a humidified atmosphere at 37 °C and 5% CO2. The 
next day the medium was removed and replaced by fresh medium supplemented with 
1000, 700, 500, 300, 200, 100 or 30 µM pro-N6pA or N6pA or 1% (v/v) DMSO as a 
control. The cells were incubated for 24 h. To determine metabolic activity of the cells, 
20 μL of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide solution 
(MTT, 5 mg/mL in PBS) were added to each well. The cells were incubated for 4 h. The 
medium was completely removed and the formazan crystals were resuspended in 200 
μL DMSO and absorbance at 570 nm and at a reference wavelength of 630 nm was 
determined in an infinite F200 pro plate reader (Tecan). All data points were measured 
in triplicate. The data was normalized with respect to the DMSO control. 
 
Protein concentration. Protein concentrations were determined by bicinchoniic acid 
assay (BCA, Carl Roth GmbH + Co.). 
 
Probe treatment, click-chemistry and enrichment. Cells (6-cm dishes) were treated 
with the probes at 80-90% confluency. Culture medium was removed and the cells or 
COs were labelled in fresh media containing 100µM pro-N6pA or 100µM N6pA (both 
stocks 100mM in DMSO) for 16 h at 37 °C in cells incubator. Subsequent cell lysis was 
done in 1 mL ice cold lysis buffer (1% (v/v) NP40, 1% (w/v) sodium deoxycholate and 1 
tablet protease inhibitor (cOmplete™, Mini, EDTA-free protease inhibitor cocktail, 
Roche) in 10 mL PBS) while mechanically detached by scraping and subsequently 
transferred into an eppendorf tube or by ultrasonication at 40 % intensity for 10 s. Lysis 
was done for 30 min at 4 °C while rotating. Insoluble fraction was pelletized (10 min, 
14,000 g, 4 °C) and protein concentration was determined by BCA. To 500 µg (HeLa, 
A549, SH-SY5Y cells, COs and fibroblasts) or 250 µg (iPSCs, NPCs, neurons) of a 
protein lysate in total volume of 970 μL 0.2% (w/v) SDS in PBS 10 μL 5-rhodmamine-
azide (10 mM in DMSO, Jena Bioscience; in-gel analysis) or 10 μL azide-PEG3-biotin 
(10 mM in DMSO, Jena Bioscience; for MS samples), 10 μL Tris(2-
carboxyethyl)phosphine (TCEP) (53 mM in ddH2O) and 1.2 μL 
tris(benzyltriazolylmethyl)amine (TBTA) (83.5 mM in DMSO) were added. Samples 
were gently vortexed and the click reaction was initiated by the addition of 20 μL 
CuSO4 solution (50 mM in ddH2O). The mixture was incubated at 25 °C for 1.5 h. 
Afterwards proteins were precipitated by addition of 4 mL acetone and incubation 
overnight at -20 °C. The protein pellet was harvested by centrifugation at 9,000 g for 15 
min at 4 °C and washed twice with 1 mL of ice cold methanol. Proteins were 
reconstituted in 500 μL 0.2% (w/v) SDS in PBS, the remaining not soluble particles 
were spun down at 9,000 g for 5 min and resulting supernatant was loaded onto the 
beads and incubated at 25 °C for 1.5 h while rotating. The 50 μL of avidin-agarose 
beads (Sigma-Aldrich) were washed in advance thrice with 1 mL 0.2% (w/v) SDS in 
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PBS. Afterwards through the enrichment protocol, the beads were always spun at 400 
g, 25 °C, for 2 min. Beads were subsequently washed thrice with 1 mL 0.2% (w/v) SDS 
in PBS, twice with 1 mL 6 M urea in ddH2O and thrice with 1 mL PBS. 
 
Endoplasmic reticulum stress induction. For induction of unfolded protein response, 
cells or COs were treated with 100µM pro-N6pA for 16 h, then the media was 
exchanged with fresh media containing 100µM pro-N6pA and 1 µg/mL thapsigargin 
(stock 10 mg/mL in DMSO) and incubated for 24 h. 
 
4-aminobenzamide (4-ABA) and Olaparib (Ola) poly(ADP-ribose) polymerases 
inhibition. In HeLa (6-cm dishes) cells 2 h before addition of the pro-N6pA probe 4 µL 
of 10M 4-ABA or 2 µL 10mM Ola (both stock solutions in DMSO) were added to the 2 
mL of the fresh culture media, after two hours 2 µL of 100mM pro-N6pA was added 
and incubated for 16 h. Subsequent cell lysis was done in 1 mL ice cold lysis buffer 
(1% (v/v) NP40, 1% (w/v) sodium deoxycholate and 1 tablet protease inhibitor 
(cOmplete™, Mini, EDTA-free protease inhibitor cocktail, Roche) in PBS) while 
mechanically detached by scraping and subsequently transferred into an eppendorf 
tube or by ultrasonication at 40 % intensity for 10 s. Lysis was done for 30 min at 4 °C 
while rotating. Insoluble fraction was pelletized (10 min, 14,000 g, 4 °C) and protein 
concentration was determined by BCA. To 200 µg of a protein lysate in total volume of 
200 μL 0.2% (w/v) SDS in PBS 2 μL 5-rhodmamine-azide (10 mM in DMSO, Jena 
Bioscience; in-gel analysis) 2 μL Tris(2-carboxyethyl)phosphine (TCEP) (53 mM in 
ddH2O) and 0.24 μL tris(benzyltriazolylmethyl)amine (TBTA) (83.5 mM in DMSO) were 
added. Samples were gently vortexed and the click reaction was initiated by the 
addition of 4 μL CuSO4 solution (50 mM in ddH2O). The mixture was incubated at 25 °C 
for 1.5 h. Afterwards proteins were precipitated by addition of 900 µl acetone and 
incubation 1 h at -20 °C. The protein pellet was harvested by centrifugation at 9,000 g 
for 15 min at 4 °C and washed once with 500 µl of ice cold methanol. Finally, it was 
dissolved in 50 µL of gel loading buffer (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromphenol blue in 125mM Tris-HCl, pH 6.8) and loaded on 
a 12.5% SDS-PAGE. 
Chemical-proteomic samples preparation. Cells were treated with Olaparib and pro-
N6pA probe in a same way as for in-gel analysis, but it was continued with click 
reaction with azide-PEG3-biotin and continued with enrichment as described above. 
 
In-gel analysis. Enriched rhodamine-tagged proteins were released from the beads 
with 50 µL of gel loading buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 
0.004% bromphenol blue in 125mM Tris-HCl, pH 6.8) and loaded on a 12.5% SDS-
PAGE. After electrophoretic separation, fluorescently labelled proteins were visualized 
using a Fujifilm LAS-4000 equipped with a Fujifilm Fujinon VR43LMD3 lens and a 
575DF20 filter (Fujifilm) operated in Cy3 fluorescence detection mode. 
 
Chemical-proteomics. Enriched proteins were on beads digested in 200 μL digestion 
buffer (20 mM HEPES, pH 7.5, 7 M urea, 2 M thiourea). Proteins were reduced (0.2 μL 
1 M DTT, 45 min, 25 °C) and alkylated (2 μL, 30 min, 25 °C, in the dark). The alkylation 
reaction was quenched by addition of 0.8 μL 1M DTT and incubation for 30 min at 25 
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°C. Proteins were pre-digested with 1 μL LysC (Wako) at 25 °C for 4 h. 600 μL 50 mM 
TEAB buffer was added and the proteins were digested overnight with 1.5 μL 
sequencing grade trypsin (0.5 mg/mL, Promega) at 37 °C. The following day the beads 
were settled and the supernatant was acidified with 10 μL formic acid to a pH of 2 – 3. 
Peptides were desalted and on-column dimethyl labelled using 50 mg SepPak C18 
cartridges (Waters Corp.) on a vacuum manifold. The cartridges were equilibrated with 
1 mL acetonitrile, 1 mL 80% acetonitrile and 3 mL 0.5% formic acid. The samples were 
loaded on the cartridges and subsequently washed with 5 mL 0.5% formic acid. 
Peptides were labelled with either 5 mL labelling buffer “light” (90 mM sodium 
phosphate, pH 7.5, 30 mM NaBH3CN, 0.2% CH2O) or 5 mL labelling buffer “heavy” (90 
mM sodium phosphate, pH 7.5, 30 mM NaBD3CN, 0.2% 
13CDO). Cartridges were 
subsequently washed with 2 mL 0.5% formic acid. The peptides were eluted with two 
times 200 μL 80% acetonitrile, 0.5% formic acid. DMSO and probe-treated samples 
were combined and dried by lyophilization. Peptides were reconstituted in 30 μL 1% 
(v/v) formic acid, prepared for mass spectrometry by filtering through a membrane filter 
(Ultrafree-MC and –LC, Durapore PVDF-0.22 μm, Merck Millipore) and transferred into 
mass vials. For label-free quantification (LFQ) samples were prepared as above 
without the use of labelling solutions “light” and “heavy” and subsequent washing with 3 
mL 0.5% formic acid. Samples were not combined. Experiments were conducted in 7 
to 12 replicates. Label switch was used for dimethyl-labelling samples. 
 
Site identification using TEV-cleavable linker. HeLa, SH-SY5Y or COs lysates in 
total volume of 2 mL 0.2% (w/v) SDS in PBS were supplemented with 20 μL azide-
TEV-biotin (10 mM in DMSO, gift from B. F. Cravatt laboratory)11, 20 μL TCEP (53 mM 
in ddH2O) and 2.5 μL TBTA (83.5 mM in DMSO). Samples were gently vortexed and 
the click reaction was initiated by the addition of 40 μL CuSO4 solution (50 mM in 
ddH2O). The mixture was incubated at 25 °C for 1.5 h. Afterwards, proteins were 
precipitated in 18 mL acetone at -20 °C overnight. Protein pellet washing, enrichment 
and on-beads trypsin digest was done as described above using 100 uL of avidin-
beads slurry and digestion buffer without the thiourea. After the overnight incubation 
with trypsin, the beads were transferred onto the membrane filter (Ultrafree-MC and –
LC, Durapore PVDF-0.22 μm, Merck Millipore) and spun down at 1,000 g for 1 min. 
The flow through was processed as described above for trypsin digest. Beads loaded 
on a membrane filter were washed twice with 50 μL of ddH2O, thrice with 600 μL PBS 
and thrice with 600 μL ddH2O. Beads were resuspended in 150 μL TEV buffer (141 μL 
of ddH2O, 7.5 μL 20xTEV buffer supplied by manufacturer, 1.5 μL of 100μM DTT) and 
transferred from the membrane filter into eppendorf tube. Beads were spun down at 
400 g for 2 min and supernatant was removed. Beads were resuspended in 150 μL of 
TEV buffer and incubated with agitation at 29 °C with 5 μL of AcTEV protease (10 
U/μL, Invitrogen) overnight. The suspension was transferred onto the membrane filter 
and spun down at 1,000 g for 1 min, beads were further washed twice with 50 μL of 
ddH2O. Flow through was collected and after addition of 4 μL of formic acid it was 
desalted on stage tips (double C18 layer, Empore disc-C18, 47MM, Agilent 
Technologies). Stage tips were equilibrated with 70 μL acetonitrile, spun at 1,000 g for 
2 min, then samples were loaded and spun at 1,000 g for 5 min. Stage tips were 
washed thrice with 70 μL 0.5% formic acid and TEV cleaved proteins eluted with two 
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portions 30 μL of 80% acetonitrile and 0.5% formic acid. Samples were combined and 
dried by lyophilization. Peptides were reconstituted in 30 μL 1% (v/v) formic acid, 
prepared for mass spectrometry by filtering through a membrane filter (Ultrafree-MC 
and –LC, Durapore PVDF-0.22 μm, Merck Millipore) and transferred into mass vials. 
 
DSSO crosslinking. HeLa cells were cultivated in 15 cm dishes and transfected with 
pCMV-SPORT6 plasmid with FICD wt or FICD E234G with GGGGS sequence 
connected to 6 x HIS tag at C-terminus. Cells were supplemented with 15 mL fresh 
DMEM media and transfected using 8 µL Lipofectamine®2000 (Thermo Fisher 
Scientific) and 16 µg of the pCMV-SPORT6 respective plasmid in 2 mL of the Opti-
MEM™ (Gibco™) media according to manufacturer protocol. Cells were incubated for 
36 h then washed twice with 3 mL PBS, scraped into the 1 mL PBS containing 2 mM 
DSSO crosslinker (20 µL of 100 mM DSSO stock in DMSO) and incubated at 37 °C for 
1 h. Crosslinking reaction was stopped by addition of 0.5 mL 50 mM Tris pH 8.0. Cells 
were harvested at 600 rpm for 5 min and washed twice with 0.5 mL ice cold PBS and 
lysed in 1 mL ice cold lysis buffer (1% (v/v) NP40, 1% (w/v) sodium deoxycholate and 1 
tablet protease inhibitor (cOmplete™, Mini, EDTA-free protease inhibitor cocktail, 
Roche) in 10 mL PBS). Lysis was done for 30 min at 4 °C while rotating. Insoluble 
fraction was pelletized (10 min, 14,000 g, 4 °C), supernatant was transferred to 
prewashed (3 x 1 mL of lysis buffer) Ni-NTA agarose (200 µL of beads slurry, QIAGEN) 
and incubated at 4 °C for 2 h. The beads were spun down at 2,000 rpm and 
supernatant was removed, beads were resuspended in 600 µL mL high salt wash 
buffer (25 mM Tris pH 8.0, 500 mM NaCl, 20 mM imidazol) and transferred on filter 
columns (Pierce® centrifuge columns), washed twice with 600 µL mL wash buffer (25 
mM Tris pH 8.0, 150 mM NaCl, 80 mM imidazol). Beads were resuspended in 600 µL 
of PBS and transferred into 1.5 eppendorf tube, spin down at 2,000 rpm and 
supernatant was removed. Enriched proteins were digested as described above for 
chemical-proteomics experiments and identified using LC-MS/MS as described below. 
 
Mass Spectrometry. MS analysis was either performed on an Orbitrap Fusion or an Q 
Exactive Plus instrument coupled to an Ultimate3000 Nano-HPLC via an electrospray 
easy source (all Thermo Fisher Scientific). Samples were loaded on a 2 cm PepMap 
RSLC C18 trap column (particles 3 µm, 100A, inner diameter 75 µm, Thermo Fisher 
Scientific) with 0.1% TFA and separated on a 50 cm PepMap RSLC C18 column 
(particles 2 µm, 100A, inner diameter 75 µm, Thermo Fisher Scientific) constantly 
heated at 50 °C. The gradient was run from 5-32% acetonitrile, 0.1% formic acid during 
a 152 min method (7 min 5%, 105 min to 22%, 10 min to 32%, 10 min to 90%, 10 min 
wash at 90%, 10 min equilibration at 5%) at a flow rate of 300 nL/min. For 
measurements of chemical-proteomic samples on the fusion instrument survey scans 
(m/z 300-1,500) were acquired in the orbitrap with a resolution of 120,000 at m/z 200 
and the maximum injection time set to 50 ms (target value 2e5). Most intense ions of 
charge states 2-7 were selected for fragmentation with high-energy collisional 
dissociation at a collision energy of 30%. The instrument was operated in top speed 
mode and spectra acquired in the ion trap with the maximum injection time set to 50 ms 
(target value 1e4). The option to inject ions for all available parallelizable time was 
enabled. Dynamic exclusion of sequenced peptides was set to 60 s. Real-time mass 
 
118 
 
calibration was based on internally generated fluoranthene ions. Data were acquired 
using Xcalibur software version 3.0sp2 (Thermo Fisher Scientific).  
Binding site identifications of AMPylated peptides were performed on the fusion 
instrument with slightly changed parameters. The scan range for survey scans in the 
orbitrap was changed to 300-1,700 with an AGC target value of 4e5. HCD 
fragmentation was performed at a collision energy of 27% and spectra first acquired in 
the ion trap with a maximum injection time of 30 ms and an AGC target value of 2e4. 
Peptides with targeted masses of m/z 501.28, 251.14 and 167.76 (adenine_TEV singly, 
doubly and triply charged), as well as m/z 615.31, 308.16 and 205.77 (adenosine_TEV 
singly, doubly and triply charged) were further selected for ETD fragmentation while 
highest charge states were prioritized. ETD fragmentation scans were acquired in the 
orbitrap with a resolution of 30,000, a maximum injection time of 1,000 and an AGC 
target value of 2e5.  
For measurements of chemical-proteomic samples on the Q Exactive Plus instrument 
survey scans (m/z 300-1,500) were acquired in the orbitrap with a resolution of 70,000 
at m/z 200 and the maximum injection time set to 80 ms (target value 3e6). 
Data dependent HCD fragmentation scans of the 12 most intense ions of the survey 
scans were acquired in the orbitrap at a resolution of 17,500, maximum injection time 
of 50 ms as well as minimum and maximum AGC targets of 5e3 and 5e4, respectively. 
The isolation window was set to 1.6 m/z. Unassigned and singly charged ions were 
excluded for measurement and the dynamic exclusion of peptides enabled for 60 s. 
The lock-mass ion 445.12002 from ambient air was used for real-time mass calibration 
on the Q Exactive Plus. Data were acquired using Xcalibur software version 3.1sp3 
(Thermo Fisher Scientific). 
 
Quick change point mutation. Quick change point mutation of FICD H363A was 
performed using following primers 
 5´-CCGTTGCCATCAATGAAAGGGGCGATGTAAACGAGTTTATAATG- 3´  
and   5´-CATTATAAACTCGTTTACATCGCCCCTTTCATTGATGGCAACGG- 3´  
and pCMV-SPORT6 with wt FICD as a template. PCR reaction mixture contained 
5xPhusion buffer 10 μL, 10 mM dNTPs 1 μL, 10 μM each primer 0.75 μL, template 50 
ng 1 μL, ddH2O 32 μL, DMSO 4 μL and Phusion polymerase (NEB) 0.5 μL. PCR cycle 
(initial denaturation 98 °C, 3 min then 25 cycles of 95 °C 45 s, 65 °C 30 s, 72 °C 3 min; 
final elongation at 72 °C for 5 min). Template was digested using DpnI (8 μL of PCR 
mixture, 10xCutSmart buffer (NEB) 1 μL and DpnI (NEB) 1 μL) at 37 °C for 4 h. 
Resulting plasmid was amplified in E. coli XL1 blue. Identity of the isolated plasmid was 
verified by sequencing. 
 
Cloning of FICD with C-terminal 6xhis tag. To construct the pCMV-SPORT6 plasmid 
containing FICD gene with C-terminal GGGGSHHHHHH tag. The FICD gene was 
extended in PCR using following primers  
5´-GACTTACACTAGTCCAGATGCTCATACCAATGGCTTC- 3´  
and  
5´- 
GTATCTACCCTCAGGACAGCCTTTGTCACTGAGGATTTCTAATGATGGTGGTGATG
GTGAGAGCCTCCACCCCCGGGCTTCACAGGAAGC- 3´.  
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PCR reaction mixture contained 5xPhusion buffer 4 μL, 10 mM dNTPs 0.4 μL, 10 μM 
each primer 1 μL, template 50 ng 0.2 μL, ddH2O 13.2 μL and Phusion polymerase 
(NEB) 0.2 μL. PCR cycle (initial denaturation 98 °C, 1 min then 25 cycles of 98 °C 20 s, 
72 °C 1 min; final elongation at 72 °C for 5 min). Next, PCR product was separated and 
isolated from the 1 % agarose gel by gel extraction and 30 μL of it was digested in 
10xCutSmart buffer (NEB), SpeI HF 1 μL (NEB) and Bsu36I 1 μL (NEB) supplied with 
13 μL ddH2O at 37 °C for 1 h. The resulting mixture was separated on 1 % agarose gel 
and desired digested DNA fragment was extracted from a gel (Gel Extraction Kit, 
OMEGA bio-tek). Ligation into pCMV-SPORT6 plasmid was performed using 2xQuick 
ligase buffer (NEB) digested pCMV-SPORT6 empty plasmid 3.5 μL (32 ng) and PCR 
product 6 μL (19.2 ng) and Quick ligase 1 μL (NEB) incubated at rt for 5 min and 
transformed into E. coli Xl1 blue. Identity of the isolated plasmid was verified by 
sequencing. 
 
ADP-ribosylation. The reference list of ADP-ribosylated proteins was taken from ref. 
23. In total, it includes 484 proteins identified as ADP-ribosylated by PARP-1, PARP-2 
or PARP-3 with known site of modification (Table S3). All presented heatmaps and 
summaries of AMPylated proteins are without the AMPylation-ADP-ribosylation 
overlapping proteins. 
 
Immunoprecipitation-click-chemistry. HeLa cells were cultivated in 15 cm dishes 
and treated with 100µM pro-N6pA (13 µL 100mM in DMSO) for 16 h as described 
above. Cells were washed twice with 3 mL ice cold PBS and lysed in 1mL ice cold IP 
lysis buffer (50mM Tris HCl, pH 8; 250mM NaCl; 1% NP-40, 5mM EDTA, with protease 
inhibitors) while mechanically detached by scraping. Lysis was done for 30 min at 4 °C 
while rotating. Insoluble fraction was pelletized (10 min, 14,000 g, 4 °C). Protein lysates 
(3.5 - 4 mg) from pro-N6pA or DMSO treated cells were incubated with 10 μL of 
primary antibodies (anti-PFKP (rabbit) or anti-PPME1 (rabbit) both 1 mg/mL, Bethyl 
laboratories Inc.) at 4 °C with gentle agitation overnight. Beads were spun at 400 g, 4 
°C for 2 min. Approximately 70 μL Pierce Protein A/G agarose beads slurry (Thermo 
Scientific) was washed twice with 0.5 mL ice-cold IP lysis buffer, added to the lysates 
and incubated at 4 °C for 4 hours with gentle agitation. The beads were washed thrice 
with 0.5 mL of ice cold IP lysis buffer, then twice with ice cold IP wash buffer (50 mM 
Tris/HCl pH 8.5, 75 mM KCl) and finally resuspended in 97 µL of PBS supplied with 1 
μL 5-rhodamine-azide (10 mM in DMSO, Carl Roth GmbH + Co. KG), 1 μL TCEP (53 
mM in ddH2O) and 0.2 μL TBTA (83.5 mM in DMSO). The click-reaction mixture was 
incubated at 25 °C for 1.5 h with agitation, supernatant was removed and 20 μL of gel 
loading buffer was added to the beads slurry. Immunoprecipitated proteins were 
released from the beads into the gel loading buffer at 95 °C for 5 min and separated on 
12.5% SDS PAGE. In-gel fluorescence was scanned as described above. 
 
Immunoblot analysis. SDS-PAGE separated proteins were blotted on a methanol-
activated PVDF membrane for 1 h at 22 V (blotting buffer: 48 mM Tris, 39 mM glycine, 
0.0375% SDS, 20% methanol) using a Bio-Rad Trans-Blot SD semi-dry transfer cell 
setup. The membrane was then blocked in blocking buffer (5% milk powder in PBS 
with 0.5% Tween-20), washed and incubated with primary antibody (Supplementary 
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Table 11) (diluted 1:1,000 in blocking buffer) for 16 h at 4 °C. The membrane was 
washed thrice 10 min in 0.5% Tween-20 in PBS, and then incubated with secondary 
antibody (goat anti-rabbit IgG-HRP (Santa Cruz), diluted 1:10,000 in blocking buffer) at 
25 °C for 1 h. The membrane was washed again with 0.5% Tween-20 in PBS and 
subsequently incubated in ECL (Bio-Rad) and imaged using a Fujifilm LAS-4000 
equipped with a Fujifilm Fujinon VR43LMD3 lens and chemoluminescence detection 
mode. 
 
Table S11 | Antibodies used in immunohistochemistry and immunoprecipitations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transfection of SH-SY5Y cells by nucleofection. SH-SY5Y cells were grown to 80 
% confluency, washed with PBS, dissociated to single cells with 0.05 % trypsin-EDTA 
and counted. Per construct, 1 mio. cells were resuspended in 100 µl nucleofection 
buffer (50 mM Hepes, 90 mM Na3PO4, 5 mM KCl, 0.15 mM CaCl2) and 2 µg pCMV-
Antigen Dilution Vendor Catalog # 
AMPylated Tyrosine 1:1000 Merck ABS184 
ARL13B 1:200 Proteintech 17711-1-AP 
CTIP2 1:500 Abcam ab18465 
Doublecortin (DCX) 1:2,000 Merck Millipore ab2253 
F-Actin (Phalloidin) 1:40 Thermo Fisher A12381 
FICD 1:100 Sigma HPA021390 
GFP 1:1,000 Aves Lab GFP-1020 
GM130 1:500 GeneTex GTX130351 
HSPA5 1:1,000 Abcam ab21685 
KI67 1:100 Dako M7248 
MAP2 1:500 Sigma Aldrich M4403 
NESTIN 1:200 Millipore MAB5326 
NEUN 1:500 Merck Millipore MAB377 
PAX6 1:500 Biolegend PRB-278p 
PDI 1:500 Abcam ab2792 
PFKP 1:100 Bethyl Lab. Inc. A304-283A 
PH3 1:500 Millipore 06-570 
Phospho-TAU (Ser202, 
Thr205) 
1:500 Thermo Fisher MN1020 
PPME1 1:100 Bethyl Lab. Inc. A304-762A 
TBR1 1:500 Abcam ab31940 
β-Catenin 1:500 BD Biosciences 610154 
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SPORT6 plasmid containing wt FICD or FICD E234G mutant (gift from A. Itzen, TUM) 
and 1 µg of pCAG-IRES-GFP or 3 µg of only pCAG-IRES-GFP (control) was added. 
The suspension was filled into an aluminium electrode cuvette and exposed to program 
G00.04 in an Amaxa II Nucleofector (Lonza). Sequentially, 30,000 cells/well were 
plated on coverslips in a 24-well-plate in triplicates. Transfected cells were cultured for 
48 h before analysis by click-reaction with rhodamine-azide for quantification of 
AMPylation. 
 
Probe staining of fixed cells. Cells and organoids were cultured with medium 
containing 100 µM pro-N6pA or 1:1,000 dilution of DMSO for 16 h prior to fixation. 
PFA-fixed cells on coverslips and thawn, rehydrated organoid sections were 
permeabilized using 0.1 % Triton X100 in PBS for 5 min. Then they were incubated 
with click-chemistry staining mix (10 µM rhodamine-azide, 1 mM CuSO4, 10 mM freshly 
prepared sodium ascorbate in PBS) at rt for 2 h in the dark, followed by several washes 
with PBS47. For nuclear counterstaining only, cells or sections were incubated with 0.1 
µg/mL DAPI in PBS for 15 min. For co-staining by immunohistochemistry, 10 min 
postfixation with 4 % PFA in PBS was performed after the click-reaction with 
rhodamine azide, followed by the immunohistochemistry protocol (see above). 
 
qPCR of FICD mRNA levels. Cells were washed and scraped with cold PBS and the 
pellet was lysed in QIAzol® Lysis Reagent (#79306, Qiagen). RNA was extracted using 
RNA Clean & Concentrator Kit (#R1015, Zymo Research) and cDNA was synthesised 
from 1 µg RNA each using SuperScript III reverse transcriptase (#18080-044, Thermo 
Fisher) with Oligo(dT)12-18 primers (#18418012, Thermo Fisher) according to the 
manufacturer’s protocol. Subsequently, qPCR was performed in triplicates on a 
LightCycler® 480 II (Roche) using the LightCycler® 480 SYBR Green I Master 
(#04707516001, Roche) with the following reaction mix: 1 µL of each primer (5 µM), 
SYBER Green I Master 5 µL, H2O 2 µL and 1 µL of cDNA. The primer sequences were 
the following for FICD: 5’-GCGGTTGGGGTTCTGAC- 3’ and 5’-
TGAAGCCATTGGTATGAGCA- 3’ and for GAPDH: 5’-
AATCCCATCACCATCTTCCAGGA- 3’ and 5’-TGGACTCCACGACGTACTCAG- 3’. 
PCR cycle (initial denaturation 95 °C, 10 min then 45 cycles of 95 °C 10 s, 60 °C 10 s 
and 72 °C 10 s) with melting curve 95 °C to 65 °C with 15s per step. Cp values were 
determined from the second derivative maximum of the amplification curve and fold 
expression was calculated using the ΔΔCp method. 
 
Quantification of AMPylation upon FICD overexpression. The transfected and 
probe-treated cells were fixed with 4 % PFA, followed by click-reaction and 
counterstaining of GFP and of nuclei with DAPI as described above. Confocal images 
were taken at 3 positions per coverslip. For quantification of AMPylation, using Fiji, the 
outline of individual GFP+ cells were drawn and then the rhodamine signal was 
measured and normalised to cell size (area). Results are shown for n = 90 cells per 
condition, normalised to GFP+ control. 
 
Reprogramming of fibroblasts to induced pluripotent stem cells (iPSCs). Human 
iPSCs were prepared by reprogramming newborn foreskin fibroblasts (CRL-2522, 
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ATCC). As feeders 2.5x105 NuFF3-RQ IRR human newborn foreskin fibroblasts (GSC-
3404, GlobalStem) were seeded per well of a 6-well tissue culture dish with advanced 
MEM (12491015, Thermo Fisher Scientific) supplemented with 5% HyClone Fetal 
Bovine Serum (SV30160.03HI, GE Healthcare), 1% MEM NEAA and GlutaMAX 
(11140050; 35050061 Thermo Fisher Scientific). On day 1, a newborn foreskin 
fibroblast culture of 70-80% confluency was dissociated using 0.25% Trypsin-EDTA 
(25200056, Life Technologies), counted and seeded on the pre-plated NuFF3-RQ cells 
at two densities: 2x104 and 4x104 cells/well. On day 2, the medium was changed to 
Pluriton Reprogramming Medium (00-0070, Stemgent) supplemented with 500 ng/ml 
carrier-free B18R Recombinant Protein (03-0017, Stemgent). On days 3-18, a cocktail 
of modified mRNAs (mmRNAs) was transfected daily. For that, OCT4, SOX2, LIN28A, 
CMYC, and KLF4 mmRNAs at a 3:1:1:1:1 stoichiometric ratio in Opti-MEM I Reduced 
Serum Medium (13778150, Thermo Fisher Scientific) in a total volume of 105µl was 
combined with a mix of 92µl Opti-MEM I Reduced Serum Medium and 13µl 
Lipofectamine RNAiMAX Transfection Reagent (31985062, Thermo Fisher Scientific) 
after an incubation at RT for 15 min. Cells were transfected for 4hrs, washed and fresh 
reprogramming medium supplemented with B18R was added to the cultures. The 
mmRNAs were provided by the RNA CORE unit of the Houston Methodist Hospital and 
contained the following modifications: 5-Methyl CTP, a 150 nt poly-A tail, ARCA cap 
and Pseudo-UTP. Already 5 days after the first transfection, initial morphological 
changes became apparent, and first induced pluripotent stem cell (iPSC) colonies 
appeared by day 12-15. On day 16, the medium was changed to STEMPRO hESC 
SFM (A1000701, Thermo Fisher Scientific) for five days. Afterwards, the iPSC colonies 
were harvested after 40min incubation at 37°C with 2mg/ml Collagenase Type IV 
(17104019, Thermo Fisher Scientific) solution in DMEM/F12 (31331093, Thermo 
Fisher Scientific). The iPSCs were plated on γ-irradiated mouse embryonic fibroblasts 
(MEFs) and grown in STEMPRO hESC SFM for 10 additional passages. Then the 
iPSCs were adapted to a feeder-free culture system, using mTeSR1 (05850, StemCell 
Technologies) and plates coated with LDEV-Free Geltrex (A1413302, Thermo Fisher 
Scientific). 
 
pro-N6pA / 5-Ethynyl-uridine and RNAse treatment. In order to exclude 
incorporation of pro-N6pA into RNAs34, HeLa cells were grown on coverslips in 24-well-
plates. For the last 16 h of culture prior to PFA fixation, they were incubated with the 
pro-N6pA probe (100 µM = 1:1,000 from stock), DMSO (1:1,000) or 5-ethynyl-uridine 
(5-EU; 1 mM = 1:100 from stock in H20) in medium. The fixed cells were treated with 
different amounts of RNAse If prior to probe staining by click-chemistry (Figure S16): 
Cells were permeabilized applying 0.3 % Triton X100 in PBS for 5 min and the 
incubated with 5 to 100 U/coverslip RNAse If (M0243S, New England Biolabs; 
unspecific RNAse cleaving both purine and pyrimidine residues) in 1 x NEB3 buffer for 
30 min or 2h at 37 °C (Figure S16) . NEB3 without RNAse served as control. After the 
RNAse treatment the fixed cells were washed thrice with PBS. 
 
Rating of MAP2+ neuronal processes intruding the progenitor zone in COs.  After 
IHC for GFP (to identify electroporated germinal zones) and MAP2 (for neuronal 
dendrites), combined with DAPI for nuclear counterstain, confocal laser scanning 
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images were acquired. A rating system was applied to categorize ventricles according 
to invading MAP2 processes within the progenitor zone, recognized in the DAPI 
channel as cell-dense zone lining the ventricle-like lumen, with the grading: 0 = no 
invading processes, 1 = few invading processes, 2 = a lot of invading processes. Every 
one ventricle was taken as n. 
 
GO Term and Network Analysis using STRING.db. STRING database was used to 
perform Network and GO Term Analysis of AMPylated proteins identified in the 
different cell lines43. Proteins overlapping with ADP-ribosylation were excluded. 
Network nodes represent the AMPylated proteins. Network edges represent protein-
protein association. Thickness of the network edges was chosen to indicate edge 
confidence, meaning strength of the data support for the shown interaction. Minimum 
required interaction score was set to 0.400. The Table S10 contains all GO Term 
analyses for the cell types. Networks with example GO Terms highlighted are shown 
for iPSCs, NPCs, neurons, and COs in Figure S13. Functional enrichments in each 
network were considered significant in case of a false discovery rate FDR < 0.05.  
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(D) NMR spectra 
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Abstract  
During embryonic development, the cerebral cortex is equipped with excitatory projection 
neurons that migrate in organized layers. Periventricular heterotopia (PH) is a rare 
disorder in which a subpopulation of new-born projection neurons fails to initiate their 
radial migration to the cortex, ultimately resulting in bands or nodules of grey matter lining 
the lateral ventricles. Although a number of genes have been implicated in its cause, 
currently they only satisfactorily explain the pathogenesis of the condition for 50% of 
patients. Complicating novel gene discovery is the extreme genetic heterogeneity 
recently described to underly its cause. Here, we study the neurodevelopmental role 
of endothelin-converting-enzyme-2 (ECE2) for which two biallelic variants have been 
identified in two seperate patients with PH. Our results show that manipulation 
of ECE2 levels in human cerebral organoids and in the developing mouse cortex leads to 
ectopic localization of neural progenitors and neurons. We uncover the role of ECE2 in 
neurogenesis and, mechanistically, we identify its involvement in the generation and 
secretion of extracellular matrix proteins in addition to cytoskeleton and adhesion.  
 
Introduction 
Mammalian neocortical development occurs through a highly complex series of 
processes including neural progenitor proliferation, migration of new-born neurons 
towards the future cortical plate (CP), and their terminal maturation and integration into 
neuronal networks [1,2]. Neuroepithelial cells give rise to apical radial glia (aRG), bipolar 
neural stem cells of the ventricular zone (VZ) spanning the thickness of the developing 
cortex, which can self-renew to increase the size of the neural progenitor cell (NPC) pool 
and differentiate to produce basal progenitors (BPs) - including intermediate progenitor 
cells (IPCs) and basal radial glia (bRG) - or neurons directly [1,3,4]. Newly generated 
projection neurons acquire a bipolar morphology and use the basal processes of RG as a 
scaffold for their radial migration towards the developing CP [5].  
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The widespread occurrence of malformations during cortical development underscores 
the importance of this tightly controlled process of events. One of the most common 
neuronal migration disorders (NMDs) is periventricular nodular heterotopia (PH) [6]. PH is 
characterized by a subset of cortical neurons failing to initiate radial migration towards the 
CP and instead remaining as nodules at the apical, ventricular surface where they were 
generated. Patients with PH can present with intellectual disability and epilepsy [3]. 
Bands or nodules of grey matter in contact with the normotopic overlaying or further 
distant cortex may represent the source of epileptogenic activity in patient brains, 
although clinical presentations are highly heterogeneous [7,8]. 
Known molecular causes of the failure of neurons to migrate include an intrinsic 
disruption in the cytoskeleton of neurons (cell-autonomous mechanism), or a disruption in 
the RG scaffold that they use for their radial migration (non-cell-autonomous mechanism) 
[9-13]. Until recently, variants in only a handful of genes have been shown to cause PH. 
These include X-linked FLNA [14-17] as the most frequent cause, rare biallelic variants in 
ARFGEF2 [15,18-22], MCPH1 [23], FAT4 [10,13,24], DCHS1 [10,13], and INTS8 [25] as 
cause for recessive forms of PH. De novo or inherited variants in NEDD4L [26] or MAP1B 
[27] also cause heterozygous forms of the disorder. Recently, high throughput analysis of 
patients with PH has revealed extreme genetic heterogeneity including single nucleotide 
and copy number variants [27-39]. Functional analyses have delivered supportive 
evidence for the potential for further candidate genes to be causative, with some of them 
implicating a role for bRG cell dysfunction in its pathogenesis [29]. 
In this study, we combined human induced pluripotent stem cell (iPSC)-based 2D and 3D 
in vitro models [31,32] with acute in vivo manipulation of gene expression in the 
developing mouse cortex [33] to characterize the role of endothelin-converting-enzyme-2 
(ECE2) in cortical development, for which two patients with PH have been identified with 
rare bialleleic variants [27]. The applicability of cerebral organoids (COs) [32] to model 
different aspects of PH and explore the role of novel candidate causative genes in human 
cortical development has been shown in several recent studies [13,28,29]. We identified 
a role for ECE2 both in RG polarity and morphology, as well as in neuronal migration and 
differentiation. Proteome analysis of genome-engineered ECE2 knockout (KO) iPSC-
derived cerebral organoids revealed an additional function in the production and secretion 
of components of the extracellular matrix (ECM) and additionally suggest an involvement 
of ECE2 in protein phosphorylation.  
 
Results and Discussion 
Identification of ECE2 as candidate gene for periventricular heterotopia (PH) 
Recent trio-based exome sequencing studies have indicated considerable genetic 
heterogeneity underlying PH, complicating the identification of causative genes given the 
large mutational landscape [27]. To aid novel disease gene identification we sought to 
functionally complement such large-scale sequencing efforts with evidence obtained from 
both in vivo and in vitro model systems. Using data obtained from a recent study in which 
202 individuals with PH were subject to whole exome sequencing using a trio based 
strategy, we designed functional experiments for genes within this cohort with rare (minor 
allele frequency MAF<0.005) bialleleic variants identified in two or more individual 
patients. Applying these criteria on this dataset, we identified three candidate genes – 
ECE2, GPR98 and PRPN13 (Table EV1). As a further filter, we limited our analysis to 
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genes whose biallelic variants were assigned as potentially deleterious by any one of four 
in silico prediction programs (Materials and Methods). Under this framework, only one 
gene – ECE2 – remained.  
ECE2, encoding for endothelin-converting-enzyme-2 [27], is a metallopeptidase that has 
previously been associated with non-classical production of neuropeptides [34,35], 
removal of intracellular amyloid-β in Alzheimer’s disease [36,37], and its knockout in 
mouse leads to deficits in spatial learning and memory acquisition [38]. The function of 
this gene in the developing cortex, however, has not been described. The two patients 
with PH had biallelic missense variants in this gene that were in silico predicted to be 
deleterious. Patient 1 (see example MRI images in Figure 1A) has two variants in ECE2, 
each inherited from a separate parent (c.655C>G, p.Arg219Gly; and c.2253, 
p.Arg752Trp; RefSeq NM_001037324.2). Patient 2 is homozygous for a missense variant 
in this locus (c.2239T>A, p.Ser747Thr; RefSeq NM_001037324.2) (Table  EV1).  
 
ECE2 is enriched in human neurons  
In order to verify that ECE2 is expressed in human iPSCs-derived models, we started 
with characterization of ECE2 expression in these model systems and we detected higher 
ECE2 expression in neurons compared to NPCs using qRT-PCR (Figure 1B). This was 
confirmed by the online database libd (http://stemcell.libd.org/scb/) [39], containing 
publically available RNA sequencing data from different stages of neuronal differentiation 
from 13 iPSC lines to neurons (Figure 1C). Additionally, in situ hybridisation (ISH) for 
ECE2, performed in 50 days old COs, confirmed higher levels in the cortical plate-like 
zone (CP’) than in the ventricular-like zone (VZ’) (Figure 1D). Immunohistochemical 
(IHC) analysis for ECE2 also demonstrated higher levels in the CP’ (colocalising with 
MAP2+ neurons) than in phospho-VIMENTIN+ (pVIM+) RG located in the VZ’ of COs, 
although an enrichment at the apical surface was also evident (Figure 1E). Human iPSC-
derived in vitro model systems are thus suitable tools to manipulate and study the role of 
ECE2 in the developing cortex. 
 
Knockdown of ECE2 leads to accumulation of neurons in the VZ of COs 
ECE2 was enriched within neurons, thus to unravel the potential function of this protein in 
these cells we performed acute knockdown (KD) of ECE2 in human COs. To this end, 
miRNAs targeting the peptidase were injected into the ventricle-like lumen of 50 days old 
COs prior to electroporation (Figure 1F). GFP+ transfected aRGs and their progeny were 
analysed 7 days post electroporation (7dpe). At this stage, due to the organisation of COs 
into separated zones containing progenitors and neurons, changes in morphology, cell 
fate and migration can be analysed at once. Interestingly, a significant increase in 
differentiated NEUN+ neurons were ectopically located within the VZ’ after ECE2 KD 
compared to control, mimicking the neuroanatomical anomalies observed in patients with 
PH (Figures 1G-I). Interestingly, most ectopically located neurons were not 
electroporated (NEUN+GFP-), but they were localised in close proximity of transfected 
aRGs, suggesting a non-cell-autonomous function of ECE2 in neuronal migration. These 
electroporated aRGs had often lost their attachment to the apical surface (arrows in 
Figure 1H), hinting at a defect in aRG morphology and consequent delamination upon 
ECE2 KD. This morphological change of transfected aRGs is already visible 4 dpe upon 
ECE2 KD in COs (Figure EV1C) and suggests a role of ECE2 in aRG and adherens 
junction integrity as suggested from its enrichment at the apical surface.  
 
132 
 
 
Inhibition of ECE2 activity changes the dynamics of neuronal migration in vitro 
To assess if the enzymatic function of ECE2 is also directly involved in neuronal 
migration, timelapse imaging of young migrating neurons was performed upon inhibition 
of ECE2 activity. To this end, NPCs were cultured under differentiating conditions in the 
presence or absence of Phosphoramidon (Phos) (scheme in Figure 1J). This compound 
was shown to inhibit the function of ECE2 at low concentrations of 1 µM [40]. Young 
neurons cultured in the presence or absence of Phos were imaged over 17 hours with 
several paramethers, such as speed of migration, resting timepoints and tortuosity being 
analysed (Figure 1K). After inhibition of ECE2 activity, neurons migrated significantly 
more slowly, rested more often and migrated in a more tortuous path compared to control 
neurons. Thus, the activity of ECE2 is required for normal neuronal dynamics, suggesting 
an additional cell-autonomous function of ECE2 directly in neuronal migration.  
Taken together, this data supports a role of ECE2 in the developing human brain.  
 
Acute KD of Ece2 in the developing mouse cortex leads to ectopic rosettes and 
nodules 
In order to reveal the role of Ece2 in the developing cerebral cortex in vivo, acute KD of 
this gene's expression was performed by in utero electroporation (IUE) of miRNAs 
targeting Ece2 in the ventricles of the developing telencephalon of mice at embryonic day 
13 (E13). Brains were then analysed 1 dpe (E14) and 3 dpe (E16).  
The distribution of the GFP+ electroporated cells was analysed 1dpe by dividing the 
developing cortex in 5 equal bins, bin1 corresponds to apical side while bin5 to pial side 
of the cortex. Upon Ece2 KD, significantly more transfected (GFP+) cells localised to bin2 
(Figure 2A). Ectopic, basally located Pax6+ progenitors were identified which, compared 
to control, tended to localise more to bin2 than bin1 (Figures 2B, C and Figure EV2A) 
and were also positive for the active cell cycle markers Ki67 and phospho-Vimentin 
(Figures EV2B, C), with reduced apical Arl13b (Figure EV 2G). This redistribution of 
Pax6+ progenitors was not met with a significant change in neuron localisation 1 dpe, 
although some ectopic neurons were detectable at this early stage with a trend to 
increased localisation to bin3, and not bins4 and 5 as per the control (Figures EV 2D-F). 
Interestingly, ectopic progenitors were often not transfected (GFP-, Figure 2C), indicating 
that – similarly to the results found in COs – non-cell-autonomous mechanisms may 
contribute to this redistriution of cortical progenitors. Similarly, the morphology of 
transfected aRG was changed to a less radial and bipolar shape (Figure 2A, Figures EV 
2B, G). 
Analysis 3 dpe (E13-E16) revealed ectopic clusters, containing delaminated non-
transfected Pax6+ (Figure 2D) and Ki67+ progenitors (Figure EV2H), accumulating in 
the parenchyma around an Arl13b+ area, surrounded by thickened processes of 
transfected cells (Figures 2E, F). In contrast, we often found a reduction in apical Arl13b 
and β-catenin (CTNNB1) in the electroporation site (Figures 2E, G). Altogether, these 
data suggest the delamination of cells from the apical surface (Arl13b+) and the formation 
of “rosettes” at more basal positions upon Ece2 knockdown. Pax6- areas were also found 
in the progenitor zone underneath the ectopic rosette both at 1 dpe and at 3dpe (circles in 
Fig. 2B, D), indicating that the delamination of radial progenitors may be the cause of the 
ectopic rosettes.  
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Figure 1: Neuronal mislocalisation and migration defects found in individuals with ECE2 
variants are recapitulated in iPSC-derived in vitro models. A, Coronal and axial brain MRI of 
the patient with compound heterozygote mutations in ECE2 shows nodules of heterotopic neurons 
lining the lateral ventricles. B-D, ECE2 expression on RNA level. B, qPCR of in vitro generated 
iPSC-derived NPCs vs. neurons shows higher ECE2 RNA expression in neurons. C, RNA 
sequencing data of different stages of neuronal differentiation from iPSCs 
(http://stemcell.libd.org/scb/) [39]. D, In situ hybridisation for ECE2 RNA in 50d old cerebral 
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organoids (COs) shows higher signal in the cortical plate-like zone (CP’) (Scalebar=100 µm). E, 
ECE2 expression on protein level. Immunohistochmistry (IHC) for ECE2 in 50d old COs shows 
accumulation in the CP’ and at the apical surface (Scalebar=50µm). F, Scheme showing the 
electroporation of DNA into ventricles of COs and the organisation of different cell types within the 
germinal zone. DNA  is injected into the ventricle-like lumen and taken up by aRG via their apical 
processes. 7 dpe, the transfected construct can be found in IPs and neurons upon differentiation 
of transfected aRG (green) (VZ’ = ventricular zone, SVZ’ = subventricular zone, IZ’ = intermediate 
zone, CP’ = cortical plate, aRG’ = apical radial glia, bRG’ = basal radial glia, IP’ = intermediate 
progenitor). G-H, COs transfected with miRNAs targeting ECE2 (KD) (H) or scrambled negative 
control (CTRL) and GFP (G) and analysed 7 days later reveal an increase in ectopic neurons upon 
ECE2 KD (Transfected cells are shown in green, NEUN+ neuronal nuclei in magenta. d=day. 
Scalebar=25 µm). I, Graph depicting the number of ectopically located NEUN+ cells in CTRL and 
KD electroporated COs. Data shown as box plot (mean = red line, median = black line, box 
represents 25th and 75th percentiles, whiskers extend to 10th and 90th percentiles, all outliers are 
shown; n=number of ventricles analysed; ***P < 0.001 in Kruskal-Wallis One Way ANOVA on 
Ranks and Dunn’s Pairwise Multiple Comparison). J, Scheme depicting the experimental setup of 
neuronal differentiation and timelapse imaging under treatment with the ECE2-inhibitor 
phosphoramidon (Phos) [40]. K, Graphs showing different parameters of neuronal migration 
dynamics, tracked via live imaging. Upon ECE2 inhibition, significant decrease in velocity, increase 
in resting TP and increase in tortuosity are observed. Data shown as z-scores (CTRL = DMSO 
control; PhR = Phosphoramidon; Resting TP = Resting timepoints; N=number of individual 
neurons analysed from 2 batches; Resting TP: *P=0.024; tortuosiy: *P=0.035, ***P < 0.001 in 2-
tailed Chi-Sqare test). See also Figure EV1. 
 
Ectopic rosettes were surrounded by clusters of (mostly non-transfected) ectopic 
neurons, with both deep and superficial layer identities, often forming “nodules” (Figures 
2H, I and Figure EV 2H). Moreover, single neurons were also more frequently localised 
to the apical surface of the lateral ventricles after Ece2 knockdown compared to control 
cortices (Figure 2H). At both analysed time points, ectopic rosettes and nodules 
contained almost exclusively non-transfected cells, but were surrounded by GFP+ 
processes of transfected cells (Figures 2E, F). We consistently observed defects in the 
position and morphology of progenitors and neurons in all brains, but the severity of the 
phenotype strongly depended on the size and position of the electroporated area. Upon 
acute KD of Ece2, we identified significantly more ventricles with reduced Pax6 in the 
electroporation site, more ectopic rosettes and nodules, more ectopic Arl13b+/β-catenin 
apical surfaces and a reduction in apical Arl13b and β-catenin (Figure 2J). 
Therefore, similar to our results with KD of ECE2 in COs, we could recapitulate some 
features of the patients’ PH phenotype in the developing mouse cortex in vivo. We 
suggest that the PH-like disruption originated from a delamination of progenitor cells, 
followed by the formation of subapical clusters of progenitors that possibly generate the 
ectopic neurons found in their proximity. Also at this stage, ectopic rosettes and nodules 
consisted almost exclusively of non-transfected cells, highlighting again the non-cell-
autonomous nature of the PH. 
 
 
 
135 
 
 
Figure 2: Acute Ece2 KD in the developing mouse cortex causes ectopic rosettes and 
nodules. A, Quantification of distribution of GFP+ transfected cell 1dpe upon CTRL and Ece2 KD 
by IUE (n=3 CTRL and 4 Ece2 KD brains; *P=0.044 in One-way ANOVA and Tukey’s Multiple 
Pairwise Comparison; data shown as mean±SEM). B-C, Ece2 KD leads to ectopic non-transfected 
Pax6+ progenitors 1 dpe (E13-E14). B, IHC staining of GFP (transfected cells) and Pax6 1 dpe 
showing ectopic Pax6+ progenitors and a reduction in their apical localisation. C, High 
magnification images of GFP and Pax6 showing ectopic progenitors are mostly not transfected. D-
J, E13-16 Ece2 KD. D, GFP
-
Pax6+ progenitors delaminate upon Ece2 KD, leaving behind a region 
free of Pax6+ cells in the VZ (circle) and forming ectopic rosettes (box). E, G, Reduction in apical 
Arl13b and β-catenin in the electroporation site indicates loss of apical belt integrity and disruption 
of apico-basal polarity upon Ece2 KD. F, Inside the nodule, which is surrounded by thickened 
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GFP+ processes, Arl13b staining shows the formation of an ectopic apical surface (enlargement of 
boxed area from D and E). H, Deep layer and I, upper layer neurons localise next to ectopic 
rosettes, forming nodules of ectopic neurons. J, Quantification at 3 dpe, counting the proportion of 
brains with reduced density of Pax6 in the VZ, ectopic progenitors or neurons, and changes in 
apico-basal polarity (including ectopic apical surface formation and reduction in apically localised 
apical markers; n=6 brains per condition; Exact binomial test: ****P < 0.0001). Scalebars in A-
I=100 µm. See also Figure EV2. 
 
Manipulation of ECE2 levels and activity reveal a role of ECE2 in cell fate 
determination  
To address the functional role of ECE2 in human cells, two parallel approaches were 
taken: COs were treated with the ECE2 inhibitor Phos prior to IHC or Fluorescence-
Activated Cell Sorting (FACS) analysis (scheme in Figure 3A, Figures 3B-D, Figures EV 
3B-D) and ECE2 KO iPSCs and COs were generated and analysed (Figures 3E-J and 
Figures EV 3E-J).  
Chronic treatment (21 days) of 60 days old COs with Phos, which did not increase cell 
death as revealed by cleaved Caspase-3 staining (Figure EV 3A), lead to a change in 
the cellular composition: FACS analysis of neural progenitors (SSEA1 and BLBP sorted 
cells) and of neurons (MAP2 sorted cells) revealed an increase in neural progenitor cells 
(Figures 3B, C) and a reduction in neurons (Figure 3D) (see Figure EV 3B for the gating 
strategy).  
CRISPR/Cas9-mediated genome editing in iPSCs resulted in a frameshift and premature 
STOP codon in one allele and fusion of first half of exon 3 and second half of exon 4 due 
to the loss of 80 AA in the second allele. The absence of ECE2 mRNA in ECE2 KO 
iPSCs (Figure EV 3E) was confirmed by qPCR (Figure 3F). COs were generated from 
ECE2 KO and the isogenic control iPSCs [32]. An initial delay in differentiation was 
visible, with a later emergence of neuroepithelial tissue in the ECE2 KO COs (Figure EV 
3E), without a significant difference in CO size compared to control (Figure EV3F). ECE2 
KO COs generated normal cortical-like regions (Figure 3E), indicating that ECE2 
deficiency is still permissive for the first steps of neurodevelopment. 
60d old COs were analysed by FACS using the progenitor marker PAX6, the mitotic 
marker PH3 and the neuronal marker DCX (see Figure EV3G for the gating strategy). 
Similarly to the above described findings for ECE2 inhibition, the proportion of progenitors 
was increased (Figures 3G, H) and that of neurons was decreased (Figure 3I) in ECE2 
KO COs compared to control. This change in cellular proportions was also confirmed by 
IHC, where we found that the number of PH3+ cycling progenitor cells (normalized by the 
length of apical surface) was significantly increased in germinal zones of ECE2 KO COs 
(Figures EV3H, I), whereas the thickness of the MAP2+ neuronal layer was decreased 
(Figure EV3J). The higher expression of ECE2 in neurons may be required for neuronal 
differentiation. 
Altogether, both chronic enzymatic inhibition and the permanent KO of ECE2 in COs lead 
to changes in the proportions of progenitor and differentiated cells, demonstrating a role 
for ECE2 in neurogenesis.  
Further exploiting the spatial organisation and separation of progenitor and CP-like zones 
in COs, we identified ectopic neurons within these COs in the VZ’ after ECE2 KO. Some 
MAP2+ neuronal processes are present throughout the progenitor zone in KO COs and 
even though these structures were also observed in control COs, there is a clear 
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significant increase in brain-like regions with progenitor zones containing neuronal cell 
bodies upon ECE2 KO, with a concomitant decrease of normally organised ventricles in 
the KO condition (Figures 3J, K). The malpositioning of neurons characterizing the 
brains of patients with PH is thus partially recapitulated both after acute ECE2 KD and in 
ECE2 KO COs. 
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Figure 3: ECE2 inhibition and KO cause a change in cell fate and neuronal positioning in 
COs. A, Scheme depicting the timeline of chronic Phos treatment in COs prior to IHC or FACS 
analysis (hES, NIM, NDM-/+A: media for CO generation, see Methods). B, C, FACS analysis of 
Phos-treated COs shows an increase in neural progenitors. D, FACS analysis of Phos-treated 
COs reveals a decrease in neurons. Data shown as z-scores. (Box plots: mean=red line, 
median=black line, box represents 25th and 75th percentiles, whiskers extend to 10th and 90th 
percentiles, all outliers are shown; B-D: *P < 0.05; **P < 0.01 in One Way ANOVA and Tukey’s 
Pairwise Multiple Comparison). E, Brightfield images of 60d old CTRL and ECE2 KO COs show 
normal formation of neuroepithelial structures. F, qPCR confirms absence of ECE2 mRNA in 2 
clones of ECE2 KO iPSCs (Data shown as mean±SEM from triplicates). G-I, FACS analysis of 60d 
old ECE2 KO COs reveals an increase in progenitors (G, H) and decrease in neurons (I) (n=7-8 
samples of 3 pooled organoids each from 3 different batches; **P < 0.01; ***P < 0.001 in One Way 
ANOVA and Tukey Pairwise Multiple Comparison). J, K, In ECE2 KO COs, more ventricles are 
disorganised in terms of neuronal localisation as revealed from MAP2+ cell bodies in the 
progenitor zone (n=number of ventricles from 2 independent batches; two-tailed Mann Whitney U 
(U = 458) and chi-square test: χ2(2)=25.42, ****P < 0.0001). See also Figure EV3. 
 
ECE2 inhibition and KO leads to changes in actin and microtubule cytoskeleton 
Due to the 3-dimensional organisation of germinal zones, COs represent a good system 
to analyse the cellular morphology, the integrity of cytoskeletal proteins and markers of 
apico-basal polarity after acute ECE2 KD in vitro and in vivo. 
Cytoskeletal dynamics and apico-basal polarity are essential both for the integrity of the 
RG scaffold used by locomoting excitatory neurons and for neuronal polarisation and 
migration itself [41]. These were thus characterized both in ECE2 KO and in Phos-treated 
COs (Figure 4) to assess a possible involvement of ECE2.  
A significant increase in thickness of the filamentous actin (F-Actin) enriched apical 
adherens belt was detected in both COs treated with Phos for two weeks (Figures 4A, B) 
and in ECE2 KO COs (Figures 4C, D). In addition, the apical F-Actin enriched honey-
comb structure was also analysed. Here, we identified morphological alterations in the 
case of ECE2 KO (Figure 4E) consistent with a loosening of the apical junctions. ECE2 
may thus directly or indirectly influence the regulation of the actin filament 
(re)organisation, contributing to the morphology and delamination of aRG in the 
developing cerebral cortex. 
Next, we analysed the stability of microtubules as the second important component of the 
cytoskeleton. We used IHC for acetylated tubulin (ac-tub), which is enriched in stabilised 
microtubules [42]. IHC of ac-tub in Phos treated and ECE2 KO COs revealed some 
normal germinal zones and some with a reduction and/or disorganisation in stabilised 
microtubules (Figures 4F, H). We quantified ventricles with normal ac-tub and reduced or 
disorganised VZ’ structures to assess the extent of disruption. This displayed a significant 
reduction in ventricles with normal stabilised microtubule cytoskeletons after both ECE2 
inhibition and KO (Figures 4G, I).  
We next assessed apico-basal polarity in Phos-treated and ECE2 KO COs by IHC for 
ARL13B as a marker for the microtubule-based primary cilium that contacts the 
ventricular lumen in aRG. We found again some normal ventricles and some with 
reduced or totally absent localisation of ARL13B at the apical surface. The number of 
ventricles with normal ARL13B was significantly reduced (Figures 4J-M). 
To further support our finding of reduction in apically localised ARL13B and to minimize 
artefacts due to cutting orientation of COs, we used iDisco [43] of Phos-treated whole 
COs.  
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Whole-mount IHC for ARL13B, tissue clearing and imaging of whole COs confirmed the 
reduction in apical ARL13B upon ECE2 enzymatic inhibition (Videos 1 and 2). 
Interestingly, an involvement of primary cilium abnormalities in ectopic neuronal 
positioning was recently suggested [28], indicating that this may be a common 
mechanism underlying the etiology of PH. 
We also analysed the levels of β-catenin, which is enriched at the apical adherens 
junctions, by WB and identified a trend towards a reduction in ECE2 KO COs (Figure 
EV4A, B). This is similar to its reduction upon Ece2 KD in the developing mouse cortex 
(Figure 2G) and in line with the delamination of aRG upon acute ECE2 KD in COs (see 
Figure 1I, Figure EV1C).  
Finally, to visualize aRG morphology upon ECE2 KO, we electroporated GAP43-GFP 
plasmid into ventricle-like structures of CTRL and KO COs to label the membrane of 
transtected aRG. Analysis 1dpe revealed that in ECE2 KO COs, aRG can lose their 
apical attachment (which was still present during electroporation for take-up of the 
construct) or even completely lose their bipolar morphology (Figure 4 N, O). This finding 
further underscores the involvement of ECE2 in RG morphological integrity.  
Altogether, we identified changes in both the microtubule and actin cytoskeleton and in 
the polarity of aRG. Loss of apically localised cilia and reduction in the stability of the 
apical F-actin belt suggest aRG delamination and formation of ectopic rosettes. These 
ectopic progenitors don’t in general lack apico-basal polarity (ectopic Arl13b) but lack 
bipolar morphology, possibly leading to a disorientation of the derived neurons, which can 
then form nodules.  
Hence, our data suggest that ECE2 directly or indirectly plays a role not only in neuronal 
migration and positioning, but also in cell fate, cytoskeletal organisation and apico-basal 
polarity of aRG. Despite the numerous processes that ECE2 is involved in, the molecular 
role of ECE2 – both causing cell-autonomous and non-cell-autonomous defects upon its 
disruption during neurogenesis – still remains undefined.  
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Figure 4: Cytoskeleton and apico-basal polarity are disrupted upon ECE2 inhibition and 
ECE2 KO. A-D, The thickness of the apical F-actin belt is increased in Phos-treated COs (A, B) 
and ECE2 KO COs (C, D). A, C, Example images of Phos and CTRL treated COs (A) and 60d old 
CTRL and ECE2 KO COs (C) with F-ACTIN labeled by AlexaFluor594-conjugated Phalloidin (A: 
Scalebar = 50 µm, C: Scalebar = 100 µm). B, D, The thickness of the F-Actin belt was assessed in 
Fiji [44] by measuring the area of F-actin and dividing by the length of apical surface (Box plots: 
mean=red line, median=black line, box represents 25th and 75th percentiles, whiskers extend to 
10th and 90th percentiles, all outliers are shown; n=number of analysed ventricles in 2 batches; 
Kruskal-Wallis One Way ANOVA on Ranks and Dunn’s Pariwise Multiple Comparison: **P=0.003; 
***P < 0.001). E, IHC for ARL13B and F-ACTIN in 60d old CTRL and ECE2 KO COs shows 
disruption of honeycomb-like structure of the apical adherens belt and of apico-basal polarity in 
terms of apically localisaed primary cilium. F-I, The microtubule cytoskeleton is changed upon 
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ECE2 inhibition (F, G) and KO (H, I). F, H, Example images of ac-tub IHC in CTRL vs. PHOS-
treated (F) and CTRL vs. ECE2 KO (H) COs (F: Scalebar = 50 µm; H: Scalebar = 100 µm). G, I, 
Quantification of ac-tub in ventricles of PHOS-treated (G) and ECE2 KO (I) COs as normal (“1”) or 
reduced/disordered (“0”) shows significant reduction in normal ventricles (n=number of analysed 
ventricles in 2 batches; ****P < 0.0001 in exact binomial test). J-M, Apico-basal polarity is impaired 
upon ECE2 inhibition and KO as visible in example images of ARL13B IHC in CTRL vs. PHOS (J) 
and KO (L) COs (J: Scalebar = 50 µm; L: Scalebar = 100 µm). K, M, Quantification of germinal 
zones for normally high (“1”) vs. reduced (“0”) apical ARL13B reveals a reduction in normal 
ventricles in the absence of ECE2 (n=number of analysed ventricles from 2 batches; ****P <0.0001 
in exact binomial test). N, O, Analysis of CTRL and ECE2 KO COs 1 dpe with GAP43-GFP reveals 
RG that delaminated and/or lost their bipolar morphology in the KO COs.  See also Figure EV4.   
 
Proteomics reveals ECE2 involvement in extracellular matrix production and 
integrity 
To gain a deeper insight into the mechanisms underlying the observed phenotypes in in 
vivo and in vitro models, we performed whole proteome analysis of 60d old CTRL and 
ECE2 KO COs. Mass Spectrometry-based proteomics has recently been used to 
compare trisomy 21 patient and control-derived COs and revealed 1) that the 
neurodevelopmental trajectory shown several times by scRNAseq [45-47] is also 
recapitulated on the protein level in COs, 2) a number of dysregulated proteins in trisomy 
21, and 3) reversal of dysregulated proteins by drug treatment [48]. Here, quantitative 
proteome analysis of whole-organoid-lysate revealed a number of significantly up- and 
downregulated proteins upon ECE2 KO (Figure 5A and Table EV2). These included 
upregulation of PAX6 and downregulation of MAP2, confirming FACS data from ECE2 
KO and Phos-treated COs (Figure 3). Additionally, the identified downregulated proteins 
included numerous proteins with functions that are highly relevant to cortical development 
and its disorders. Figure 5B illustrates a classification of all downregulated proteins into 
the following classes (see colour code in Table EV3) [49-51]. These included 
genes/proteins whose disruption is known to cause PH (e.g. FLNA [14-17]) or disorders 
of neurodevelopment. A number of additional microtubule and microtubule-associated 
proteins were also downregulated, strengthening our previous findings (Figure 4), as 
were additional actin-associated/-organizing proteins, such as ezrin and moesin, which 
are interactors of RHOA and FLNA (Figure EV4C). Decrease in phosphorylated ezrin, 
radiaxin and moesin (pERM) was confirmed by WB of ECE2 KO iPSCs (Figures EV4D). 
Some guidance and adhesion factors such as SLITs and FLRTs were downregulated in 
ECE2 KO COs, similarly to other COs derived from patients with PH [13]. In the context of 
neuronal migration this is of relevance as differential expression of adhesion molecules 
such as FLRT1 and FLRT3 between future gyri and sulci was recently identified to 
influence the migration of cortical neurons, thereby regulating gyrification independantly 
of progenitor cell expansion [52]. 
In addition, a number of adhesion proteins were downregulated in ECE2 KO organoids, 
which may explain the delamination of transfected RG observed upon acute KD in 
cerebral organoids and in the developing mouse cortex (Figures 1 and 2) and the 
reduction in apically localised β-catenin and ARL13B both in vivo (Figures 2G-E, Figure 
EV2F) and upon chronic ECE2 inhibition or KO in COs (Figure 4J-M and Figure EV4A, 
B).  
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Figure 5: Proteomics reveal a role for ECE2 in ECM production and integrity. Volcano plot 
visualizes the proteomic analysis from 60d old CO lysates showing proteins with significantly lower 
and higher expression upon ECE2 KO (n=3 batches of 60d old CTRL and ECE2 KO COs; FDR 
0.05; s0 1; dashed lines indicating the cut-off). B, Pie chart with proteins downregulated in ECE2 
KO COs sorted by relevant categories (Number in the elements = number of proteins falling into 
each category, with numerous proteins falling into several ones) [49-51]. C, Volcano plot of MS of 
cell culture supernatant from 55d old CTRL and ECE2 KO COs shows two significantly 
downregulated proteins in the secretome (n=3 batches of 60d old CTRL and ECE2 KO COs; FDR 
0.05; s0 1; dashed lines indicating the cut-off). Non-significantly changed proteins of interest are 
highlighted in green below the cut-off curves. D, GO cellular component analysis of dysregulated 
phosphorylation sites (either found excusively in CTRL or KO or up- or downregulated in ECE2 KO 
COs relative to CTRL) identified in whole CO proteomic analysis. E, F Schemes summarizing 
identified phenotypes in in vivo and in vitro model systems upon acute ECE2 KD (E) or chronic 
inhibition or KO (F) and thus the molecular action of ECE2 (Abbreviations: d = day, pe = post 
electroporation, VZ = ventricular zone, SVZ = subventricular zone, IZ = intermediate zone, CP = 
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cortical plate, aRG = apical radial glia, bRG = basal radial glia, IP = intermediate progenitor, ECM 
= extracellular matrix). See also Figure EV4 and Tables EV1-8. 
 
The largest group of downregulated proteins, however, consisted of ECM components 
and their receptors, e.g. laminins, lumican, decorin, and six different collagens (see 
Figure 5B and Table EV3), not surprisingly since we observed non cell-autonomous 
effects upon modulation of ECE2 expression. 
Analysis of protein-protein-interactions (PPI) of downregulated proteins, using String.db 
[51], showed an arrangement of downregulated proteins into a tightly interconnected 
network (Figure EV4E) and GO Term analysis [50,51] revealed an enrichment of proteins 
with functions that are highly relevant to cortical development, such as adhesion, polarity, 
and cytoskeleton (Figure 5B, Table EV4). 
As ECE2 is a protease localised in secretory vesicles [53], the cell culture supernatant of 
COs was also analysed by MS for differences in the “secretome” between ECE2 KO and 
control COs. Two proteins were identified as significantly downregulated upon ECE2 KO 
(see Figure 5C, Table EV5): Lumican and TGFBI, both collagen-binding proteins (Table 
EV6). Additionally, other collgens in the secretome of ECE2 KO COs were somewhat 
decreased. These findings support the involvement of ECE2 in ECM generation or 
regulation. 
The ECM is implicated both in neuronal migration and differentiation as well as in cortical 
expansion and folding [54-56], with human-enriched ECM components contributing to 
inter-species differences such as in gyrification [57]. Here, the identified 
overrepresentation of ECM components among the downregulated proteins may explain 
the non-cell-autonomous nature of mechanism observed both in in vitro and in in vivo 
model systems.  
Microtubule dynamics is regulated by different types of microtubule-associated proteins 
(MAPs), such as EML4, MAP2 and MAP4, which were downregulated in the proteome of 
ECE2 KO COs. Additionaly, posttranslational modifications (PTMs) of tubulins and MAPs 
influence microtubule stability, the interaction capability of MAPs, and microtubule-based 
transport [58]. To this end, we futher investigated differentially phosphorylated protein 
sites from the whole proteome analysis between CTRL and ECE2 KO COs (Table EV7). 
Strikingly, we detected differences in several proteins involved in apical adhesion, 
cytoskeletal and motor functions, with special enrichment of microtubule-related proteins 
among exclusive phosphorylation sites (Table EV8) and of actin cytoskeleton-related 
proteins among differentially phosphorylated sites (Table EV9) (Figure 5D). Our analysis 
of phospho-proteins suggests an additional role of ECE2 in the regulation of the actin and 
microtubule cytoskeleton through PTMs such as phosphorylation.  
Altogether, we studied the role of ECE2 in brain development and identified ECE2 as a 
promising novel candidate gene for PH, showing that ECE2 controls apical adhesion, 
cytoskeleton dynamics and ECM composition.  
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Materials and Methods 
Candidate gene prioritization. The recent trio-based whole exome sequencing study in 
patients with PH [27] was interrogated for genes with rare (MAF<0.005) biallelic variants 
(homozygous recessive or compound heterotzyote) in two or more patients. As outlined 
in Table S3 and S4 of this report [27], only three genes remained of interest - ECE2, 
GPR98 and PTPN13. Note, although two separate homozygous recessive variants are 
identified for SPEG, they are all present within the same patient. As a further filter to 
identify a potential candidate gene for functional investigation, we restricted our analysis 
to any of these three genes whose variants in each individual were reported as potentially 
deleterious by one of four in silico prediction programs [59-62] (see Table EV1). Such 
prediction programs asses functional (i.e the resulting properties of the amino changes) 
and/or evolutionary properties (such as sequence conservation). Although such genic 
effects are not a proxy for disease association, any gene satisfying this criteria in this 
study would be prioritized for detailed functional investigation that further corroborates 
insight into the potential effect of the variants on gene function. Here, only one gene was 
prioritized – ECE2.    
Reprogramming of fibroblasts to induced pluripotent stem cells. Human induced 
pluripotent stem cells (iPSCs) were obtained by reprogramming of foreskin fibroblasts as 
described before [28]. 
iPSC culture. IPSCs were cultured at 37 °C, 5 % CO2 and ambient oxygen level on 
plates coated with Matrigel (Corning; diluted 1:100 in DMEM/F12+Glutamax, Thermo 
Fisher Scientific) in mTeSR1 medium (StemCell Technologies) with daily medium 
change. For passaging, iPSC colonies were washed with PBS and incubated with 
StemPro Accutase Cell Dissociation Reagent (#A1110501, Life Technologies) diluted 1:4 
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in PBS for 3 min. Detached pieces of colonies were collected by washing with DMEM/F12 
and 5 min centrifugation at 300 x g. They were then resuspended in mTeSR1 
supplemented with 10 µM Rock inhibitor Y-27632(2HCl) (#72304, StemCell 
Technologies) for the first day with splitting ratios 1:3 – 1:6. 
Generation of neural progenitor cells (NPCs) and neurons from iPSCs. Neural 
progenitors were generated as described previously [31] (Figure EV 1A) with some 
modifications. Embryoid bodies (EBs) were obtained by incubation of feeder-free iPSC 
colonies with Collagenase Type IV (#7909, StemCell Technologies) for 15 min, followed 
by washing with DMEM/F12, manual disruption and scraping with a cell lifter (3008, 
Corning Life Sciences). Resulting detached pieces of iPSC colonies were plated in 
suspension in Neural Induction Medium (NIM) consisting of DMEM/F12+Hepes 
(#31330095, Life Technologies) with 1x N2 and B27 supplements (without vitamin A, 
Thermo Fisher) with medium change every other day. EBs were plated on 
Polyornithine/Laminin plates after 1 week of suspension culture and after another week of 
culture in NIM, neural rosettes were picked and disrupted manually using a P20 tip. 
Resulting NPCs were cultured in NPM (NIM + 20 ng/ml basic fibroblast growth factor 
(bFGF/FGF-2), #100-18b-50, Preprotech) and passaged using Accutase (StemCell 
Technologies) splitting at a maximum ratio of 1:4. NPCs were only used for up to seven 
passages. For differentiation to neurons, single NPCs were plated at a density of 104 
cells/cm2 on Polyornithine/Laminin plates and cultured in NPM for 1 more day to reach 
about 30% cell density. Afterwards, medium was changed to Neuronal Differentiation 
Medium NDM (NIM containing 20 ng/mL BDNF (#248-BD, R&D Systems) and 20 ng/mL 
GDNF (#212-GD, R&D Systems)) and were differentiated for 20 days with medium 
change every 5 days. 
Cerebral organoids. Cerebral organoids (COs) were generated starting from 9,000 
single iPS cells/well as previously described [32] (Figure EV 1B) with the following 
alterations. Organoids were cultured in 10 cm dishes on a DOS-10L orbital shaker at 37 
°C, 5% CO2 and ambient oxygen level with medium changes twice a week. Organoids 
were electroporated at 50 days after plating (see Electroporation of cerebral organoids 
and Figure 1G) and analysed 4 and 7 days post electroporation (dpe). For 
immunostaining, 14 µm sections of COs were prepared using a cryotome. For 7 dpe 
analysis, 41 (CTRL) and 88 (ECE2 KD) different ventricles in a total of 17 (CTRL) and 25 
(ECE2 KD) organoids from 3 independent batches were analysed. 
Generation and validation of microRNAs targeting ECE2/Ece2: MicroRNAs (miRNAs) 
targeting human or mouse ECE2 were generated using the BLOCK-iT system from 
Invitrogen (Thermo Fisher). MiRNA sequences were determined using Invitrogen’s RNAi 
design tool  
https://rnaidesigner.thermofisher.com/rnaiexpress/setOption.do?designOption=mirnapid=
1961720787891316464. Three miRNA sequences per species were chosen and ordered 
as oligonucleotides from Sigma. ECE2-targeting miRNA oligonucleotides were annealed 
and ligated into a GFP-containing entry vector pENTR-GW/EmGFP-miR containing the 
miRNA backbones using T4 DNA Ligase (Thermo Fisher), following the 
recommendations in the BLOCKiT system. Subsequently, the miRNA sequences (plus 
GFP) were cloned into the pCAG-GS destination vector using the Gateway system 
(Thermo Fisher) according to the manufacturer’s recommendations. The resulting miRNA 
expression plasmids were sequenced using emGFP forward primer (5′- 
GGCATGGACGAGCTGTACAA-3′). The knockdown efficiency of the miRNAs were 
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tested via qPCR with validation of those targeting human ECE2 in SH-SY5Y 
neuroblastoma cells and validation of those targeting mouse Ece2 in P19 cells. The most 
efficient construct was used for neural progenitor transfection in COs by electroporation 
(see Electroporation of Cerebral Organoids and Figure 1G) and in the developing mouse 
cortex by in utero electroporation (see In utero electroproation). The following constructs 
were chosen. A miRNA with scrambled sequence (“miRneg“) was used as negative 
control: 
 
 
Plasmid preparation. Small-scale plasmid preparation was carried out using the 
QIAprep Spin Miniprep Kit (Qiagen) and large-scale preparation with the Plasmid Maxi Kit 
(Qiagen) after transformation in Subcloning Efficiency™ DH5α™ Competent Cells 
(Thermo Fisher).  
Electroporation of cerebral organoids. For transfection of aRG in germinal zones of 
COs by electroporation (see scheme in Figure 1G), COs were kept in NDM+A without 
antibiotics-antimycotics. The organoids were placed in an electroporation chamber 
(Harvard Apparatus) and miRECE2 or miRneg at a concentration of 1 µg/µl, 
supplemented with fast green (0.1%; Sigma) for visualization, was injected into ventricle-
like cavities at several positions per organoid. Electroporation was performed with an 
ECM830 electroporation device (Harvard Apparatus) by subjecting the organoids to a 1 
second interval with 5 pulses of 50 ms duration at 80mV. Medium was changed to 
antibiotics-containing NDM+A on the next day. 
In utero electroporation. As approved by the Government of Upper Bavaria under the 
license number 55.2-1-54-2532-79-2016, pregnant C57BL/6 mice were used. They were 
weighed and anesthetized by intraperitoneal injection of saline solution containing 
fentanyl (0.05 mg per kg body weight), midazolam (5 mg per kg body weight) and 
medetomidine (0.5 mg per kg body weight) (Btm license number 4518395), and embryos 
were electroporated at E13 as described [63]. Plasmids were mixed with fast green 
(0.1%; Sigma) and injected at a final concentration of 1 μg/μl. After would closure and 
sterilization, anesthesia was terminated by injection of buprenorphine (0.1 mg per kg 
body weight), atipamezole (2.5 mg per kg body weight) and flumazenil (0.5 mg per kg 
body weight). Brains were fixed 1dpe or 3dpe in 4% PFA for 4h (1 dpe) or overnight 
(3dpe) and were subsequently transferred to 30 % (w/v) sucrose in PBS for 
cryoprotection before embedding and freezing in OCT (VWR). For immunohistochemistry, 
12 µm sections were prepared using a cryotome. For each experiment, at least 3 different 
mouse brains per condition were analyzed. 
Analysis of cerebral organoids. For immunohistochemistry, cerebral organoids at the 
desired time point were washed with PBS and fixed in 4% formaldehyde (PFA) for 2 h at 
4°C. They were then left in a 30% sucrose solution overnight at 4°C. After this, they were 
embedded in embedding molds with OCT (VWR), embedding 3-4 organoids per mold, 
and kept at -20°C until further processing. Frozen organoid samples were cut at a 
cryotome, preparing 14 μm sections.  
Oligo name Sequence(5' to 3')
miR ECE2 top TGCTGTAATGTTCCAACCACCAATCTGTTTTGGCCACTGACTGACAGATTGGTTTGGAACATTA
miR ECE2  bottom CCTGTAATGTTCCAAACCAATCTGTCAGTCAGTGGCCAAAACAGATTGGTGGTTGGAACATTAC
miR Ece2 top TGCTGTCAATGAGGTCTCTAAGTGGCGTTTTGGCCACTGACTGACGCCACTTAGACCTCATTGA
miR Ece2  bottom CCTGTCAATGAGGTCTAAGTGGCGTCAGTCAGTGGCCAAAACGCCACTTAGAGACCTCATTGAC
miRneg top TGCTGAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTCTCCACGCAGTACATTTCAGG
miRneg bottom CCTGAAATGTACTGCGTGGAGACGTCAGTCAGTGGCCAAAACGTCTCCACGCGCAGTACATTTCAGCA
 
147 
 
Immunohistochemistry: Frozen organoid or mouse brain sections were thawn to RT for 
20 min and then rehydrated in PBS for 5 min. For nuclear antigens, an antigen retrieval 
step (HIER) was performed, boiling the sections in 0.01M citric buffer (pH 6) for 1 min at 
720 Watt and 10 min at 120 W. The slides were then left to cool down for 20 min. Half of 
the citric buffer was replaced by H2O, slides were incubated for another 10 min and then 
washed in PBS. Subsequently, a postfixation step of 10 min was carried out with 4 % 
PFA in PBS. Then, the sections were permeabilized using 0.3 % Triton X100 in PBS for 5 
min. After permeabilization, sections were blocked at RT for at least 1 h with 10 % Normal 
Goat Serum (#VEC-S-100, Biozol) and 3 % BSA (#A4503-50G, Sigma-Aldrich) in 0.1 % 
Tween in PBS. The primary antibody (see Table below) in blocking solution was then 
incubated overnight at 4 °C. Following several washes with 0.1 % Tween in PBS, 
sections were incubated with 1:1,000 dilutions of Alexa Fluor-conjugated secondary 
antibodies (Life Technologies) in blocking solution for at least 1h at RT, using 0.1 µg/ml 
4,6-diamidino-2-phenylindole (DAPI, Sigma Aldrich) to counterstain nuclei. Finally, 
sections were washed again several times with 0.1 % Tween in PBS and mounted with 
Aqua Polymount (#18606, Polysciences). Sections were visualized using a Leica SP8 
confocal laser scanning microscope. For immunohistochemistry of NPCs and neurons, 
cells were cultured on round coverslips (13 mm diameter, VWR) in 24 well plates, washed 
with PBS and fixed with 4 % PFA in PBS for 15 min at RT. For HIER, citric buffer was 
boiled, added to coverslips and left to cool down, while permeabilization, blocking and 
staining were carried out as described for the tissue sections.  
 
Table: Primary antibodies. 
Antigen Dilution Vendor Catalog # 
ARL13B 1:500 Proteintech 17711-1-AP 
ACETYLATED TUBULIN 1:6,000 Sigma- Aldrich T7451 
BLBP 1:150 Merck Millipore ABN14 
CTNNB1 (β-catenin) 1:500 BD Biosciences 610154 
CTIP2 1:500 Abcam ab18465 
DoubleCortin (DCX) 1:2,000 Merck Millipore ab2253 
ECE2 1:300 Novus Biologicals NBP1-81495 
F-ACTIN (Phalloidin-594) 1:40 Thermo Fisher A12381 
GAPDH 1:6,000 Merck Millipore CB1001 
GFP 1:1,000 Aves Lab GFP-1020 
MAP2 1:500 Sigma Aldrich M4403 
NEUN 1:500 Merck Millipore MAB377 
PAX6 1:500 Biolegend PRB-278p 
Phospho-Ezrin (Thr567)/Radiaxin 
(Thr564)/Moesin (Thr558) (41A3) 
1:1000 Cell Signalling 3149S 
Phospho-Histone H3 (PH3) 1:500 Millipore 06-570 
P-VIMENTIN (Ser55)   Biozol D076-3 
SATB2 1:500 Abcam ab51502 
SSEA1 (eBioMC-480 (MC-480)), 
Alexa Fluor 488 
1:200 eBioscience™ 53-8813-41 
TUBB3 1:500 Sigma Aldrich T8660 
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Generation of isogenic ECE2 Exon3/4 KO iPSC line. Two CrRNAs (one each in Exon 
3 and Exon 4) of the ECE2 gene were selected based on Geneious Prime, CCtop [64] 
and the guide design tool by Zhang lab (CRISPR.MIT.EDU).  The selected Exon 3- 
CrRNA (5’ GTTAGGCTCACGCACGCAGC 3’) and Exon 4- CrRNA (5’ 
GTTCCAGCGAGAACGCCCAT 3’) were individually assembled and in vitro transcribed 
into guideRNA (gRNA) using the EnGen sgRNA Synthesis Kit, S. pyogenes (#E3322S, 
NEB). The in vitro transcribed guides were assembled into a gRNA-CAS9-NLS RNP 
complex by incubating the CAS9-NLS (#M0646M, NEB) and both in vitro transcribed 
gRNAs for 20 min at RT, followed by electroporation into single cells of the control iPSC 
line (see above) using Amaxa 4D nucleofector (Lonza). Electroporated cells were plated 
onto a 10 cm Geltrex (#A1413302, Thermo Fisher) coated dish supplemented with 
mTesR1 (#85850, StemCell Technologies) and Y-27632 (#72308, StemCell 
Technologies). The electroporated cells were allowed to recover for 10 days with daily 
media changes of mTeSR1 before single cell live sorting into Geltrex coated 96 well 
plates using CloneR (#05888, StemCell Technologies). The iPSC colonies were 
screened for INDELS using the protocol by Yusa K (doi:10.1038/nprot.2013.126) with the 
following primers:      
        FW: 5’ -CAGACTCAAGGCTCAACTCACTGGCTGGCCTCATTG- 3’ 
        RV:  5’ –CCATCAAACCCATCTGCACTTCTCAATAGTCC- 3’. 
Putative positive clones were grown as individual KO lines. Genomic DNA was isolated 
from the generated KO iPSC lines using QIAamp DNA Mini Kit (#51306, Qiagen) and 
used as template with the above-mentioned primer pair. The resulting PCR product (906 
bp) was cloned using NEB PCR Cloning Kit (#E1202S, NEB) and Sanger sequenced to 
screen the individual genomic alleles. All the Sanger sequencing was performed at the 
Sequencing facility of the Max Planck Institute of Molecular Cell Biology and Genetics, 
Dresden, Germany.  
Manufacturer’s recommendations and kit protocols were followed for all the kits and 
reagents mentioned above. 
Two ECE2 KO clones with the following modifications resulted, shown aligned to the 
consensus sequence (Yellow boxes summarize the introduced changes): 
 
 
RNA isolation and RT-qPCR for ECE2/Ece2 levels in miRNA validation and in NPCs 
and neurons. Cells were washed and scraped with cold PBS and the pellet was lysed in 
QIAzol® Lysis Reagent (#79306, Qiagen). RNA was extracted using RNA Clean & 
Concentrator Kit (#R1015, Zymo Research) and cDNA was synthesised from 2 µg RNA 
each using SuperScript III reverse transcriptase (#18080-044, Thermo Fisher) with 
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Oligo(dT)12-18 primers (#18418012, Thermo Fisher) according to the manufacturer’s 
protocol. Subsequently, qPCR was performed in triplicates on a LightCycler® 480 II 
(Roche) using the LightCycler® 480 SYBR Green I Master (#04707516001, Roche) with 
the following reaction mix 1 µL of each primer (5 µM), SYBR Green I Master 5 µL, H2O 2 
µL and 1 µL of cDNA. The primers sequences were the following for ECE2:  
        FW: 5’- AGAAGTCCTGTGTGCCGAGG- 3’ 
RV:  5’- ATGCGGTCCGGATTTCGCT- 3’  
and for GAPDH: 
    FW: 5’- AATCCCATCACCATCTTCCAGGA- 3’ 
    RV:  5’- TGGACTCCACGACGTACTCAG- 3’.  
qPCR was done with: initial denaturation at 95 °C for 10 min, then 45 cycles of 95 °C 10 
s, 60 °C 10 s and 72 °C 10 s) and a melting curve from 95 °C to 65 °C with 15s per step. 
Cp values were determined from the second derivative maximum of the amplification 
curve and fold expression was calculated using the ΔΔCp method. 
In situ hybridisation on cerebral organoids sections. In-situ hybridization (ISH) was 
performed based on exons 7-12 of full-length ECE2 coned into pBluescript SK(+) 
(ordered from Genscript). For the generation of probes, 20 µg plasmid were digested for 
linearization with EcoRV for the sense and Kpn1 for the antisense probe (NEB). DNA was 
extracted using phenol-chloroform-isoamyl alcohol, pelleted using ammonium acetate 
and resuspended in RNAse free water. In vitro transcription was performed from 1 µg 
each of the linearized plasmids using T7 polymerase for the sense probe and T3 for the 
antisense probe, together with the Digoxigenin (DIG) RNA labeling mix (Roche) according 
to the manufacturer’s protocol.  
For detection of mRNA transcripts, 16 μm frozen sections were hybridized with 1 µl probe 
in 150 µl hybridization buffer (formamide 50%, 1x SSC buffer (20x stock: 3M sodium 
chloride, 300 mM trisodium citrate, adjusted to pH 7.0 with HCl), 2% SDS, 50 μg/ml yeast 
tRNA (Roche), 2% blocking reagent (Roche) 2%, 50 μg /ml heparin (Sigma)) per slide at 
65 °C overnight. 
The next day, hybridization buffer was replaced by washing buffer (50% formamide, 1x 
SSC,0.1 % Tween20 in H20) and the sections were washed at 65 °C for 10 min. This step 
was repeated twice for 30 min. Subsequently, the washing buffer was replaced by MABT 
(5x stock: 100 mM maleic acid, 150 mM sodium chloride, 0.1 % Tween20 in H2O, pH 
adjusted to 7.5 with sodium hydroxide). Sections were incubated in MABT twice for 30 
minutes at RT. Subsequently, sections were blocked using ISH blocking buffer (1x MABT, 
2% blocking reagent (Roche), 2% FCS in H2O) for 1 h at RT. Anti-DIG Fab Fragments 
(Roche) were then diluted 1:2,500 in ISH blocking buffer and incubated on the sections at 
4 °C overnight.  
The next day, sections were washed with MABT solution 5 times for 20 min. Afterwards, 
sections were incubated twice for 10 min in AP staining solution (100 mM Tris, pH 9.5, 50 
mM magnesium chloride, 200 mM sodium chloride, 0.1 % Tween20 inH2O). The AP 
staining solution was then replaced by AP staining solution containing NBT and BCIP 
(both Roche) in a 0.35% concentration, using 150 µl per slide. The color reaction was 
allowed to proceed overnight at 4°C and stopped by washing the sections with PBS. 
Sections were then stained with DAPI (0.02 mg/ml in PBS) to visualize nuclei. 
Drug treatment and 2D timelapse imaging of young neurons. For timelapse imaging, 
NPCs were plated on a polyornithin/laminin coated 24-well-plate and left in neural 
progenitor medium (DMEM/F12 with HEPES and Glutamine, N2 1:100, B27 without 
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Vitamin A 1:50) without bFGF for 4 days with medium changes every other day to allow 
the cells to start differentiation. The control condition (CTRL) was additionally treated with 
DMSO 1:1,000, whereas in the other wells, 1µM Phosphoramidon (PHOS) (#R7385, 
Sigma) was added for ECE2 enzymatic inhibition [40]. After this, cells were imaged for 17 
h using a Zeiss Axiovision Observer fluorescence microscope (Zeiss), maintaining 37°C 
and 5% carbon dioxide concentration. The cells were imaged every 10 min, several 
positions being taken per well. From the time lapse movies, movement data of single cells 
was derived using the Manual Tracking plugin for ImageJ [44]. No centering correction 
was applied. From the tracking data, cell movement parameters were calculated using 
Microsoft Excel 2013. Neuronal identity of tracked cells was confirmed after the time 
lapse imaging by TUBB3 immunostaining. 
The average velocity was directly calculated from the measured velocities. The number of 
resting timepoints (TP) was calculated by counting the number of time points with a 
velocity of 0, and dividing this number by the length of the whole dataset for each cell. 
The tortousity was calculated as division of the length of the path actually migrated by the 
net displacement of a cell from the beginning to the end of the track. Data is shown as z-
scores calculated relative to the mean and standard deviation of the control within each 
experiment (N= total number of cells from two independent experiments). Stastical 
significance was tested via 2-tailed Chi-Sqare test.  
Image acquisition. All imaging except for time lapse microscopy was performed using a 
Leica SP8 with the LASX Software from Leica and 25 x and 40 x water immersion 
objectives. Images were acquired in sequential xyz mode with at least 1024 x 1024 pixels 
and 1-1.5 µm thickness of optical z layers. Images were saved as .lif file format to contain 
the metadata for the subsequent image analysis. 
Image analysis. Image analysis was done in Fiji [44] using the manual cell counter and 
length and area measurement tools, as well as the Scalebar tool. Images are shown as 
Z-stacks. For the quantification of ectopic neurons upon ECE2 KD, all NEUN+ cells in the 
progenitor zone within the electroporated area were counted. For normalization to the 
electroporation size, this number was related to the number of GFP+ RG. The size of 
cerebral organoids was measured based on the perimeter from brightfield images 
acquired at a Zeiss Axiovision Observer fluorescence microscope (Zeiss) with at least 10 
organoids per timepoint and batch. Cell quantifications in the developing mouse cortex 1 
dpe were done on a single image of the z-stack with the brightest staining in the middle of 
the stack by binning of the electroporated area, from apical to basal surface, into 5 
equally big areas. Afterwards, single cells were counted using the manual cell counter. 
For quantification of brains 3 dpe, 6 brains per condition were analysed concerning the 
presence of ectopically positioned progenitors or deep- or upper layer neurons (at least 5 
cells per parameter) and concerning the quality of the apical belt, including the 
appearance of additional ectopic apical surface in a yes-or-no system. Quantification of 
PH3+ mitotic apical neural progenitor cells in COs was done by counting apically 
localised PH3+ cells and normalization to the ventricle’s apical surface length. 
Quantification of intruding MAP2. To assess zonal disorganization in COs upon ECE2 
KO, the amount of ventricles in CTRL and ECE2 KO organoids with intruding MAP2+ 
neuronal processes and/or with MAP2+ cell bodies localized in the progenitor zone were 
counted. In detail, ventricular zones containing more than 3 MAP2+ processes were 
categorized as “intruding processes” and those with MAP2+ cell bodies fell into the 
second, even more disorganized category. 
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Measurement of the thickness of apical F-ACTIN. The thickness of the apical F-ACTIN 
belt in ventricle-like zones of COs was determined by drawing and measuring the area of 
the Phalloidin-594-positive belt, measuring the length of the apical belt in its middle in 
parallel to the apical ventricular surface and dividing the area by the length. 
Quantification of Acetylated tubulin. The quality of the microtubule cytoskeleton in 
COs was assessed by IHC for acetylated tubulin as marker for stabilized microtubules. 
Independent germinal zones of COs were rated as “1” if the acetylated tubulin staining 
revealed a radial organization of fibers in the progenitor zone, whereas “0” was given to 
ventricles with a reduced signal or with disorganized microtubule structure.  
Quantification of Arl13B. Similar to quantification of acetylated tubulin, apical ARL13B 
in CO ventricles was rated as “1” for high signal and density of primary cilia and as “0” in 
case of reduced signal intensity and/or reduced apical localization of primary cilia. 
FACS Analysis. For every FACS sample, 3 cerebral organoids were pooled. Organoids 
were washed with PBS and then enzymatically dissociated to single cells using Accutase 
(StemCell Technologies) for 3 x 10 min at 37 °C with gentle trituration using a P1000 
pipette in between. After dissociation, samples were washed with PBS and centrifuged at 
1,200 rpm for 5 min. Subsequently, the suspension was filtered through a 100 µm cell 
strainer and cells were collected by centrifugation at 1,200 rpm for 5 min. Cells were then 
fixed with 5 ml ice cold 70 % EtOH for 1h at -20 °C. Afterwards, they were centrifuged for 
30 min at 2000 rpm and 4 °C, resuspended in 5 ml staining buffer (1 % FBS in PBS) for 
washing and centrifuged by further centrifugation for 30 min at 2000 rpm and 4 °C, 
afterwards removing all except for 50 µl supernatant containing the cells that were kept at 
4 °C. A few µl of each sample were collected and pooled to be used as isotype controls 
(IC). Staining was performed the next day by diluting primary antibodies in staining buffer 
(Concentrations different from Antibodies Table: gp-α-DCX 1:1,000; mIgG1-α-MAP2 
1:500; rb-α-PAX6 1:300; rb-α-PH3 1:300) and adding 20 µl resulting staining solution to 
each sample and incubating on ice for 30 min, followed by addition of 1 ml staining buffer 
each and 30 min centrifugation for washing. Supernatant was again removed, leaving the 
cells in 50 µl leftover staining buffer. They were resuspended with staining solution 
containing the AlexaFluor-conjugated secondary antibodies (1:800 final dilution), 
incubated for another 30 min on ice and washed as before. IC were also immunostained 
with secondary antibodies. The labeled cells were then resuspended in PBS for FACS 
analysis. FACS analysis was performed using a FACS Aria (BD) in BD FACS Flow TM 
Medium with a nozzle diameter of 100 µm and a flow rate below 500 events/sec. Debris 
and cell aggregates were gated out by forward scatter (FSC) – side scatter (SSC); single 
cells were gated out by FSC-W/FSC-A. Gating strategies for fluorophores were selected 
using ICs for the different secondary antibodies. Examples of the gating strategy are 
shown in Figure EV3.  
Statistics. Statistics for quantifications of immunohistochemical stainings in COs and 
embryonic mouse brain was performed in SigmaPlot (Version 13.0; Systat Software, San 
Jose, CA) unless stated otherwise below. Data was tested for normal distribution by 
Shapiro-Wilk test. Normally distributed data was analysed further by Brown-Forsythe test 
for equal variance. One-way ANOVA and Tukey test was then applied for normally 
distributed data of equal variance. Kruskal-Wallis ANOVA on Ranks and Dunn’s Pairwise 
Multiple Comparison were used for non-normally distributed data. Exact binomial test was 
done using Graphpad Prism. Mann Whitney U test and hierarchical clustering analysis 
using chi-square test were done in STATISTICA (StatSoft Inc.). For timelapse imaging 
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results, stastical significance was tested in SPSS (Statistical Package for Social Science, 
IBM®) via 2-tailed Chi-Sqare test. For electroporation of COs, 4 batches of organoids 
were analysed for each construct with several organoids each. Data is shown with n = 
total number of electroporated ventricles analysed per construct from organoids from all 
batches combined. For in vivo analyses after in utero electroporation, 3 CTRL and 4 Ece2 
KD brains were analysed with at least 2 sections per brain in the binning analysis 1 dpe 
(E13-14) and 6 brains per condition for 3 dpe (E13-16). For ECE2 KO COs, FACS 
analysis, WB and MS was performed on 3 independent batches and IHC was performed 
on COs from 2 different batches. In detail, 3 organoids were combined to be one FACS or 
WB sample (1 n), 20 organoids per condition and batch were combined for MS, and IHC 
was done using 6 organoids per condition and batch. Whenever data is shown as box 
plot, the mean is marked by a red line, the median with a black line, and the box 
represents 25th and 75th percentiles with whiskers extending to 10th and 90th 
percentiles, with all outliers shown. 
Westernblot. Cells or whole cerebral organoids were collected and washed with PBS 
prior to lysis in lysis buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, and 10% saccharose in 
H2O with protease inhibitor mix (Roche) added just before use) and protein concentration 
was determined with the Pierce™ BCA Protein Assay Kit (#23227, Thermo Fisher). 20 µg 
protein per lane were then loaded and separated by SDS-PAGE with 10-12% gels. 
Proteins were transferred onto a nitrocellulose membrane (GE Healthcare) with blotting 
buffer (129 mM Glycine, 25 mM Tris-base, methanol 20%) for 90 min at 100 V. After 
blotting, the membrane was blocked with 5 % milk powder in TBS-T before incubation 
with the primary antibody in 2.5 % Milk in TBS-T at 4°C overnight (see Table: Primary 
antibodies). After washes with TBS-T, membranes were incubated with HRP-conjugated 
secondary antibody diluted 1:10,000 in 2.5 % milk in TBS-T for 1h at RT. For protein 
detection, membranes were incubated with ECL detection reagent (Millipore) and 
visualized using the ChemiDoc system (Biorad). Band intensities were quantified using 
the ImageLabTM Software (Biorad). 
Whole-mount staining and clearing (iDISCO). For staining and clearing of whole 
organoids, the iDISCO method was used [43] with the antibodies staining ARL13B, 
NEUN and DCX and DAPI for nuclear counterstain. Prior to use in whole-mount staining, 
antibodies were tested for methanol (MeOH) compatibility as suggested. The staining and 
clearing protocol was then followed with minor changes. In detail, organoids were 
dehydrated with increasing volumes of MeOH in water (20%, 40%, 60%, 80% and 100% 
MeOH), 1h incubation at RT each, while shaking. Organoids were washed further with 
100% MeOH and incubated 1h at 4°C. Then, organoids were incubated with a 66% 
DiChloroMethane (DCM)/33% MeOH solution overnight at RT in continuos agitation. The 
following day, they were washed twice in 100% MeOH for 15 min at RT. Samples were 
subsequentially bleached in 5% H2O2 in MeOH overnight at 4°C. The samples were then 
rehydrated with decreasing volumes of MeOH in water (80%, 60%, 40%, 20% and PBS), 
continuously shaking for 1h each at RT. After this, the samples were permeabilized using 
a 0.2% TritonX solution in PBS twice for 1h at RT. In order to further facilitate the 
permeabilization of primary antibodies in following steps, the samples were incubated in 
permeabilization solution (0.2% TritonX in PBS + 2% DMSO, 0.3M Glycine) at 37°C for 1 
day. Following permeabilization, samples were incubated with 0.2% TritonX in PBS + 
10% DMSO and 6% Normal Goat Serum at 37°C for 1d for blocking. Primary antibodies 
(rb-α-ARL13B 1:200, mIgG1-α-NEUN 1:200, gp-α-DCX 1:800) were diluted in washing 
solution (0.2% Tween-20 in PBS, 10 mg/ml heparin) supplemented with 5% DMSO and 
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3% NGS and added to the samples, incubating at 37°C for 2d. Afterwards, samples were 
washed with washing solution 5 times over the course of 1d. The AlexaFluor-conjugated 
secondary antibodies were diluted 1:300 (DAPI 1:1000) in washing solution, adding 3% 
NGS without DMSO, and incubated for 2d at 37°C. Organoids were then washed 4-5 
times over 1d before clearing.  
For clearing, organoids were first dehydrated with increasing concentrations of MeOH in 
water (20%, 40%, 60% 80% and 100%) for 1h each at RT with continuos agitation. The 
100% MeOH was repeated twice and the organoids kept overnight at this stage. The 
following day, they were transferred to a solution containing 66% DCM/33% MeOH at RT 
in continuous agitation. Organoids were washed twice with 100% DCM for 15 minutes in 
order to completely remove the MeOH. Eventually, the solution was removed and 
samples were placed in 100% DiBenzyl Ether (DBE) without agitation for clearing. 
Samples were covered completely with the DBE solution to prevent oxidation.  
Organoids were positioned in self-made silicon chambers filled with DBE for imaging at 
the Leica SP8 laser scanning microscope. Videos were generated using Imaris Software. 
Whole proteome analysis from COs. COs were washed twice with PBS and 
homogenized in ice-cold lysis buffer (1% (v/v) NP40, 1% (w/v) sodium deoxycholate and 
1 tablet protease inhibitor (cOmplete™, Mini, EDTA-free protease inhibitor cocktail, 
Roche) in 10 mL PBS) using ultrasonication at 40 % intensity for 10 s. Lysis was done for 
30 min at 4 °C while rotating. The insoluble fraction was pelletized (10 min, 14,000 g, 4 
°C) and protein concentration was determined by bicinchoniic acid assay (BCA, Carl Roth 
GmbH + Co.). For the next analysis, 200 μg of the total protein was used. Proteins were 
precipitated by addition of 900 μL acetone and incubation overnight at -20 °C. The protein 
pellet was harvested by centrifugation at 9,000 g for 15 min at 4 °C and washed once 
with 0.5 mL of ice cold methanol. Proteins were reconstituted in 200 μL digestion buffer 
(20 mM HEPES, pH 7.5, 7 M urea, 2 M thiourea), reduced (0.2 μL 1 M DTT, 45 min, 25 
°C) and alkylated (2 μL, 30 min, 25 °C, in the dark). The alkylation reaction was quenched 
by addition of 0.8 μL 1M DTT and incubation for 30 min at 25 °C. Proteins were pre-
digested with 1 μL LysC (Wako) at 25 °C for 4 h. 600 μL 50 mM TEAB buffer was added 
and the proteins were digested overnight with 1.5 μL sequencing grade trypsin (0.5 
mg/mL, Promega) at 37 °C. The following day the samples were acidified with 10 μL 
formic acid to a pH of 2 – 3. Peptides were desalted on 50 mg SepPak C18 cartridges 
(Waters Corp.) on a vacuum manifold. The cartridges were equilibrated with 1 mL 
acetonitrile, 1 mL 80% acetonitrile and 3 mL 0.5% formic acid. The samples were loaded 
on the cartridges and subsequently washed with 5 mL 0.5% formic acid. The peptides 
were eluted with two times 250 μL 80% acetonitrile, 0.5% formic acid. Samples were 
combined and dried by lyophilization. Peptides were reconstituted in 30 μL 1% (v/v) 
formic acid, prepared for mass spectrometry by filtering through a membrane filter 
(Ultrafree-MC and –LC, Durapore PVDF-0.22 μm, Merck Millipore) and transferred into 
mass vials. 
Secretome analysis from COs. For secretome analysis, 5 ml culture medium (NDM+A) 
was collected from 60d old COs after 4 days of conditioning. The medium was cleared 
from dead cells and debris by centrifugation at 600 rpm for 5 min. To the cleared medium, 
30 ml MeOH was added for protein precipitation at -20 °C overnight. Precipitated protein 
was then harvested by centrifugation at 9,000 g and 4 °C for 15 min. Secretome samples 
were then further prepared for proteomic analysis as described above for the whole CO 
proteome. 
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Mass Spectrometry. MS analysis was performed on Q Exactive Plus instrument coupled 
to an Ultimate3000 Nano-HPLC via an electrospray easy source (all Thermo Fisher 
Scientific). Samples were loaded on a 2 cm PepMap RSLC C18 trap column (particles 3 
µm, 100A, inner diameter 75 µm, Thermo Fisher Scientific) with 0.1% TFA and separated 
on a 50 cm PepMap RSLC C18 column (particles 2 µm, 100A, inner diameter 75 µm, 
Thermo Fisher Scientific) constantly heated at 50 °C. The gradient was run from 5-32% 
acetonitrile, 0.1% formic acid during a 152 min method (7 min 5%, 105 min to 22%, 10 
min to 32%, 10 min to 90%, 10 min wash at 90%, 10 min equilibration at 5%) at a flow 
rate of 300 nL/min. For measurements of chemical-proteomic samples on the Q Exactive 
Plus instrument survey scans (m/z 300-1,500) were acquired in the orbitrap with a 
resolution of 70,000 at m/z 200 and the maximum injection time set to 80 ms (target value 
3e6). Data dependent HCD fragmentation scans of the 12 most intense ions of the survey 
scans were acquired in the orbitrap at a resolution of 17,500, maximum injection time of 
50 ms as well as minimum and maximum AGC targets of 5e3 and 5e4, respectively. The 
isolation window was set to 1.6 m/z. Unassigned and singly charged ions were excluded 
for measurement and the dynamic exclusion of peptides enabled for 60 s. The lock-mass 
ion 445.12002 from ambient air was used for real-time mass calibration on the Q Exactive 
Plus. Data were acquired using Xcalibur software version 3.1sp3 (Thermo Fisher 
Scientific). 
Raw files were analysed using MaxQuant software (1.6.2.10). Searches were performed 
against the Uniprot database for Homo sapiens (taxon identifier: 9606, 21st December 
2018, including isoforms). At least two unique peptides were required for protein 
identification. False discovery rate determination was carried out using a decoy database 
and thresholds were set to 1 % FDR both at peptide-spectrum match and at protein 
levels. 
Phosphosites were identified by MaxQuant default settings for pSTY and quantified by 
LFQ. Average protein occupacy of the phosphosites were compared between CTRL and 
KO COs (Tables EV7-9). Phosphosites identified only in CTRL or KO COs (Table EV8) 
were required to be found at least twice within the replicates with localization probability 
higher than 70%.  
Statistical analysis of the MaxQuant result table proteinGroups.txt was done with Perseus 
1.5.1.6. Putative contaminants and reverse hits were removed. LFQ intensities were log2-
transformed, hits with less than 3 valid values in each group were removed and -log10(p-
values) were obtained by a two-sided one sample Student’s t-test over replicates with the 
initial significance level of p = 0.05 adjustment by the multiple testing correction method of 
Benjamini and Hochberg (FDR = 0.05), the -log10 of p-values were plotted by volcano 
plot function. Final volcano plots were edited in Origin. 
GO Term analysis. Protein interaction network analysis was performed using 
STRING.db [51]. For GO Term analysis of proteins significantly downregulated in ECE2 
KO COs underlying the categories in Figure 5B, both STRING.db [51] and PANTHER 
(pantherdb.org; [50]), choosing homo sapiens as species, were used to identify 
overrepresented functional protein groups and single proteins falling into those. For the 
category 'neurodevelopmental disorder', the effect of known mutations in each gene was 
analysed using DECIPHER [49] and focusing on SNVs and small indels (monogenic 
variants). Dysregulated phosphosites from Table EV7, illustrated in Figure 5D, were 
uploaded into PANTHER database and searched for enrichment of cellular component 
complete using Fisher’s exact test and FDR threshold of 0.05. 
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Figure legends expanded view (EV) 
Figure EV1: aRG delamination 4dpe upon ECE2 KD in in vitro human model systems.  A, B, 
Schemes depicting the generation of NPCs and neurons in 2D (A) [31] and in 3D in cerebral 
organoids (COs, B) [32]. C, Analysis of immunostaining of COs 4 dpe upon ECE2 KD by 
electroporation shows delamination of transfected aRG, in contrast to bipolar morphology of aRG 
in the control condition (aRG = apical radial glia, dpe = days post electroporation; transfected cells 
are shown in green, MAP2+ neuronal processes in magenta; Scalebar = 50µm).     
 
 
Figure EV2: Ece2 KD in vivo leads to changes in apico-basal polarity and in progenitor and 
neuron positioning. A-G, 1 dpe upon Ece2 KD, proliferative progenitors acquire ectopic positions 
(A-C). Some deep- (D, E) and upper-layer (F) neurons show the same tendency. A, Quantification 
of distribution of Pax6+ transfected progenitors upon Ece2 KD relative to CTRL shows tendential 
shift to bin 2 (n=3 CTRL and 4 Ece2 KD brains; P = 0.082 in One-way ANOVA; data shown as 
mean±SEM). E, Quantification of ectopic deep-layer neurons 1 dpe shows trend to ectopic, less 
basal position upon Ece2 KD (n=3 CTRL and 4 Ece2 KD brains; P = 0.156 in One-way ANOVA; 
data shown as mean±SEM). G, aRG morphology is changed and the apical surface shows 
patches lacking apically localised Arl13b 1 dpe. H, Example images of 3 dpe showing delaminated 
ectopic progenitors form rosettes and nodules. A-H, Electroporated cells shown in green; Scalebar 
= 100 µm. 
 
 
Figure EV 3: ECE2 inhibition and KO in COs reveal its influence on cell fate. A, IHC for 
cleaved Caspase-3 shows no difference in cell death upon ECE2 inhibition (Scalebar = 50 µm). B, 
FACS plots illustrating gating strategies for SSEA, BLBP and MAP2 gated cells in CTRL and 
PHOS treated COs. Gates were established using 2ndary antibody only as isotype control. C, 
Example images of IHC of germinal zones in COs after two weeks of PHOS treatment with mitotic 
cells stained for PH3 (green) (Scalebar = 50 µm). D, Quantification of PH3+ cells per length of 
apical surface in PHOS-treated vs. CTRL COs reveals no difference (Data shown as box plots with 
median as black line, mean red line; n=number of analysed ventricles from 2 batches of COs; One 
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Way ANOVA: P = 0.633). E, Brightfield images of ECE2 KO and isogenic control iPSCs and of 
COs generated from them. F, Size measurement ECE2 KO vs. CTRL COs revealed no consistent 
difference (Data shown as z-scores; n=4 batches of COs with at least 10 COs each per timepoint, 
area measured from 2D BF images in Fiji [44]). G, FACS plots illustrating the gating strategies for 
PAX6, PH3 and MAP2 gated cells in CTRL and ECE2 KO COs. Gates were established from the 
2ndary only control. H, Example images of IHC for PH3+ cells in 60d old CTRL and ECE2 KO 
COs (Scalebar = 50 µm). I, Quantification of PH3+ cycling cells in 60d old COs, normalised to 
length of the apical surface of ventricle-like structures, shows an increase upon ECE2 KO (Data 
shown as box plots with median as black line, mean red line; n=number of analysed ventricles 
from 2 batches of COs; One Way ANOVA: **P = 0.004). J, Example images of progenitor zone 
(SOX2) and neuronal layer (MAP2) staining by IHC (Scalebar = 50 µm).   
 
 
 
Figure EV4: The apical belt is disrupted in the absence of ECE2. A, WB on CO lysate for 
CTNNB1 with GAPDH as loading control. B, Quantification from WB shows a slight reduction in 
CTNNB1 in ECE2 KO COs (Data shown as box plots with median as black line, mean red line; 
n=3 batches of COs with 3 COs each; One Way ANOVA: n.s., P = 0.178). C, Protein interaction 
analysis [51] shows network with ECE2 (red circle) and 3 interacting proteins that were identified 
as downregulated upon KO (green squares), including the known PH gene FLNA. D, WB of iPSC 
lysate confirms a strong reduction of pERM, detected by MS of ECE2 KO COs. E, Network 
analysis [51] reveals that downregulated proteins in ECE2 KO COs are part of a tightly 
interconnected PPI network with ECM proteins as the biggest subnetwork.  
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Figure EV1 
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Figure EV2 
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Figure EV3 
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Figure EV4 
 
 
 
 
 
 
 
 
EXPANDED VIEW TABLES 
The Expanded View Tables of this study have been deposited online in the “Nextcloud 
Bio II” LMU data cloud. 
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5. DISCUSSION 
 
In the main parts of this discussion, the presented studies will be related to separately. I 
will summarize the findings of each study, followed by a discussion of the findings that 
goes beyond the compact discussion that is part of the paper or manuscript and that shall 
place the findings into a bigger context. Then I will wrap up mechanisms and pathways 
commonly identified between the different studies. This leads us to a summary of what 
knowledge this work has added to the field. 
In the discussion of the individual projects, the ECE2 project (Chapter 4) will be 
discussed most extensively because the ECE2 manuscript was only submitted and sent 
to reviewers shortly before submission of this thesis, thus instigating the need for most 
detailed critical analysis of this study.  
  
5.1. SPG11 - A DEVELOPMENTAL ROLE FOR A KNOWN 
NEUROLOGICAL DISEASE GENE 
In the first study (Chapter 2; (Pérez-Brangulí et al., 2018)), we analyzed the 
neurodevelopmental role of the HSP gene SPG11. For simplicity, “(derived from patients 
with) HSP caused by SPG11 mutations” will be abbreviated here as “SPG11”. The 
spectrum of disorders associated with SPG11 mutations has traditionally been classified 
as neurodegenerative, including young onset Amyotrophic Lateral Sclerosis and Charcot-
Marie-Tooth disease in addition to spastic paraplegia (Montecchiani et al., 2016; 
Orlacchio et al., 2010; Stevanin et al., 2007). The fact that affected patients show 
cognitive impairment, thin corpus callosum, enlarged ventricles, and reduced grey matter 
thickness (Faber et al., 2018; Hehr et al., 2007; Pensato et al., 2014; Stromillo et al., 
2011), is a hint for a possible involvement of SPG11 in neurodevelopment. A preceding 
study revealed a proliferation defect in NPCs generated from SPG11 patient-derived 
iPSCs that could be rescued by inhibition of the kinase GSK3β (Mishra et al., 2016). 
Here, we used NPCs, neurospheres and COs to further analyze this defect. Both 2D and 
3D in vitro models recapitulated the formerly described impairment of progenitor 
proliferation, which resulted in premature neurogenesis and smaller CO size. An early 
reduction in mitotic NPCs in COs lead to a reduced thickness of the progenitor zone over 
time and an enlargement of ventricle-like structures in patient-derived COs, reminiscent of 
the enlarged lateral ventricles in patient brains (Pensato et al., 2014). Besides, progenitor 
zone and neuronal layer were less separated, in line with premature differentiation 
compared to controls. Making use of the internal organization of COs, we identified a 
switch towards more horizontal, asymmetric aRG divisions at the basis of the impaired 
self-renewal and premature neurogenesis. This was further supported by the detection of 
a prolonged cell cycle by single cell tracking of NPCs and a reduced final number of 
neurons produced from the smaller NPC pool in neurospheres. As a hint to a possible 
mechanism, we observed holes in the apical apical β-catenin belt, although apico-basal 
polarity was established in SPG11 COs. Indeed, we found that upon SPG11 KD in 
Hek293 cells and in patient-derived COs, the amount of phosphorylated β-catenin was 
increased due to reduction in inactivated GSK3β. Phosphorylation of β-catenin promotes 
its ubiquitination and proteasome degradation (Orford et al., 1997). The amount of 
GSK3β-interactor pCREB (Ilouz et al., 2006) was also increased, with pCREB acting as 
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driver of neurogenic gene transcription (Mantamadiotis et al., 2012). Thus, the increased 
amount of active GSK3β lead to decreased proliferation through promoted degradation of 
β-catenin and to increased differentiation through activation of CREB. As reduced grey 
matter thickness in the patients may also originate from increased cell death, we tested 
this in a NPC-differentiation approach and in COs. Interestingly, whereas apoptosis was 
increased already after 2 weeks of neuronal differentiation in 2D, we saw no difference in 
apoptosis in COs.  
In an effort to rescue the observed phenotypes in SPG11-derived model systems, we 
overexpressed (OX) SPG11 in NPCs, which reversed the premature neurogenesis. 
Accordingly, addition of GSK3 inhibitors CHIR99021 (CHIR) and Tideglusib (Tide) to 
NPCs, neurospheres and COs rescued the NPC proliferation and premature 
neurogenesis defect and significantly increased the size of patient-derived COs. While 
CHIR affected also control CO size, the GSK3β-targeting Tide specifically rescued only 
patient CO size without affecting controls. 
From these summarized findings of our study, we can conclude that the SPG11-encoded 
spatacsin plays a role in negatively regulating GSK3β activity as a major component of 
the canonical Wnt pathway (see summary scheme in Figure 6). This is in line with a 
preceding pioneer study on the neurodevelopmental role of SPG11 (Mishra et al., 2016): 
An analysis of differentially expressed genes in control and SPG11 patient iPSCs-derived 
NPCs revealed downregulation of Wnt pathway activators and upregulation of its 
negative regulators. Additionally, cytoskeletal and motor components were dysregulated 
and so were genes involved in the autophagosomal and lysosomal pathway (Mishra et 
al., 2016). 
 
 
 
Figure 6: Suggested mechanism underlying neurodevelopmental defects in HSP-SPG11. A, 
B, Wnt/β-catenin pathway components that are implicated in the neurodevelopmental defect in 
SPG11 and their role in the regulation of NPC proliferation versus neuronal differentiation are 
illustrated for the healthy control (A) and SPG11 patient condition (B). SPG11-encoded spatacsin 
is suggested to play a role in the inhibition of active GSKβ. C, Application of GSK3(β) inhibitors to 
SPG11 patient-derived neural in vitro cultures partially rescues the defects of premature 
neurogenesis at the expense of NPC proliferation.  
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Cerebral organoids reveal novel functions of SPG11. Two different mouse models 
were generated in the past that differently and only partly recapitulated phenotypes found 
in SPG11 patients (Branchu et al., 2017; Varga et al., 2015). Namely, the first mouse 
model, generated by insertion of a genetrap cassette in the first intron of the Spg11 gene, 
only showed a loss of cortical neurons and Purkinje cells and an autophagy defect, 
without an effect on the animals’ motor and cognitive performance (Varga et al., 2015). 
The newer mouse model, generated by insertion of stop codons into exon 32 of Spg11, 
mimicking the most frequent mutations found in patients, differed from the first one in that 
it showed upper and lower motorneuron degeneration, progressive thinning of the corpus 
callosum, cognitive and motor behavioral defects, and accumulation of lipids in 
lysosomes (Branchu et al., 2017). In parallel to the improvement of mouse models, 
human models were developed that can serve the identification of human-specific 
aspects of SPG11. Based on growing knowledge on differences in mouse and human 
cortical development, they may help to circumvent the difficulty of mouse models of 
human disease mutations to recapitulate the expected phenotype. To this end, the recent 
focus of SPG11 research has been on the use of human iPSC-derived in vitro systems.  
While a former study used 2D in vitro models only (Mishra et al., 2016), ours gave 
valuable insigts into the role of SPG11 in neurodevelopment by using 3D models. COs 
represent a more “complete” system than 2D models, closely recapitulating human fetal 
development (Camp et al., 2015; Paşca et al., 2015).  
While upon 2D neuronal differentiation from NPCs, SPG11 mutant cells showed 
increased apoptosis in both our and the previous study, this was not the case in cerebral 
organoids. The phenotypes identified in COs suggest that cortical atrophy and reduced 
grey matter thickness found in SPG11 patient brains (Faber et al., 2018) result merely 
from defective NPC proliferation during development, with a smaller progenitor pool 
producing fewer neurons. Postnatally, over time, problems in homeostasis of the long 
axon may then contribute to them dying back, resulting in a loss of grey matter over the 
years. In line with that, the cortical grey matter thickness is most severely affected in 
motor regions (Faber et al., 2018).  
Consistent with β-catenin’s known developmental role in G1 phase progression and 
proliferation (Chenn and Walsh, 2003; Woodhead et al., 2006), we identified changes in 
cell cycle length, division angle and proliferation in SPG11 NPCs and COs, which were 
rescued by re-establishment of β-catenin levels through GSK3 inhibition. The observed 
changes in cell cycle length and division angles upon SPG11 mutations resemble 
findings reported for Miller-Dieker syndrome patient-derived COs (Bershteyn et al., 2017; 
Iefremova et al., 2017): Changes in the division angle of aRG and a prolongation of the 
bRG cell cycle were found to underlie increased neurogenic divisions in this severe form 
of lissencephaly type I. Besides, the β-catenin signaling axis was disturbed in these 
models (Iefremova et al., 2017), equally to our SPG11 COs. It would thus be interesting 
to analyse the gyrification index in SPG11 patients to decipher if misregulation of the 
same molecular pathway leads to a similar phenotype. 
The change in division angle may be caused by GSK3 overactivation: GSK3s regulate 
the activity of several MAPs (Zhou and Snider, 2005), and so might control mitotic spindle 
reorganization during cell division. The division angle of apical progenitors is decisive for 
the distribution of polarity proteins, cell fate determinants, the apical membrane 
compartment, and the centrosomes into the daughter cells (Götz and Huttner, 2005; 
Taverna et al., 2014; Wang et al., 2009a). The apically concentrated Rho GTPase Cdc42, 
for example, regulates both AJ integrity and cell fate: cKO of Cdc42 in the developing 
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mouse telencephalon leads to loss of AJs, followed by aRG delamination, which then 
undergo basal mitoses and change their cell fate to basal progenitors (Cappello et al., 
2006). We thus made use of the 3D organization of COs to analyze the quality of the 
apical AJs, among others established by apically concentrated β-catenin, and found 
indeed a defect (see Figure S1b-c of the SPG11 study in Chapter 2). The change in fate 
towards premature neurogenesis may thus also be caused by the loss of AJs. Changes 
in GSK3-mediated phosphorylation of MT-stabilizing MAPs (Zhou and Snider, 2005) 
would cause changes in the integrity and dynamics of the MT cytoskeleton and MT-based 
trafficking (Pérez-Brangulí et al., 2014) and contribute to changes in MT-based polarity 
both in apical progenitors and in migrating neurons (Etienne-Manneville, 2010). The fact 
that we found the progenitor zone and neuronal layer in SPG11 COs less separated than 
in controls also fits into this line of thought: The delaminating progenitors may lose their 
polarization and spatial orientation and prematurely start the expression of neuronal 
markers within the progenitor zone. 
The treatment of COs with the two different GSK3 inhibitors revealed that the GSK3β-
specific Tide rescued the patient phenotype of premature differentiation by restoring 
progenitor proliferation. While CHIR equally affected both control and patient-derived 
COs, Tide had only a slight effect on control COs. This suggests that Tide acts more 
specifically on GSK3β than other GSK3 inhibitor, bringing a chance for is to cause fewer 
side effects when administered to patients. Moreover, this experiment stresses the great 
potential of COs in the identification of disease mechanisms and the development of 
therapy strategies.  
Remaining questions around SPG11 in cortical development. We suggest the 
reduced grey matter thickness in SPG11 patients to developmentally originate from the 
smaller progenitor pool size used for the generation of neurons – but we did not quantify 
the amount of neurons produced in CO germinal zones. To further support this 
hypothesis, it would be of interest to analyze the proportion of progenitors to neurons in 
COs. The measurement of the thickness of the neuronal layer after IHC staining is 
difficult: It differs with the location of a germinal zone within an organoid - Germinal zones 
being located at the rim of organoids differ from those inside the CO, and germinal zones 
in isolation are different from those surrounded by others, which makes it hard to 
distinguish CP-like zones of neighboring ventricles. This is why we focused our analysis 
in COs on the proliferation capacity and progenitor pool size as inferred from mitotic cells 
and the thickness of the progenitor zone. In the meantime, we established FACS analysis 
of COs in our lab (see (Klaus et al., 2019) and Chapter 4), which enables to gain a quick 
and unbiased impression of cell type proportions within COs. FACS analysis of control 
and SPG11 COs at different ages may thus be a good method to fill this gap. 
Other processes that spatacsin has been implicated in are lipid turnover by autophagy 
and via the lysosome (Branchu et al., 2017; Chang et al., 2014; Vantaggiato et al., 2019; 
Varga et al., 2015), axonal vesicle transport and cytoskeletal integrity (Pérez-Brangulí et 
al., 2014) with accumulation of lipid material in lysosomal structures in patient brains 
(Denora et al., 2016). Specifically, the transport of synaptic vesicles and the amount of 
stabilized microtubules, characterized by ac-tub, were changed in SPG11 patient iPSC-
derived neurons. Besides, the morphology of neurites was less complex (Pérez-Brangulí 
et al., 2014). A recent study showed that the treatment of SPG11 neurons with Tide 
ameliorated both phenotypes of membraneous inclusions and of changed neurite 
morphology (Pozner et al., 2018). It would thus be interesting to use the CO model to 
further investigate these questions: Is the cytoskeleton of NPC and neurons in SPG11 
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COs changed compared to control? Do neurons in SPG11 COs also show accumulation 
of lipid materials – and is this rescued by Tide treatment? It has been suggested that the 
defects in neurite morphology, lipid turnover, and axonal transport may contribute to 
changes in neuronal activity (Pérez-Brangulí et al., 2014). This may, together with 
reduced grey matter thickness, contribute to cognitive defects characterized in SPG11 
patients. Thus, electrophysiology on patient-derived COs may help to tell if neuronal 
activity is actually affected.  
SPG11 is not the first neurodegenerative disorder for which a developmental aspect was 
identified. For example, a developmental origin of Timothy syndrome, a monogenic 
multisystem disorder in which patients present with cardiac and extracardiac defects 
including ASD and epilepsy, has been characterized using assembloids (Birey et al., 
2017). Several other genes whose mutations cause HSP play a role in protein and lipid 
homeostasis, lysosome physiology, and autophagy, e.g. SPG15, 17, 39, 46-52, and 
SPG54 (Tesson et al., 2015). These processes are especially crucial in the maintenance 
of the long axons of motorneurons (Boutry et al., 2019; Elert-Dobkowska et al., 2019). It 
would thus be interesting to analyze if there is also a developmental aspect to these 
forms of HSP.  
Besides, GSK3s phosphorylate a myriad of targets and thus plays diverse roles in 
neurodevelopment (see also Chapter 1.1.3 and 1.1.4): GSK3s act as key regulators in 
multiple neurodevelopmental processes, including neurogenesis, neuronal migration, 
neuronal polarization, and axon growth and guidance (Hur and Zhou, 2010). For 
example, GSK3 has been associated with microcephaly (Novorol et al., 2013; Spittaels et 
al., 2002), fragile x syndrome (Portis et al., 2012), and psychiatric disorders such as 
schizophrenia and depression (Matsuda et al., 2019), as well as with neurodegenerative 
Alzheimer’s disease (Hooper et al., 2008; Parr et al., 2012). Hence, this suggests a 
potential contribution of the GSK3 inhibitor spatacsin to these diseases. Especially the 
etiologies of microcephaly and lissencephaly type I, which may be caused by proliferation 
defects or increased apoptosis, shows some overlap with our study, as we have seen 
reduced progenitor proliferation and premature neurogenesis. It would thus be highly 
interesting to identify the exact mechanism through which SPG11 inhibits GSK3β.  
A function of spatacsin in autophagy and lysosome reformation has been implicated by 
different studies (Branchu et al., 2017; Chang et al., 2014; Vantaggiato et al., 2019; 
Varga et al., 2015). The importance of autophagy for several aspects of 
neurodevelopment has been demonstrated in the past (reviewed in (Lee et al., 2013)) 
and is has also been shown that defective autophagy can contribute to neurode-
generative disorders such as Alzheimer’s and Parkinson’s disease has also been shown 
(reviewed in (Nixon, 2013)). In neurodevelopment, autophagy-mediated recycling of 
(membrane) lipids, mitochondria and proteins is required in differentiation, for 
morphological changes such as during migration and neuritogenesis, and in 
synaptogenesis. Disruptions of autophagy-related pathways such as the mTOR and the 
Rap pathway thus lead to neurodevelopmental disorders such as ASD (Lee et al., 2013). 
It would thus be highly interesting to analyze the exact molecular function of spatacsin in 
autophagy, which may contribute to both developmental and degenerative aspects of 
SPG11. 
Heterogenetity of SPG11 and HSPs. The diversity of cellular processes that spatacsin 
has been implicated in, combined with the many substrates of its downstream factor 
GSK3β, leads to a huge heterogeneity in phenotypes in SPG11 patients. No correlation 
between genotype and phenotype has been shown in SPG11 patients, which means that 
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the same mutation can lead to different phenotypes, affecting different regions of the 
nervous system besides the cortico-spinal tract, and mutations in different parts of the 
gene may lead to the same physiological outcome (Branchu et al., 2017; Pensato et al., 
2014; Stevanin et al., 2007). On top of that, the genetic background and epigenetic and 
environmental factors may add to the variability.  
For example, a recent study characterized grey and white matter changes in MRI, 
neuropathological, and other symptoms in a cohort of 25 SPG11 patients (see Figure 7; 
(Faber et al., 2018)) and found 84% of patients fulfilling the criteria for dementia and 28% 
with the criteria for parkinsonism, which is coherent with the previously reported 30% 
(Anheim et al., 2009), and supported by basal ganglia abnormalities that became 
apparent in patient brain MRIs (Faber et al., 2018). The phenotypes caused by SPG11 
mutations overlap with other spastic paraplegia genes (Pensato et al., 2014). SPG11 is 
not the only HSP gene making HSPs a diverse spectrum of disorders – many HSP-
causing pathological mutations, including frameshift, nonsense, truncating, missense 
mutations, large exon deletions, and splice site mutations in more than 60 genes, have 
been reported to lead to HSP and other co-occurring neuropathies (see Figure 8; 
(Tesson et al., 2015)) (Boutry et al., 2019). 
The categorization of HSP caused by mutations in SPG11 as a complex form of HSP is 
thus well supported. Our work further suggests its classification as a neurodevelopmental 
disorder.  
 
 
Figure 7: Frequencies of phenotypic traits identified in 25 SPG11 patients underline the 
heterogeneity of SPG11-HSP. Image reused from (Faber et al., 2018). 
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Figure 8: Scheme illustrating phenotypic heterogeneity associated with HSP  and the 
classification of HSP genes according to the upper and lower motor neuron diseases phenotypic 
presentation. Image reused from (Tesson et al., 2015). 
 
Altogether, we show evidence linking SPG11-HSP to neurodevelopmental disorders and 
underline the potential of human in vitro models in the identification of human-specific 
cellular and molecular mechanisms and in therapy development for precision medicine. 
 
 
5.2. AMPYLATION - A NOVEL PARAMETER TO FINE-TUNE 
NEUROGENESIS 
The process of interest in the second study (Chapter 3; (Kielkowski et al., Under 
Revision)) was the PTM AMPylation, which has been understudied due to the lack of 
methods for its monitoring. We thus designed a cell-permeable probe that is intracellularly 
metabolized to alkine-tagged ATP and utilized for AMPylation of substrate proteins. This 
probe thus labels AMPylated proteins and enables their detection under physiological 
conditions. We then used this probe to identify AMPylated proteins in several human 
cancer cell lines and fibroblasts, as well as in iPSC, NPCs, and neurons which model 
different stages of neurodevelopment in a 2D environment, and COs as 3D model of the 
early fetal human brain. In all analyzed cell types and COs, metabolic enzymes 
represented the largest functional group of AMPylated proteins. Interestingly, the set of 
AMPylated proteins was different and only partly overlapping for the analysed cell types. 
ER stress induction by thapsigargin (tg) lead to a change in AMPylated proteins, 
indicating cell type and environmental condition-specific AMPylation. In neuroblastoma 
cells, a large number of proteins were AMPylated at baseline conditions and even more 
got induced upon ER stress, hinting at a critical role for AMPylation in the nervous 
system.  
Functionally, we showed that AMPylation of cathepsins (as example enzymes) at serine 
residues in close vicinity to their active site cysteine obstructed their proteolytic activity, 
probably through steric hindrance of substrate binding.  
DISCUSSION 
172 
 
In neurons, a large and unique set of proteins was AMPylated, with an additional 
enrichment of cytoskeletal and motor proteins. This suggested a remodeling of the 
AMPylation pattern in the course of neuronal differentiation, as the small set of 
AMPylated proteins in NPCs was completely distinct to that in neurons.  
We paralleled the identification of AMPylated proteins in the different cell types through 
proteomics by immunohistochemical characterization of their intracellular localization, as 
well as of the localization of the eukaryotic AMPylating enzyme FICD. This revealed a 
localization of FICD and its targets to the ER and cytoplasm. In neurons, we found high 
levels of FICD and a huge number of AMPylated proteins, both being enriched in the 
processes. To analyze the role of AMPylation in cortical development, we manipulated 
the levels of the AMPylating and de-AMPylating enzyme FICD. KD of FICD in 
differentiating NPCs and in germinal zones of COs lead to an increase in cells that 
remained proliferative. OX of wildtype and a constitutively active mutant FICD (FICD 
E234G) in COs increased the amount of neurons produced by electroporated 
progenitors. Finally, to exclude that a function of FICD other than its AMPylating activity 
caused the observed change in neurogenesis, we electroporated COs with an 
enzymatically inactive mutant of FICD (FICD H363A). This revealed no difference to 
control, stressing that indeed AMPylation remodeling by FICD fine-tunes neurogenesis. 
The Scheme in Figure 9 summarizes these findings from COs. 
 
 
Figure 9: Scheme depicting the effect of FICD KD or OX by electroporation of aRG in 
germinal zones of COs. FICD KD (left) leads to an increase in progenitors 7 dpe, while OX of 
wildtype FICD and the constitutively active mutant FICD E234G (right) increases the neuronal 
production compared to control (middle). Electroporation of catalytically inactive FICD H363A is 
indifferent from the control and thus reveals that the AMPylation activity of FICD underlies its 
influence on neurogenesis. 
 
 
FICD/AMPylation functions in the nervous system – known and inferred. The Fic 
domain is highly conserved across species, suggesting a critical role for Fic domain 
containing proteins and for AMPylation remodeling in cellular functions (Ham et al., 
2014). In the discussion of this study, I will focus on cellular functions relevant to cortical 
development.  
A function of FICD-mediated AMPylation in the nervous system has been suggested by 
previous studies: In C.elegans, AMPylation of chaperones was shown to modulate the 
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aggregation and with that the toxicity of polypeptides implicated in neurodegenerative 
diseases, for example Amyloid-β and α-synuclein (Truttmann et al., 2018). Another study 
found that the direct AMPylation of α-synuclein reduced its neurotoxicity by hindering it 
from permeabilizing and invading the ER and by interfering with its aggregation to fibrils. 
They suggested – same as what we proposed for AMPylation of CTSB – steric hindrance 
by the covalently bound AMP to be at the origin of these effects (Mattoo et al., 2019). 
This molecular mechanism of activity regulation, also suggested for the ER chaperone 
BiP, the first eukaryotic target ever described (Ham et al., 2014), may be a common one 
in all AMPylated enzymes.  
In addition to this proposed protective role of AMPylation in neurodegeneration, a role for 
drosophila AMPylating enzyme Fic was described. Flies lacking Fic are blind due to a 
neurotransmission defect, caused by a glia-specific defect in histamine recycling. Thus, 
Fic-mediated AMPylation may play a role in the endocytosis needed for the re-uptake of 
the neurotransmitter (Rahman et al., 2012).  
Bacterial Fic domain containing AMPylating enzymes, more than a thousand of which 
were identified, act on cytoskeleton-associated proteins: Secreted Fic proteins AMPylate 
mammalian host cell Rho GTPases RhoA, Rac1, and Cdc42, rendering them inactive, 
which leads to cytoskeletal collapse of the host cell (Mattoo et al., 2011; Worby et al., 
2009). Host cell endocytosis and exocytosis were also found to be altered by bacterial 
AMPylation of Rab1 (Mukherjee et al., 2011). If conserved, AMPylation remodeling of the 
cytoskeleton to affect endocytosis represents a good candidate mechanism that may 
underlie the defect in histamine recycling in the Fic deficient flies (Rahman et al., 2012). 
What remains unresolved in our study and shall thus be addressed here is the question 
of the exact mechanism underlying FICD’s influence on neural progenitor proliferation 
versus differentiation. Although we identified numerous AMPylated proteins in the 
relevant cell types and in COs, we don’t know the AMPylation remodeling of which one(s) 
led to increased neurogenesis upon FICD OX. Using the term “remodeling”, we are being 
careful to avoid a clear statement if the phenotype arose from AMPylation or 
deAMPylation, as FICD can do both reversibly (Casey et al., 2017). Our stainings in 
probe-treated COs, though, revealed an increase in AMPylated proteins in the transition 
zone from progenitors to neurons. Also in 2D, we identified far more AMPylated proteins 
in neurons (71 compared to 6 in NPCs). Panther gene ontology (GO) term analysis of all 
AMPylated proteins in the screened cell types revealed an enrichment of neuron-specific 
pathways, namely Rho-GTPase and FGF signaling and neurodegenerative disease 
pathways related to Alzheimer’s and Huntington’s disease. The following hypotheses will 
therefore be based on those proteins in neurons and COs that are AMPylated, and not 
deAMPylated, as we have no means of analyzing deAMPylation of proteins by FICD 
WT/E234G OX. 
It may be that the (de)AMPylation of one or a few proteins changes their structure and 
thereby alters their function, which may cause the increased neurogenesis. Though, it 
could also be the combined additive effects of the modification of numerous or all of 
them. This way, slight changes in their structure and activity may sum up and altogether 
contribute to the observed phenotype. Of course, it would be interesting to nail down the 
responsible target(s). Considering the large number of 71 AMPylated proteins in 2D 
neurons and 34 in COs and that the phenotype is relatively mild (albeit statistically 
significant), this would be a Sisyphean task, though. Unfortunately, we did not succeed in 
the identification of AMPylation site in all proteins, which may have given a clue to the 
functional impact of the modification. In neurons and COs, according to protein interaction 
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network analysis in String.db (Szklarczyk et al., 2017), the most enriched functional 
protein groups act in 1) MT-based processes and vesicle-mediated transport, 2) 
Chaperone-mediated proteostasis, 3) basic metabolism, 4) ECM constitution, and 5) RNA 
splicing and mRNA stability. In the following, I will forward a few different hypotheses that 
try to explain the AMPylation of which protein groups may have the power to influence 
neurogenesis. 
The cytoskeleton and transport hypothesis. The most attractive candidate proteins in 
which we would like to know the exact AMPylation site are tubulins and myosin and 
kinesin motors. Tubulins are known to be highly modified by PTMs in their C-terminal 
region, which is exposed at the outer surface of MTs, and these PTMs are implicated in 
the regulation of MT stability, MT dynamics, and the interaction of MTs with binding 
partners (Ayala et al., 2007). The interaction of motor protein complexes with MTs and 
the activity of kinesins, myosins, and dyneins are in turn also fine-tuned by PTMs 
(Muretta et al., 2018). For example, reorganization of the MT cytoskeleton – regulated by 
PTMs and MAPs – is at the basis of neuronal polarization required for migration and 
underlies the establishment of neuronal morphology (Song and Brady, 2015) (see 1.1.3 
and 1.1.4). Other PTMs on cytoskeletal proteins, for example palmitoylation of MAP6 
(Tortosa et al., 2017) and phosphorylation of MAP2 (Sánchez et al., 2000) promotes their 
stabilizing interaction with MTs. Thus, AMPylation may be a novel PTM exerting a 
function in neurogenesis through the fine-tuning of cytoskeletal and motor protein 
structure and function. When overexpressing FICD WT or E234G in COs, we found not 
only more differentiated neurons: Some of them also differentiated prematurely within the 
progenitor zone of the CO ventricle as indicated by intruding MAP2+ neuronal processes 
and NEUN+ neuronal nuclei at the apical surface (see blue and pink arrowheads in 
Figure 7c, d in Chapter 3). This suggests that cytoskeletal remodeling through FICD-
mediated AMPylation may directly influence neuronal migration. 
Knowledge of the exact AMPylation sites in tubulins and motor proteins would enable in 
silico prediction of the effect the modification has on MT dynamics, on the interaction of 
MTs with motors and other MAPs, and on the activity of molecular motors. In a next step, 
one could use site-directed mutagenesis and assays such as EB1/3 life imaging for MT 
dynamics to analyze the functional effect of AMPylation.  
Closely connected with cytoskeletal and motor function and their regulation by PTMs is 
vesicle trafficking, which is pivotal for cellular polarization and migration (Etienne-
Manneville, 2010), for example through directional transport of transmembrane proteins 
required for cell adhesion and for response to extracellular signals by cytoskeletal 
rearrangement (see also 1.1.3). AMPylated proteins both in neurons and in COs are 
highly enriched for biological function in vesicle transport (see Figure 10A for the COs). 
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Figure 10: Proteins with function in vesicle trafficking (A) and proteostasis (B) are enriched 
among CO AMPylation targets. Respective proteins were highlighted after protein interaction 
network analysis in String.db (Szklarczyk et al., 2017). 
 
 
The proteostasis hypothesis. Another candidate group of proteins is suggested from 
the eukaryotic FICD function most consistently found in publications: FICD-mediated 
AMPylation and deAMPylation of chaperones. The ER-based chaperone BiP/HSPA5 was 
shown to be both AMPylated and de-AMPylated by FICD (Casey et al., 2017; Ham et al., 
2014). This altered BiP’s ATPase activity and the downstream activation of the UPR and 
suggested a crucial role for AMPylation remodeling in the regulation of protein 
homeostasis in the ER (Preissler et al., 2017b; Sanyal et al., 2015). Yeast Ficd was found 
to inactivate the cytosolic heat shock protein Hsp70, which showed a function for 
AMPylation in protein homeostasis outside the ER (Truttmann et al., 2017). In our study, 
we identified several proteins that function in protein homeostasis including synthesis, 
folding, and lysosome-based degradation – summarized as “proteostasis” – to be 
AMPylated in COs (Figure 10B). In a series of experiments, we incubated the screened 
cell types and COs with ER-stress-inducing tg. During ER stress, unfolded proteins 
accumulate and this activates the UPR and chaperones and, if the stress cannot be 
reversed, apoptosis is induced. Interestingly, while tg treatment increased the amount of 
significantly AMPylated proteins in all other cell types, neurons responded very 
specifically to tg with the upregulation of two proteins – BiP/HSPA5 and SQSTM1. And 
also FICD expression was higher in neurons compared to NPCs as detected by our study 
and others (Mattoo et al., 2019). These findings from COs and neurons indicate a critical 
role for proteostasis in neurodevelopment: The complex process of development, where 
change of cell fate and localization from progenitor to neuron requires complete change 
of the morphology, is based on the cytoskeleton and transport processes. And for the 
morphological and functional remodeling to work properly, protein production, correct 
folding, and turnover are required. Growing evidence suggests indeed a pivotal role for 
ER proteostasis through UPR in brain development (Martínez et al., 2018), and its 
dysfunction at the basis of psychiatric disorders (Olivero et al., 2018) and 
neurodegenerative diseases (Hetz and Mollereau, 2014; Martínez et al., 2018; Olivero et 
al., 2018). In line with this, the role of drosophila Fic-mediated AMPylation in visual 
transmission and adaptation to stress has been shown to execute through ER 
homeostasis (Ham et al., 2014; Moehlman et al., 2018; Rahman et al., 2012). 
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The metabolism hypothesis. AMPylated proteins in all analyzed cell types were highly 
enriched for functions in basal metabolism such as citric acid cycle and glycolysis. 
Interestingly, though, there was only one protein target in common between neurons and 
other cell types, the PFKP. During (neuronal) differentiation, the cellular energy 
metabolism changes profoundly (Gascón et al., 2017): While proliferating stem and 
cancer cells depend on glycolysis and highly express glycolysis regulating enzymes, their 
metabolism shifts to mitochondria-based oxidative phosphorylation with differentiation 
(Gascón et al., 2017; Zhang et al., 2012b). In glycolysis as “incomplete” glucose 
metabolization, side products remain that are subsequently used for the production of 
metabolites required in dividing cells, such as nucleotides, amino acids and lipids (Zhang 
et al., 2012b). This finding of metabolic change preceding cell fate change has 
revolutionized the field of direct reprogramming for example from astrocytes to neurons, 
where formation of reactive oxygen species that are a toxic byproduct of oxidative 
phosphorylation are now reduced to improve reprogramming efficiency and survival 
(Gascón et al., 2016). In the differentiation process from stem cells to neurons (both in 
vitro from iPSCs via NPCs to neurons and in vivo), the metabolic switch is regulated by 
downregulation of key glycolytic enzymes and upregulation of enzyme splice variants and 
of mitochondrial biogenesis required for oxidative phosphorylation (Gascón et al., 2017). 
We identified an enrichment for proteins involved in amino acid biogenesis among 
AMPylation targets in NPCs, namely ASNS and PSAT1 – which were not AMPylated in 
neurons. In neurons, for example proteins acting in glucose and galactose metabolism 
and in small molecule biosynthesis were enriched among the AMPylated targets. It would 
of course be interesting to understand the molecular effect of AMPylation of each of these 
enzymes – activation or inhibition. 
 
 
Figure 11: Hourglass model of AMPylation remodeling and metabolism remodeling suggests 
a role for AMPylation in the metabolic change from glycolysis to oxidative phosphorylation that 
NPCs undergo in neuronal differentiation. The sketched hourglass shape is adopted from Fig. 4b 
of the AMPylation study (Chapter 3), in which we described the AMPylation remodeling process in 
the differentiation from iPSCs via NPCs to neurons as an hourglass model-like process. 
 
The fact that in all cell types, AMPylated proteins were significantly enriched for metabolic 
functions, combined with reported molecular regulation of enzyme function through 
AMPylation, are strong indicators for a role of AMPylation in this metabolic switch: On top 
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of differential gene expression, AMPylation may represent a fast and reversible 
mechanism to adjust to metabolic needs. This way, AMPylation remodeling may support 
metabolism remodeling during neurogenesis (see Figure 11). And thus, increased 
AMPylation upon FICD OX may lead to increased / faster neurogenesis. 
The ECM hypothesis. To the reader, it may be surprising that the set of AMPylated 
proteins in COs does not equal the sum of those identified in NPCs and neurons but is 
actually distinct. This difference may be explained by COs being a more complete system 
than just the 3D organization of the same cell types (Camp et al., 2015; Pașca et al., 
2015). For example, ECM components are produced that stabilize the internal 
architecture and are involved in signaling and guidance processes (Long and Huttner, 
2019). Accordingly, GO Term analysis of the AMPylated proteins in COs revealed 
enrichment for “extracellular exosome” components. Considering the role that was 
ascribed to ECM components in the regulation of human cortical development and 
gyrification by others (Long and Huttner, 2019; Long et al., 2018) and us ((Kyrousi et al.; 
Under Revision); see ECE2 study Chapter 4 (Buchsbaum et al., Under Revsion)), this is 
highly interesting. ECM remodeling through AMPylation may serve as an additional 
hypothesis of how FICD may influence neurogenesis. On the other hand, COs were 
repeatedly shown to contain additional cell types, such as astrocytes (Paşca et al., 2015; 
Sloan et al., 2017) and cells of mesodermal origin (Camp et al., 2015; Quadrato et al., 
2017) which may give rise to microglia during CO differentiation (Ormel et al., 2018) and 
contribute to differences between targets identified in 2D and 3D models. As COs contain 
several different cell types, the background in the proteomic analysis of AMPylated 
proteins is higher and consequently, fewer proteins appear to be significantly AMPylated. 
Interestingly, “myelin sheath” was another GO term enriched solely in CO targets 
(String.db (Szklarczyk et al., 2017)), highlighting a closer resemblance of COs to the 
developing human cortex than 2D in vitro models (Camp et al., 2015).  
The alternative splicing hypothesis. A further hypothesis I would like to forward is 
based on another functional group enriched in AMPylated proteins in neurons: factors 
acting in RNA splicing and mRNA stability. It has been shown that alternative splicing as 
a crucial step to correct gene expression is tightly regulated during neural development: 
Switch between alternative splice variants of the same gene defines neuronal maturation 
stages (Weyn-Vanhentenryck et al., 2018). Alternative splicing is regulated by distinct 
RNA binding proteins. This functional group of proteins is exclusively AMPylated in 
neurons, which may thus indicate an additional level of regulation, fine-tuning neuro-
developmental stage-specific alternative splicing. 
The phosphorylation competition hypothesis. The amino acids that can get stably 
AMPylated are those carrying a hydroxyl group in their amino acid side chain: serine, 
threonine and tyrosine (Casey and Orth, 2018). These are also the amino acids most 
commonly phosphorylated (Cohen, 2000). Besides, both phosphorylation and AMPylation 
use ATP as a substrate (Casey and Orth, 2018). Phosphorylation being the most 
widespread PTM, it has been estimated that about 30% of proteins in a mammalian cell 
are phosphorylated at any time, thereby mediating numerous pathways (Cohen, 2000). 
The last hypothesis I want to bring up here is therefore, that AMPylation of amino acids 
may compete with phosphorylation of the same site. Both PTMs add a negative charge to 
the side chain, but AMPylation is a more bulky modification than phosphorylation, that 
may thus have a different effect on the protein structure and characteristics. For example, 
in the ER chaperone BiP and other Hsp70 homologs, the highly conserved Tyr366 was 
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identified as site for FICD-mediated AMPylation (Ham et al., 2014). Tyr366 is in close 
proximity to the ATP binding site of BiP, thus its AMPylation was suggested to sterically 
hinder ATP hydrolysis (Ham et al., 2014). The same site can also be phosphorylated 
(https://www.phosphosite.org/ (Hornbeck et al., 2015)) – thus, AMPylation may compete 
with phosphorylation. As already alluded to, cytoskeletal, motor and MT associated 
proteins also get heavily modified by phosphorylation (see 1.1.4 and The cytoskeleton 
and transport hypothesis), while we identified a number of them as AMPylation targets. 
For example, of the 71 AMPylated proteins in neurons, 58 are also prone to be 
phosphorylated (classified as “phosphoprotein” in String.db (Szklarczyk et al., 2017)) and 
of the 34 targets in COs, 25 are also phospho-proteins. A shift in the balance of 
AMPylation and phosphorylation may thus change the dynamics of the MT cytoskeleton 
and the interaction with motors and other MAPs, and affect all other protein groups 
functionally discussed above. This may in turn influence relevant processes of 
neurodevelopment.  
Further unresolved questions of this study.  In our study, we further characterized the 
localization of both FICD and AMPylated proteins in different cell types and COs. In line 
with previous findings, we detected co-localization of FICD with the ER (Preissler et al., 
2017b; Sanyal et al., 2015), but also outside the ER (Rahman et al., 2012; Truttmann et 
al., 2017). A recent study developed a novel labeling and imaging technique of 
membrane-bound proteins and detected FICD exclusively in the ER, which can be close 
to Golgi or mitochondria (Sengupta et al., 2019). Our results, though, are in line with 
another study that generated an atlas of subcellular localization of thousands of proteins 
by fractionation of cellular compartments followed by proteomics (Orre et al., 2019). As 
did we, they found 1) that FICD localizes to several subcellular comportments in addition 
to the ER and 2) that intracellular FICD localisation is cell-type specific (Orre et al., 2019). 
A localization of AMPylated proteins outside the ER makes sense considering their 
individual function. For example, we find MAP2 and TUBB3 in neuronal processes 
labeled with our probe, which indicates that AMPylation does not affect their natural 
localization to MTs. The tubulous system of the ER in neurons extends into their neurites 
(Wu et al., 2017), which fits to this observation as this would enable local AMPylation by 
ER-based FICD.  
Concerning the localization of AMPylated proteins to the nucleus of all screened cell 
types except for fibroblasts, it remains questionable which AMPylating enzyme acts there. 
Proteins involved in alternative splicing that we detected as AMPylated in neurons are an 
example of AMPylated targets with nuclear localization – for others see Table S8.  
The finding that fibroblasts show no AMPylated proteins localized to the nucleus, 
although FICD was found to be spread throughout the cells, further supports the 
specificity of the nuclear probe staining in other cell types. To further investigate if 
AMPylation of nuclear structures is specific for differentiation or cell type identity, we will 
next analyze probe localization in different stages of iPSC-to-astrocyte in vitro 
differentiation as additional neural cell type. 
Differences in localization of FICD and AMPylated proteins within the screened cell types, 
which only partly overlapped, indicate the presence of additional AMPylating enzymes 
with a possibly different cellular distribution. During this project, the discovery of a new 
eukaryotic AMPylator was reported: The highly conserved pseudokinase SelO (Sreelatha 
et al., 2018). The putative AMP transferase activity of this pseudokinase opens up the 
possibility that the number of eukaryotic AMPylating enzymes is larger than previously 
expected. Also, homologs of the bacterial glutamine synthase adelylyltransferase 
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(Kingdon et al., 1967), another AMPylator without a Fic domain, may be identified. As 
only a subset of targets in cancer cell lines responded to changes in FICD levels, they 
may for example be AMPylated by SelO. It will thus be interesting to manipulate the 
expression of SelO in 2D and 3D in vitro models of neurodevelopment and to identify 
targets of SelO in human cells.  
FICD was shown to be glycosylated (Sanyal et al., 2015). The importance of N-
glycosylation for different aspects of neural development has been well documented, 
acting for example through influencing protein stability and activity (Scott and Panin, 
2014a). For instance, N-glycans were found to play key roles in neural cell adhesion and 
axonal targeting during development (Scott and Panin, 2014a) and in neural excitability 
and synaptic transmission (Scott and Panin, 2014b). It would thus be of interest to 
analyse the molecular effect of N-glycosylation on FICD function. As the glycosylated 
residue (Asn275) is close to the conserved autoinhibitory Glu234 (Preissler et al., 2017a), 
its modification with bulky glycan residues may for example affect FICD’s autoregulation 
(Engel et al., 2012). 
  
Altogether, we suggest an additive effect of small changes in the structure and function of 
many proteins (with heterogeneous functions in cytoskeleton, motors, metabolism, 
splicing, and ECM) to underlie the subtle but significant changes in neurogenesis upon 
FICD OX and KD. The heterogeneity of processes the AMPylated proteins are involved in 
led to diverse hypotheses that try to explain the role of AMPylation in neurogenesis. A 
combination of all hypotheses may also be true – and all of them remain to be confirmed. 
Further, our findings suggest that mutations of prospective AMPylation sites could affect 
neurodevelopment. Due to the lacking knowledge of exact AMPylation sites for instance 
in tubulin and MT-associated proteins, we are unable to proof our hypotheses. But 
several single nucleotide variants which lead to depletion or addition of “AMPylatable” 
amino acids have been identified in patients with neurodevelopmental disorders (see 
Table 3; Decipher (Firth et al., 2009)). And the effect of FICD on neurogenesis was 
clearly dependent on its AMPylation activity as it was absent when we electroporated 
COs with the active site mutant H363A. So far, one patient with a point mutation in FICD 
has been reported by Deciphering Developmental Disorders (DDD) database (see Table 
3 (Firth et al., 2009)). Interestingly, this individual shows abnormality of the eye and the 
nervous system – which further supports a role for FICD-mediated AMPylation in 
neurodevelopment.  
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Table 3: DDD patient with FICD variant and Decipher patients with tubulin, kinesin and 
myosin variants resulting in gain or loss of possible AMPylation site and nervous system 
phenotypes.  
 
Information extracted from the Decipher database (Firth et al., 2009). 
 
 
  
Gene 
(Transcript) Position Size Consequence Inheritance Genotype
Pathogenicity / 
Contribution Phenotype(s)
FICD Chr12:108912413-
108912413          
C>T
SNV missense 
variant
De novo 
constitutive
Heterozygous Uncertain Abnormality of head or neck                         
Abnormality of the eye                                
Abnormality of the nervous system                             
Growth abnormality
TUBB3        
(ENST00000
556922)
Chr16:90001548-
90001548       
c.1730C​>T     
p.Ser577Leu
SNV missense 
variant
Paternally 
inherited, 
mosaic in 
father
Heterozygous Likely 
pathogenic       
Full
Abnormality of connective tissue                         
Abnormality of the eye
TUBB3        
(ENST00000
556922)
Chr16:90001548-
90001548       
c.1730C​>T     
p.Ser577Leu
SNV missense 
variant
De novo 
constitutive
Heterozygous Abnormality of the digestive system                                  
Abnormality of the eye                               
Abnormality of head or neck: postnatal microcephaly                                
Abnormality of the nervous system
TUBB3        
(ENST00000
556922)
Chr16:90001151-
90001151            
c.1333G​>A      
p.Gly445Ser
SNV missense 
variant
Maternally 
inherited, 
constitutive 
in mother
Heterozygous Pathogenic           
Full 
Abnormality of the eye   Abnormality of head or neck    
Abnormality of the musculature                    
Abnormality of the nervous system
TUBB3        
(ENST00000
556922)
Chr16:90001454-
90001454                
c.1636A​>T                 
p.Thr546Ser
SNV missense 
variant
De novo 
constitutive
Heterozygous Abnormality of the digestive system                            
Abnormality of head or neck: postnatal microcephaly       
Abnormality of the integument                     
Abnormality of the nervous system: generalized-
onset seizures
TUBB2B  
(ENST00000
259818)
Chr6:3227774-
3227774        
c.4C​>A              
p.Arg2Ser
SNV missense 
variant
Unknown Heterozygous Uncertain  
Uncertain 
Abnormality of the eye                                 
Abnormality of head or neck                      
Abnormality of the nervous system: seizures
KIF5C 
(ENST00000
435030 )
Chr2:149835499-
149835499      
c.1357G​>T     
p.Asp453Tyr
SNV missense 
variant
Paternally 
inherited, 
constitutive 
in father
Heterozygous Uncertain  
Uncertain 
Abnormality of the digestive system                               
Abnormality of head or neck   Abnormality of the 
nervous system: focal-onseit seizure
KIF5C 
(ENST00000
435030 )
Chr2:149799272-
149799272   
c.587C​>A      
p.Thr196Ly
SNV missense 
variant
De novo 
constitutive
Heterozygous Abnormality of the nervous system
MYH3 
(ENST00000
583535)
Chr17:10550528-
10550528   
c.869T​>G    
p.Ile290Ser
SNV missense 
variant
De novo 
constitutive
Heterozygous Pathogenic           
Full 
Abnormality of the ear                                         
Growth abnormality                                    
Abnormality of head or neck                           
Abnormality of prenatal development or birth       
Abnormality of the skeletal system
MYH3 
(ENST00000
583535)
Chr17:10554954-
10554954       
c.380A​>G     
p.Asn127Ser
SNV missense 
variant
Maternally 
inherited, 
constitutive 
in mother
Heterozygous Uncertain  
Uncertain 
Abnormality of the ear                                 
Abnormality of head or neck                           
Abnormality of the musculature
MYH3 
(ENST00000
583535)
Chr17:10554954-
10554954       
c.380A​>G     
p.Asn127Ser
SNV missense 
variant
Maternally 
inherited, 
constitutive 
in mother
Heterozygous Uncertain  
Uncertain 
Abnormality of the ear                                        
Abnormality of the eye                                 
Abnormality of head or neck                       
Abnormality of the musculature
MYH3 
(ENST00000
583535)
Chr17:10532970-
10532970       
c.5740G​>A     
p.Ala1914Thr
SNV missense 
variant
Paternally 
inherited, 
constitutive 
in father
Heterozygous Uncertain    
None
Growth abnormality                                        
Abnormality of head or neck                          
Abnormality of the integument                     
Abnormality of limbs                                   
Abnormality of the nervous system                          
Abnormality of the skeletal system
MYH3 
(ENST00000
583535)
Chr17:10543429-
10543429   
c.2566G​>C   
p.Glu856Gln
SNV missense 
variant
Maternally 
inherited, 
constitutive 
in mother
Heterozygous Uncertain Abnormality of connective tissue                         
Abnormality of limbs
MYH8 
(ENST00000
403437 )
17:10304859-
10304859     
c.2931+1G​>A
splice_donor_ 
variant
Unknown Heterozygous Uncertain  
Uncertain 
Abnormality of the cardiovascular system                            
Abnormality of limbs
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5.3. ECE2 - A NOVEL PH CANDIDATE WITH OLD AND NOVEL 
DISEASE-CAUSING MECHANISMS 
In the third study (Chapter 4; (Buchsbaum et al. , Under Revision)), we identified ECE2 
as a promising novel candidate gene for PH. Biallelic point mutations, detected in two 
unrelated patients with MRIs showing heterotopic nodules of grey matter lining the lateral 
ventricles, were predicted to have a disease-causing effect. Hence, our studies focused 
on mimicking LOF both in human iPSC-derived in vitro and mouse in vivo model systems. 
The characterization of ECE2 expression in human in vitro models revealed highest 
expression in neurons and an additional enrichment at the apical surface of CO 
ventricles. Acute KD in COs lead to ectopic positioning of non-transfected differentiated 
neurons to the VZ, adjacent to transfected aRG. The patient phenotype of ectopically 
positioned neurons was thus partly recapitulated in vitro, the underlying mechanisms 
being predominantly non-cell-autonomous. Moreover, inhibition of ECE2 activity in young, 
migrating iPSC-derived neurons caused significant changes in their migratory dynamics.  
In the developing mouse cortex, acute Ece2 KD resulted in loosening of apical AJs and 
consequently in delamination of progenitor cells towards ectopic, more basal locations (1 
dpe) where they formed ectopic rosettes, giving rise to ectopic neurons that formed 
nodules containing deep and upper layer neurons (3dpe). Also in vivo, the patient 
phenotype was thus partly recapitulated. Both malpositioned progenitors and neurons 
were mostly non-transfected, underscoring again non-cell-autonomous contribution to the 
malformation upon ECE2 mutation.  
Further, chronic inhibition of total ECE2 by Phos treatment and permanent loss of ECE2 
by genome-edited KO in iPSCs was used to reveal cellular functions of ECE2 and both 
produced very similar phenotypes in COs. Namely, the cell composition was changed to 
an increased number of progenitors at the expense of neurons. Cytoskeletal components 
including actin and MTs were disorganized with impaired apico-basal polarity and apical 
neuro-ependymal lining. Considering the highest expression levels of ECE2 in neurons 
and at the apical surface, a role for ECE2 both in apical belt integrity or apico-basal 
polarity and in neuronal differentiation are likely – and was indeed revealed in our 
experiments. Additionally, significantly more neuronal cell bodies failed to leave the VZ in 
ECE2 KO COs compared to control, reminiscent of PH. Proteomics of ECE2 KO COs 
confirmed a reduction in factors needed for normal cortical development, including actin 
and MT cytoskeletal components, cell polarity, migration, and adhesion regulators, and 
even downregulation of some proteins known to play a role in neurodevelopmental 
disorders. In addition to these proteins with known functions in cortical development, 
whole-CO and secretome proteomics revealed a reduction in ECM proteins and 
receptors, which may be responsible for non-cell-autonomous changes in neuronal 
migration and in cell fate. Proteomics further revealed changes in phosphorylation of 
cytoskeletal and motor proteins, indicating an involvement of ECE2 in the regulation of 
PTMs.  
In total, our findings add ECE2 to the list of genes whose mutations may underlie PH and 
stress that – although genetically heterogeneous – PH is often caused by similar cellular 
mechanisms. Besides, we suggest deregulation of the ECM as a novel causative 
mechanism. 
How minor genomic changes can disrupt cortical development. Together with other 
recent examples (Heinzen et al., 2018; Klaus et al., 2019; O’Neill et al., 2018a; O’Neill et 
al., 2018b), our study shows how genomic changes as small a SNVs can disrupt 
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processes pivotal to cortical development. Besides, it underlines the power of next 
generation genetic analyses, such as the WES used here on DNA from healthy parents 
and affected children, for the identification of responsible genes. Specifically for ECE2, 
one healthy allele seems to be sufficient for its function as the parents of the two patients 
with biallelic variants are heterozygous carriers of SNVs. Of course, by analyzing only the 
protein-coding genes in the patient exome, intronic variants may have been missed and 
the detection of copy number variants, which are enriched in PH (Cellini et al., 2019), is 
also limited in WES.  
The power of combining model systems and unbiased analysis methods. As was 
elaborated on in sufficient detail in the introduction of this thesis, it has been difficult in the 
past to recapitulate patient phenotypes of NMDs in mice carrying human patient 
mutations in the homologous gene. To this end, we combined here in vitro and in vivo 
model systems to understand the role of ECE2 in cortical development and disease. The 
phenotypes observed upon ECE2/Ece2 KD were highly similar in both models and were 
reminiscent of PH, indicating that the role for ECE2 may be comparable in mouse and 
human cortical development. As a next step, we generated ECE2 KO iPSCs via the 
relatively novel genome editing method CRISPR/Cas9 (Ben Jehuda et al., 2018) in 
collaboration with Shahryar Khattak. In the analysis of derived ECE2 KO COs and 
isogenic controls, we applied several unbiased methods to identify differences. Using 
FACS, we were able to detect changes in composition of the COs in terms of progenitors 
and neurons, both upon chronic inhibition of ECE2 enzymatic activity and upon ECE2 
KO. These changes could not be detected by immunohistochemical analysis of 
electroporated organoids, neither from in vivo analysis. This may be due to the sparse 
transfection upon electroporation and due to the non-cell-autonomous role of ECE2: 
Upon ECE2 KD in few cells, the neighboring, non-transfected cells can still generate and 
secrete products of ECE2 enzymatic activity. Thus, it is highly valuable to combine acute 
with chronic or permanent manipulation methods to distinguish cell-intrinsic from non-
autonomous mechanisms. A similar discrepancy between underlying genetics in the 
mouse models of a human NMD  was described for Dcx: While Dcx KO mice showed no 
cortical lamination defect, acute shRNA-mediated Dcx KD in rats lead to a better 
morphological and functional recapitulation of the human cortical phenotypes, including 
aberrant electrophysiology reminiscent of epilepsy (Nosten-Bertrand et al., 2008; Ramos, 
2005).  
The second unbiased method we applied in the analysis of ECE2 KO and control COs 
was MS-based proteomics, which we used for the analysis of whole organoids lysate to 
identify changes in protein expression and to decipher differentially phosphorylated 
cytoskeletal and motor protein, and for the analysis of culture medium to identify changes 
in the CO secretome. Our study is among the first to use proteomics in COs. The only 
other study that reported the use of proteomics in COs applied it to identify differences 
between trisomy 21 (Down syndrome) and control COs (McClure-Begley et al., 2018). In 
an analysis of COs of different stages, they revealed that MS-detected proteins reflect 
well the neurodevelopmental trajectory in COs – similarly to scRNA-seq as was shown 
several times (Camp et al., 2015; Pollen et al., 2019; Quadrato et al., 2017). Comparing 
trisomy 21 patient-derived and control COs, they found a number of dysregulated 
proteins and demonstrated reversal of this dysregulation by drug treatment (McClure-
Begley et al., 2018). Interestingly, some proteins identified to be changed in trisomy 21 
overlap with proteins we detected as downregulated upon ECE2 KO. Namely, several 
collagens and collagen-binding TGFBI were expressed at lower level in patient-like COs 
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in both studies. This indicates overlapping mechanisms at the basis of different 
developmental disorders. We further demonstrated the possibility to detect even 
differences in secretome, although this method requires improvement due to high 
background from culture medium components.  
This example stresses how useful unbiased analysis methods are to detect phenotypes 
in the rather variable COs. Besides, the fact that we can detect (dysregulated) proteins 
both in CO lysate and secretome shows the advantage of 3D over 2D in vitro human 
models as COs generate an elaborated ECM.  
With this study, we set an example on how combining objective analysis methods and in 
vivo and in vitro models can help to reveal phenotypes and mechanisms that may have 
remained hidden with standard ISH-based quantification methods.  
Setting ECE2 in the context of other PH-genes. The aim with which we started the 
ECE2 project was to identify novel genes whose mutations lead to PH, but also to 
highlight mechanisms that commonly arise from the heterogeneous genetic causes. To 
this end, several examples shall be given here that put PH caused by biallelic mutations 
in ECE2 into a wider context of the disorder.  
As detected by proteomics of COs, FLNA was downregulated upon ECE2 KO. Mutations 
in FLNA were identified as genetic cause for familial PH more than 20 years ago (Fox et 
al., 1998). The F-actin cross-linking protein is essential for cytoskeleton rearrangement 
and cell migration and both insufficiency and excess of FLNA were shown to inhibit 
migration (Carabalona et al., 2012; Sarkisian et al., 2006), indicating the importance of 
precise regulation of FLNA expression during neuronal migration. Upon acute FlnA KD in 
rats, the polarized RG structure is disrupted in a similar way to what we detected upon 
ECE2 KD and both cell cycle progression and neuronal migration towards the CP are 
altered (Carabalona et al., 2012). Similar phenotypes were identified in mice with 
mutations in Mekk4 and upon Rcan1 KD in rats, both of which act in the FLNA pathway. 
The intrinsic downregulation of FLNA in ECE2 KO COs may thus represent a cell-
autonomous contribution to the observed neuronal migration defect (Zhang et al., 2013). 
The close relative of FLNA that was also downregulated in upon ECE2 KO, FLNC, has 
not been associated with neurological disorders yet, although being expressed in the 
brain at low levels (Sheen et al., 2002) (proteinatlas.org). It has been associated with 
myopathies (Fürst et al., 2013).   
A process that has been implicated as main disease-causing mechanism in PH is vesicle 
trafficking (Sheen, 2014). Mutations in ARFGEF2, which encodes the vesicle transport 
protein Big2, cause autosomal recessive PH with microcephaly (Sheen et al., 2004a). 
Big2 and the related Napa, whose cKO leads to PH in the developing mouse brain 
(Ferland et al., 2009), mediate Golgi transport, trans-Golgi to endosome transport, and 
vesicle fusion. FLNA is also involved in Golgi membrane budding and trafficking of 
transport vesicles (Sheen, 2014). The more recently identified PH-gene TMTC3 
colocalizes with the vesicular GABA transporter vGat and was thus suggested to mediate 
synaptic vesicle transport (Farhan et al., 2017). All these genes play into the final 
common pathway of disrupted vesicle trafficking, leading to impaired cell adhesion and 
loss of neuroependymal integrity. Among the significantly enriched GO Terms of the 
proteins downregulated upon ECE2 KO are several ones that fit into this pathway 
(String.db (Szklarczyk et al., 2017)): “positive regulation of cytoplasmic transport” (MSN, 
EZR, MAP2), “membrane to membrane docking” and “positive regulation of early 
endosome to late endosome trafficking” (MSN and EZR), and “vesicle budding from 
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membrane” (S100A10, ANXA2, SEC24D, CTSZ). This indicates that vesicle trafficking 
may also be affected by the lack of ECE2.  
Vesicle trafficking depends on both actin and MT cytoskeleton and their transport 
processes. Upon ECE2 KO, IHC analyses and proteomics of COs revealed a disruption 
of both actin and MT cytoskeleton(-associated) integrity. This included differential 
phosphorylation of some MAPs, motor, and vesicle trafficking proteins, and 
downregulation of a tubulin and several MAPs such as MAP2, MAP4 and EM41. 
Interestingly, EML1 has been associated with primary cilia function and positioning and 
with MT dynamics: In Eml1 mutant HeCo mice, neural progenitors acquire ectopic 
positions due to ectopic primary cilia and abnormal spindle orientation and location and 
give rise to ectopic neurons (Bizzotto et al., 2017; Kielar et al., 2014). Furthermore, a role 
for primary cilia in the etiology of PH was recently suggested from KD of the novel PH-
associated gene MOB2 in vivo and in COs (O’Neill et al., 2018a): MOB2 was found to 
play a role in cilia number and positioning, nuclear-cilia coupling and with that in neuronal 
positioning. Additionally, Mob2 was implicated in phosphorylation of FlnA, impairing actin 
cytoskeletal remodeling and suggesting a link between FlnA and the primary cilium 
(O’Neill et al., 2018a). 
We see a reduction in apically localized primary cilia upon acute Ece2 KD in vivo, upon 
chronic ECE2 inhibition in COs, and in ECE2 KO COs (with concomitant spread of 
ARL13B+ cilia throughout the thickness of the VZ in COs and the VZ and SVZ in the 
mouse cortex). This indicates that progenitors delaminate and generate neurons at 
ectopic locations. The cilium-localized GTPase ARL13B regulates both cell migration and 
cell cycle progression (Pruski et al., 2016) and its reduction and redistribution upon ECE2 
KD, KO or inhibition may be at the core of the observed changes in migration and 
proliferation. Whenever apial cilia acquire non-apical positions, affected cells lack their 
contact to the signals within the cerebrospinal fluid. Besides, the delaminating cells are 
placed into a different microenvironmental niche. These effects may contribute to the 
observed changes upon lack of ECE2. 
Closely related to cytoskeletal integrity and to vesicle transport mediating their positioning 
are apical AJ proteins or, more generally, cell adhesion proteins. We found a significant 
reduction in numerous cell adhesion and polarity proteins in ECE2 KO COs with 
loosening of the AJ belt and delamination of NPCs. Also the increased expression of 
ECE2 at the apical ventricular surface in COs suggests a function of ECE2 in the apical 
aRG compartment. In mice, several studies revealed the importance of the actin 
cytoskeleton and its anchoring to AJs for NMDs: Conditional deletion of α-E-catenin 
disrupted the coupling of AJ proteins with intracellular actin fibers, lead to loss of apico-
basal polarity and increased G/F actin ratio and resulted in SBH (Schmid et al., 2014). 
Rapgef2 and 6 were also implicated in AJs (Maeta et al., 2016): (c)KO of one or both 
Rapgefs resulted in RG scaffold disruption and delamination through the loss of AJs, with 
the ectopic RG and IPCs giving rise to a huge ectopic cortical mass. Similarly, loss of the 
polarity regulator Lgl1 in the mouse cortex disrupted AJs, leading to ectopic aRG and 
IPCs, disorganized aRG fibers with rosette-like deformation, and ectopic neurons (Zhang 
et al., 2019). Besides, aRG lacking Lgl1 showed hyperproliferation and impaired neuronal 
differentiation (Zhang et al., 2019), stressing a role for AJs and polarity proteins in cell 
fate. From co-occurrence of PH with microcephaly it becomes obvious that PH genes can 
regulate proliferation. For example, PH patients with ARFGEF2 mutations have 
microcephaly and males with FLNA mutations that die at birth have thinner cortices 
(Guerrini et al., 2004). Moreover, mutations in the cadherin-ligand pair FAT4 and DCHS1 
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cause PH (Cappello et al., 2013), which has recently been recapitulated and further 
investigated in COs (Klaus et al., 2019). Reduced expression of Fat4 or Dchs1 in the 
developing mouse cortex lead to increased progenitor and reduced neuronal numbers 
and resulted in accumulation of ectopic neurons (Cappello et al., 2013). In COs with 
FAT4 or DCHS1 mutations, IHC of nestin and IHC and WB of ac-tub cytoskeletal markers 
showed a similar disruption of the neuro-ependymal integrity as we found in the absence 
of ECE2. Besides, apico-basal polarity was affected with premature progenitor 
delamination and neuronal migration deficit in a subset of patient-derived neurons. For 
instance, scRNA-seq revealed a reduction in FLRT2, involved in cell-cell adhesion, cell 
migration and axon guidance, which we also found downregulated in ECE2 KO COs via 
proteomics (Klaus et al., 2019). Recent findings on the role of FLRT1 and FLRT3 in 
neuronal migration (del Toro et al., 2017) suggest that the reduced FLRT2 level in ECE2 
KO COs may contribute to the observed neuronal migration defect. 
Opposite to the phenotype upon acute KD of Fat4 and Dchs1 in the developing mouse 
cortex, the proportion of proliferating progenitors was decreased and neuronal 
differentiation was increased in patient-derived COs (Klaus et al., 2019). Also Cdc42 and 
RhoA disruptions cause changes in progenitor proliferation and brain size (Cappello et 
al., 2006; Katayama et al., 2011). cKO of RhoA destabilized both actin and MT 
cytoskeleton in RG, with increased G/F actin ratio. Although cKO neurons would migrate 
normally, these RG defects produced SBH due to non-cell-autonomous mechanisms – 
similar to what we saw upon ECE2 KD. The recently discovered PH candidate gene 
PLEKHG6 was also found to regulate NPC differentiation and neuronal migration via 
RHOA and its KD in COs phenotypically recapitulated PH (O’Neill et al., 2018b).  
An additional functional group of proteins we identified as downregulated in ECE2 KO 
COs play a role in splicing and/or mRNA stability. These 13 proteins formed a tight sub-
network of interactors in protein-protein interaction analysis. RNA processing and 
transcription regulation have been implicated in brain development and PH etiology 
before: The integrator complex gene INTS8 plays an important role in transcriptome 
integrity and PH patient mutations and INTS8 deletion alter gene expression and 
neuronal differentiation (Oegema et al., 2017) (see also The alternative splicing 
hypothesis in Chapter 5.2). 
Altogether, these comparisons to known PH genes in human and mouse show that the 
regulation of cytoskeleton, cell adhesion, polarity, migration, and proliferation versus 
differentiation are common mechanisms in PH. They are regulated by a heterogeneous 
set of proteins – and we suggest that ECE2 is a new one of them. 
ECE2 and the ECM in PH. In addition to implication of ECE2 in the above discussed 
processes known to be important in cortical development and to be disrupted in NMDs, 
we identified a less studied but important functional group: ECM proteins. ECM 
components represented the biggest group of downregulated proteins in ECE2 KO COs 
and their secretome with 49 implicated proteins. In the context of ECE2 as a membrane-
bound protease that resides in the lumen of acidified trans-Golgi (Emoto and 
Yanagisawa, 1995), a function of ECE2 in the production of secreted factors is not 
surprising. Neither was it surprising to us because the mechanism underlying the 
observed phenotypes reminiscent of PH clearly had non-cell-autonomous aspects 
involved. ECM proteins such as collagens, galectins, and lumican have been shown to be 
highly important during brain development, where they regulate – among others – 
proliferation, migration, and differentiation of neural cells (Dityatev and Fellin, 2008; Long 
and Huttner, 2019). Collagen I and lumican have been shown to drive folding of the 
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human neocortex (Long et al., 2018). The collagen VI (COLVI) family, three members of 
which were downregulated in ECE2 KO COs, forms characteristic beaded microfilament 
nets in the ECM, where it modulates the stiffness and mechanical properties of the ECM, 
but also impacts several intracellular processes and pathways (Gregorio et al., 2018). 
COLVI is involved in basal lamina organization and neural homeostasis, with a 
neuroprotective effect in stress and ageing (Gregorio et al., 2018). Furthermore, 
collagens and ECM remodeling are relevant to the onset of epilepsies, which patients 
with PH often present with (Dityatev and Fellin, 2008), thus highlighting a fundamental 
role of the ECM in brain physiology and pathology. For example, mutations in COL6A2 
were linked to progressive myoclonus epilepsy (Karkheiran et al., 2013). Interestingly, 
COL6A1 was reported within a set of genes that are upregulated in the human cerebral 
cortex with respect to non-human primates, indicating a human-specific role of this gene 
in brain development and evolution (Caceres et al., 2003). 
Another ECM gene that our group identified as PH candidate is LGALS3BP (Kyrousi et 
al.; Under Revision). Interestingly, LGALS3BP is a galectin binding protein – and we 
found galectins-1 and -4 reduced in ECE2 KO COs, indicating another link between 
different cases of PH. 
Ezrin and moesin, which are downregulated upon ECE2 KO, are both implicated in 
vesicle trafficking (see above) and are involved in establishing a connection between 
ECM receptors and the intracellular actin cytoskeleton (Kawaguchi et al., 2017). Besides, 
they integrate Rho GTPase signaling and thereby affect the actin cytoskeleton, for 
example by recruiting and locally activating PLEKHG6 and RhoG to the apical side 
(D’Angelo et al., 2007).  
Protein phosphorylation in PH. The importance of posttranslational modifications in 
functional fine-tuning of proteins involved in cortical development has been extensively 
demonstrated (see examples in 1.1.4). Here, we were especially interested in phosphory-
lation as the most widespread PTM (Cohen, 2000), which is abundant on cytoskeletal 
and associated proteins in neurons to regulate their morphology and polarity (Song and 
Brady, 2015) (see also 5.1 and 5.2). For example, phosphorylation of Ser2086 in MAP4 
was only detected in the CTRL COs, whereas Ser25 and Ser1653 of MAP1B were 
exclusively phosphorylated in ECE2 KO COs. Although the differentially phosphorylated 
sites did not overlap with the positions of the SNVs in MAP1B, a gene in which variants 
were recently discovered to cause PH (Heinzen et al., 2018), this further supports a 
general deregulation of the microtubule cytoskeleton in the absence of ECE2. A motor 
protein site only phosphorylated after upon ECE2 KO was Ser207 in DYNC1LI1 and 
phosphorylation of Ser942 in the vesicle transport factor USO1 was exclusively detected 
in the CTRL. These differences between CTRL and KO indicate changes in vesicle 
transport, which have formerly been found to underlie PH (Cellini et al., 2019; Sheen et 
al., 2004a). Ser292 of the actin organizer CDC42EP4 and Ser24 in the tight junction 
protein TJP2 were only phosphorylated in the CTRL, which may further support observed 
changes in the actin cytoskeleton, in line with loosening of the apical adherens belt. 
Further, the proteins with up- or downregulated phospho-sites upon ECE2 KO were 
enriched for GO functions in actin binding and organization (String.db. (Szklarczyk et al., 
2017)). 
Based on our findings of differential protein phosphorylation upon ECE2 KO, we propose 
that misregulation of PTMs such as phosphorylation can also contribute to the etiology of 
PH. In this context it would be of interest to analyse CTRL and ECE2 KO COs for 
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dysregulation of additional PTMs with known nervous systems functions, such as 
acetylation and polyglutamylation (see 1.1.4). 
Unresolved questions for future investigations. So far, the focus of this discussion 
was on similarities of ECE2 KD and KO phenotypes with other cases of PH (and SBH). 
But several open questions remain that would be highly interesting to resolve. 
First of all, we called the ectopic accumulation of neural progenitors around an ectopic 
apical surface, which we observed 3dpe upon Ece2 KD in vivo, “rosette”. This term, 
reused from 2D in vitro systems, describes the inside-out organization of neural 
progenitors and neurons around an apical surface. Rosettes have been described in 
mouse models of PH before, for example upon ectopic expression of reelin (Kubo et al., 
2010) and upon RhoA cKO (Katayama et al., 2011). In these studies, the circular shape 
of cell aggregates was more clearly defined and the apical surface seemed bigger, plus 
several rosettes formed per brain. It may thus be interesting to 1) analyze the effect of 
Ece2 KD after more time post electroporation and 2) to further characterize if – as is the 
case upon ectopic reelin expression (Kubo et al., 2010) – rosettes give rise to neurons 
that arrange in inside-out manner, also forming a dendrite-rich ectopic MZ. We called the 
ectopic clusters of neurons in the developing mouse brain that form upon Ece2 KD 
“nodules”, as they are reminiscent of heterotopic nodules in patient brains, which line the 
surface of the lateral ventricles. For these nodules, it would also be of interest to analyze 
the outcome at later timepoints: Which final localization will the ectopic neurons acquire? 
Do the neurons within nodules undergo terminal differentiation and become synaptically 
and electrophysiologically active? Do they establish connectivity to the overlaying 
normotopic cortical neurons? Is their activity epileptogenic (Chevassus-au-Louis et al., 
1999; Kothare et al., 1998)?  
In addition to nodules in the cortical parenchyma, basal ectopic neurons were observed 
upon Ece2 KD in vivo (see Figure 12). These may either resemble cobblestone-like 
overmigrating neurons that occur in lissencephaly type II due to disruption of the basal 
membrane or may actually not overmigrate but represent the start of a cortical fold. The 
difference between these options can be analysed by IHC staining for basal lamina 
components such as laminin and, again, a longer timepoint after electroporation would be 
instrumental.  
In the context of cortical folding, I would like to mention the study of de Juan Romero et 
al. who analyzed differential gene expression in the different germinal layers of the 
developing cortex between future gyri and sulci in the ferret cortex (de Juan Romero et 
al., 2015). For instance, high levels of Trnp1 are responsible for tangential expansion of 
NSCs and localize to sulci in human fetal cortex, whereas in gyri, which are regions of low 
Trnp1 expression, radial expansion increases of the number of intermediate progenitors 
and basal radial glial cells. Accordingly, KD of Trnp1 in the developing mouse cortex can 
induce folding (Stahl et al., 2013). Similarly, differential expression of adhesion molecules 
FLRT1 and FLRT3 in future gyri and sulci underlies gyrification of the human and ferret 
cortex  - but without involvement of progenitor cell amplification: differential intercellular 
neuronal adhesion acts as a regulator of cortical folding with increased radial migration of 
excitatory neurons in the absence of FLRT adhesion molecules (del Toro et al., 2017). 
The downregulation of FLRT2 protein levels that we detected in ECE2 KO COs may 
contribute to the overmigration phenotype discussed above. Interestingly, the fold change 
of expression in gyrus over sulcus in ferret shows a similar pattern for different genes 
involved in PH (data extracted from (de Juan Romero et al., 2015)): gene expression of 
most of them is higher in the oSVZ of gyri and may additionally be higher in iSVZ and VZ:  
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Fold-change Gyrus/Sulcus, with p<0.05:   FAT4     1.06 (VZ), 1.65 (ISVZ), 1.5 (OSVZ) 
    DCHS1    1.58 (VZ), 1.57 (OSVZ) 
And this relation is also similar for ECE2 and a collagen downregulated upon its KO: 
       ECE2     0.8 (ISVZ), 1.35 (OSVZ) 
  COL6A1     1.98 (VZ), 1.22 (ISVZ), 1.38 (OSVZ) 
This suggests some extent of involvement of PH genes, including ECE2, in gyrification. 
Another hint in that direction is that ECE2 seems to have a role in the production of 
lumican and collagens as these were downregulated in the absence of ECE2. LUM and 
COL1 were shown to be required for folding of human fetal cortical explant and to induce 
folding when added externally (Long et al., 2018). Here, we need to consider also the 
question how similar is the ECM in the fetal cortex and in COs – which to my knowledge 
has not been studied to date. 
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Figure 12: Overmigration of neurons upon acute Ece2 KD in vivo. Examples of images of 
E13-16 electroporated control (CTRL) and Ece2 KD brains illustrating overmigrating deep- (A) and 
upper layer neurons (B) upon Ece2 KD (Scalebar = 100 µm). 
 
 
A later timepoint of analysis would also be interesting in ECE2 KO and control COs, for 
example 90d, to see if the relative composition of progenitors and neurons changes. Is 
there just a delay in neuronal differentiation that normalizes later on or does the larger 
progenitor pool at the analyzed timepoint of 60d result in a final overproduction of 
neurons?  
For the two patients with biallelic variants in ECE2 and PH, we don’t have information 
about any other cortical phenotype so far. With the hints that we got from both in vivo and 
in vitro analyses about differences in progenitor versus neuron numbers and possible 
overmigration, it would be highly interesting to analyze the patient MRIs in more detail. 
Measurement of the grey matter thickness and determination of the gyrification index 
would be useful parameters. In order to have good reason to request the help from 
clinicians for these analyses, we need to proof, though, that the patient mutations lead to 
a loss of function of the enzyme, which we model here via its KD/KO. An approach to 
showing that the patient mutations indeed disrupt the protein function would be to 
introduce them into an ECE2 OX plasmid via site-specific mutagenesis. Making use of the 
fact that ECE2 is an enzyme, we can then test the effect of the patient mutations in an 
enzymatic activity assay, for example with a fluorigenic substrate (Ouimet et al., 2010). 
Having the normal and patient-like ECE2 constructs, the next step will be to overexpress 
them both in COs and in the developing mouse cortex.  
Another feature typical for PH is epilepsy that may arise from the ectopic neuronal 
nodules (Kothare et al., 1998). Although ECE2 patients did not present with seizures, it 
may be interesting to perform electrophysiology in ECE2 KO COs and in mice in which 
Ece2 is acutely downregulated. A novel advancement in 3D cell culture are assembloids/ 
fused-organoids, in which spheroids of different regional identity are generated by 
separate patterning and subsequently fused together. The result is a relatively high 
complexity with defined identities, such as dorsal and ventral telencephalon (Bagley et 
al., 2017; Birey et al., 2017; Xiang et al., 2017) (see 1.4.2). For example, the fusion of 
dorsally and ventrally patterned spheroids with different genetic background (i.e. patient 
and control) can be used to distinguish cell-autonomous from non-cell-autonomous 
disease mechanisms. As epilepsy often results from an imbalance of excitation and 
inhibition, assembloids are highly useful for studying not only radial migration of excitatory 
neurons within the developing cortex, but also the tangential migration of interneurons 
from ventral to dorsal cortex and their integration (Bagley et al., 2017; Birey et al., 2017; 
Xiang et al., 2017). A possible involvement of GABAergic interneurons in the etiology of 
PH was shown e.g. for TMTC3 (Farhan et al., 2017) and a reduction in inhibitory synaptic 
activity within both heterotopic and normotopic cortex has been described for irradiation 
models of neuronal heterotopia (Chen and Roper, 2003). A recent study identified Ece2 
expression in synaptosomes of parvalbumin-expressing interneurons in the cortex and 
hippocampus of adult mice (Pacheco-Quinto et al., 2016). An analysis of the relative 
contribution of different interneuron subtypes to heterotopia in post-mortem brains 
showed that – although interneurons of all subtypes may be present within the 
heterotopia – the density of parvalbumin-positive neurons was lower than in the cortex 
(Thom et al., 2004). The same was found for an irradiation model of heterotopia: The 
densities of both parvalbumin- and somatostatin-positive interneurons were significantly 
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decreased in cortical dysplasia and heterotopia, which may contribute to hyperexcitability 
(Akakin et al., 2013). These findings indicate that ECE2 may also function in interneurons 
and its reduction may contribute to epileptogenic potential of heterotopic nodules. This 
could be further studied in the developing brain using assembloids and in utero 
electroporation directed at Ece2 KD in the ventral telencephalon.  
Comorbidity of PH with different neuropsychiatric disorders has been reported for many 
cases (Fry et al., 2013; Lippi, 2017). For example, schizophrenia (Nopoulos et al., 1995) 
and others like major depressive disorder, bipolar disorder, ASD (Fry et al., 2013) were 
described. Also de novo variants in ECE2 have been detected in patients with ASD (De 
Rubeis et al., 2014; Iossifov et al., 2012) that may contribute to the etiology of ASD. ASD 
is also often caused by imbalance of excitation and inhibition, so again assembloids 
would be a good model to use for further studies in this direction.  
Finally, the big remaining question after our study is: What is the exact molecular pathway 
of ECE2 action in the developing cortex? We don’t know enough on how ECE2 executes 
all the deciphered functions. Information that can be found in literature is very sparse: 
ECE2 expression was shown to be restricted to a secretory intracellular compartment in 
neural tissues, namely to the trans-Golgi, whose acidified pH fits the pH-optimum of 
ECE2 activity (Davenport and Kuc, 2000; Emoto and Yanagisawa, 1995; Pan et al., 
2004). The catalytic peptidase domain facing the Golgi lumen is common to all isoforms 
(Mzhavia et al., 2003) and the patient mutations localize to this domain. ECE2 produces 
not only the vasoconstrictor endothelin-1 that influences cerebral blood flow (Ehrenreich 
and Schilling, 1995; Mzhavia et al., 2003), but also a number of regulatory neuropeptides 
by cleavage of precursors at non-classical amino acid residues (Mzhavia et al., 2003; 
Pan et al., 2004). Neuropeptides are produced and released from storage and synaptic 
vesicles by both neurons and glia for their communication and act via metabotropic and 
G-protein coupled receptors (Leng and Ludwig, 2008; van den Pol, 2012). This 
modulates intracellular pathways, for example resulting in changes in gene expression 
and glial cell morphology (Oliet and Bonfardin, 2010; van den Pol, 2012). One possible 
hypothesis could thus be that ECE2 – via the production of neuropeptides – influences a 
diversity of pathways. So far, only two related studies analyzed ECE2-mediated 
hydrolysis of the biologically active peptides that were previously found to be cleaved by 
other related metalloproteases (Mzhavia et al., 2003; Pan et al., 2004). They found that 
ECE2 partially hydrolyzed big-endothelin-1, bradykinin, neurotensin, angiotensin I, 
substance P, peptide E, BAM 22P, and little PEN-LEN, and completely hydrolyzed BAM 
18P and dynorphin B at selective sites (Mzhavia et al., 2003). PEN-LEN peptides are 
inhibitors of prohormone-convertase 1, which acts in the generation of a large number of 
neuroendocrine peptides. Hydrolysis of PEN-LEN by ECE2 thus leads to loss if this 
inhibition and change in the levels of neuroendocrine peptides (Mzhavia et al., 2003). 
Proenkephalin-derived peptide E, BAM 18 and BAM 22 are opioids that bind µ- opioid 
receptors, whereas the resulting BAM 16 and BAM 12 peptides exhibit κ-opioid receptors 
(Davis et al., 1990). This suggests a role of ECE2 in selective activation of different opioid 
receptors (Pan et al., 2004). In addition to its role in opioid peptide production and 
hydrolysis, ECE2 was reported to be involved in the recycling of μ- receptors when these 
are co-localized in the same vesicle (Gupta et al., 2015). Opioids function in the 
regulation of pain, stress and affect (Valentino and Volkow, 2018). Furthermore, the 
endogenous opioid system has been implicated in crucial neurodevelopmental functions, 
which may explain some of the phenotypes we observed upon reduction or KO of ECE2. 
For example, agonist-mediated activation of µ- and κ-opioid receptors acts via ERK and 
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MAPK pathways to modulate the cell fate decision and differentiation of NPCs to 
neurons, astrocytes and myelinating oligodendrocytes (Hahn et al., 2010; Kim et al., 
2006; Vestal-Laborde et al., 2014): Opioids drive embryonic stem cell differentiation and 
inhibit NPC proliferation in vitro (Kim et al., 2006). Another study found that binding of 
opioid agonists to the δ‐opioid receptor promoted neural differentiation from multipotent 
forebrain stem cells through activation of Trk-dependent tyrosine kinase (Narita et al., 
2006). Thus, reduced production of opioid peptides upon lack of ECE2 may contribute to 
the increased proportion of progenitors over neurons that we observed in ECE2 KO COs. 
This neuropeptide production hypothesis, exemplified with opioids, is of course only one 
of many possible ones: The mentioned studies only analyzed neuropeptides known to be 
hydrolyzed by the relatives of ECE2, ECE1 and neprilysin (Mzhavia et al., 2003; Pan et 
al., 2004). There may thus be many more intracellular and secreted products of ECE2 
protease activity that remain to be elucidated and may help to shed light on the molecular 
mechanisms of ECE2 neurodevelopmental roles. 
Summary of the ECE2 study. Altogether, we have shown in this study that the 
phenotypes resulting from ECE2 inhibition, KD and KO strongly suggest its role in cortical 
development and in the etiology of PH. Our aim in this project was to identify common 
pathways and mechanisms underlying PH. This was fulfilled with the identification of cell 
polarity, adhesion, and migration and underlying actin and MT cytoskeleton as most 
important mechanisms. In addition, we identified the secretion and regulation of ECM 
components (and of PTMs) as so far less studied components contributing to non-cell-
autonomous phenotypes. 
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5.4. SUMMARY OF THE KNOWLEDGE GAINED IN THIS THESIS  
In the course of this discussion, it should have become already clear that, although the 
three studies presented in this thesis differ in focus, they share common pathways and 
mechanisms whose function is required in cortical development. The following graph aims 
at summarizing the most important findings of all studies individually and at highlighting 
common processes they identified as pivotal (Figure 13). 
 
 
 
Figure 13: Key findings of each study and highlighted common mechanisms.  
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Altogether, the studies presented and discussed in this thesis highlight the heterogeneity 
and complexity of the processes underlying the development of the human cerebral 
cortex – both in health and disease. The overlapping functions of different genes in 
different stages of neurodevelopment and between mechanisms underlying different 
disorders suggests a classification of MCDs as spectrum disorders.  
The fact that subtle changes as small as SNVs and resulting amino acid changes and 
disruption of PTM target sites can lead to cortical malformations therefore stresses the 
requirement for tight regulation on genome, transcriptome, proteome, and 
“posttranslatome” levels.  
Besides, it is hardly surprising that a partly developmental origin has been ascribed to 
epilepsies, many psychiatric disorders, and even neurodegenerative diseases.  
The combination of in vivo mouse and in vitro human model systems with genome editing 
and unbiased analysis methods will help to further illuminate the fascinating yet 
unresolved questions of how our brain evolved and develops. And how our enlarged 
cerebral cortex made us – if we believe in it – the pride of creation. 
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